{"8572737d576f22bf1ee475413edf8fa72a4617e6": [["IntroductionThe new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, the coronavirus disease that was first reported in December 2019 in the city of Wuhan, China (1) .", [["acute respiratory syndrome", "DISEASE", 27, 53], ["COVID-19", "CHEMICAL", 115, 123], ["coronavirus disease", "DISEASE", 129, 148], ["severe acute respiratory syndrome-related coronavirus 2", "ORGANISM", 20, 75], ["SARS-CoV-2", "ORGANISM", 77, 87], ["COVID-19", "CELL", 115, 123], ["coronavirus", "ORGANISM", 129, 140], ["severe acute respiratory syndrome-related coronavirus", "SPECIES", 20, 73], ["SARS-CoV-2", "SPECIES", 77, 87], ["The new severe acute respiratory syndrome", "PROBLEM", 12, 53], ["coronavirus 2", "PROBLEM", 62, 75], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["COVID", "TEST", 115, 120], ["the coronavirus disease", "PROBLEM", 125, 148], ["new", "OBSERVATION_MODIFIER", 16, 19], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["respiratory syndrome", "OBSERVATION", 33, 53], ["coronavirus disease", "OBSERVATION", 129, 148]]], ["Due to its easy inter-human transmission, SARS-CoV-2 has since quickly spread worldwide, causing more than 8 million COVID-19 diagnosed infections and more than 450 thousand deaths officially reported as off mid June 2020 (https://covid19.who.int/).", [["SARS", "DISEASE", 42, 46], ["infections", "DISEASE", 136, 146], ["deaths", "DISEASE", 174, 180], ["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["infections", "PROBLEM", 136, 146], ["infections", "OBSERVATION", 136, 146]]], ["The rapid, sensitive and specific detection of the SARS-CoV-2 virus in large cohorts of clinical samples is of utmost importance to identify infected people and control the propagation of the virus by specific containment measures.", [["samples", "ANATOMY", 97, 104], ["SARS-CoV-2 virus", "ORGANISM", 51, 67], ["samples", "CANCER", 97, 104], ["people", "ORGANISM", 150, 156], ["CoV-2 virus", "SPECIES", 56, 67], ["people", "SPECIES", 150, 156], ["SARS-CoV-2 virus", "SPECIES", 51, 67], ["the SARS", "TEST", 47, 55], ["CoV", "TEST", 56, 59], ["2 virus", "PROBLEM", 60, 67], ["the virus", "TREATMENT", 188, 197], ["large", "OBSERVATION_MODIFIER", 71, 76]]], ["At the same time, being able to catch the numerous SARS-CoV-2 variants represents an opportunity to identify attenuated forms of the virus (2) .", [["SARS", "DISEASE", 51, 55], ["CoV-2", "GENE_OR_GENE_PRODUCT", 56, 61], ["SARS-CoV-2 variants", "DNA", 51, 70], ["the virus", "PROBLEM", 129, 138]]], ["However, the occurrence of specific mutations, especially deletions, may challenge current molecular detection methodologies.IntroductionThe research community has been placing great efforts in the development of quick and accurate detection tests (3, 4) .", [["specific mutations", "PROBLEM", 27, 45], ["accurate detection tests", "TEST", 223, 247]]], ["The gold standard in diagnostics relies on the amplification and measurement of the viral RNA by reverse transcription polymerase chain reaction (RT-PCR).", [["viral RNA", "RNA", 84, 93], ["the amplification", "TEST", 43, 60], ["the viral RNA", "TREATMENT", 80, 93], ["reverse transcription polymerase chain reaction", "PROBLEM", 97, 144], ["RT-PCR", "TEST", 146, 152], ["gold", "OBSERVATION_MODIFIER", 4, 8], ["viral RNA", "OBSERVATION", 84, 93]]], ["RT-PCR is highly specific and achieves a good compromise between speed (90-300 min) and sensitivity.", [["RT-PCR", "TEST", 0, 6], ["good", "OBSERVATION_MODIFIER", 41, 45], ["compromise", "OBSERVATION", 46, 56]]], ["However, due to the great demand for PCR-based testing, shortage of RNA extraction kits and PCR reagents may have limited the testing capacity in some countries at the early stage of the pandemic (5) .", [["PCR", "TEST", 37, 40], ["based testing", "TEST", 41, 54], ["RNA extraction kits", "TEST", 68, 87], ["PCR reagents", "TEST", 92, 104], ["the testing capacity", "TEST", 122, 142]]], ["Besides, RT-PCR testing of clinical samples may be in some case less efficient due to nucleic acid variations in the targeted regions -primers or their close vicinity -that could affect the amplification rate (6, 7) .", [["samples", "ANATOMY", 36, 43], ["nucleic acid", "CHEMICAL", 86, 98], ["nucleic acid", "SIMPLE_CHEMICAL", 86, 98], ["targeted regions", "DNA", 117, 133], ["RT-PCR testing", "TEST", 9, 23], ["clinical samples", "TEST", 27, 43], ["nucleic acid variations", "PROBLEM", 86, 109], ["the amplification rate", "TEST", 186, 208]]], ["For these reasons, alternative detection strategies that address these concerns should be developed to complement conventional tools.IntroductionImmunoassays, whole-genome sequencing (8) and mass spectrometry (MS) (9) technologies are commonly suggested alternatives to PCR-based assays.", [["alternative detection strategies", "TREATMENT", 19, 51], ["IntroductionImmunoassays", "TEST", 133, 157], ["mass spectrometry", "PROBLEM", 191, 208], ["PCR", "TEST", 270, 273]]], ["The typing of organisms by tandem mass spectrometry (MS/MS), commonly referred to as \"proteotyping\", is based on the identification of specific peptide sequences that allow the unambiguous identification of organisms (9) (10) (11) .", [["organisms", "PROBLEM", 14, 23], ["tandem mass spectrometry", "PROBLEM", 27, 51], ["MS/MS)", "PROBLEM", 53, 59], ["specific peptide sequences", "TEST", 135, 161]]], ["The uniqueness of the mass to charge ratios and fragmentation patterns measured in MS/MS allows identifying peptides that differentiate organisms at the subspecies level.", [["the mass", "PROBLEM", 18, 26], ["charge ratios", "TEST", 30, 43], ["fragmentation patterns", "PROBLEM", 48, 70], ["MS/MS", "PROBLEM", 83, 88], ["peptides", "PROBLEM", 108, 116], ["mass", "OBSERVATION", 22, 26]]], ["Although classical MS-based identification of pathogens in the clinical setting is based on whole-cell MALDI-TOF technology (12) , the field has thrived with the increases in speed, sensitivity, and accuracy of new MS instrumentation in the last decade.", [["cell", "CELL", 98, 102], ["classical MS", "PROBLEM", 9, 21], ["pathogens", "PROBLEM", 46, 55], ["new MS instrumentation", "TREATMENT", 211, 233], ["pathogens", "OBSERVATION", 46, 55], ["increases", "OBSERVATION_MODIFIER", 162, 171]]], ["The coupling of new generation instruments with the separation power of liquid chromatography makes LC-MS/MS a valuable technology to implement in the routine of clinical laboratories.", [["new generation instruments", "TREATMENT", 16, 42], ["liquid chromatography", "TEST", 72, 93], ["MS", "PROBLEM", 106, 108], ["new", "OBSERVATION_MODIFIER", 16, 19]]], ["Despite their high potential, the application of LC-MS/MS approaches for virus proteotyping is still scarce.", [["LC-MS/MS approaches", "TREATMENT", 49, 68], ["virus proteotyping", "PROBLEM", 73, 91], ["high potential", "OBSERVATION_MODIFIER", 14, 28]]], ["Among the few examples available in the literature, LC-MS/MS was shown to be able to detect purified influenza virus (13) and human metapneumovirus in clinical samples (14) .IntroductionBecause of the considerable damages of the COVID19 pandemic, the mass spectrometry community quickly proposed to mobilize its efforts at helping to understand the molecular mechanisms of infection (15) (16) (17) and at improving detection methods (18) .", [["samples", "ANATOMY", 160, 167], ["influenza virus", "DISEASE", 101, 116], ["infection", "DISEASE", 373, 382], ["influenza virus", "ORGANISM", 101, 116], ["human", "ORGANISM", 126, 131], ["metapneumovirus", "ORGANISM", 132, 147], ["influenza virus", "SPECIES", 101, 116], ["human", "SPECIES", 126, 131], ["metapneumovirus", "SPECIES", 132, 147], ["influenza virus", "SPECIES", 101, 116], ["human metapneumovirus", "SPECIES", 126, 147], ["MS", "PROBLEM", 58, 60], ["purified influenza virus", "PROBLEM", 92, 116], ["human metapneumovirus in clinical samples", "TEST", 126, 167], ["the COVID19 pandemic", "PROBLEM", 225, 245], ["the mass spectrometry", "PROBLEM", 247, 268], ["infection", "PROBLEM", 373, 382], ["metapneumovirus", "OBSERVATION", 132, 147], ["infection", "OBSERVATION", 373, 382]]], ["Several research groups started investigating MS-based quantification of peptides for the detection of SARS-CoV-2 in clinical samples, but these results are not yet published (19) (20) (21) (22) .", [["samples", "ANATOMY", 126, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 103, 113], ["samples", "CANCER", 126, 133], ["SARS-CoV", "SPECIES", 103, 111], ["the detection", "TEST", 86, 99], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["clinical samples", "TEST", 117, 133]]], ["These preliminary results indicate that targeted MS, in which the mass spectrometer is programmed to precisely detect and quantify a limited number of peptides of interest, can be successfully applied to virus detection.", [["targeted MS", "PROBLEM", 40, 51], ["the mass spectrometer", "TEST", 62, 83], ["virus detection", "TEST", 204, 219]]], ["Targeted MS is considered as the gold standard for peptide quantification due to its higher sensitivity when compared to shotgun proteomics approaches.", [["peptide quantification", "TEST", 51, 73], ["its higher sensitivity", "PROBLEM", 81, 103]]], ["By being more flexible, the latter provides a more comprehensive picture of the viral peptidome, including the detection of variant sequences because of the possibility of detecting peptides without any previous knowledge of their sequences.IntroductionHere we established the proof of concept of the use of MS/MS for the rapid proteotyping of SARS-CoV-2 from clinical samples.", [["samples", "ANATOMY", 369, 376], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 344, 354], ["samples", "CANCER", 369, 376], ["SARS-CoV", "SPECIES", 344, 352], ["the viral peptidome", "TEST", 76, 95], ["variant sequences", "TEST", 124, 141], ["MS/MS", "TREATMENT", 308, 313], ["SARS", "PROBLEM", 344, 348], ["CoV", "TEST", 349, 352], ["clinical samples", "TEST", 360, 376]]], ["We recently published a dataset from a shotgun LC-MS/MS experiment performed with SARS-CoV-2 infected cells and proposed a list of specific viral peptides that could be used for the development of targeted approaches (23) .", [["cells", "ANATOMY", 102, 107], ["SARS-CoV-2", "CELL", 82, 92], ["cells", "CELL", 102, 107], ["SARS-CoV-2 infected cells", "CELL_LINE", 82, 107], ["SARS-CoV", "SPECIES", 82, 90], ["a shotgun LC", "TEST", 37, 49], ["MS", "PROBLEM", 50, 52], ["MS experiment", "PROBLEM", 53, 66], ["SARS", "PROBLEM", 82, 86], ["2 infected cells", "PROBLEM", 91, 107], ["specific viral peptides", "TREATMENT", 131, 154]]], ["Interestingly, we observed that some SARS-CoV-2 specific peptides eluted from the LC column at narrow windows of retention time.", [["some SARS", "PROBLEM", 32, 41], ["CoV", "TEST", 42, 45], ["specific peptides", "TEST", 48, 65], ["LC", "ANATOMY", 82, 84], ["retention time", "OBSERVATION", 113, 127]]], ["Here, we used LC-MS/MS with an Orbitrap instrument (Q Exactive HF) for analyzing the peptidome from nasal swabs spiked with different quantities of viral material.", [["nasal swabs", "ANATOMY", 100, 111], ["nasal swabs", "ORGANISM_SUBSTANCE", 100, 111], ["LC", "TEST", 14, 16], ["MS", "PROBLEM", 20, 22], ["an Orbitrap instrument", "TREATMENT", 28, 50], ["Exactive HF)", "TREATMENT", 54, 66], ["analyzing the peptidome", "PROBLEM", 71, 94], ["nasal swabs", "TEST", 100, 111], ["viral material", "PROBLEM", 148, 162], ["nasal", "ANATOMY", 100, 105], ["viral material", "OBSERVATION", 148, 162]]], ["By using a short LC gradient focusing on the region of interest identified in our previous study, we tested the detection of the virus in samples containing different quantities of viral peptides, as well as COVID-19 clinical samples, paving the way for the development of time-efficient viral diagnostic tests based on an alternative platform.Materials and MethodsNasopharyngeal swab collection and processing for reference matrices.Materials and MethodsTwo nasopharyngeal swabs were collected using a sterile polyester swab with semi-flexible polystyrene handle (Puritan) from two healthy volunteers (swabs R1 and R2).", [["samples", "ANATOMY", 138, 145], ["samples", "ANATOMY", 226, 233], ["Nasopharyngeal swab", "ANATOMY", 365, 384], ["nasopharyngeal swabs", "ANATOMY", 459, 479], ["swabs", "ANATOMY", 603, 608], ["polyester", "CHEMICAL", 511, 520], ["polystyrene", "CHEMICAL", 545, 556], ["nasopharyngeal swabs", "CANCER", 459, 479], ["volunteers", "ORGANISM", 591, 601], ["a short LC gradient", "PROBLEM", 9, 28], ["our previous study", "TEST", 78, 96], ["the virus", "PROBLEM", 125, 134], ["viral peptides", "PROBLEM", 181, 195], ["COVID", "TEST", 208, 213], ["viral diagnostic tests", "TEST", 288, 310], ["Materials", "TREATMENT", 344, 353], ["MethodsNasopharyngeal swab collection", "TEST", 358, 395], ["Materials", "TREATMENT", 434, 443], ["Methods", "TREATMENT", 448, 455], ["nasopharyngeal swabs", "TREATMENT", 459, 479], ["a sterile polyester swab", "TREATMENT", 501, 525], ["semi-flexible polystyrene handle (Puritan", "TREATMENT", 531, 572], ["virus", "OBSERVATION", 129, 134], ["viral peptides", "OBSERVATION", 181, 195], ["Nasopharyngeal", "ANATOMY", 365, 379], ["swab collection", "OBSERVATION", 380, 395], ["nasopharyngeal", "ANATOMY", 459, 473]]], ["Each swab was soaked into a tube containing 200 \u00b5L of sterile water, incubated for 10 min at room temperature, and then rinsed with 200 \u00b5L of sterile water.", [["swab", "ANATOMY", 5, 9], ["tube", "ANATOMY", 28, 32], ["tube", "TISSUE", 28, 32], ["Each swab", "TREATMENT", 0, 9], ["a tube", "TREATMENT", 26, 32], ["sterile water", "TREATMENT", 54, 67], ["sterile water", "TREATMENT", 142, 155], ["tube", "OBSERVATION", 28, 32]]], ["The biological material from the 400 \u00b5L of solution was precipitated with the addition of 100 \u00b5L of trichloroacetic acid at 50% (w/v) and centrifugation at 16,000 g for 10 min.", [["trichloroacetic acid", "CHEMICAL", 100, 120], ["trichloroacetic acid", "CHEMICAL", 100, 120], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 100, 120], ["trichloroacetic acid", "TREATMENT", 100, 120], ["centrifugation", "TREATMENT", 138, 152]]], ["The supernatant was discarded.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15]]], ["The hardly visible pellet was dissolved into 50 \u00b5L of LDS1X containing 5% beta-mercaptoethanol, heated for 5 min at 99\u00b0C, and centrifuged briefly.", [["LDS1X", "CHEMICAL", 54, 59], ["beta-mercaptoethanol", "CHEMICAL", 74, 94], ["beta-mercaptoethanol", "CHEMICAL", 74, 94], ["LDS1X", "SIMPLE_CHEMICAL", 54, 59], ["beta-mercaptoethanol", "SIMPLE_CHEMICAL", 74, 94], ["LDS1X", "TREATMENT", 54, 59], ["5% beta-mercaptoethanol", "TREATMENT", 71, 94], ["visible", "OBSERVATION_MODIFIER", 11, 18], ["pellet", "OBSERVATION", 19, 25]]], ["For each swab sample, a volume of 20 \u00b5L of LDS1X sample was deposited on a SDS-PAGE gel and run for 5 min.", [["swab sample", "ANATOMY", 9, 20], ["LDS1X sample", "ANATOMY", 43, 55], ["each swab sample", "TEST", 4, 20], ["a volume", "TEST", 22, 30], ["a SDS", "TREATMENT", 73, 78]]], ["After migration, the gel was rinsed with water, stained with Simply Blue SafeStain (Invitrogen), and destained overnight in water.", [["the gel", "TREATMENT", 17, 24], ["Simply Blue SafeStain (Invitrogen", "TREATMENT", 61, 94], ["migration", "OBSERVATION_MODIFIER", 6, 15]]], ["The two polyacrylamide gel bands corresponding to the whole proteome of each matrix were excised, processed as described (24) , and then subjected to trypsin Gold proteolysis (Promega) using 0.01% ProteaseMAX surfactant (Promega).", [["matrix", "ANATOMY", 77, 83], ["polyacrylamide", "CHEMICAL", 8, 22], ["matrix", "CELLULAR_COMPONENT", 77, 83], ["ProteaseMAX surfactant", "SIMPLE_CHEMICAL", 197, 219], ["trypsin", "PROTEIN", 150, 157], ["The two polyacrylamide gel bands", "TREATMENT", 0, 32], ["trypsin Gold proteolysis (Promega)", "TREATMENT", 150, 184], ["0.01% ProteaseMAX surfactant (Promega)", "TREATMENT", 191, 229]]], ["The nasal matrix peptide fractions were 50 \u00b5L for each swab.NanoLC-MS/MS characterization of the peptides extracted from the nasopharyngeal swab matricesPeptides from the nasal swab matrices were analysed with a Q-Exactive HF mass spectrometer (Thermo) coupled with an UltiMate 3000 LC system (Dionex-LC) and operated in datadependent mode as previously described (25) .", [["nasal matrix", "ANATOMY", 4, 16], ["swab", "ANATOMY", 55, 59], ["nasopharyngeal swab", "ANATOMY", 125, 144], ["nasal swab", "ANATOMY", 171, 181], ["NanoLC", "CHEMICAL", 60, 66], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 125, 144], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 171, 181], ["The nasal matrix peptide fractions", "TEST", 0, 34], ["MS characterization", "TEST", 70, 89], ["the peptides", "PROBLEM", 93, 105], ["the nasopharyngeal swab matrices", "TREATMENT", 121, 153], ["Peptides", "TEST", 153, 161], ["the nasal swab matrices", "TEST", 167, 190], ["nasal matrix", "ANATOMY", 4, 16], ["nasopharyngeal swab", "ANATOMY", 125, 144], ["nasal swab", "ANATOMY", 171, 181]]], ["A volume of 4 \u00b5L of peptides was injected, desalted onto an Acclaim PepMap100 C18 pre-column (5 \u00b5m, 100 \u00c5, 300 \u00b5m id x 5 mm), and then resolved onto a nanoscale Acclaim PepMap 100 C18 column (3 \u00b5m, 100 \u00c5, 75 \u00b5m id x 50 cm) with a 90-min gradient at a flow rate of 0.2 \u00b5L/min.", [["A volume of 4 \u00b5L of peptides", "TREATMENT", 0, 28], ["an Acclaim PepMap100 C18 pre-column", "TREATMENT", 57, 92], ["a nanoscale Acclaim PepMap", "TREATMENT", 149, 175], ["a flow rate", "TEST", 249, 260], ["volume", "OBSERVATION_MODIFIER", 2, 8]]], ["The gradient was developed from 4 to 25% of CH3CN, 0.1% formic acid in 75 min, and then from 25 to 40% in 15 min, washed, and re-equilibrated.", [["CH3CN", "CHEMICAL", 44, 49], ["formic acid", "CHEMICAL", 56, 67], ["CH3CN", "CHEMICAL", 44, 49], ["formic acid", "CHEMICAL", 56, 67], ["CH3CN", "SIMPLE_CHEMICAL", 44, 49], ["formic acid", "SIMPLE_CHEMICAL", 56, 67], ["The gradient", "TEST", 0, 12], ["CH3CN", "TEST", 44, 49], ["formic acid", "TEST", 56, 67], ["gradient", "OBSERVATION_MODIFIER", 4, 12]]], ["Peptides were analysed with scan cycles initiated by a full scan of peptide ions in the Orbitrap analyser, followed by high-energy collisional dissociation and MS/MS scans on the 20 most abundant precursor ions (Top20 method).", [["Peptides", "TEST", 0, 8], ["scan cycles", "TEST", 28, 39], ["a full scan of peptide ions", "TEST", 53, 80], ["the Orbitrap analyser", "TEST", 84, 105], ["high-energy collisional dissociation", "PROBLEM", 119, 155], ["MS", "PROBLEM", 160, 162], ["MS scans", "TEST", 163, 171], ["collisional dissociation", "OBSERVATION", 131, 155]]], ["Full scan mass spectra were acquired from m/z 350 to 1500 at a resolution of 60,000 with internal calibration activated on the m/z 445.12002 signal.", [["Full scan mass spectra", "TEST", 0, 22], ["internal calibration", "TEST", 89, 109], ["mass", "OBSERVATION", 10, 14]]], ["Ion selection for MS/MS fragmentation and measurement was performed applying a dynamic exclusion window of 10 sec and an intensity threshold of 5x10 4 .", [["Ion selection", "TREATMENT", 0, 13], ["MS/MS fragmentation", "PROBLEM", 18, 37], ["an intensity threshold", "TEST", 118, 140]]], ["Only ions with positive charges 2+ and 3+ were considered.Cell culture and VirusVero E6 (ATCC, CLR-1586) cells were cultured at 37\u00b0C in 9% CO2 in Dulbecco's modified Eagle's medium (DMEM, Gibco, ThemoFisher) supplemented with 5% fetal calf serum (FCS) and 0.5% penicillin-streptomycin.", [["Cell culture", "ANATOMY", 58, 70], ["ATCC", "ANATOMY", 89, 93], ["CLR-1586) cells", "ANATOMY", 95, 110], ["fetal calf serum", "ANATOMY", 229, 245], ["CLR-1586", "CHEMICAL", 95, 103], ["CO2", "CHEMICAL", 139, 142], ["penicillin", "CHEMICAL", 261, 271], ["streptomycin", "CHEMICAL", 272, 284], ["CO2", "CHEMICAL", 139, 142], ["penicillin", "CHEMICAL", 261, 271], ["streptomycin", "CHEMICAL", 272, 284], ["ions", "SIMPLE_CHEMICAL", 5, 9], ["3+", "SIMPLE_CHEMICAL", 39, 41], ["Cell", "CELL", 58, 62], ["VirusVero E6", "CELL", 75, 87], ["ATCC", "CELL", 89, 93], ["CLR-1586) cells", "CELL", 95, 110], ["CO2", "SIMPLE_CHEMICAL", 139, 142], ["fetal calf", "ORGANISM_SUBSTANCE", 229, 239], ["serum", "ORGANISM_SUBSTANCE", 240, 245], ["FCS", "ORGANISM_SUBSTANCE", 247, 250], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 261, 284], ["VirusVero E6 (ATCC, CLR-1586) cells", "CELL_LINE", 75, 110], ["calf", "SPECIES", 235, 239], ["VirusVero E6 (ATCC, CLR-1586", "SPECIES", 75, 103], ["Cell culture", "TEST", 58, 70], ["VirusVero", "TEST", 75, 84], ["ATCC", "TEST", 89, 93], ["CLR", "TEST", 95, 98], ["cells", "TEST", 105, 110], ["CO2", "TEST", 139, 142], ["Dulbecco", "TEST", 146, 154], ["Gibco", "TEST", 188, 193], ["5% fetal calf serum (FCS", "TREATMENT", 226, 250], ["penicillin", "TREATMENT", 261, 271], ["streptomycin", "TREATMENT", 272, 284], ["positive charges", "OBSERVATION_MODIFIER", 15, 31]]], ["The SARS-CoV-2 strains 2019-nCoV/Italy-INMI1 (Genbank MT066156) was provided by the Lazzaro Spallanzani National Institute of Infectious Diseases (Rome, Italy) via the EVAg network (European Virus Archive goes global).", [["Infectious Diseases", "DISEASE", 126, 145], ["SARS-CoV-2", "ORGANISM", 4, 14], ["nCoV", "ORGANISM", 28, 32], ["Italy-INMI1", "ORGANISM", 33, 44], ["EVAg network", "MULTI-TISSUE_STRUCTURE", 168, 180], ["SARS-CoV-2 strains 2019-nCoV/Italy-INMI1", "SPECIES", 4, 44], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["the EVAg network", "TREATMENT", 164, 180], ["Infectious", "OBSERVATION", 126, 136]]], ["SARS-CoV-2 stocks used in the experiments had undergone two passages on Vero E6 cells and were stored at -80\u00b0C. Virus titer was 7.25x10 5 plaque forming units (PFU)/mL, as determined by standard plaque assay (three dilutions in duplicates).", [["cells", "ANATOMY", 80, 85], ["plaque", "ANATOMY", 195, 201], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["Vero E6 cells", "CELL", 72, 85], ["Virus", "ORGANISM", 112, 117], ["Vero E6 cells", "CELL_LINE", 72, 85], ["Vero E6", "SPECIES", 72, 79], ["SARS", "PROBLEM", 0, 4], ["CoV-2 stocks", "TREATMENT", 5, 17], ["Vero E6 cells", "TREATMENT", 72, 85], ["Virus titer", "TEST", 112, 123], ["plaque", "OBSERVATION", 195, 201]]], ["All experiments entailing live SARS-CoV-2 were performed in our biosafety level 3 facility and strictly followed its approved standard operating procedures.Infection and virus purificationVero E6 cells (1x10 6 ) seeded into 150 cm 2 flasks were grown to cell confluence in 15 ml DMEM supplemented with 5% FCS and 0.5% penicillin-streptomycin for one night at 37\u00b0C under 9% CO2.", [["cells", "ANATOMY", 196, 201], ["cell", "ANATOMY", 254, 258], ["FCS", "CHEMICAL", 305, 308], ["penicillin", "CHEMICAL", 318, 328], ["streptomycin", "CHEMICAL", 329, 341], ["CO2", "CHEMICAL", 373, 376], ["penicillin", "CHEMICAL", 318, 328], ["streptomycin", "CHEMICAL", 329, 341], ["CO2", "CHEMICAL", 373, 376], ["Vero E6 cells", "CELL", 188, 201], ["cell", "CELL", 254, 258], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 318, 341], ["CO2", "SIMPLE_CHEMICAL", 373, 376], ["Vero E6 cells", "CELL_LINE", 188, 201], ["1x10 6", "CELL_LINE", 203, 209], ["SARS-CoV", "SPECIES", 31, 39], ["Vero E6", "SPECIES", 188, 195], ["Infection", "PROBLEM", 156, 165], ["virus purificationVero E6 cells", "TREATMENT", 170, 201], ["5% FCS", "TREATMENT", 302, 308], ["penicillin", "TREATMENT", 318, 328], ["streptomycin", "TREATMENT", 329, 341], ["virus", "OBSERVATION_MODIFIER", 170, 175], ["E6 cells", "OBSERVATION", 193, 201], ["150 cm", "OBSERVATION_MODIFIER", 224, 230]]], ["They were infected at multiplicity of infection (MOI) of 0.001.", [["infection", "DISEASE", 38, 47], ["infection", "PROBLEM", 38, 47], ["infected", "OBSERVATION_MODIFIER", 10, 18], ["infection", "OBSERVATION", 38, 47]]], ["Cells were harvested at 3 days post infection (dpi) and viral suspension was recovered after centrifugation at 2,500 rpm for 5 min to remove cell debris.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 141, 145], ["Cells", "CELL", 0, 5], ["cell", "CELL", 141, 145], ["infection", "PROBLEM", 36, 45], ["viral suspension", "TREATMENT", 56, 72], ["centrifugation", "TREATMENT", 93, 107], ["cell debris", "PROBLEM", 141, 152], ["infection", "OBSERVATION", 36, 45], ["viral suspension", "OBSERVATION", 56, 72], ["cell debris", "OBSERVATION", 141, 152]]], ["33 ml of the viral suspension were laid on 5 ml of 20% (w/v) sucrose cushion prepared in NaCl 0.1 M, EDTA 1m M, 10 mM Tris HCl buffer (pH 7.4) (TNE buffer) in Ultra-Clear 38 ml tubes (Beckman Coulter).", [["sucrose", "CHEMICAL", 61, 68], ["NaCl", "CHEMICAL", 89, 93], ["Tris HCl", "CHEMICAL", 118, 126], ["sucrose", "CHEMICAL", 61, 68], ["NaCl", "CHEMICAL", 89, 93], ["EDTA", "CHEMICAL", 101, 105], ["Tris HCl", "CHEMICAL", 118, 126], ["Tris HCl", "SIMPLE_CHEMICAL", 118, 126], ["the viral suspension", "TREATMENT", 9, 29], ["w/v) sucrose cushion", "TREATMENT", 56, 76], ["NaCl", "TREATMENT", 89, 93], ["EDTA", "TREATMENT", 101, 105], ["pH", "TEST", 135, 137], ["TNE buffer", "TREATMENT", 144, 154], ["Ultra", "TEST", 159, 164]]], ["Samples were centrifuged at 25,000 rpm for 2h at 4\u00b0C. Pellets were solubilised in 150 \uf06dL of cold TNE buffer and a volume of 1.5 ml was laid on a five step 20 -60% (w/v) sucrose gradient prepared in Ultra-Clear 13 ml tubes (Beckman Coulter).", [["Samples", "ANATOMY", 0, 7], ["Pellets", "ANATOMY", 54, 61], ["sucrose", "CHEMICAL", 169, 176], ["sucrose", "CHEMICAL", 169, 176], ["Samples", "TEST", 0, 7], ["cold TNE buffer", "TREATMENT", 92, 107], ["a volume", "TREATMENT", 112, 120], ["sucrose gradient", "TREATMENT", 169, 185], ["Clear 13 ml tubes (Beckman Coulter", "TREATMENT", 204, 238]]], ["The tubes were centrifuged at 35,000 rpm for 2h at 4\u00b0C in a Beckman SW41 rotor.", [["tubes", "ANATOMY", 4, 9], ["tubes", "TISSUE", 4, 9], ["C", "GENE_OR_GENE_PRODUCT", 53, 54], ["Beckman SW41 rotor", "CELL_LINE", 60, 78], ["The tubes", "TREATMENT", 0, 9], ["tubes", "OBSERVATION", 4, 9]]], ["After recovery of the virus band, the viral suspension was inactivated by incubation with betapropiolactone at a final concentration of 0.5% for 72h at 4\u00b0C. Plaque assay titration was used to quantify the purified virus and validate the viral inactivation.Proteolysis of purified SARS-CoV-2 virusThe inactivated purified virus sample (equivalent to 7.25x10 5 PFU/mL) was quantified in terms of protein concentration (0.614 mg/mL) by UV spectrophotometry.", [["Plaque", "ANATOMY", 157, 163], ["sample", "ANATOMY", 327, 333], ["betapropiolactone", "CHEMICAL", 90, 107], ["betapropiolactone", "CHEMICAL", 90, 107], ["betapropiolactone", "SIMPLE_CHEMICAL", 90, 107], ["SARS-CoV-2 virus", "ORGANISM", 280, 296], ["CoV-2 virus", "SPECIES", 285, 296], ["SARS-CoV-2 virus", "SPECIES", 280, 296], ["the virus band", "TREATMENT", 18, 32], ["the viral suspension", "TREATMENT", 34, 54], ["betapropiolactone", "TREATMENT", 90, 107], ["Plaque assay titration", "TREATMENT", 157, 179], ["the purified virus", "PROBLEM", 201, 219], ["the viral inactivation", "PROBLEM", 233, 255], ["Proteolysis", "TEST", 256, 267], ["purified SARS", "PROBLEM", 271, 284], ["CoV", "TEST", 285, 288], ["2 virus", "PROBLEM", 289, 296], ["The inactivated purified virus sample", "TREATMENT", 296, 333], ["protein concentration", "TREATMENT", 394, 415], ["virus band", "OBSERVATION", 22, 32], ["viral suspension", "OBSERVATION", 38, 54], ["viral inactivation", "OBSERVATION", 237, 255], ["SARS", "OBSERVATION", 280, 284]]], ["A volume of 60 \u00b5L was mixed with 20 \u00b5L of LDS3X to obtain a protein fraction of 0.46 mg/mL.", [["LDS3X", "CHEMICAL", 42, 47], ["LDS3X", "SIMPLE_CHEMICAL", 42, 47], ["A volume", "TEST", 0, 8], ["LDS3X", "TREATMENT", 42, 47], ["a protein fraction", "TEST", 58, 76]]], ["After denaturation at 99\u00b0C for 5 min, a volume of 25 \u00b5L (11.5 \u00b5g of proteins) was deposited on a NuPAGE 4-12% gel (Invitrogen) and subjected to 5 min electrophoretic migration.", [["NuPAGE", "CHEMICAL", 97, 103], ["a volume", "TEST", 38, 46], ["a NuPAGE 4", "TREATMENT", 95, 105]]], ["The whole proteome was excised as a single polyacrylamide gel band and subjected to trypsin proteolysis as previously described (24) .", [["polyacrylamide", "CHEMICAL", 43, 57], ["trypsin", "GENE_OR_GENE_PRODUCT", 84, 91], ["trypsin", "PROTEIN", 84, 91], ["a single polyacrylamide gel band", "TREATMENT", 34, 66], ["trypsin proteolysis", "PROBLEM", 84, 103]]], ["An aliquot of 50 \u00b5L of peptides was extracted.", [["An aliquot of 50 \u00b5L of peptides", "TREATMENT", 0, 31]]], ["MS/MS analysis was performed to confirm the high content of viral proteins in this sample (data not shown).Preparation of simili SARS-CoV-2 contaminated swabsSARS-CoV-2 viral peptides (3 \u00b5L) were diluted in 6 \u00b5L of H2O, 0.1% TFA.", [["sample", "ANATOMY", 83, 89], ["H2O", "CHEMICAL", 215, 218], ["TFA", "CHEMICAL", 225, 228], ["H2O", "CHEMICAL", 215, 218], ["TFA", "CHEMICAL", 225, 228], ["CoV-2", "ORGANISM", 134, 139], ["TFA", "SIMPLE_CHEMICAL", 225, 228], ["viral proteins", "PROTEIN", 60, 74], ["CoV-2", "SPECIES", 163, 168], ["MS/MS analysis", "TEST", 0, 14], ["viral proteins", "PROBLEM", 60, 74], ["this sample", "TEST", 78, 89], ["simili SARS", "TEST", 122, 133], ["CoV", "TEST", 134, 137], ["CoV", "TEST", 163, 166], ["2 viral peptides", "TREATMENT", 167, 183], ["H2O", "TREATMENT", 215, 218], ["viral proteins", "OBSERVATION", 60, 74]]], ["After mixing, 3 \u00b5L of this tube was removed and diluted with 6 \u00b5L of H2O, 0.1% TFA.", [["tube", "ANATOMY", 27, 31], ["H2O", "CHEMICAL", 69, 72], ["TFA", "CHEMICAL", 79, 82], ["H2O", "CHEMICAL", 69, 72], ["TFA", "CHEMICAL", 79, 82], ["tube", "TISSUE", 27, 31], ["TFA", "SIMPLE_CHEMICAL", 79, 82], ["this tube", "TREATMENT", 22, 31], ["H2O", "TREATMENT", 69, 72], ["tube", "OBSERVATION", 27, 31]]], ["This was repeated several times to obtain a one third dilution cascade of viral peptides.", [["viral peptides", "TREATMENT", 74, 88], ["viral peptides", "OBSERVATION", 74, 88]]], ["Two series of simili swabs were prepared in parallel.", [["simili swabs", "TREATMENT", 14, 26]]], ["The two peptide fractions obtained from nasopharyngeal swabs (35\u00b5L) were diluted with 15 \u00b5L of H20, 0.1% TFA.", [["nasopharyngeal swabs", "ANATOMY", 40, 60], ["TFA", "CHEMICAL", 105, 108], ["TFA", "CHEMICAL", 105, 108], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 40, 60], ["TFA", "SIMPLE_CHEMICAL", 105, 108], ["The two peptide fractions", "TEST", 0, 25], ["nasopharyngeal swabs", "TEST", 40, 60], ["H20", "TREATMENT", 95, 98], ["nasopharyngeal swabs", "ANATOMY", 40, 60]]], ["A volume of 6 \u00b5L of this diluted matrix was added to each simili swab samples, giving a final volume of 12 \u00b5L per sample.", [["matrix", "ANATOMY", 33, 39], ["swab samples", "ANATOMY", 65, 77], ["matrix", "CELLULAR_COMPONENT", 33, 39], ["this diluted matrix", "TREATMENT", 20, 39], ["volume", "OBSERVATION_MODIFIER", 2, 8]]], ["Thus, each simili swab contained the equivalent of 8.4% of the proteins harvested by a nasal swab.", [["nasal swab", "ANATOMY", 87, 97], ["each simili swab", "TEST", 6, 22], ["a nasal swab", "TEST", 85, 97], ["nasal", "ANATOMY", 87, 92]]], ["Two biological replicates were prepared using each nasal swab matrix.", [["nasal swab matrix", "ANATOMY", 51, 68], ["Two biological replicates", "TREATMENT", 0, 25], ["each nasal swab matrix", "TREATMENT", 46, 68]]], ["A volume of 10 \u00b5L per sample was injected in the Q-Exactive HF tandem mass spectrometer.", [["sample", "ANATOMY", 22, 28], ["A volume of 10 \u00b5L per sample", "TREATMENT", 0, 28], ["volume", "OBSERVATION_MODIFIER", 2, 8], ["mass", "OBSERVATION", 70, 74]]], ["They were analysed in the same conditions as above except that the gradient was developed from 8 to 12.5% of CH3CN, 0.1% formic acid for 30 min at a flow rate of 0.2 \u00b5L/min.", [["CH3CN", "CHEMICAL", 109, 114], ["formic acid", "CHEMICAL", 121, 132], ["CH3CN", "CHEMICAL", 109, 114], ["formic acid", "CHEMICAL", 121, 132], ["CH3CN", "SIMPLE_CHEMICAL", 109, 114], ["formic acid", "SIMPLE_CHEMICAL", 121, 132], ["the gradient", "TEST", 63, 75], ["a flow rate", "TEST", 147, 158]]], ["The 20 min MS/MS acquisition started 17 min after injection.COVID-19 nasopharyngeal swabs and MS/MS measurementsNasopharyngeal swabs were collected from COVID-19 diagnosed adult patients as routine medical controls and tested by RT-PCR assay for detecting SARS-CoV-2 in a nasopharyngeal sample (swabs T1-T9).", [["nasopharyngeal swabs", "ANATOMY", 69, 89], ["Nasopharyngeal swabs", "ANATOMY", 112, 132], ["nasopharyngeal sample", "ANATOMY", 272, 293], ["swabs", "ANATOMY", 295, 300], ["Nasopharyngeal swabs", "CANCER", 112, 132], ["patients", "ORGANISM", 178, 186], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 256, 266], ["nasopharyngeal sample", "CANCER", 272, 293], ["patients", "SPECIES", 178, 186], ["SARS-CoV", "SPECIES", 256, 264], ["The 20 min MS/MS acquisition", "TREATMENT", 0, 28], ["COVID", "TEST", 60, 65], ["nasopharyngeal swabs", "TEST", 69, 89], ["MS/MS measurements", "TEST", 94, 112], ["Nasopharyngeal swabs", "TEST", 112, 132], ["routine medical controls", "TREATMENT", 190, 214], ["PCR assay", "TEST", 232, 241], ["SARS", "PROBLEM", 256, 260], ["CoV", "TEST", 261, 264], ["a nasopharyngeal sample", "TEST", 270, 293], ["nasopharyngeal", "ANATOMY", 69, 83], ["nasopharyngeal", "ANATOMY", 272, 286], ["T9", "ANATOMY", 304, 306]]], ["This study was approved by the institutional review boards of the University Hospital of N\u00eemes, France (2020-05-01).", [["This study", "TEST", 0, 10]]], ["Patients have been previously be informed that part of these samples could be used for research purpose and agreed.", [["Patients", "ORGANISM", 0, 8], ["samples", "CANCER", 61, 68], ["Patients", "SPECIES", 0, 8]]], ["Each swab was soaked into a tube containing 5 mL of Phosphate Buffered Saline (pH 7.4) sterile solution and transferred in the biosafety level 3 facility.", [["swab", "ANATOMY", 5, 9], ["tube", "ANATOMY", 28, 32], ["Phosphate", "CHEMICAL", 52, 61], ["Phosphate", "CHEMICAL", 52, 61], ["tube", "TISSUE", 28, 32], ["Phosphate", "SIMPLE_CHEMICAL", 52, 61], ["Saline", "SIMPLE_CHEMICAL", 71, 77], ["Each swab", "TREATMENT", 0, 9], ["a tube", "TREATMENT", 26, 32], ["Phosphate Buffered Saline (pH", "TREATMENT", 52, 81], ["sterile solution", "TREATMENT", 87, 103]]], ["The biological material was precipitated with the addition of 1.25 mL of trichloroacetic acid at 50% (w/v).", [["trichloroacetic acid", "CHEMICAL", 73, 93], ["trichloroacetic acid", "CHEMICAL", 73, 93], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 73, 93], ["trichloroacetic acid", "TREATMENT", 73, 93]]], ["After centrifugation, the supernatant was discarded and the pellet was dissolved into 25 \u00b5L of LDS1X containing 5% betamercaptoethanol, heated for 5 min at 99\u00b0C, and deposited on a NuPAGE 4-12% gel (Invitrogen).", [["supernatant", "ANATOMY", 26, 37], ["pellet", "ANATOMY", 60, 66], ["LDS1X", "CHEMICAL", 95, 100], ["betamercaptoethanol", "CHEMICAL", 115, 134], ["betamercaptoethanol", "CHEMICAL", 115, 134], ["NuPAGE", "CHEMICAL", 181, 187], ["LDS1X", "SIMPLE_CHEMICAL", 95, 100], ["betamercaptoethanol", "SIMPLE_CHEMICAL", 115, 134], ["centrifugation", "TREATMENT", 6, 20], ["the supernatant", "TREATMENT", 22, 37], ["the pellet", "TREATMENT", 56, 66], ["LDS1X", "TREATMENT", 95, 100], ["5% betamercaptoethanol", "TREATMENT", 112, 134], ["a NuPAGE 4", "TREATMENT", 179, 189]]], ["The proteins were subjected to 5 min electrophoresis and treated as described here above to obtain tryptic peptides.", [["5 min electrophoresis", "TREATMENT", 31, 52], ["tryptic peptides", "TREATMENT", 99, 115]]], ["MS/MS acquisition was done as for the simili swabs.", [["MS acquisition", "TEST", 3, 17], ["the simili swabs", "TEST", 34, 50]]], ["The 20 min MS/MS acquisition started 17 min after injection with an inclusion list comprising 28 m/z values corresponding to 23 viral peptides.Peptide assignation and proteomics data analysisMS/MS spectra from the nasopharyngeal swabs were searched against the generalist NCBInr database (108,307,546 sequences totalling 41,817,980,956 amino acids) with the MASCOT Daemon 2.3.2 search engine (Matrix Science).", [["nasopharyngeal swabs", "ANATOMY", 214, 234], ["amino acids", "CHEMICAL", 336, 347], ["amino acids", "CHEMICAL", 336, 347], ["nasopharyngeal swabs", "CANCER", 214, 234], ["amino acids", "AMINO_ACID", 336, 347], ["NCBInr database", "DNA", 272, 287], ["108,307,546 sequences", "DNA", 289, 310], ["The 20 min MS/MS acquisition", "TREATMENT", 0, 28], ["z values", "TEST", 99, 107], ["23 viral peptides", "TREATMENT", 125, 142], ["Peptide assignation", "TEST", 143, 162], ["proteomics data", "TEST", 167, 182], ["analysisMS", "TEST", 183, 193], ["MS spectra", "PROBLEM", 194, 204], ["the nasopharyngeal swabs", "TEST", 210, 234], ["amino acids", "TEST", 336, 347], ["the MASCOT Daemon", "TREATMENT", 354, 371], ["nasopharyngeal", "ANATOMY", 214, 228]]], ["The search parameters were as follows: fulltrypsin specificity, maximum of two missed cleavages, mass tolerances of 5 ppm on the parent ion and 0.02 Da on the MS/MS, carbamidomethylated cysteine (+57.0215) as a fixed modification, and oxidized methionine (+15.9949) and deamidation of asparagine and glutamine (+0.9848) as variable modifications.", [["carbamidomethylated cysteine", "CHEMICAL", 166, 194], ["methionine", "CHEMICAL", 244, 254], ["asparagine", "CHEMICAL", 285, 295], ["glutamine", "CHEMICAL", 300, 309], ["cysteine", "CHEMICAL", 186, 194], ["methionine", "CHEMICAL", 244, 254], ["asparagine", "CHEMICAL", 285, 295], ["glutamine", "CHEMICAL", 300, 309], ["fulltrypsin", "GENE_OR_GENE_PRODUCT", 39, 50], ["carbamidomethylated cysteine", "SIMPLE_CHEMICAL", 166, 194], ["methionine", "SIMPLE_CHEMICAL", 244, 254], ["asparagine", "AMINO_ACID", 285, 295], ["glutamine", "AMINO_ACID", 300, 309], ["carbamidomethylated cysteine", "TREATMENT", 166, 194], ["a fixed modification", "TREATMENT", 209, 229], ["oxidized methionine", "TREATMENT", 235, 254], ["deamidation of asparagine", "TREATMENT", 270, 295], ["glutamine", "TREATMENT", 300, 309]]], ["PSMs with an FDR<1% were selected for peptide inference.", [["PSMs", "TEST", 0, 4], ["an FDR", "TEST", 10, 16], ["peptide inference", "PROBLEM", 38, 55]]], ["Peptides were assigned to taxa using the Unipept 4.3 web interface (26) with default parameters (equate I/L, filter duplicate peptides).Peptide assignation and proteomics data analysisMS/MS spectra from the simili SARS-CoV-2 contaminated swabs and from the COVID-19 nasopharyngeal swabs were assigned with the MASCOT Daemon 2.3.2 search engine (Matrix Science) as follows: the spectra were first queried against the cRAP_contaminants_2020-05-18.fasta file and then against the Swissprot_Human_ISL_410545_2020-05-18 database (20,139 sequences totalling 11,330,214 amino acids) in follow-up mode and with the decoy option activated.", [["swabs", "ANATOMY", 238, 243], ["nasopharyngeal swabs", "ANATOMY", 266, 286], ["amino acids", "CHEMICAL", 563, 574], ["cRAP_contaminants_2020-05-18", "CHEMICAL", 416, 444], ["amino acids", "CHEMICAL", 563, 574], ["nasopharyngeal swabs", "CANCER", 266, 286], ["amino acids", "AMINO_ACID", 563, 574], ["cRAP_contaminants_2020-05-18", "DNA", 416, 444], ["Swissprot_Human_ISL_410545_2020-05-18 database", "DNA", 477, 523], ["taxa", "TEST", 26, 30], ["default parameters", "TEST", 77, 95], ["filter duplicate peptides", "TREATMENT", 109, 134], ["Peptide assignation", "TEST", 136, 155], ["proteomics data", "TEST", 160, 175], ["analysisMS", "TEST", 176, 186], ["MS spectra", "TEST", 187, 197], ["the simili SARS", "TEST", 203, 218], ["CoV", "TEST", 219, 222], ["contaminated swabs", "TEST", 225, 243], ["the COVID", "TEST", 253, 262], ["nasopharyngeal swabs", "TEST", 266, 286], ["the cRAP_contaminants_2020-05", "TEST", 412, 441], ["amino acids", "TEST", 563, 574], ["the decoy option", "TREATMENT", 603, 619]]], ["This last database is the merge of the SARS-CoV-2 viral proteins and the Swissprot Human proteome.", [["SARS", "DISEASE", 39, 43], ["Human", "ORGANISM", 83, 88], ["SARS-CoV-2 viral proteins", "PROTEIN", 39, 64], ["Swissprot", "PROTEIN", 73, 82], ["Human", "SPECIES", 83, 88], ["the SARS", "TEST", 35, 43], ["CoV", "TEST", 44, 47]]], ["The MASCOT search was performed with the same parameters as above.", [["The MASCOT search", "TEST", 0, 17]]], ["All peptide matches presenting a MASCOT peptide score with a FDR lower than 1% were assigned to protein sequences.", [["All peptide matches", "PROBLEM", 0, 19], ["a MASCOT peptide score", "TEST", 31, 53], ["protein sequences", "TEST", 96, 113]]], ["MS1 peak areas were evaluated with Skyline (27) .", [["MS1 peak areas", "TEST", 0, 14], ["Skyline", "TEST", 35, 42]]], ["Briefly, we created spectral libraries based on the DAT files from each MASCOT search (cut-of 0.99) and uploaded the MS1 full scan information contained in the raw files.", [["DAT files", "DNA", 52, 61], ["MASCOT search", "TEST", 72, 85], ["cut", "TEST", 87, 90], ["the MS1 full scan information", "TEST", 113, 142], ["spectral libraries", "OBSERVATION", 20, 38]]], ["The protein database previously used for the MASCOT search was used as background proteome.", [["The protein database", "TEST", 0, 20], ["the MASCOT search", "TEST", 41, 58]]], ["Only the viral proteins were added to the target panel.", [["viral proteins", "PROTEIN", 9, 23], ["the viral proteins", "TEST", 5, 23], ["the target panel", "TEST", 38, 54], ["viral proteins", "OBSERVATION", 9, 23]]], ["Peptide settings were matched to those used in the MASCOT search.", [["Peptide settings", "TREATMENT", 0, 16]]], ["Peak peaking was manually checked for all peptides.Mass spectrometry and proteomics dataThe mass spectrometry and proteomics data acquired on simili swabs have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (28) with the dataset identifiers PXD019686 and 10.6019/PXD019686.A shotgun MS-based strategy elaborated with simili COVID-19 swabs.To assess the performance of shotgun MS-based proteomics in detecting SARS-CoV-2 peptides in a background matrix consisting of nasopharyngeal swab protein material, we experimentally created tryptic peptidomes from i) a purified virus solution obtained from Vero E6 cells infected with a SARS-CoV-2 reference strain, and ii) nasopharyngeal swabs obtained from two healthy volunteers (Figure 1) .", [["matrix", "ANATOMY", 480, 486], ["nasopharyngeal swab", "ANATOMY", 501, 520], ["cells", "ANATOMY", 640, 645], ["nasopharyngeal swabs", "ANATOMY", 699, 719], ["PXD019686", "CHEMICAL", 276, 285], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 501, 520], ["Vero E6 cells", "CELL", 632, 645], ["SARS-CoV-2", "ORGANISM", 662, 672], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 699, 719], ["Vero E6 cells", "CELL_LINE", 632, 645], ["SARS-CoV", "SPECIES", 444, 452], ["Vero E6", "SPECIES", 632, 639], ["Peak peaking", "TEST", 0, 12], ["Mass spectrometry", "TEST", 51, 68], ["proteomics data", "TEST", 73, 88], ["The mass spectrometry", "TEST", 88, 109], ["proteomics data", "TEST", 114, 129], ["simili swabs", "TEST", 142, 154], ["A shotgun MS", "TEST", 308, 320], ["simili COVID", "TREATMENT", 352, 364], ["shotgun MS", "TEST", 403, 413], ["based proteomics", "TEST", 414, 430], ["SARS", "PROBLEM", 444, 448], ["CoV", "TEST", 449, 452], ["a background matrix", "PROBLEM", 467, 486], ["nasopharyngeal swab protein material", "PROBLEM", 501, 537], ["a purified virus solution", "TREATMENT", 592, 617], ["Vero E6 cells", "PROBLEM", 632, 645], ["a SARS", "TEST", 660, 666], ["CoV", "TEST", 667, 670], ["nasopharyngeal swabs", "TEST", 699, 719], ["mass", "OBSERVATION", 92, 96], ["nasopharyngeal", "ANATOMY", 501, 515], ["nasopharyngeal", "ANATOMY", 699, 713]]], ["We first characterized the nasal peptidomes and searched for the presence of detectable microorganisms by metaproteomic data analysis.", [["nasal peptidomes", "ANATOMY", 27, 43], ["the nasal peptidomes", "TEST", 23, 43], ["detectable microorganisms", "PROBLEM", 77, 102], ["metaproteomic data analysis", "TEST", 106, 133], ["nasal", "ANATOMY", 27, 32]]], ["Then, the virus peptidome was serially diluted into nasopharyngeal swab peptidomes to obtain two sets of seven tubes containing from 460 ng (equivalent to 544 infectious particles) to 0.6 ng (equivalent to 1 infectious particle) of viral protein material.", [["nasopharyngeal swab", "ANATOMY", 52, 71], ["the virus peptidome", "PROBLEM", 6, 25], ["nasopharyngeal swab peptidomes", "TEST", 52, 82], ["seven tubes", "TREATMENT", 105, 116], ["viral protein material", "PROBLEM", 232, 254], ["tubes", "OBSERVATION", 111, 116], ["viral protein material", "OBSERVATION", 232, 254]]], ["The fourteen samples were subsequently analyzed by LC-MS/MS. A window of 20 min of acquisition within a 30 min LC gradient was adjusted to target the region of elution of five previously identified virusspecific peptides (23) .", [["samples", "ANATOMY", 13, 20], ["The fourteen samples", "TEST", 0, 20], ["a 30 min LC gradient", "TREATMENT", 102, 122]]], ["The rationale for focussing the mass spectrometry measurements on these peptides was their remarkable sequence conservation amongst the numerous SARS-CoV-2 strains sequenced to date or/and their specificity to the novel coronavirus (23) .", [["SARS-CoV-2", "ORGANISM", 145, 155], ["coronavirus", "ORGANISM", 220, 231], ["the mass spectrometry measurements", "TEST", 28, 62], ["these peptides", "TEST", 66, 80], ["CoV", "TEST", 150, 153]]], ["These peptides were the following: EITVATSR, GFYAEGSR, HTPINLVR, IAGHHLGR, and ADETQALPQR.", [["IAGHHLGR", "PROTEIN", 65, 73], ["ADETQALPQR", "PROTEIN", 79, 89], ["ADETQALPQR", "TREATMENT", 79, 89]]], ["While known variants exist for the latter, the other four peptides are conserved along the several SARS-CoV-2 sequenced genomes.Metaproteomics analysis of the two nasopharyngeal swabs excludes the presence of abundant microorganisms.The MS/MS spectra acquired over 90 min on the two nasopharyngeal swabs were analyzed to infer the main microbial components present in these samples as such presence should be taken into account for creating an ad hoc database for MS/MS interpretation.", [["nasopharyngeal swabs", "ANATOMY", 163, 183], ["nasopharyngeal swabs", "ANATOMY", 283, 303], ["samples", "ANATOMY", 374, 381], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 163, 183], ["nasopharyngeal swabs", "CANCER", 283, 303], ["SARS-CoV-2 sequenced genomes", "DNA", 99, 127], ["Metaproteomics analysis", "TEST", 128, 151], ["the two nasopharyngeal swabs", "TEST", 155, 183], ["abundant microorganisms", "PROBLEM", 209, 232], ["The MS/MS spectra", "TEST", 233, 250], ["the two nasopharyngeal swabs", "TEST", 275, 303], ["MS interpretation", "TEST", 467, 484], ["several", "OBSERVATION_MODIFIER", 91, 98], ["SARS", "OBSERVATION_MODIFIER", 99, 103], ["abundant", "OBSERVATION_MODIFIER", 209, 217], ["microorganisms", "OBSERVATION", 218, 232], ["main", "OBSERVATION_MODIFIER", 331, 335]]], ["Swabs R1 and R2 yielded 60,932 and 61,053 MS/MS spectra, respectively, from which 13,602 and 13,802 were attributed to 6,460 and 6,421 peptide sequences from organisms present in the NCBInr database (FDR <1%).", [["R1", "DNA", 6, 8], ["R2", "DNA", 13, 15], ["Swabs", "TEST", 0, 5], ["MS/MS spectra", "TEST", 42, 55], ["6,421 peptide sequences", "PROBLEM", 129, 152], ["organisms", "PROBLEM", 158, 167], ["the NCBInr database", "TEST", 179, 198], ["FDR", "TEST", 200, 203]]], ["These peptide sequences were analyzed with the Unipept tool (26) to assess the biodiversity present in each sample through their taxon-specificity characteristics based on the lowest common ancestor approach.", [["sample", "ANATOMY", 108, 114], ["These peptide sequences", "TEST", 0, 23], ["the Unipept tool", "TEST", 43, 59], ["biodiversity", "OBSERVATION", 79, 91]]], ["Only a small proportion of the peptide sequences mapped by Unipept belonged to microorganisms (Table S2) .", [["Unipept", "PROTEIN", 59, 66], ["the peptide sequences", "TEST", 27, 48], ["small", "OBSERVATION_MODIFIER", 7, 12]]], ["A rather low number (38 and 69) of peptides from the R1 and R2 swabs, respectively, were attributed to Bacteria, Archaea or Fungi.", [["peptides", "TEST", 35, 43], ["the R1 and R2 swabs", "TEST", 49, 68], ["Bacteria", "PROBLEM", 103, 111], ["Archaea", "PROBLEM", 113, 120], ["Fungi", "PROBLEM", 124, 129], ["low number", "OBSERVATION_MODIFIER", 9, 19], ["Bacteria", "OBSERVATION", 103, 111], ["Fungi", "OBSERVATION", 124, 129]]], ["These corresponded to 0.6 % and 0.9% of the mapped peptide sequences, respectively.", [["the mapped peptide sequences", "TEST", 40, 68]]], ["To exclude false positive identifications, we applied a threshold of at least threetaxon specific peptides for organism validation at the species level, corresponding to 0.5% of the total number of species-specific peptides (405 and 454 in each sample), as suggested by (29) .", [["false positive identifications", "PROBLEM", 11, 41], ["threetaxon specific peptides", "TREATMENT", 78, 106], ["organism validation", "PROBLEM", 111, 130], ["positive identifications", "OBSERVATION", 17, 41]]], ["Thus, one low-abundant Corynebacterium was identified in sample R1, namely Corynebacterium accolens, with 6 specific peptides.", [["sample", "ANATOMY", 57, 63], ["Corynebacterium accolens", "ORGANISM", 75, 99], ["Corynebacterium accolens", "SPECIES", 75, 99], ["Corynebacterium accolens", "SPECIES", 75, 99], ["one low-abundant Corynebacterium", "PROBLEM", 6, 38], ["abundant", "OBSERVATION_MODIFIER", 14, 22], ["Corynebacterium", "OBSERVATION", 23, 38]]], ["In swab R2, Corynebacterium propinguum, Corynebacterium pseudodiphtheriticum, and Dolosigranulum pigrum could be identified at the species taxonomical rank with 4, 5 and 15 specific peptide sequences, respectively.Detection of SARS-CoV-2 viral peptides in the simili swabs.Simili swabs containing specific quantities of SARS-CoV-2 virus and the equivalent of 8.4% of the nasal matrix protein material collected during sampling were analysed by MS/MS with a short gradient.", [["swabs", "ANATOMY", 267, 272], ["nasal matrix", "ANATOMY", 371, 383], ["SARS", "DISEASE", 320, 324], ["Corynebacterium propinguum", "ORGANISM", 12, 38], ["Corynebacterium pseudodiphtheriticum", "ORGANISM", 40, 76], ["Dolosigranulum pigrum", "ORGANISM", 82, 103], ["SARS-CoV-2", "ORGANISM", 227, 237], ["SARS-CoV-2 virus", "ORGANISM", 320, 336], ["4, 5 and 15 specific peptide sequences", "DNA", 161, 199], ["Corynebacterium propinguum", "SPECIES", 12, 38], ["Corynebacterium pseudodiphtheriticum", "SPECIES", 40, 76], ["Dolosigranulum pigrum", "SPECIES", 82, 103], ["CoV-2 virus", "SPECIES", 325, 336], ["Corynebacterium propinguum", "SPECIES", 12, 38], ["Corynebacterium pseudodiphtheriticum", "SPECIES", 40, 76], ["Dolosigranulum pigrum", "SPECIES", 82, 103], ["SARS-CoV", "SPECIES", 227, 235], ["SARS-CoV-2 virus", "SPECIES", 320, 336], ["swab R2", "TEST", 3, 10], ["Corynebacterium", "PROBLEM", 12, 27], ["Corynebacterium pseudodiphtheriticum", "PROBLEM", 40, 76], ["Dolosigranulum pigrum", "PROBLEM", 82, 103], ["specific peptide sequences", "TEST", 173, 199], ["SARS", "TEST", 227, 231], ["CoV", "TEST", 232, 235], ["viral peptides", "TREATMENT", 238, 252], ["Simili swabs", "TEST", 273, 285], ["SARS", "PROBLEM", 320, 324], ["CoV", "TEST", 325, 328], ["2 virus", "PROBLEM", 329, 336], ["the nasal matrix protein material", "TREATMENT", 367, 400], ["a short gradient", "PROBLEM", 455, 471], ["Corynebacterium pseudodiphtheriticum", "OBSERVATION", 40, 76], ["Dolosigranulum pigrum", "ANATOMY", 82, 103], ["nasal", "ANATOMY", 371, 376]]], ["We first confirmed on the most diluted fraction that the bacterial signal was negligible for both fractions, thus not to consider at the MS/MS attribution search stage.", [["the bacterial signal", "TEST", 53, 73]]], ["For this, the two datasets were searched against the generalist database NCBInr to check for the presence of non-human peptides in the swab peptidomes.", [["swab peptidomes", "ANATOMY", 135, 150], ["non-human peptides", "PROBLEM", 109, 127]]], ["The Unipept analysis of the detected peptide sequences showed that only 3 and 2 peptides, from replicate 1 and 2, respectively, were attributed to Bacteria and no bacterial species could be confidently identified ( Table S2) .Detection of SARS-CoV-2 viral peptides in the simili swabs.The results from the short gradient MS analysis on the simili swabs against the specific human/virus database yielded 139,404 MS/MS spectra recorded in the fourteen samples.", [["swabs", "ANATOMY", 279, 284], ["samples", "ANATOMY", 450, 457], ["SARS-CoV-2", "ORGANISM", 239, 249], ["human", "ORGANISM", 374, 379], ["human", "SPECIES", 374, 379], ["SARS-CoV", "SPECIES", 239, 247], ["human/virus", "SPECIES", 374, 385], ["The Unipept analysis", "TEST", 0, 20], ["the detected peptide sequences", "TEST", 24, 54], ["Bacteria", "PROBLEM", 147, 155], ["bacterial species", "PROBLEM", 163, 180], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247], ["viral peptides", "TREATMENT", 250, 264], ["the short gradient MS analysis", "TEST", 302, 332], ["the simili swabs", "TEST", 336, 352], ["the specific human/virus database", "TEST", 361, 394], ["MS", "TEST", 411, 413], ["MS spectra", "TEST", 414, 424], ["attributed to", "UNCERTAINTY", 133, 146], ["Bacteria", "OBSERVATION", 147, 155], ["no", "UNCERTAINTY", 160, 162], ["bacterial species", "OBSERVATION", 163, 180]]], ["This data allowed for the identification of 1,094 protein groups (Table S4) .", [["This data", "TEST", 0, 9], ["the identification", "TEST", 22, 40]]], ["A small fraction of 173 peptide-to-spectrum matches (PSMs), corresponding to 0.5% of the total PSMs, allowed identifying 18 different viral peptide sequences, including the five peptides of interest.", [["A small fraction", "TEST", 0, 16], ["the total PSMs", "TEST", 85, 99], ["18 different viral peptide sequences", "TREATMENT", 121, 157], ["small", "OBSERVATION_MODIFIER", 2, 7], ["fraction", "OBSERVATION_MODIFIER", 8, 16]]], ["The 18 peptides report for 3 structural proteins from the virus: 8 peptides from the nucleocapsid protein (N), 7 peptides from the spike protein (S), and 3 peptides from the membrane glycoprotein (M).Detection of SARS-CoV-2 viral peptides in the simili swabs.At least one viral peptide was identified in all samples independently of the concentration of the viral material, from 460 ng (544 PFU) to 2 ng (2 PFU).", [["membrane", "ANATOMY", 174, 182], ["swabs", "ANATOMY", 253, 258], ["samples", "ANATOMY", 308, 315], ["membrane", "CELLULAR_COMPONENT", 174, 182], ["SARS-CoV-2", "ORGANISM", 213, 223], ["structural proteins", "PROTEIN", 29, 48], ["nucleocapsid protein", "PROTEIN", 85, 105], ["N", "PROTEIN", 107, 108], ["spike protein", "PROTEIN", 131, 144], ["S", "PROTEIN", 146, 147], ["membrane glycoprotein", "PROTEIN", 174, 195], ["SARS-CoV", "SPECIES", 213, 221], ["3 structural proteins", "PROBLEM", 27, 48], ["the virus", "TEST", 54, 63], ["the nucleocapsid protein", "TEST", 81, 105], ["the spike protein", "TEST", 127, 144], ["SARS", "TEST", 213, 217], ["CoV", "TEST", 218, 221], ["viral peptides", "TREATMENT", 224, 238], ["one viral peptide", "PROBLEM", 268, 285], ["viral peptide", "OBSERVATION", 272, 285], ["viral material", "OBSERVATION", 358, 372]]], ["However, no peptide from the virus was identified in the sample containing viral peptides corresponding to 0.6 ng (1 PFU).", [["sample", "ANATOMY", 57, 63], ["peptide from the virus", "PROBLEM", 12, 34], ["viral peptides", "PROBLEM", 75, 89], ["no", "UNCERTAINTY", 9, 11], ["virus", "OBSERVATION", 29, 34], ["viral peptides", "OBSERVATION", 75, 89]]], ["The heatmap in Figure 2 displays the MS1 peak areas, the number of PSMs attributed to each peptide in each sample, and the number of viral peptides identified in each sample.", [["sample", "ANATOMY", 107, 113], ["The heatmap", "TEST", 0, 11], ["the MS1 peak areas", "PROBLEM", 33, 51], ["each peptide in each sample", "PROBLEM", 86, 113], ["viral peptides", "PROBLEM", 133, 147], ["peak", "OBSERVATION_MODIFIER", 41, 45], ["viral peptides", "OBSERVATION", 133, 147]]], ["The five peptides with the highest MS1 peak areas across samples were the following: EITVATSR, GFYAEGSR, LNQLESK, ADETQALPQR, and KADETQALPQR.", [["KADETQALPQR", "TREATMENT", 130, 141]]], ["Among them, EITVATSR, GFYAEGSR, and ADETQALPQR are between the five peptides of interest.", [["EITVATSR, GFYAEGSR, and ADETQALPQR", "DNA", 12, 46], ["ADETQALPQR", "TREATMENT", 36, 46]]], ["Peptide HTPINLVR was the seventh most abundant.", [["HTPINLVR", "GENE_OR_GENE_PRODUCT", 8, 16]]], ["Inversely, peptide IAGHHLGR was amongst the peptides with the lowest MS1 peak areas, along with peptides MSECVLGQSK, LDDKDPNFK, and EIDRLNEVAK.Detection of SARS-CoV-2 viral peptides in the simili swabs.As expected, the number of identified peptides decreased with the decreasing viral load in the sample.", [["swabs", "ANATOMY", 196, 201], ["sample", "ANATOMY", 297, 303], ["SARS-CoV-2", "ORGANISM", 156, 166], ["SARS-CoV", "SPECIES", 156, 164], ["LDDKDPNFK", "TEST", 117, 126], ["SARS", "TEST", 156, 160], ["CoV", "TEST", 161, 164], ["viral peptides", "TREATMENT", 167, 181], ["identified peptides", "PROBLEM", 229, 248], ["the decreasing viral load in the sample", "PROBLEM", 264, 303], ["peak", "OBSERVATION_MODIFIER", 73, 77], ["peptides MSECVLGQSK", "OBSERVATION", 96, 115], ["peptides", "OBSERVATION", 240, 248], ["decreased", "OBSERVATION_MODIFIER", 249, 258], ["decreasing", "OBSERVATION_MODIFIER", 268, 278], ["viral load", "OBSERVATION", 279, 289]]], ["While all 18 peptides were identified in the initial dilution containing 460 ng of viral proteins (544 PFU), in highly-diluted samples containing 6 ng of viral proteins (7 PFU) and 2 ng (2 PFU), the virus was proteotyped with only 3 and 1 peptides, respectively.", [["samples", "ANATOMY", 127, 134], ["viral proteins", "PROTEIN", 83, 97], ["viral proteins", "PROTEIN", 154, 168], ["viral proteins", "TEST", 83, 97], ["PFU", "TEST", 103, 106], ["viral proteins", "TEST", 154, 168], ["the virus", "TEST", 195, 204]]], ["In these samples only peptides from protein N were detected (ADETQALPQR, KADETQALPQR, and GFYAEGSR).", [["samples", "ANATOMY", 9, 16], ["protein N", "PROTEIN", 36, 45], ["ADETQALPQR", "PROTEIN", 61, 71], ["KADETQALPQR", "PROTEIN", 73, 84], ["GFYAEGSR", "PROTEIN", 90, 98], ["protein N", "TEST", 36, 45]]], ["Generally, the peptides from protein N were the most consistently detected across samples.", [["samples", "ANATOMY", 82, 89], ["protein N", "GENE_OR_GENE_PRODUCT", 29, 38], ["protein N", "PROTEIN", 29, 38], ["the peptides from protein N", "TEST", 11, 38]]], ["Despite being among the peptides with higher peak areas in the chromatograms, peptides of interest HTPINLVR and EITVATSR were only detected in the simili swabs containing an estimated 460 ng of viral proteins (544 PFU).", [["HTPINLVR", "GENE_OR_GENE_PRODUCT", 99, 107], ["EITVATSR", "GENE_OR_GENE_PRODUCT", 112, 120], ["EITVATSR", "PROTEIN", 112, 120], ["viral proteins", "PROTEIN", 194, 208], ["higher peak areas in the chromatograms", "PROBLEM", 38, 76], ["interest HTPINLVR", "TEST", 90, 107], ["EITVATSR", "TEST", 112, 120], ["the simili swabs", "TEST", 143, 159], ["viral proteins", "TEST", 194, 208], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["peak", "OBSERVATION_MODIFIER", 45, 49]]], ["On the other hand, the two other peptides of interest from protein N, GFYAEGSR and ADETQALPQR, allowed virus proteotyping in the sample containing 6 ng of viral proteins (7 PFU).", [["sample", "ANATOMY", 129, 135], ["protein N", "PROTEIN", 59, 68], ["GFYAEGSR", "PROTEIN", 70, 78], ["ADETQALPQR", "PROTEIN", 83, 93], ["viral proteins", "PROTEIN", 155, 169], ["protein N", "TEST", 59, 68], ["GFYAEGSR", "TEST", 70, 78], ["ADETQALPQR", "TREATMENT", 83, 93], ["the sample", "TEST", 125, 135], ["viral proteins", "PROBLEM", 155, 169]]], ["Of note, the peptide identified in the condition with 2 ng of viral proteins (2 PFU) is a miss-cleaved version of the ADETQALPQR peptide: KADETQALPQR.", [["viral proteins", "PROTEIN", 62, 76], ["the peptide", "TEST", 9, 20], ["viral proteins", "PROBLEM", 62, 76]]], ["Peptide ASANLAATK, that had not been previously selected among the \"best\" candidates for SARS-CoV-2 proteotyping (23), was detected in the dilution with 17 ng of viral proteins (20 PFU) and was the most sensitive peptide from protein S. With the LC gradient used in this experiment and the delay for starting the acquisition, the retention times of peptides are minus 4-6 minutes compared to those described in our previous paper.", [["viral proteins", "PROTEIN", 162, 176], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["the dilution", "TEST", 135, 147], ["viral proteins", "TREATMENT", 162, 176], ["the LC gradient", "TREATMENT", 242, 257], ["the acquisition", "TEST", 309, 324]]], ["Peptides are generally well distributed along the gradient, with some exceptions of peptide pairs that co-elute:Detection of SARS-CoV-2 viral peptides in the simili swabs.KADETQALPQR/RVDFCGK, QLQQSMSSADSTQA/CYGVSPTK, ADETQALPQR/GFYAQGSR, or HTPINLVR/EIDRLNEVAK.", [["swabs", "ANATOMY", 165, 170], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 125, 135], ["HTPINLVR", "PROTEIN", 241, 249], ["EIDRLNEVAK", "PROTEIN", 250, 260], ["peptide pairs", "PROBLEM", 84, 97], ["SARS", "TEST", 125, 129], ["CoV", "TEST", 130, 133], ["viral peptides", "TREATMENT", 136, 150], ["the simili swabs", "TEST", 154, 170], ["gradient", "OBSERVATION_MODIFIER", 50, 58]]], ["Six peptides elute in the first ten minutes of the gradient: IAGHHLGR, KKADETQALPQR, ASANLAATK, LNQLESK, KADETQALPQR, and RVDFCGK.", [["RVDFCGK", "TREATMENT", 122, 129], ["elute", "OBSERVATION_MODIFIER", 13, 18]]], ["Of the utmost interest, three of the most conserved and well-detected peptides, EITVATSR, ADETQALPQR, and GFYAQGSR, elute in a 3-min window between 13 and 16 min of the gradient.Detection of SARS-CoV-2 in clinical nasopharyngeal swab samples from COVID-19 diagnosed patients.Nasopharyngeal swabs were sampled from nine COVID-19 diagnosed patients with different clinical manifestations (moderate symptoms and asymptomatic) and at different postdiagnostic stages ( Table 1) .", [["nasopharyngeal swab samples", "ANATOMY", 214, 241], ["Nasopharyngeal swabs", "ANATOMY", 275, 295], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 191, 201], ["nasopharyngeal swab samples", "CANCER", 214, 241], ["patients", "ORGANISM", 266, 274], ["Nasopharyngeal swabs", "CANCER", 275, 295], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 266, 274], ["patients", "SPECIES", 338, 346], ["SARS-CoV", "SPECIES", 191, 199], ["the gradient", "TEST", 165, 177], ["SARS", "PROBLEM", 191, 195], ["CoV", "TEST", 196, 199], ["clinical nasopharyngeal swab samples", "TEST", 205, 241], ["COVID", "TEST", 247, 252], ["Nasopharyngeal swabs", "TEST", 275, 295], ["different clinical manifestations", "PROBLEM", 352, 385], ["moderate symptoms", "PROBLEM", 387, 404], ["asymptomatic", "PROBLEM", 409, 421], ["nasopharyngeal", "ANATOMY", 214, 228], ["moderate", "OBSERVATION_MODIFIER", 387, 395]]], ["Due to the complexity of the samples, an inclusion list of m/z signals corresponding to the five peptides of interest as well as other SARS-CoV-2 peptides detectable in this gradient region (17) was added to the acquisition method to increase the likelihood of their detection.", [["samples", "ANATOMY", 29, 36], ["m/z signals", "TEST", 59, 70], ["other SARS", "TEST", 129, 139], ["CoV", "TEST", 140, 143]]], ["Table S1 reports this inclusion list which contained m/z values for 28 different precursors from 23 different viral peptide sequences.", [["m/z values", "TEST", 53, 63], ["different viral peptide sequences", "TEST", 100, 133]]], ["The short gradient MS analysis on these clinical samples yielded between 655 and 1,151 MS/MS spectra recorded per sample.", [["The short gradient MS analysis", "TEST", 0, 30], ["these clinical samples", "TEST", 34, 56], ["MS", "TEST", 87, 89], ["MS spectra", "TEST", 90, 100]]], ["Sixty-five spectra were attributed to viral peptide sequences with a FDR below 1% (Table S5) .", [["viral peptide sequences", "TEST", 38, 61]]], ["This data allowed for the detection of six peptides reporting for two viral proteins (Table S6) : LDDKDPNFK, KADETQAIPQR, KKADETQAIPQR, ADETQAIPQR, GFYAEGSR from protein N, and EITVATSR from protein M. The heatmap in Figure 4 displays the MS1 peak areas, the number of PSMs attributed to each peptide in each sample, the number of viral peptides identified in each sample, and the result from the PCR testing performed on the same sample.", [["sample", "ANATOMY", 309, 315], ["sample", "ANATOMY", 365, 371], ["LDDKDPNFK", "GENE_OR_GENE_PRODUCT", 98, 107], ["viral proteins", "PROTEIN", 70, 84], ["S6", "PROTEIN", 92, 94], ["LDDKDPNFK", "PROTEIN", 98, 107], ["KADETQAIPQR", "PROTEIN", 109, 120], ["KKADETQAIPQR", "PROTEIN", 122, 134], ["ADETQAIPQR", "PROTEIN", 136, 146], ["GFYAEGSR", "PROTEIN", 148, 156], ["protein N", "PROTEIN", 162, 171], ["EITVATSR", "PROTEIN", 177, 185], ["the detection", "TEST", 22, 35], ["six peptides", "TEST", 39, 51], ["two viral proteins", "PROBLEM", 66, 84], ["ADETQAIPQR", "TREATMENT", 136, 146], ["protein N", "TEST", 162, 171], ["The heatmap", "TEST", 202, 213], ["the MS1 peak areas", "PROBLEM", 235, 253], ["viral peptides", "PROBLEM", 331, 345], ["the PCR testing", "TEST", 393, 408], ["peak", "OBSERVATION_MODIFIER", 243, 247], ["viral peptides", "OBSERVATION", 331, 345]]], ["The virus was confidently proteotyped in clinical swabs T7 and T8, with four and five peptides respectively.", [["swabs", "ANATOMY", 50, 55], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["T8", "ANATOMY", 63, 65]]], ["Peptide EITVATSR was identified in swab T4 with two spectral counts, but virus detection in this sample cannot be validated since this peptide is not specific to SARS-CoV-2 (23).", [["sample", "ANATOMY", 97, 103], ["SARS-CoV-2", "ORGANISM", 162, 172], ["SARS-CoV", "SPECIES", 162, 170], ["Peptide EITVATSR", "TEST", 0, 16], ["swab T4", "TEST", 35, 42], ["two spectral counts", "TEST", 48, 67], ["virus detection", "TEST", 73, 88], ["SARS", "TEST", 162, 166], ["CoV", "TEST", 167, 170]]], ["As shown in Table 1 , swabs T7 and T8 correspond to patients that were diagnosed as SARS-CoV-2 positive by RT-PCR with relatively clear viral loads (CT values of 28 and 25, respectively) and were sampled 11 and 4 days after their diagnostic and confinement.", [["swabs", "ANATOMY", 22, 27], ["SARS", "DISEASE", 84, 88], ["patients", "ORGANISM", 52, 60], ["CoV-2", "ORGANISM", 89, 94], ["patients", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 84, 92], ["swabs T7 and T8", "PROBLEM", 22, 37], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["RT-PCR", "TEST", 107, 113], ["CT values", "TEST", 149, 158], ["T7", "ANATOMY", 28, 30], ["T8", "ANATOMY", 35, 37]]], ["MS/MS samples were negative for swabs that yielded a relatively low PCR signal (CT of 35 and 36 for swabs T9 and T5), with undetectable PCR signal (swabs T2, T3, T4, and T6) or 14 days after their diagnostic (swab T1).", [["samples", "ANATOMY", 6, 13], ["swabs", "ANATOMY", 32, 37], ["MS/MS samples", "TEST", 0, 13], ["swabs", "TEST", 32, 37], ["a relatively low PCR signal", "PROBLEM", 51, 78], ["CT", "TEST", 80, 82], ["swabs", "TEST", 100, 105], ["undetectable PCR signal", "PROBLEM", 123, 146], ["swabs T2", "TEST", 148, 156], ["T3", "TEST", 158, 160], ["T5", "ANATOMY", 113, 115], ["T6", "ANATOMY", 170, 172]]], ["The negative MS/MS signals for swabs T9, T5, and T1 patients are explained by the very low viral load probably present in these samples.DISCUSSIONTo foster the development of alternative detection methods for SARS-CoV-2, we performed a proof-of-concept study to assess the potential of MS/MS for proteotyping SARS-CoV-2: i) in simulated nasal swabs containing different quantities of viral peptides; and ii) in nasopharyngeal swabs from COVID-19 diagnosed patients.", [["swabs", "ANATOMY", 31, 36], ["samples", "ANATOMY", 128, 135], ["nasal swabs", "ANATOMY", 337, 348], ["nasopharyngeal swabs", "ANATOMY", 411, 431], ["SARS", "DISEASE", 209, 213], ["SARS", "DISEASE", 309, 313], ["patients", "ORGANISM", 52, 60], ["samples", "CANCER", 128, 135], ["nasopharyngeal swabs", "CANCER", 411, 431], ["patients", "ORGANISM", 456, 464], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 456, 464], ["SARS-CoV", "SPECIES", 209, 217], ["The negative MS/MS signals", "TEST", 0, 26], ["swabs", "TEST", 31, 36], ["the very low viral load", "PROBLEM", 78, 101], ["SARS", "PROBLEM", 209, 213], ["concept study", "TEST", 245, 258], ["MS", "PROBLEM", 286, 288], ["MS", "PROBLEM", 289, 291], ["proteotyping SARS", "PROBLEM", 296, 313], ["simulated nasal swabs", "PROBLEM", 327, 348], ["viral peptides", "PROBLEM", 384, 398], ["nasopharyngeal swabs", "TEST", 411, 431], ["T5", "ANATOMY", 41, 43], ["viral load", "OBSERVATION", 91, 101], ["nasal", "ANATOMY", 337, 342], ["nasopharyngeal", "ANATOMY", 411, 425]]], ["The two nasal peptidomes collected from healthy donors for the first experiment were first analyzed with a gradient of 90 min to check for the presence of detectable microorganisms from the natural microbiota.", [["nasal peptidomes", "ANATOMY", 8, 24], ["donors", "ORGANISM", 48, 54], ["The two nasal peptidomes", "TREATMENT", 0, 24], ["a gradient", "TEST", 105, 115], ["detectable microorganisms", "PROBLEM", 155, 180], ["nasal peptidomes", "ANATOMY", 8, 24], ["microorganisms", "OBSERVATION", 166, 180], ["natural microbiota", "OBSERVATION", 190, 208]]], ["A search against a generalist database such as NCBInr detected only trace levels of very low abundant bacteria commonly found in the nasal tract (30) , thus confirming the absence of a measurable microbiome in the swab samples.", [["nasal tract", "ANATOMY", 133, 144], ["swab samples", "ANATOMY", 214, 226], ["nasal tract", "ORGANISM_SUBDIVISION", 133, 144], ["swab samples", "ORGANISM_SUBSTANCE", 214, 226], ["NCBInr", "PROTEIN", 47, 53], ["a generalist database", "TEST", 17, 38], ["NCBInr", "TEST", 47, 53], ["trace levels", "PROBLEM", 68, 80], ["very low abundant bacteria", "PROBLEM", 84, 110], ["the swab samples", "TEST", 210, 226], ["bacteria", "OBSERVATION", 102, 110], ["nasal tract", "ANATOMY", 133, 144]]], ["Based on this metaproteomic analysis, we used a human-only database as representative of the nasopharyngeal matrices for the subsequent analysis.DISCUSSIONThe simili SARS-CoV-2 contaminated swabs contained a fixed amount of swab peptidome, plus a precise amount of viral peptidome corresponding to the expected quantities extracted from 460 ng (544 PFU), 153 ng (181 PFU), 51 ng (60 PFU), 17 ng (20 PFU), 6 ng (7 PFU), 2 ng (2 PFU), and 0.6 ng (1 PFU) of SARS-CoV-2.", [["nasopharyngeal matrices", "ANATOMY", 93, 116], ["swabs", "ANATOMY", 190, 195], ["human", "ORGANISM", 48, 53], ["nasopharyngeal matrices", "MULTI-TISSUE_STRUCTURE", 93, 116], ["swabs", "ORGANISM", 190, 195], ["viral peptidome", "PROTEIN", 265, 280], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["SARS-CoV", "SPECIES", 455, 463], ["this metaproteomic analysis", "TEST", 9, 36], ["the nasopharyngeal matrices", "TREATMENT", 89, 116], ["the subsequent analysis", "TEST", 121, 144], ["simili SARS", "PROBLEM", 159, 170], ["CoV", "TEST", 171, 174], ["contaminated swabs", "TEST", 177, 195], ["swab peptidome", "TEST", 224, 238], ["viral peptidome", "PROBLEM", 265, 280], ["PFU", "TEST", 367, 370], ["ng", "TEST", 376, 378], ["PFU", "TEST", 383, 386], ["ng", "TEST", 392, 394], ["PFU", "TEST", 399, 402], ["ng", "TEST", 407, 409], ["SARS", "TEST", 455, 459], ["CoV", "TEST", 460, 463], ["nasopharyngeal", "ANATOMY", 93, 107], ["viral peptidome", "OBSERVATION", 265, 280]]], ["It is important to note that the virus produced in Vero E6 cells and purified on sucrose gradient is only partially infectious, and thus the data are also presented in quantities of viral proteins.", [["Vero E6 cells", "ANATOMY", 51, 64], ["sucrose", "CHEMICAL", 81, 88], ["sucrose", "CHEMICAL", 81, 88], ["Vero E6 cells", "CELL", 51, 64], ["sucrose", "SIMPLE_CHEMICAL", 81, 88], ["Vero E6 cells", "CELL_LINE", 51, 64], ["viral proteins", "PROTEIN", 182, 196], ["Vero E6", "SPECIES", 51, 58], ["the virus", "PROBLEM", 29, 38], ["Vero E6 cells", "TREATMENT", 51, 64], ["sucrose gradient", "TREATMENT", 81, 97], ["partially infectious", "PROBLEM", 106, 126], ["viral proteins", "PROBLEM", 182, 196], ["E6 cells", "OBSERVATION", 56, 64], ["sucrose gradient", "OBSERVATION_MODIFIER", 81, 97], ["partially", "OBSERVATION_MODIFIER", 106, 115], ["infectious", "OBSERVATION", 116, 126], ["viral proteins", "OBSERVATION", 182, 196]]], ["The real number of viral particles could be much higher in these samples and could be roughly estimated as the molecular weights of each viral protein are known and if the numbers of molecules per virus particle were documented for SARS-CoV-2.", [["samples", "ANATOMY", 65, 72], ["samples", "CANCER", 65, 72], ["CoV-2", "ORGANISM", 237, 242], ["viral protein", "PROTEIN", 137, 150], ["SARS-CoV", "SPECIES", 232, 240], ["viral particles", "PROBLEM", 19, 34], ["each viral protein", "PROBLEM", 132, 150], ["SARS", "PROBLEM", 232, 236], ["CoV", "TEST", 237, 240], ["viral particles", "OBSERVATION", 19, 34]]], ["Here, we refer to the infectious dose as this is the most important parameter in terms of health concern, but the ratio of infectious particles in the nasopharyngeal swabs of patients may drastically differ from the purified virus fraction used here, and could even fluctuate during the course of the pathology.", [["nasopharyngeal swabs", "ANATOMY", 151, 171], ["nasopharyngeal swabs", "ORGAN", 151, 171], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["infectious particles", "PROBLEM", 123, 143], ["the nasopharyngeal swabs", "TEST", 147, 171], ["the purified virus fraction", "PROBLEM", 212, 239], ["the pathology", "TEST", 297, 310], ["infectious", "OBSERVATION", 123, 133], ["nasopharyngeal", "ANATOMY", 151, 165]]], ["The strategy proposed for the analysis of these simili swabs consisted in a shotgun MS analysis based on a short acquisition of 20 min with a short LC gradient.", [["the analysis", "TEST", 26, 38], ["these simili swabs", "TEST", 42, 60], ["a shotgun MS analysis", "TEST", 74, 95], ["a short LC gradient", "PROBLEM", 140, 159]]], ["For the clinical samples, we added an inclusion list of viral peptides in the MS method.", [["samples", "ANATOMY", 17, 24], ["viral peptides", "TREATMENT", 56, 70], ["viral peptides", "OBSERVATION", 56, 70]]], ["The inclusion list allowed forcing the fragmentation of candidate viral peptide ions contained in the background matrix, even when they were not included in the top 20 from the data dependent acquisition method.DISCUSSIONThe shotgun strategy resulted in the detection of viral peptides in six out of the seven conditions tested for the simili swab experiment.", [["matrix", "CELLULAR_COMPONENT", 113, 119], ["viral peptide ions", "PROBLEM", 66, 84], ["The shotgun strategy", "TREATMENT", 221, 241], ["viral peptides", "PROBLEM", 271, 285], ["the simili swab experiment", "TEST", 332, 358], ["viral peptides", "OBSERVATION", 271, 285]]], ["From the five peptides of interest, GFYAQGSR and ADETQALPQR proved to be the most detectable and most sensitive in this background matrix, allowing proteotyping the virus up to the condition of 6 ng of viral material (7 PFU).", [["GFYAQGSR", "GENE_OR_GENE_PRODUCT", 36, 44], ["ADETQALPQR", "GENE_OR_GENE_PRODUCT", 49, 59], ["GFYAQGSR", "PROTEIN", 36, 44], ["ADETQALPQR", "PROTEIN", 49, 59], ["GFYAQGSR", "TEST", 36, 44], ["ADETQALPQR", "TREATMENT", 49, 59], ["the virus", "PROBLEM", 161, 170], ["viral material", "TREATMENT", 202, 216]]], ["One of the most interesting result was the omnipresence of peptide ADETQALPQR and its two miss-cleaved versions KADETQALPQR and KKADETQALPQR.", [["KKADETQALPQR", "PROTEIN", 128, 140], ["peptide ADETQALPQR", "TREATMENT", 59, 77], ["KKADETQALPQR", "TREATMENT", 128, 140]]], ["These peptides were consistently detected in 30 out of 36 identifications in the six most abundant conditions from the simili swab experiment.", [["These peptides", "TEST", 0, 14], ["the simili swab experiment", "TREATMENT", 115, 141]]], ["Peptide KADETQALPQR was identified in all simili swabs from Figure 2 .", [["Peptide KADETQALPQR", "TREATMENT", 0, 19]]], ["These results clearly show that ADETQALPQR, despite being prone to missedcleavages, is one the most abundant and ionisable peptides and should be the main target for proteotyping SARS-CoV-2.", [["ADETQALPQR", "CHEMICAL", 32, 42], ["SARS", "DISEASE", 179, 183], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 179, 189]]], ["This result was confirmed from the analysis of the clinical swab samples, since peptides ADETQALPQR, KADETQALPQR, and KKADETQALPQR were undoubtedly the most abundant in samples from COVID-19 patients (Figure 4 and Table 1 ).", [["swab samples", "ANATOMY", 60, 72], ["samples", "ANATOMY", 169, 176], ["KKADETQALPQR", "GENE_OR_GENE_PRODUCT", 118, 130], ["samples", "CANCER", 169, 176], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["the analysis", "TEST", 31, 43], ["the clinical swab samples", "TEST", 47, 72], ["peptides ADETQALPQR", "TREATMENT", 80, 99], ["KADETQALPQR", "TREATMENT", 101, 112], ["KKADETQALPQR", "TREATMENT", 118, 130], ["COVID", "TEST", 182, 187]]], ["In our previous work, we showed that this peptide sequence is also specific to SARS-CoV-2, but presented several variants among the available SARS-CoV-2 genomes (23) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["SARS-CoV-2", "ORGANISM", 142, 152], ["SARS-CoV-2 genomes", "DNA", 142, 160], ["SARS-CoV", "SPECIES", 79, 87], ["this peptide sequence", "TEST", 37, 58], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["several variants", "PROBLEM", 105, 121], ["CoV", "TEST", 147, 150]]], ["Therefore, when targeting this peptide for viral detection with MS/MS we can also take into account both its missed-cleaved versions, and its different variants.DISCUSSIONSurprisingly, the high intensity peptide EITVATSR was only identified in simili swabs with high concentration of viral proteic material (Figure 2) .", [["swabs", "ANATOMY", 251, 256], ["viral detection", "TEST", 43, 58], ["MS/MS", "PROBLEM", 64, 69], ["the high intensity peptide EITVATSR", "PROBLEM", 185, 220], ["simili swabs", "TEST", 244, 256], ["viral proteic material", "PROBLEM", 284, 306], ["viral proteic material", "OBSERVATION", 284, 306]]], ["By analyzing the MS and MS/MS spectra from these samples, we confirmed that this peptide co-eluted with another intense precursor from the background matrix that was fragmented simultaneously.", [["matrix", "CELLULAR_COMPONENT", 150, 156], ["MS/MS spectra", "PROBLEM", 24, 37], ["these samples", "TEST", 43, 56], ["this peptide", "PROBLEM", 76, 88], ["background matrix", "OBSERVATION", 139, 156], ["fragmented", "OBSERVATION", 166, 176]]], ["The low MASCOT ion score attributed to these spectra hindered the confident identification of this peptide.", [["The low MASCOT ion score", "PROBLEM", 0, 24], ["this peptide", "TREATMENT", 94, 106], ["low MASCOT", "OBSERVATION", 4, 14]]], ["This coelution effect is most likely due to the use of the short chromatographic gradient, and one way to tackle it would be to use smaller isolation windows for fragmentation.", [["the short chromatographic gradient", "PROBLEM", 55, 89], ["smaller isolation windows", "TREATMENT", 132, 157], ["fragmentation", "PROBLEM", 162, 175], ["most likely due to", "UNCERTAINTY", 25, 43]]], ["This parameter was tested for the analysis of clinical swabs, but little or no improvement was observed.", [["the analysis", "TEST", 30, 42], ["clinical swabs", "TEST", 46, 60]]], ["No MS/MS spectra were validated at FDR 1% for this peptide in swabs T7 and T8, even with the presence of a MS1 peak corresponding to this peptide in swab T8.", [["swabs", "ANATOMY", 62, 67], ["MS", "PROBLEM", 3, 5], ["MS spectra", "PROBLEM", 6, 16], ["FDR", "TEST", 35, 38], ["this peptide in swabs T7 and T8", "PROBLEM", 46, 77], ["a MS1 peak", "PROBLEM", 105, 115], ["this peptide in swab T8", "PROBLEM", 133, 156], ["MS", "OBSERVATION", 3, 5], ["T7", "ANATOMY", 68, 70], ["T8", "ANATOMY", 75, 77], ["T8", "ANATOMY", 154, 156]]], ["This peptide is therefore problematic in this type of matrix and probably not suited for tracking SARS-CoV-2 in nasal swab samples with our specific experimental setup.DISCUSSIONThe distribution of the peptides along with the chromatogram from Figure 3 shows that the two most detectable peptides GFYAQGSR and ADETQALPQR eluted in a narrow window of retention time between 15 -16 min in simili swab samples.", [["matrix", "ANATOMY", 54, 60], ["nasal swab samples", "ANATOMY", 112, 130], ["swab samples", "ANATOMY", 394, 406], ["matrix", "CELLULAR_COMPONENT", 54, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["nasal swab samples", "CANCER", 112, 130], ["ADETQALPQR", "SIMPLE_CHEMICAL", 310, 320], ["tracking SARS", "PROBLEM", 89, 102], ["CoV", "TEST", 103, 106], ["nasal swab samples", "TEST", 112, 130], ["the peptides", "PROBLEM", 198, 210], ["the chromatogram", "TEST", 222, 238], ["ADETQALPQR", "TREATMENT", 310, 320], ["a narrow window of retention time", "TREATMENT", 331, 364], ["simili swab samples", "TEST", 387, 406], ["probably not suited", "UNCERTAINTY", 65, 84], ["nasal", "ANATOMY", 112, 117], ["distribution", "OBSERVATION_MODIFIER", 182, 194], ["narrow window", "OBSERVATION_MODIFIER", 333, 346], ["retention", "OBSERVATION_MODIFIER", 350, 359]]], ["For the clinical swab samples, we observed that the retention time for these two peptides was 15.42\u00b11.09 min for peptide ADETQALPQR, and 15.93\u00b11.06 minutes for peptide GFYAQGSR as established with Skyline (Table S7 ).", [["swab samples", "ANATOMY", 17, 29], ["Skyline", "PROTEIN", 197, 204], ["the clinical swab samples", "TEST", 4, 29], ["these two peptides", "TEST", 71, 89], ["peptide GFYAQGSR", "TEST", 160, 176]]], ["In the light of these new results, we argue that targeting peptides ADETQALPQR and GFYAQGSR with an extra short LC gradient of 3 min coupled to the enrichment of these hydrophilic peptides prior the LC injection could be one way to develop quick and robust assays for detection of the virus in clinical samples and gain in signal/noise ratio.", [["samples", "ANATOMY", 303, 310], ["GFYAQGSR", "CHEMICAL", 83, 91], ["GFYAQGSR", "SIMPLE_CHEMICAL", 83, 91], ["an extra short LC gradient", "PROBLEM", 97, 123], ["these hydrophilic peptides", "TREATMENT", 162, 188], ["the LC injection", "TREATMENT", 195, 211], ["the virus", "PROBLEM", 281, 290], ["clinical samples", "TEST", 294, 310], ["signal/noise ratio", "TEST", 323, 341]]], ["Besides their high intensity, these peptides provide the needed specificity for a confident assay: peptide GFYAEGSR is highly conserved among different SARS-CoV-2 genomes, and peptide ADETQALPQR is specific to SARS-CoV-2.", [["GFYAEGSR", "GENE_OR_GENE_PRODUCT", 107, 115], ["SARS-CoV-2", "ORGANISM", 210, 220], ["SARS-CoV-2 genomes", "DNA", 152, 170], ["SARS-CoV", "SPECIES", 152, 160], ["SARS-CoV", "SPECIES", 210, 218], ["a confident assay", "TEST", 80, 97], ["peptide GFYAEGSR", "PROBLEM", 99, 115], ["different SARS", "PROBLEM", 142, 156], ["CoV", "TEST", 157, 160], ["CoV", "TEST", 215, 218], ["high intensity", "OBSERVATION_MODIFIER", 14, 28]]], ["The simultaneous detection of these two peptides could provide therefore unequivocal evidence for the presence of the virus.", [["these two peptides", "PROBLEM", 30, 48], ["the virus", "PROBLEM", 114, 123], ["virus", "OBSERVATION", 118, 123]]], ["Interestingly, a recent not yet published study showed the high potential of the same two peptides by using a targeted proteomics assay (19) .", [["published study", "TEST", 32, 47], ["a targeted proteomics assay", "TEST", 108, 135]]], ["The authors report limits of detection in the mid-attomole range corresponding to theoretically 10,000 SARS-CoV-2 particles in their specific experimental set-up.DISCUSSIONBesides shortening the LC gradient to less than three min, sample preparation can also be optimized to develop more rapid peptidome preparation assays and remove too hydrophilic and too hydrophobic peptides that could saturate the chromatography column.", [["rapid peptidome preparation assays", "TEST", 288, 322], ["too hydrophilic and too hydrophobic peptides", "PROBLEM", 334, 378], ["chromatography column", "OBSERVATION", 403, 424]]], ["Here, we performed a SDS-PAGE gel and in-gel proteolysis with trypsin to denature proteins and to remove any mass spectrometry-chromatography deleterious compounds that could be present in the nasal swab.", [["nasal swab", "ANATOMY", 193, 203], ["trypsin", "SIMPLE_CHEMICAL", 62, 69], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 193, 203], ["trypsin", "PROTEIN", 62, 69], ["denature proteins", "PROTEIN", 73, 90], ["a SDS-PAGE gel", "TREATMENT", 19, 33], ["trypsin to denature proteins", "TREATMENT", 62, 90], ["any mass spectrometry", "PROBLEM", 105, 126], ["chromatography deleterious compounds", "PROBLEM", 127, 163], ["the nasal swab", "TEST", 189, 203], ["nasal swab", "ANATOMY", 193, 203]]], ["This procedure is known to not be optimal as only 10% of the peptide material deposited on the gel is recovered.", [["This procedure", "TREATMENT", 0, 14], ["the peptide material", "TREATMENT", 57, 77], ["known to not be", "UNCERTAINTY", 18, 33]]], ["The literature is becoming rich in alternative sample preparation protocols for MS-based proteomics.", [["sample", "ANATOMY", 47, 53], ["alternative sample preparation protocols", "TREATMENT", 35, 75], ["MS", "TEST", 80, 82]]], ["For example, we recently proposed a proteotyping assay based on SP3 magnetic beads for protein purification and digestion in roughly 30 min (31) .", [["SP3", "GENE_OR_GENE_PRODUCT", 64, 67], ["SP3", "PROTEIN", 64, 67], ["a proteotyping assay", "TEST", 34, 54], ["SP3 magnetic beads", "TREATMENT", 64, 82], ["protein purification", "TREATMENT", 87, 107]]], ["Being easily adapted to 96-well plates and robotization, SP3based digestion is the method of choice for quick, high-throughput, and highly reproducible proteome digestions, as recently demonstrated (20, 32) .", [["robotization", "TREATMENT", 43, 55], ["SP3based digestion", "PROBLEM", 57, 75], ["highly reproducible proteome digestions", "PROBLEM", 132, 171], ["reproducible", "OBSERVATION_MODIFIER", 139, 151], ["proteome digestions", "OBSERVATION", 152, 171]]], ["Such sample preparation may further significantly increase the sensitivity of the tandem mass spectrometry proteotyping proposed in the present work.", [["sample", "ANATOMY", 5, 11], ["Such sample preparation", "TREATMENT", 0, 23], ["the tandem mass spectrometry proteotyping", "TREATMENT", 78, 119]]], ["Furthermore, more sensitive instrument and MS acquisition modes could be tested to gain further sensitivity.DISCUSSIONIn conclusion, we tested in this study the potential of LC-MS/MS based methods for proteotyping SARS-CoV-2 in nasopharyngeal swabs.", [["nasopharyngeal swabs", "ANATOMY", 228, 248], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 214, 224], ["nasopharyngeal swabs", "CANCER", 228, 248], ["SARS-CoV", "SPECIES", 214, 222], ["MS acquisition modes", "TEST", 43, 63], ["further sensitivity", "TEST", 88, 107], ["this study", "TEST", 146, 156], ["LC", "TEST", 174, 176], ["MS", "PROBLEM", 180, 182], ["proteotyping SARS", "PROBLEM", 201, 218], ["CoV", "TEST", 219, 222], ["nasopharyngeal swabs", "TREATMENT", 228, 248], ["nasopharyngeal swabs", "ANATOMY", 228, 248]]], ["With a 20 min MS-acquisition window, we were able to identify and quantify several virus-specific peptides that allowed proteotyping the virus in simulated swabs and clinical swabs from COVID-19 patients.", [["swabs", "ANATOMY", 156, 161], ["swabs", "ANATOMY", 175, 180], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["several virus-specific peptides", "PROBLEM", 75, 106], ["the virus", "PROBLEM", 133, 142], ["clinical swabs", "TEST", 166, 180], ["COVID", "TEST", 186, 191]]], ["We argue that peptides ADETQALPQR (and its variant forms) and GFYAQGSR from the nucleocapsid protein are of utmost interest to develop quick and robust targeted assays for proteotyping the virus in nasopharyngeal swab samples.", [["nasopharyngeal swab samples", "ANATOMY", 198, 225], ["ADETQALPQR", "GENE_OR_GENE_PRODUCT", 23, 33], ["GFYAQGSR", "GENE_OR_GENE_PRODUCT", 62, 70], ["nasopharyngeal swab samples", "CANCER", 198, 225], ["GFYAQGSR", "PROTEIN", 62, 70], ["nucleocapsid protein", "PROTEIN", 80, 100], ["GFYAQGSR", "PROBLEM", 62, 70], ["the nucleocapsid protein", "PROBLEM", 76, 100], ["the virus", "PROBLEM", 185, 194], ["nasopharyngeal swab samples", "TEST", 198, 225], ["nasopharyngeal", "ANATOMY", 198, 212]]], ["Further research must be done to validate their usefulness and their limits of detection in clinical samples, and develop the shortest possible pipeline.Author's contributionsJA conceived the study with help from DG, GM, LG, and OP.", [["samples", "ANATOMY", 101, 108], ["GM", "CHEMICAL", 217, 219], ["OP", "CHEMICAL", 229, 231], ["DG", "SIMPLE_CHEMICAL", 213, 215], ["clinical samples", "TEST", 92, 108], ["the study", "TEST", 188, 197], ["DG", "TEST", 213, 215], ["LG", "TEST", 221, 223], ["LG", "ANATOMY", 221, 223]]], ["GM and JCG performed the mass spectrometry experimental work.", [["GM", "CHEMICAL", 0, 2], ["JCG", "TEST", 7, 10]]], ["JPL and AS contributed the medical COVID-19 swab samples.", [["swab samples", "ANATOMY", 44, 56], ["JPL", "CHEMICAL", 0, 3], ["JPL", "PROBLEM", 0, 3], ["the medical COVID", "TEST", 23, 40], ["swab samples", "TEST", 44, 56]]], ["FG, SD, and LB contributed the SARS-CoV-2 biological material.", [["SARS", "DISEASE", 31, 35], ["FG", "TEST", 0, 2], ["the SARS", "PROBLEM", 27, 35], ["LB", "ANATOMY", 12, 14], ["SARS", "OBSERVATION", 31, 35]]], ["DG, LG, GM, OP and JA analysed the data.", [["GM", "CHEMICAL", 8, 10], ["OP", "CHEMICAL", 12, 14], ["JA", "CHEMICAL", 19, 21], ["DG", "SIMPLE_CHEMICAL", 0, 2], ["DG", "TEST", 0, 2], ["LG", "ANATOMY", 4, 6]]], ["DG and JA wrote the manuscript with help from LG.Supplementary data (available upon request)Table S1.", [["JA", "CHEMICAL", 7, 9], ["DG", "SIMPLE_CHEMICAL", 0, 2], ["LG", "ANATOMY", 46, 48]]], ["UNIPEPT taxonomical analysis of Swab R1, Swab R2, and simili swab 7R1-1pfu samples; Table S3 .", [["Swab R1", "CELL", 32, 39], ["Swab R2", "CELL", 41, 48], ["taxonomical analysis", "TEST", 8, 28], ["Swab", "TEST", 32, 36], ["Swab", "TEST", 41, 45], ["simili swab", "TEST", 54, 65]]], ["List of peptide-to-spectrum matches (PSMs) assigned from the simili SARS-CoV-2 swabs (FDR<1%); Table S4 .", [["the simili SARS", "TEST", 57, 72], ["CoV", "TEST", 73, 76], ["FDR", "TEST", 86, 89]]], ["List of proteins from the simili SARS-CoV-2 swabs and their spectral counts; Table S5 .", [["the simili SARS", "TEST", 22, 37], ["CoV", "TEST", 38, 41], ["their spectral counts", "TEST", 54, 75]]], ["List of peptideto-spectrum matches (PSMs) assigned in the clinical samples (FDR<1%); Table S6 .", [["samples", "ANATOMY", 67, 74], ["the clinical samples", "TEST", 54, 74], ["FDR", "TEST", 76, 79]]], ["List of proteins identified in the clinical samples and their spectral counts; Table S7 .", [["samples", "ANATOMY", 44, 51], ["the clinical samples", "TEST", 31, 51], ["their spectral counts", "TEST", 56, 77]]], ["Skyline report with experimental data on precursor ions from the nine swabs from COVID-19 patients.", [["swabs", "ANATOMY", 70, 75], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98]]], ["Patients were numbered from \"swab T1\" to \"swab T9\".", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]]], "c942949a0b9dac850af511fc986f72199fa34ee0": [["IntroductionSevere Acute Respiratory Syndrome (SARS) was detected in China during the spring of 2004 [1] .", [["Acute Respiratory Syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["Acute Respiratory Syndrome", "PROBLEM", 19, 45], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory Syndrome", "OBSERVATION", 25, 45]]], ["A total of nine cases (including three suspected cases) were reported and a female patient died.", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90]]], ["SARS is caused by a new strain of human coronavirus (CoV) that has been isolated from SARS patients [2, 3] .", [["SARS", "DISEASE", 0, 4], ["human coronavirus", "DISEASE", 34, 51], ["SARS", "DISEASE", 86, 90], ["human coronavirus", "ORGANISM", 34, 51], ["CoV", "ORGANISM", 53, 56], ["patients", "ORGANISM", 91, 99], ["human", "SPECIES", 34, 39], ["coronavirus", "SPECIES", 40, 51], ["patients", "SPECIES", 91, 99], ["human coronavirus", "SPECIES", 34, 51], ["CoV", "SPECIES", 53, 56], ["SARS", "PROBLEM", 0, 4], ["a new strain of human coronavirus (CoV", "PROBLEM", 18, 56], ["new", "OBSERVATION_MODIFIER", 20, 23]]], ["Unlike other human CoVs, which cause mild respiratory infection [4] [5] [6] [7] comprising approximately 15-30% of common colds [8, 9] , the SARS-CoV causes severe respiratory infection, which progresses to acute lung injury or acute respiratory distress syndrome (ARDS) and the mortality around 10% [10] .", [["respiratory", "ANATOMY", 42, 53], ["respiratory", "ANATOMY", 164, 175], ["lung", "ANATOMY", 213, 217], ["respiratory", "ANATOMY", 234, 245], ["respiratory infection", "DISEASE", 42, 63], ["[4] [5] [6]", "CHEMICAL", 64, 75], ["colds", "DISEASE", 122, 127], ["SARS", "DISEASE", 141, 145], ["respiratory infection", "DISEASE", 164, 185], ["acute lung injury", "DISEASE", 207, 224], ["acute respiratory distress syndrome", "DISEASE", 228, 263], ["ARDS", "DISEASE", 265, 269], ["human", "ORGANISM", 13, 18], ["CoVs", "GENE_OR_GENE_PRODUCT", 19, 23], ["SARS-CoV", "ORGANISM", 141, 149], ["lung", "ORGAN", 213, 217], ["human CoVs", "PROTEIN", 13, 23], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["SARS-CoV", "SPECIES", 141, 149], ["other human CoVs", "PROBLEM", 7, 23], ["mild respiratory infection", "PROBLEM", 37, 63], ["common colds", "PROBLEM", 115, 127], ["the SARS", "PROBLEM", 137, 145], ["severe respiratory infection", "PROBLEM", 157, 185], ["acute lung injury", "PROBLEM", 207, 224], ["acute respiratory distress syndrome", "PROBLEM", 228, 263], ["ARDS", "PROBLEM", 265, 269], ["human CoVs", "OBSERVATION", 13, 23], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["respiratory", "ANATOMY", 42, 53], ["infection", "OBSERVATION", 54, 63], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["respiratory", "ANATOMY", 164, 175], ["infection", "OBSERVATION", 176, 185], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["lung", "ANATOMY", 213, 217], ["injury", "OBSERVATION", 218, 224], ["acute", "OBSERVATION_MODIFIER", 228, 233], ["respiratory distress", "OBSERVATION", 234, 254]]], ["In the early stage of SARS or in atypical SARS, patients usually demonstrate symptoms similar to the common cold or influenza.", [["SARS", "DISEASE", 22, 26], ["SARS", "DISEASE", 42, 46], ["influenza", "DISEASE", 116, 125], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["SARS", "PROBLEM", 22, 26], ["atypical SARS", "PROBLEM", 33, 46], ["symptoms", "PROBLEM", 77, 85], ["influenza", "PROBLEM", 116, 125], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["SARS", "OBSERVATION", 22, 26], ["influenza", "OBSERVATION", 116, 125]]], ["In this situation, the detection of antibodies against SARS-CoV has been used to confirm the diagnosis of SARS.", [["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 106, 110], ["SARS-CoV", "ORGANISM", 55, 63], ["antibodies", "PROTEIN", 36, 46], ["SARS-CoV", "SPECIES", 55, 63], ["the detection of antibodies", "TEST", 19, 46], ["SARS", "PROBLEM", 55, 59], ["CoV", "PROBLEM", 60, 63], ["SARS", "PROBLEM", 106, 110]]], ["It is also important to analyze the immunogens in SARS-CoV and their capacity to elicit protective immunity, to better characterize the immune response for early diagnosis, and to understand the immunopathogenesis of the SARS.IntroductionThe spike (S) protein from the SARS-CoV is a heterodimer, a characteristic of coronaviruses, and consists of two noncovalently bound S protein subunits, S1 and S2, derived from the N and C terminal halves of the S protein.", [["SARS", "DISEASE", 50, 54], ["SARS", "DISEASE", 221, 225], ["SARS", "DISEASE", 269, 273], ["N", "CHEMICAL", 419, 420], ["C", "CHEMICAL", 425, 426], ["SARS-CoV", "ORGANISM", 50, 58], ["SARS-CoV", "ORGANISM", 269, 277], ["S1", "GENE_OR_GENE_PRODUCT", 391, 393], ["S2", "GENE_OR_GENE_PRODUCT", 398, 400], ["spike (S) protein", "PROTEIN", 242, 259], ["SARS-CoV", "PROTEIN", 269, 277], ["heterodimer", "PROTEIN", 283, 294], ["noncovalently bound S protein subunits", "PROTEIN", 351, 389], ["S1", "PROTEIN", 391, 393], ["S2", "PROTEIN", 398, 400], ["N and C terminal halves", "PROTEIN", 419, 442], ["S protein", "PROTEIN", 450, 459], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 269, 277], ["The spike (S) protein", "TEST", 238, 259], ["the SARS", "PROBLEM", 265, 273], ["a heterodimer", "PROBLEM", 281, 294], ["coronaviruses", "PROBLEM", 316, 329], ["coronaviruses", "OBSERVATION", 316, 329], ["S2", "ANATOMY", 398, 400]]], ["During a coronavirus infection, the S1 subunit binds to its specific receptors on host cells [11, 12] , followed by the S2 subunit mediating fusion between the virus and host cell membrane leading to the entry of virus into the cells.", [["cells", "ANATOMY", 87, 92], ["cell membrane", "ANATOMY", 175, 188], ["cells", "ANATOMY", 228, 233], ["coronavirus infection", "DISEASE", 9, 30], ["coronavirus", "ORGANISM", 9, 20], ["S1", "GENE_OR_GENE_PRODUCT", 36, 38], ["host cells", "CELL", 82, 92], ["S2", "GENE_OR_GENE_PRODUCT", 120, 122], ["cell membrane", "CELLULAR_COMPONENT", 175, 188], ["cells", "CELL", 228, 233], ["S1 subunit", "PROTEIN", 36, 46], ["host cells", "CELL_TYPE", 82, 92], ["S2 subunit", "PROTEIN", 120, 130], ["a coronavirus infection", "PROBLEM", 7, 30], ["the S1 subunit binds", "PROBLEM", 32, 52], ["the S2 subunit mediating fusion", "TREATMENT", 116, 147], ["the virus", "PROBLEM", 156, 165], ["host cell membrane", "TREATMENT", 170, 188], ["coronavirus", "OBSERVATION_MODIFIER", 9, 20], ["infection", "OBSERVATION", 21, 30], ["fusion", "OBSERVATION", 141, 147], ["virus", "OBSERVATION", 160, 165], ["host cell membrane", "OBSERVATION", 170, 188], ["cells", "ANATOMY", 228, 233]]], ["In previous studies of coronavirus infection, the S protein is a potent immunogen, which induces neutralizing antibodies [13] .", [["coronavirus infection", "DISEASE", 23, 44], ["coronavirus", "ORGANISM", 23, 34], ["S protein", "PROTEIN", 50, 59], ["neutralizing antibodies", "PROTEIN", 97, 120], ["coronavirus", "SPECIES", 23, 34], ["coronavirus", "SPECIES", 23, 34], ["coronavirus infection", "PROBLEM", 23, 44], ["the S protein", "TEST", 46, 59], ["a potent immunogen", "TREATMENT", 63, 81], ["neutralizing antibodies", "PROBLEM", 97, 120], ["coronavirus", "OBSERVATION_MODIFIER", 23, 34], ["infection", "OBSERVATION", 35, 44]]], ["After infection, neutralizing antibodies are typically directed against certain fragments of S1 or S2, which can block the receptor recognition and membrane fusion of the coronavirus [14] .", [["membrane", "ANATOMY", 148, 156], ["infection", "DISEASE", 6, 15], ["S1", "GENE_OR_GENE_PRODUCT", 93, 95], ["S2", "GENE_OR_GENE_PRODUCT", 99, 101], ["membrane", "CELLULAR_COMPONENT", 148, 156], ["neutralizing antibodies", "PROTEIN", 17, 40], ["S1", "PROTEIN", 93, 95], ["S2", "PROTEIN", 99, 101], ["infection", "PROBLEM", 6, 15], ["neutralizing antibodies", "TREATMENT", 17, 40], ["certain fragments of S1 or S2", "PROBLEM", 72, 101], ["membrane fusion", "TREATMENT", 148, 163], ["the coronavirus", "PROBLEM", 167, 182], ["infection", "OBSERVATION", 6, 15], ["S1", "ANATOMY", 93, 95], ["S2", "ANATOMY", 99, 101]]], ["Recent reports showed that the viral receptor, ACE2, binding site was linked to the fragment of the C terminal of S1 and S2 [15, 16] , and this suggests that antibodies against S1-C and S2 may be associated with the generation of protective immune response.IntroductionIn order to understand the immunogenecity of fragments of the S protein of SARS-CoV and to evaluate their potential use as target antigens for a diagnostic ELISA assay.", [["SARS", "DISEASE", 344, 348], ["C", "CHEMICAL", 100, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["S1", "GENE_OR_GENE_PRODUCT", 114, 116], ["S2", "GENE_OR_GENE_PRODUCT", 121, 123], ["S1-C", "GENE_OR_GENE_PRODUCT", 177, 181], ["S2", "GENE_OR_GENE_PRODUCT", 186, 188], ["SARS-CoV", "ORGANISM", 344, 352], ["viral receptor", "PROTEIN", 31, 45], ["ACE2", "PROTEIN", 47, 51], ["C terminal", "PROTEIN", 100, 110], ["S1", "PROTEIN", 114, 116], ["S2", "PROTEIN", 121, 123], ["antibodies", "PROTEIN", 158, 168], ["S1", "PROTEIN", 177, 179], ["S2", "PROTEIN", 186, 188], ["S protein", "PROTEIN", 331, 340], ["SARS-CoV", "SPECIES", 344, 352], ["the viral receptor", "PROBLEM", 27, 45], ["binding site", "PROBLEM", 53, 65], ["antibodies", "TEST", 158, 168], ["S1-C and S2", "PROBLEM", 177, 188], ["a diagnostic ELISA assay", "TEST", 412, 436], ["fragment", "OBSERVATION_MODIFIER", 84, 92], ["terminal", "ANATOMY_MODIFIER", 102, 110], ["S1", "ANATOMY", 114, 116], ["S2", "ANATOMY", 121, 123], ["S2", "ANATOMY", 186, 188]]], ["We prepared recombinant S1 and S2 subunits and S1 fragments ( Fig. 1 ) to evaluate the serum from SARS-recovered patients for possible antibodies to these antigens.Patients and seraIn order to compare the utility of ELISA and WB assay with the two recombinant fragments of S protein, we used sera obtained from SARS patient samples at The First Hospital of Peking University.", [["serum", "ANATOMY", 87, 92], ["sera", "ANATOMY", 292, 296], ["SARS", "DISEASE", 98, 102], ["SARS", "DISEASE", 311, 315], ["S2", "GENE_OR_GENE_PRODUCT", 31, 33], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["patients", "ORGANISM", 113, 121], ["Patients", "ORGANISM", 164, 172], ["S protein", "GENE_OR_GENE_PRODUCT", 273, 282], ["sera", "ORGANISM_SUBSTANCE", 292, 296], ["patient", "ORGANISM", 316, 323], ["recombinant S1 and S2 subunits", "PROTEIN", 12, 42], ["S1 fragments", "PROTEIN", 47, 59], ["antibodies", "PROTEIN", 135, 145], ["antigens", "PROTEIN", 155, 163], ["S protein", "PROTEIN", 273, 282], ["patients", "SPECIES", 113, 121], ["Patients", "SPECIES", 164, 172], ["patient", "SPECIES", 316, 323], ["recombinant S1 and S2 subunits and S1 fragments", "TREATMENT", 12, 59], ["the serum", "TEST", 83, 92], ["SARS", "PROBLEM", 98, 102], ["antibodies to these antigens", "PROBLEM", 135, 163], ["ELISA", "TEST", 216, 221], ["WB assay", "TEST", 226, 234], ["S1", "ANATOMY", 47, 49]]], ["The sera were collected from marker, the molecule weights of S1, S1-C, S1-N, and S2 recombinant proteins are 108, 64, 59, and 79.9 kDa, respectively.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["S1-C", "GENE_OR_GENE_PRODUCT", 65, 69], ["S1-N", "GENE_OR_GENE_PRODUCT", 71, 75], ["S1", "PROTEIN", 61, 63], ["S1", "PROTEIN", 65, 67], ["C", "PROTEIN", 68, 69], ["S1", "PROTEIN", 71, 73], ["N", "PROTEIN", 74, 75], ["S2", "PROTEIN", 81, 83], ["recombinant proteins", "PROTEIN", 84, 104], ["The sera", "TEST", 0, 8], ["the molecule weights", "TEST", 37, 57], ["S1", "TEST", 61, 63], ["S1", "TEST", 65, 67], ["S1", "TEST", 71, 73], ["S2 recombinant proteins", "TEST", 81, 104], ["S1", "ANATOMY", 61, 63], ["S1", "ANATOMY", 65, 67]]], ["The numbers of patients are showed above the figures of W.B. 1 and 2: sera from health donor (with SARS contact history); 3 and 4: sera from patients recovered from SARS.", [["sera", "ANATOMY", 70, 74], ["sera", "ANATOMY", 131, 135], ["SARS", "DISEASE", 165, 169], ["patients", "ORGANISM", 15, 23], ["sera", "ORGANISM_SUBSTANCE", 70, 74], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 141, 149], ["SARS", "PROBLEM", 165, 169]]], ["Date of sample collecting c ELISA S1 S2 S1-N S1-C The patients gave written consent for blood collection and Hospital Ethics Review Committee approved this study.", [["blood", "ANATOMY", 88, 93], ["patients", "ORGANISM", 54, 62], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["S1", "PROTEIN", 40, 42], ["N S1", "PROTEIN", 43, 47], ["patients", "SPECIES", 54, 62], ["sample", "TEST", 8, 14], ["this study", "TEST", 151, 161], ["S1", "ANATOMY", 45, 47]]], ["Testing for antibodies against GST or thioredoxin (TRX) was negative in all of the serum samples used in this study, and all of the samples were stored at \u00c0808C before evaluation.Expression of recombinant SARS-CoV S fragments and Western blotFour fragments of SARS-CoV S protein, S1 (a TRX fusion recombinant protein of S1 subunit), S2 (a recombinant protein of S2 subunit with 6X His tail), S1-N (a GST fusion recombinant protein of the 344 amino acid residues of S1 N terminal), and S1-C (a GST fusion recombinant protein of the 311 amino acid residues of S1-C terminal) were expressed in Escherichia coli as described previously [17] .", [["serum samples", "ANATOMY", 83, 96], ["samples", "ANATOMY", 132, 139], ["amino acid", "CHEMICAL", 442, 452], ["amino acid", "CHEMICAL", 535, 545], ["His", "CHEMICAL", 381, 384], ["amino acid", "CHEMICAL", 442, 452], ["N", "CHEMICAL", 468, 469], ["amino acid", "CHEMICAL", 535, 545], ["GST", "GENE_OR_GENE_PRODUCT", 31, 34], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 38, 49], ["TRX", "GENE_OR_GENE_PRODUCT", 51, 54], ["serum samples", "ORGANISM_SUBSTANCE", 83, 96], ["SARS-CoV S protein", "GENE_OR_GENE_PRODUCT", 260, 278], ["S1", "GENE_OR_GENE_PRODUCT", 280, 282], ["TRX fusion recombinant protein of S1 subunit", "GENE_OR_GENE_PRODUCT", 286, 330], ["S2", "GENE_OR_GENE_PRODUCT", 333, 335], ["S2", "GENE_OR_GENE_PRODUCT", 362, 364], ["S1-N", "GENE_OR_GENE_PRODUCT", 392, 396], ["GST", "GENE_OR_GENE_PRODUCT", 400, 403], ["amino acid", "AMINO_ACID", 442, 452], ["S1-C", "GENE_OR_GENE_PRODUCT", 485, 489], ["GST", "GENE_OR_GENE_PRODUCT", 493, 496], ["amino acid", "AMINO_ACID", 535, 545], ["Escherichia coli", "ORGANISM", 591, 607], ["antibodies", "PROTEIN", 12, 22], ["GST", "PROTEIN", 31, 34], ["thioredoxin", "PROTEIN", 38, 49], ["TRX", "PROTEIN", 51, 54], ["recombinant SARS-CoV S fragments", "DNA", 193, 225], ["Western blotFour fragments", "DNA", 230, 256], ["SARS-CoV S protein", "PROTEIN", 260, 278], ["S1", "PROTEIN", 280, 282], ["TRX fusion recombinant protein", "PROTEIN", 286, 316], ["S1 subunit", "PROTEIN", 320, 330], ["S2", "PROTEIN", 333, 335], ["recombinant protein", "PROTEIN", 339, 358], ["S2 subunit", "PROTEIN", 362, 372], ["6X His tail", "PROTEIN", 378, 389], ["S1", "PROTEIN", 392, 394], ["N", "PROTEIN", 395, 396], ["GST fusion recombinant protein", "PROTEIN", 400, 430], ["344 amino acid residues", "PROTEIN", 438, 461], ["S1 N terminal", "PROTEIN", 465, 478], ["S1", "PROTEIN", 485, 487], ["C", "PROTEIN", 488, 489], ["GST fusion recombinant protein", "PROTEIN", 493, 523], ["311 amino acid residues", "PROTEIN", 531, 554], ["S1", "PROTEIN", 558, 560], ["C terminal", "PROTEIN", 561, 571], ["Escherichia coli", "SPECIES", 591, 607], ["SARS-CoV", "SPECIES", 205, 213], ["SARS-CoV", "SPECIES", 260, 268], ["Escherichia coli", "SPECIES", 591, 607], ["Testing", "TEST", 0, 7], ["antibodies", "TEST", 12, 22], ["GST", "TEST", 31, 34], ["thioredoxin (TRX)", "TEST", 38, 55], ["the serum samples", "TEST", 79, 96], ["this study", "TEST", 105, 115], ["the samples", "TEST", 128, 139], ["evaluation", "TEST", 168, 178], ["recombinant SARS", "PROBLEM", 193, 209], ["CoV S fragments", "PROBLEM", 210, 225], ["Western blotFour fragments", "PROBLEM", 230, 256], ["SARS", "PROBLEM", 260, 264], ["CoV S protein", "TEST", 265, 278], ["a TRX fusion", "TREATMENT", 284, 296], ["S1", "TEST", 392, 394], ["a GST fusion recombinant protein", "TEST", 398, 430], ["amino acid residues", "TEST", 442, 461], ["S1", "TEST", 485, 487], ["a GST fusion recombinant protein", "TEST", 491, 523], ["amino acid residues", "TEST", 535, 554], ["S1-C terminal)", "PROBLEM", 558, 572], ["Escherichia coli", "PROBLEM", 591, 607], ["recombinant", "OBSERVATION_MODIFIER", 193, 204], ["SARS", "OBSERVATION", 205, 209], ["CoV S fragments", "OBSERVATION_MODIFIER", 210, 225], ["S1", "ANATOMY", 280, 282], ["S2", "ANATOMY", 333, 335], ["S1", "ANATOMY", 485, 487], ["Escherichia coli", "OBSERVATION", 591, 607]]], ["Briefly, each expressed fragment of S protein was amplified with the template of plasmid containing corresponding full-length cDNA of SARS-CoV S gene (Gifts from Dr. Yong Xie, Hong Kong University of Science and Technology) and specific primers ( Table 2 ).", [["plasmid", "ANATOMY", 81, 88], ["-CoV S", "GENE_OR_GENE_PRODUCT", 138, 144], ["S protein", "PROTEIN", 36, 45], ["plasmid", "DNA", 81, 88], ["full-length cDNA", "DNA", 114, 130], ["SARS-CoV S gene", "DNA", 134, 149], ["S protein", "PROBLEM", 36, 45], ["the template of plasmid", "TREATMENT", 65, 88], ["fragment", "OBSERVATION_MODIFIER", 24, 32]]], ["The amplified products were digested with restriction endonuclease BamHI and KpnI.", [["BamHI", "GENE_OR_GENE_PRODUCT", 67, 72], ["KpnI", "GENE_OR_GENE_PRODUCT", 77, 81], ["restriction endonuclease BamHI and KpnI", "DNA", 42, 81], ["The amplified products", "TREATMENT", 0, 22], ["restriction endonuclease BamHI", "TREATMENT", 42, 72], ["KpnI", "TREATMENT", 77, 81]]], ["The fragments of S1 and S2 cDNAs were inserted into the pET32a-TRX and pET32a expression plasmids, respectively, whereas the fragments of S1-N and S1-C cDNAs were inserted into the pGEX-4T-2.", [["fragments", "ANATOMY", 4, 13], ["plasmids", "ANATOMY", 89, 97], ["fragments", "ANATOMY", 125, 134], ["S1", "GENE_OR_GENE_PRODUCT", 17, 19], ["S2", "GENE_OR_GENE_PRODUCT", 24, 26], ["pET32a", "GENE_OR_GENE_PRODUCT", 56, 62], ["TRX", "GENE_OR_GENE_PRODUCT", 63, 66], ["pET32a", "GENE_OR_GENE_PRODUCT", 71, 77], ["S1-N", "GENE_OR_GENE_PRODUCT", 138, 142], ["S1-C", "GENE_OR_GENE_PRODUCT", 147, 151], ["pGEX-4T-2", "GENE_OR_GENE_PRODUCT", 181, 190], ["S1 and S2 cDNAs", "DNA", 17, 32], ["pET32a", "DNA", 56, 62], ["TRX and pET32a expression plasmids", "DNA", 63, 97], ["S1", "DNA", 138, 140], ["N", "DNA", 141, 142], ["S1", "DNA", 147, 149], ["C cDNAs", "DNA", 150, 157], ["pGEX-4T-2", "DNA", 181, 190], ["S1 and S2 cDNAs", "TREATMENT", 17, 32], ["pET32a expression plasmids", "TREATMENT", 71, 97], ["S1", "TEST", 138, 140], ["S1-C cDNAs", "TREATMENT", 147, 157], ["the pGEX", "TEST", 177, 185], ["fragments", "OBSERVATION_MODIFIER", 4, 13], ["S1", "ANATOMY", 17, 19], ["S2 cDNAs", "OBSERVATION", 24, 32], ["TRX", "ANATOMY", 63, 66], ["fragments", "OBSERVATION_MODIFIER", 125, 134], ["S1", "ANATOMY", 138, 140], ["S1", "ANATOMY", 147, 149]]], ["After verification of the correct sequences, the plasmids were transformed into E. coli BL-21 (pET32a-TRX/S1 and pET32a/S2) and DH5a (pGEX-4T-2/S1-N and pGEX-4T-2/S1-C), respectively.", [["plasmids", "ANATOMY", 49, 57], ["E. coli BL-21", "ORGANISM", 80, 93], ["pET32a-TRX", "GENE_OR_GENE_PRODUCT", 95, 105], ["DH5a", "GENE_OR_GENE_PRODUCT", 128, 132], ["S1-C", "CELL", 163, 167], ["plasmids", "DNA", 49, 57], ["pET32a", "PROTEIN", 95, 101], ["TRX", "PROTEIN", 102, 105], ["S1", "PROTEIN", 106, 108], ["pET32a", "DNA", 113, 119], ["S2", "PROTEIN", 120, 122], ["DH5a", "DNA", 128, 132], ["pGEX", "DNA", 134, 138], ["S1", "DNA", 144, 146], ["pGEX", "DNA", 153, 157], ["4T", "DNA", 158, 160], ["S1", "DNA", 163, 165], ["E. coli", "SPECIES", 80, 87], ["E. coli BL-21", "SPECIES", 80, 93], ["the correct sequences", "TEST", 22, 43], ["the plasmids", "TREATMENT", 45, 57], ["E. coli BL", "TEST", 80, 90], ["pET32a", "TEST", 95, 101], ["pET32a", "TEST", 113, 119], ["DH5a", "TEST", 128, 132], ["pGEX", "TEST", 134, 138], ["S1", "TEST", 144, 146], ["pGEX", "TEST", 153, 157], ["coli BL", "OBSERVATION", 83, 90], ["S1", "ANATOMY", 106, 108], ["S2", "ANATOMY", 120, 122]]], ["The E. coli was cultured in 2-YT medium at 378 and induced with IPTG for 6 h.", [["IPTG", "CHEMICAL", 64, 68], ["IPTG", "CHEMICAL", 64, 68], ["E. coli", "ORGANISM", 4, 11], ["E. coli", "SPECIES", 4, 11], ["E. coli", "SPECIES", 4, 11], ["The E. coli", "TEST", 0, 11], ["IPTG", "TREATMENT", 64, 68], ["E. coli", "OBSERVATION", 4, 11]]], ["The E. coli was harvested and lysed by ultrasonication.", [["E. coli", "ORGANISM", 4, 11], ["E. coli", "SPECIES", 4, 11], ["E. coli", "SPECIES", 4, 11], ["The E. coli", "TREATMENT", 0, 11], ["E. coli", "OBSERVATION", 4, 11]]], ["The inclusion bodies (IB) were collected and thoroughly washed.", [["bodies", "OBSERVATION_MODIFIER", 14, 20]]], ["The recombinant S1-TRX fusion protein and S2 protein, both of which contain a 6xHis tag, were purified with Ni-NTA resin (Qiagen QIAexpress).", [["Ni-NTA", "CHEMICAL", 108, 114], ["Ni-NTA", "CHEMICAL", 108, 114], ["TRX", "GENE_OR_GENE_PRODUCT", 19, 22], ["S2", "GENE_OR_GENE_PRODUCT", 42, 44], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 108, 120], ["recombinant S1-TRX fusion protein", "PROTEIN", 4, 37], ["S2 protein", "PROTEIN", 42, 52], ["6xHis tag", "PROTEIN", 78, 87], ["The recombinant S1-TRX fusion protein", "TEST", 0, 37], ["S2 protein", "TEST", 42, 52], ["a 6xHis tag", "TREATMENT", 76, 87], ["Ni-NTA resin", "TREATMENT", 108, 120], ["Qiagen QIAexpress)", "TREATMENT", 122, 140], ["TRX fusion", "OBSERVATION", 19, 29]]], ["As the S1-N and S1-C proteins were fused with GST proteins on N terminus, they were purified with GST-glutathione sepharose 4B affinity system.Western blottingThe screening of the S protein of SARS-CoV against sera from SARS patients or from healthy donors was performed by Western blotting (WB).", [["sera", "ANATOMY", 210, 214], ["glutathione", "CHEMICAL", 102, 113], ["SARS", "DISEASE", 220, 224], ["glutathione", "CHEMICAL", 102, 113], ["S1-C", "GENE_OR_GENE_PRODUCT", 16, 20], ["GST", "GENE_OR_GENE_PRODUCT", 46, 49], ["GST-glutathione sepharose 4B", "GENE_OR_GENE_PRODUCT", 98, 126], ["SARS-CoV", "ORGANISM", 193, 201], ["sera", "ORGANISM_SUBSTANCE", 210, 214], ["patients", "ORGANISM", 225, 233], ["donors", "ORGANISM", 250, 256], ["S1", "PROTEIN", 7, 9], ["N", "PROTEIN", 10, 11], ["S1", "PROTEIN", 16, 18], ["C proteins", "PROTEIN", 19, 29], ["GST proteins", "PROTEIN", 46, 58], ["N terminus", "PROTEIN", 62, 72], ["GST", "PROTEIN", 98, 101], ["glutathione sepharose 4B", "PROTEIN", 102, 126], ["S protein", "PROTEIN", 180, 189], ["patients", "SPECIES", 225, 233], ["SARS-CoV", "SPECIES", 193, 201], ["the S1-N and S1-C proteins", "TEST", 3, 29], ["GST proteins on N terminus", "PROBLEM", 46, 72], ["GST", "TEST", 98, 101], ["The screening", "TEST", 159, 172], ["the S protein", "TEST", 176, 189], ["SARS", "PROBLEM", 193, 197], ["S1", "ANATOMY", 16, 18]]], ["Briefly, every purified SARS recombinant protein was separated on 10% SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes.", [["membranes", "ANATOMY", 145, 154], ["SDS-polyacrylamide", "CHEMICAL", 70, 88], ["SDS", "CHEMICAL", 70, 73], ["polyacrylamide", "CHEMICAL", 74, 88], ["nitrocellulose", "CHEMICAL", 130, 144], ["membranes", "CELLULAR_COMPONENT", 145, 154], ["SARS recombinant protein", "PROTEIN", 24, 48], ["every purified SARS recombinant protein", "PROBLEM", 9, 48], ["10% SDS", "TREATMENT", 66, 73], ["polyacrylamide gel electrophoresis", "TREATMENT", 74, 108], ["nitrocellulose membranes", "TREATMENT", 130, 154]]], ["After blocking with 5% milk, the membranes were sequentially incubated with sera diluted in 1:500, goat anti-human IgG (H + L) alkaline phosphatase conjugate (1:10,000, Promega), and the substrate NBT/BCIP (Promega).", [["milk", "ANATOMY", 23, 27], ["membranes", "ANATOMY", 33, 42], ["sera", "ANATOMY", 76, 80], ["NBT", "CHEMICAL", 197, 200], ["NBT", "CHEMICAL", 197, 200], ["milk", "ORGANISM_SUBSTANCE", 23, 27], ["membranes", "CELLULAR_COMPONENT", 33, 42], ["sera", "ORGANISM_SUBSTANCE", 76, 80], ["goat", "ORGANISM", 99, 103], ["alkaline phosphatase conjugate", "SIMPLE_CHEMICAL", 127, 157], ["Promega", "ORGANISM", 169, 176], ["NBT", "SIMPLE_CHEMICAL", 197, 200], ["Promega", "ORGANISM", 207, 214], ["goat anti-human IgG (H + L) alkaline phosphatase conjugate", "PROTEIN", 99, 157], ["goat", "SPECIES", 99, 103], ["goat", "SPECIES", 99, 103], ["5% milk", "TREATMENT", 20, 27], ["sera diluted", "TEST", 76, 88], ["goat anti-human IgG", "TEST", 99, 118], ["alkaline phosphatase conjugate", "TEST", 127, 157], ["the substrate NBT/BCIP (Promega)", "TREATMENT", 183, 215]]], ["The antibody-positive sera were tested twice to verify the immunoreaction.", [["sera", "ANATOMY", 22, 26], ["sera", "ORGANISM_SUBSTANCE", 22, 26], ["The antibody", "TEST", 0, 12]]], ["Mock-transfected E. coli lysate made in the same vectors were used in WB analysis as negative controls.ELISAIgG antibodies against sera from SARS patients were detected by ELISA using ELISA kit (Huada Bioscience, China), which was made up with the killed SARS virus and served as the main antigens.", [["lysate", "ANATOMY", 25, 31], ["WB", "ANATOMY", 70, 72], ["sera", "ANATOMY", 131, 135], ["SARS", "DISEASE", 141, 145], ["SARS", "DISEASE", 255, 259], ["E. coli", "ORGANISM", 17, 24], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["patients", "ORGANISM", 146, 154], ["ELISAIgG antibodies", "PROTEIN", 103, 122], ["E. coli", "SPECIES", 17, 24], ["patients", "SPECIES", 146, 154], ["E. coli", "SPECIES", 17, 24], ["SARS virus", "SPECIES", 255, 265], ["transfected E. coli lysate", "TREATMENT", 5, 31], ["WB analysis", "TEST", 70, 81], ["ELISAIgG antibodies", "TEST", 103, 122], ["SARS", "PROBLEM", 141, 145], ["ELISA kit", "TEST", 184, 193], ["the killed SARS virus", "PROBLEM", 244, 265], ["coli lysate", "OBSERVATION", 20, 31]]], ["In brief, 100 Al/well of diluted serum (1:200) was added and incubated for 2 h at room temperature (RT).", [["serum", "ANATOMY", 33, 38], ["Al", "CHEMICAL", 14, 16], ["Al", "CHEMICAL", 14, 16], ["serum", "ORGANISM_SUBSTANCE", 33, 38]]], ["Plates were washed, followed by the addition of 100 Al/well diluted goat anti-human IgG (H + L) alkaline phosphatase conjugate (1:10,000, Promega) for 1 h at RT.", [["Al", "CHEMICAL", 52, 54], ["goat", "ORGANISM", 68, 72], ["H + L) alkaline phosphatase conjugate", "SIMPLE_CHEMICAL", 89, 126], ["goat anti-human IgG (H + L) alkaline phosphatase conjugate", "PROTEIN", 68, 126], ["goat", "SPECIES", 68, 72], ["goat", "SPECIES", 68, 72], ["Al/well diluted goat anti-human IgG", "TREATMENT", 52, 87], ["alkaline phosphatase conjugate", "TEST", 96, 126]]], ["Plates were washed, incubated with 100 Al/well of substrate solution for 30 min at RT, and immediately read with a microtiter plate reader (Anthos 2001, Anthos, Austria) at 450 nm.", [["Al", "CHEMICAL", 39, 41], ["substrate solution", "TREATMENT", 50, 68], ["a microtiter plate", "TREATMENT", 113, 131]]], ["Samples with an optical density (OD) over the cutoff (CO) value were identified as positive.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["an optical density", "TEST", 13, 31], ["the cutoff (CO) value", "TEST", 42, 63], ["optical", "OBSERVATION_MODIFIER", 16, 23], ["density", "OBSERVATION", 24, 31], ["positive", "OBSERVATION", 83, 91]]], ["CO value was defined as CO value = [0.13 + N OD ], and this translated into 0.135 for IgG in our study (N OD b 0.005, so the CO was set at 0.135).", [["CO", "CHEMICAL", 0, 2], ["CO", "CHEMICAL", 24, 26], ["CO", "CHEMICAL", 125, 127], ["CO", "SIMPLE_CHEMICAL", 0, 2], ["IgG", "PROTEIN", 86, 89], ["CO value", "TEST", 0, 8], ["CO value", "TEST", 24, 32], ["IgG", "TREATMENT", 86, 89], ["our study", "TEST", 93, 102], ["the CO", "TEST", 121, 127]]], ["Table 2 The sequences of primers for amplification of S fragmentsFragmentSense Antisense S1 5V -ggggatccagtgaccttgaccggtgcaccac-3V 5V -ccggtaccaactgtatggtaactagcacaaatgcc-3V S2Fragment5V -ggggatcctctttattacgtagtactagcc-3V 5V -ccggtacctgtgtaatgtaatttgacacc-3V S1-N 5V -ggggatcctttattttcttattatttcttactc-3V 5V -ccggtaccaactgtatggtaactagcacaaatgc-3V S1-C 5V -ggggatcctcaacatttttttcaacctttaagtgc-3V 5V -ccggtacctgtatggtaactagcacaaatgccagc-3VAnti-SARS-CoV-specific antibodies could be detected in serum by WB with recombinant SARS-CoV S protein fragments as well as by ELISA with killed SARS-CoVThe recombinant S protein fragments were recognized by the sera from SARS-recovered donors, and S1, S2, S1-N, and S1-C recombinant proteins were estimated to be around 108 kDa (TRX-S1), 90 kDa (S2), 64 kDa (S1-N-GST), and 59 kDa (S1-C-GST), respectively (Fig. 1) .", [["serum", "ANATOMY", 492, 497], ["WB", "ANATOMY", 501, 503], ["sera", "ANATOMY", 649, 653], ["SARS", "DISEASE", 659, 663], ["5V -ccggtacctgtgtaatgtaatttgacacc-3V S1-N 5V -ggggatcctttattttcttattatttcttactc-3V", "CHEMICAL", 222, 304], ["serum", "ORGANISM_SUBSTANCE", 492, 497], ["WB", "ORGANISM_SUBSTANCE", 501, 503], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 521, 531], ["sera", "ORGANISM_SUBSTANCE", 649, 653], ["donors", "ORGANISM", 674, 680], ["S2", "CELL", 690, 692], ["S1-N", "CELL", 694, 698], ["S1-C recombinant", "ORGANISM", 704, 720], ["TRX-S1", "GENE_OR_GENE_PRODUCT", 767, 773], ["N-GST", "GENE_OR_GENE_PRODUCT", 800, 805], ["S1-C-GST", "GENE_OR_GENE_PRODUCT", 820, 828], ["S fragments", "DNA", 54, 65], ["ggggatccagtgaccttgaccggtgcaccac-3V", "DNA", 96, 130], ["5V -ccggtaccaactgtatggtaactagcacaaatgcc-3V S2Fragment5V", "DNA", 131, 186], ["C 5V", "DNA", 350, 354], ["5V", "PROTEIN", 395, 397], ["ccggtacctgtatggtaactagcacaaatgccagc-3VAnti-SARS-CoV-specific antibodies", "PROTEIN", 399, 470], ["recombinant SARS-CoV S protein fragments", "DNA", 509, 549], ["SARS-CoVThe recombinant S protein fragments", "DNA", 582, 625], ["S1", "PROTEIN", 686, 688], ["S2", "PROTEIN", 690, 692], ["S1", "PROTEIN", 694, 696], ["N", "PROTEIN", 697, 698], ["S1", "PROTEIN", 704, 706], ["C recombinant proteins", "PROTEIN", 707, 729], ["TRX", "PROTEIN", 767, 770], ["S1", "PROTEIN", 771, 773], ["90 kDa", "PROTEIN", 776, 782], ["S2", "PROTEIN", 784, 786], ["64 kDa", "PROTEIN", 789, 795], ["S1", "PROTEIN", 797, 799], ["N", "PROTEIN", 800, 801], ["GST", "PROTEIN", 802, 805], ["59 kDa", "PROTEIN", 812, 818], ["S1", "PROTEIN", 820, 822], ["C", "PROTEIN", 823, 824], ["GST", "PROTEIN", 825, 828], ["SARS-CoV", "SPECIES", 521, 529], ["The sequences of primers", "TREATMENT", 8, 32], ["amplification of S fragmentsFragment", "TREATMENT", 37, 73], ["ggggatccagtgaccttgaccggtgcaccac-3V", "TREATMENT", 96, 130], ["ccggtaccaactgtatggtaactagcacaaatgcc-3V", "TREATMENT", 135, 173], ["ccggtacctgtgtaatgtaatttgacacc-3V S1", "TREATMENT", 226, 261], ["ggggatcctttattttcttattatttcttactc-3V", "TREATMENT", 268, 304], ["ccggtaccaactgtatggtaactagcacaaatgc-3V S1", "TREATMENT", 309, 349], ["C 5V", "TREATMENT", 350, 354], ["ggggatcctcaacatttttttcaacctttaagtgc-3V", "TREATMENT", 356, 394], ["ccggtacctgtatggtaactagcacaaatgccagc-3VAnti-SARS-CoV-specific antibodies", "TEST", 399, 470], ["serum", "TEST", 492, 497], ["WB", "TEST", 501, 503], ["recombinant SARS", "PROBLEM", 509, 525], ["CoV S protein fragments", "PROBLEM", 526, 549], ["ELISA", "TEST", 564, 569], ["killed SARS", "PROBLEM", 575, 586], ["CoVThe recombinant S protein fragments", "TREATMENT", 587, 625], ["the sera", "TEST", 645, 653], ["SARS", "TEST", 659, 663], ["donors", "TEST", 674, 680], ["S1", "TEST", 686, 688], ["S2", "TEST", 690, 692], ["S1", "TEST", 694, 696], ["S1", "TEST", 704, 706], ["C recombinant proteins", "PROBLEM", 707, 729], ["kDa", "TEST", 762, 765], ["TRX", "TEST", 767, 770], ["kDa", "TEST", 792, 795], ["S1", "TEST", 797, 799], ["kDa", "TEST", 815, 818], ["S1", "TEST", 820, 822], ["S1", "ANATOMY", 686, 688], ["S2", "ANATOMY", 690, 692], ["S1", "ANATOMY", 694, 696], ["S1", "ANATOMY", 704, 706], ["S1", "ANATOMY", 771, 773]]], ["Seroreactivity analysis was performed using WB and ELISA.", [["Seroreactivity analysis", "TEST", 0, 23], ["WB", "TEST", 44, 46], ["ELISA", "TEST", 51, 56]]], ["In the 20 sera collected from the donors who have fully recovered from SARS infection, there were 17 sera reactive to killed SARS virus as measured by an ELISA kit (Table 1 ).", [["sera", "ANATOMY", 10, 14], ["sera", "ANATOMY", 101, 105], ["SARS infection", "DISEASE", 71, 85], ["SARS", "DISEASE", 125, 129], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["donors", "ORGANISM", 34, 40], ["sera", "ORGANISM_SUBSTANCE", 101, 105], ["SARS virus", "ORGANISM", 125, 135], ["SARS virus", "SPECIES", 125, 135], ["SARS infection", "PROBLEM", 71, 85], ["17 sera reactive to killed SARS virus", "PROBLEM", 98, 135], ["an ELISA kit", "TEST", 151, 163], ["SARS", "OBSERVATION_MODIFIER", 71, 75], ["infection", "OBSERVATION", 76, 85]]], ["In these 20 sera from SARSrecovered donors, there were 15, 17, 11, and 5 sera reactive to S1, S2, S1-N, and S1-C recombinant proteins, respectively, as detected by WB (details in Table 1 ).", [["sera", "ANATOMY", 12, 16], ["sera", "ANATOMY", 73, 77], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["donors", "ORGANISM", 36, 42], ["sera", "ORGANISM_SUBSTANCE", 73, 77], ["S2", "CELL", 94, 96], ["S1-N", "SIMPLE_CHEMICAL", 98, 102], ["S1-C", "SIMPLE_CHEMICAL", 108, 112], ["S1", "PROTEIN", 90, 92], ["S2", "PROTEIN", 94, 96], ["S1", "PROTEIN", 98, 100], ["N", "PROTEIN", 101, 102], ["S1", "PROTEIN", 108, 110], ["C", "PROTEIN", 111, 112], ["recombinant proteins", "PROTEIN", 113, 133], ["WB", "PROTEIN", 164, 166], ["SARSrecovered donors", "TEST", 22, 42], ["sera", "TEST", 73, 77], ["S1", "TEST", 90, 92], ["S2", "TEST", 94, 96], ["S1", "TEST", 98, 100], ["S2", "ANATOMY", 94, 96]]], ["None of the sera from control healthy donors was reactive using the killed SARS virus ELISA kit, with the exception of a very weak reaction found in two samples from sera collected prior to the outbreak of SARS (OD 0.172 and 0.136, respectively).", [["sera", "ANATOMY", 12, 16], ["samples", "ANATOMY", 153, 160], ["sera", "ANATOMY", 166, 170], ["SARS", "DISEASE", 206, 210], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["donors", "ORGANISM", 38, 44], ["sera", "ORGANISM_SUBSTANCE", 166, 170], ["SARS virus", "SPECIES", 75, 85], ["a very weak reaction", "PROBLEM", 119, 139], ["sera", "TEST", 166, 170], ["SARS", "PROBLEM", 206, 210], ["very", "OBSERVATION_MODIFIER", 121, 125], ["weak", "OBSERVATION_MODIFIER", 126, 130], ["reaction", "OBSERVATION", 131, 139]]], ["Antibodies against S1 and S1-N were also detected by WB in sera from the three groups of healthy donors (the positive rate is shown in Table 2 ).", [["WB", "ANATOMY", 53, 55], ["sera", "ANATOMY", 59, 63], ["S1", "GENE_OR_GENE_PRODUCT", 19, 21], ["S1-N", "GENE_OR_GENE_PRODUCT", 26, 30], ["sera", "ORGANISM_SUBSTANCE", 59, 63], ["donors", "ORGANISM", 97, 103], ["S1", "PROTEIN", 19, 21], ["S1", "PROTEIN", 26, 28], ["N", "PROTEIN", 29, 30], ["WB", "PROTEIN", 53, 55], ["Antibodies", "TEST", 0, 10], ["the positive rate", "TEST", 105, 122]]], ["In contrast, antibodies against S1-C and S2 fragments by WB were only detected in the sera from the healthy donors with SARS contact history, but not in the sera from the other healthy donors (Table 3) .WB with recombinant S2 subunit could be useful in diagnosis of SARSAnti-SARS-CoV antibodies and anti-S2-subunit antibodies could be detected in sera from SARS-suspected patients from Hong Kong and Beijing by ELISA and WB, respectively ( Table 4 ).", [["WB", "ANATOMY", 57, 59], ["sera", "ANATOMY", 86, 90], ["sera", "ANATOMY", 157, 161], ["WB", "ANATOMY", 203, 205], ["sera", "ANATOMY", 347, 351], ["SARS", "DISEASE", 120, 124], ["SARS", "DISEASE", 357, 361], ["S1-C", "GENE_OR_GENE_PRODUCT", 32, 36], ["S2", "GENE_OR_GENE_PRODUCT", 41, 43], ["WB", "GENE_OR_GENE_PRODUCT", 57, 59], ["sera", "ORGANISM_SUBSTANCE", 86, 90], ["donors", "ORGANISM", 108, 114], ["sera", "ORGANISM_SUBSTANCE", 157, 161], ["donors", "ORGANISM", 185, 191], ["S2", "GENE_OR_GENE_PRODUCT", 223, 225], ["SARSAnti-SARS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 266, 294], ["anti-S2-subunit", "GENE_OR_GENE_PRODUCT", 299, 314], ["sera", "ORGANISM_SUBSTANCE", 347, 351], ["patients", "ORGANISM", 372, 380], ["antibodies", "PROTEIN", 13, 23], ["S1-C and S2 fragments", "DNA", 32, 53], ["WB", "PROTEIN", 57, 59], ["WB", "PROTEIN", 203, 205], ["recombinant S2 subunit", "PROTEIN", 211, 233], ["SARSAnti-SARS-CoV antibodies", "PROTEIN", 266, 294], ["anti-S2", "PROTEIN", 299, 306], ["subunit antibodies", "PROTEIN", 307, 325], ["patients", "SPECIES", 372, 380], ["SARSAnti-SARS-CoV", "SPECIES", 266, 283], ["antibodies", "TEST", 13, 23], ["S1-C and S2 fragments", "PROBLEM", 32, 53], ["WB", "TEST", 203, 205], ["recombinant S2 subunit", "TREATMENT", 211, 233], ["SARSAnti-SARS", "TEST", 266, 279], ["CoV antibodies", "TEST", 280, 294], ["anti-S2", "TEST", 299, 306], ["subunit antibodies", "PROBLEM", 307, 325], ["SARS", "PROBLEM", 357, 361], ["ELISA", "TEST", 411, 416], ["S2", "ANATOMY", 41, 43], ["fragments", "OBSERVATION", 44, 53]]], ["The positive rate of the antibodies in these sera is less than that in sera from SARS patients in The First Hospital of Peking University who were diagnosed as SARS confirmed.", [["sera", "ANATOMY", 45, 49], ["sera", "ANATOMY", 71, 75], ["SARS", "DISEASE", 81, 85], ["SARS", "DISEASE", 160, 164], ["sera", "ORGANISM_SUBSTANCE", 45, 49], ["sera", "ORGANISM_SUBSTANCE", 71, 75], ["patients", "ORGANISM", 86, 94], ["antibodies", "PROTEIN", 25, 35], ["patients", "SPECIES", 86, 94], ["the antibodies", "TEST", 21, 35], ["SARS", "PROBLEM", 160, 164], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["rate", "OBSERVATION_MODIFIER", 13, 17]]], ["Furthermore, in 10 selected ELISA-positive serum samples from patients with a compatible history of disease prior to 2003, antibodies against S2 recombinant protein were detected in three samples (Table 4 ).DiscussionIn order to evaluate the diagnostic utility of a WB assay using recombinant S protein fragments, sera from 20 SARSrecovered donors were tested in this study.", [["serum samples", "ANATOMY", 43, 56], ["samples", "ANATOMY", 188, 195], ["sera", "ANATOMY", 314, 318], ["serum samples", "ORGANISM_SUBSTANCE", 43, 56], ["patients", "ORGANISM", 62, 70], ["S2", "GENE_OR_GENE_PRODUCT", 142, 144], ["sera", "ORGANISM_SUBSTANCE", 314, 318], ["donors", "ORGANISM", 341, 347], ["antibodies", "PROTEIN", 123, 133], ["S2 recombinant protein", "PROTEIN", 142, 164], ["recombinant S protein fragments", "PROTEIN", 281, 312], ["patients", "SPECIES", 62, 70], ["selected ELISA", "TEST", 19, 33], ["serum samples", "TEST", 43, 56], ["disease", "PROBLEM", 100, 107], ["antibodies", "TEST", 123, 133], ["S2 recombinant protein", "PROBLEM", 142, 164], ["a WB assay", "TEST", 264, 274], ["recombinant S protein fragments", "TREATMENT", 281, 312], ["sera", "TEST", 314, 318], ["20 SARSrecovered donors", "TREATMENT", 324, 347], ["this study", "TEST", 363, 373], ["disease", "OBSERVATION", 100, 107]]], ["All patients were diagnosed as SARS cases and infected in the same time interval.", [["SARS", "DISEASE", 31, 35], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["SARS cases", "PROBLEM", 31, 41], ["infected", "OBSERVATION_MODIFIER", 46, 54]]], ["The samples were collected at the same time to avoid any possible error caused by sample collection differences.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["error", "PROBLEM", 66, 71], ["sample collection differences", "PROBLEM", 82, 111]]], ["In the 85% of these serum samples, antibodies against SARS-CoV were detected with a commercial ELISA assay were also positive using the WB with recombinant S2 protein that we developed.", [["serum samples", "ANATOMY", 20, 33], ["serum samples", "ORGANISM_SUBSTANCE", 20, 33], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["S2", "GENE_OR_GENE_PRODUCT", 156, 158], ["antibodies", "PROTEIN", 35, 45], ["WB", "PROTEIN", 136, 138], ["recombinant S2 protein", "PROTEIN", 144, 166], ["SARS-CoV", "SPECIES", 54, 62], ["these serum samples", "TEST", 14, 33], ["antibodies", "TEST", 35, 45], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["a commercial ELISA assay", "TEST", 82, 106], ["the WB", "TEST", 132, 138]]], ["Antibodies were not detected using either test method in the healthy control sera with the exception of two weakly reactive samples.", [["sera", "ANATOMY", 77, 81], ["samples", "ANATOMY", 124, 131], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["Antibodies", "TEST", 0, 10], ["test method", "TEST", 42, 53], ["reactive", "OBSERVATION", 115, 123]]], ["Furthermore, only serum from one patient was negative with both the commercial ELISA and WB based on the S2 recombinant protein.", [["serum", "ANATOMY", 18, 23], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["patient", "ORGANISM", 33, 40], ["WB", "PROTEIN", 89, 91], ["S2 recombinant protein", "PROTEIN", 105, 127], ["patient", "SPECIES", 33, 40], ["serum", "TEST", 18, 23], ["the commercial ELISA", "TEST", 64, 84], ["the S2 recombinant protein", "TREATMENT", 101, 127]]], ["This suggests that the commercial ELISA kit for SARS combined with the WB assay using the recombinant S2 subunit may provide improved diagnostic capability.DiscussionAntibodies against S1 and S1-N were detected by WB in sera both from SARS-recovered donors and all the control groups.", [["WB", "ANATOMY", 214, 216], ["sera", "ANATOMY", 220, 224], ["SARS", "DISEASE", 48, 52], ["SARS", "DISEASE", 235, 239], ["S2", "GENE_OR_GENE_PRODUCT", 102, 104], ["S1", "GENE_OR_GENE_PRODUCT", 185, 187], ["S1-N", "GENE_OR_GENE_PRODUCT", 192, 196], ["WB", "ORGANISM_SUBSTANCE", 214, 216], ["sera", "ORGANISM_SUBSTANCE", 220, 224], ["donors", "ORGANISM", 250, 256], ["recombinant S2 subunit", "PROTEIN", 90, 112], ["S1", "PROTEIN", 185, 187], ["S1", "PROTEIN", 192, 194], ["WB", "PROTEIN", 214, 216], ["the commercial ELISA kit", "TEST", 19, 43], ["SARS", "PROBLEM", 48, 52], ["the WB assay", "TEST", 67, 79], ["the recombinant S2 subunit", "TREATMENT", 86, 112], ["WB in sera", "TEST", 214, 224], ["SARS", "PROBLEM", 235, 239]]], ["Thus, it appears that antibodies directed against S1 or S1-N are less useful for making a diagnosis of SARS.", [["SARS", "DISEASE", 103, 107], ["antibodies directed against S1", "GENE_OR_GENE_PRODUCT", 22, 52], ["S1-N", "GENE_OR_GENE_PRODUCT", 56, 60], ["antibodies", "PROTEIN", 22, 32], ["S1", "PROTEIN", 50, 52], ["S1", "PROTEIN", 56, 58], ["antibodies", "TEST", 22, 32], ["SARS", "PROBLEM", 103, 107]]], ["On the other hand, antibodies against S1-C and S2 by WB were detected only in sera from SARS-recovered donors and some donors with SARS contact history.", [["WB", "ANATOMY", 53, 55], ["sera", "ANATOMY", 78, 82], ["SARS", "DISEASE", 88, 92], ["SARS", "DISEASE", 131, 135], ["S1-C", "GENE_OR_GENE_PRODUCT", 38, 42], ["S2", "GENE_OR_GENE_PRODUCT", 47, 49], ["WB", "GENE_OR_GENE_PRODUCT", 53, 55], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["donors", "ORGANISM", 103, 109], ["donors", "ORGANISM", 119, 125], ["antibodies", "PROTEIN", 19, 29], ["S1", "PROTEIN", 38, 40], ["C", "PROTEIN", 41, 42], ["S2", "PROTEIN", 47, 49], ["WB", "PROTEIN", 53, 55], ["antibodies", "TEST", 19, 29]]], ["In some commercial ELISA-negative serum samples, antibodies to S1-C and S2 by WB were positive possibly due to the destruction or alteration of SARS-CoV surface protein during the viral preparation process for the ELISA kits.", [["serum samples", "ANATOMY", 34, 47], ["WB", "ANATOMY", 78, 80], ["serum samples", "ORGANISM_SUBSTANCE", 34, 47], ["S1-C", "GENE_OR_GENE_PRODUCT", 63, 67], ["S2", "GENE_OR_GENE_PRODUCT", 72, 74], ["WB", "GENE_OR_GENE_PRODUCT", 78, 80], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["antibodies", "PROTEIN", 49, 59], ["S1", "PROTEIN", 63, 65], ["S2", "PROTEIN", 72, 74], ["WB", "PROTEIN", 78, 80], ["SARS-CoV surface protein", "PROTEIN", 144, 168], ["SARS-CoV", "SPECIES", 144, 152], ["some commercial ELISA", "TEST", 3, 24], ["serum samples", "TEST", 34, 47], ["antibodies", "TEST", 49, 59], ["S1", "TEST", 63, 65], ["WB", "TEST", 78, 80], ["the destruction", "PROBLEM", 111, 126], ["alteration of SARS", "PROBLEM", 130, 148], ["CoV surface protein", "PROBLEM", 149, 168], ["the viral preparation process", "TREATMENT", 176, 205], ["the ELISA kits", "TEST", 210, 224], ["S2", "ANATOMY", 72, 74], ["possibly due to", "UNCERTAINTY", 95, 110], ["destruction", "OBSERVATION", 115, 126]]], ["This suggests that detecting antibodies to S1-C or S2 by WB may be useful in making a diagnosis of SARS exposure in the setting of a negative SARS ELISA assay.DiscussionHowever, clinicians should cautious in interpreting a weakly positive ELISA result (OD b 0.5).", [["WB", "ANATOMY", 57, 59], ["SARS", "DISEASE", 99, 103], ["S1-C", "GENE_OR_GENE_PRODUCT", 43, 47], ["S2", "GENE_OR_GENE_PRODUCT", 51, 53], ["WB", "GENE_OR_GENE_PRODUCT", 57, 59], ["antibodies", "PROTEIN", 29, 39], ["S1", "PROTEIN", 43, 45], ["S2", "PROTEIN", 51, 53], ["antibodies", "TEST", 29, 39], ["SARS exposure", "PROBLEM", 99, 112], ["a negative SARS ELISA assay", "PROBLEM", 131, 158], ["SARS", "OBSERVATION", 99, 103]]], ["This could represent an antibody to a non-SARS-CoV that cross-reacts with the SARS-CoV antigen preparation in the ELISA kit, a phenomenon that has been reported previously [18, 19] .", [["non-SARS-CoV", "GENE_OR_GENE_PRODUCT", 38, 50], ["SARS-CoV antigen", "GENE_OR_GENE_PRODUCT", 78, 94], ["SARS-CoV antigen", "PROTEIN", 78, 94], ["non-SARS-CoV", "SPECIES", 38, 50], ["SARS-CoV", "SPECIES", 78, 86], ["an antibody", "PROBLEM", 21, 32], ["the SARS", "TEST", 74, 82], ["CoV antigen preparation", "TREATMENT", 83, 106], ["the ELISA kit", "TEST", 110, 123], ["a phenomenon", "PROBLEM", 125, 137], ["could represent", "UNCERTAINTY", 5, 20], ["antibody", "OBSERVATION", 24, 32]]], ["As shown above, recombinant S1 and its fragments as a target for antibody detection do not appear to provide additional useful diagnostic information.", [["fragments", "ANATOMY", 39, 48], ["recombinant S1", "GENE_OR_GENE_PRODUCT", 16, 30], ["recombinant S1", "PROTEIN", 16, 30], ["recombinant S1 and its fragments", "PROBLEM", 16, 48], ["antibody detection", "TEST", 65, 83], ["S1", "ANATOMY", 28, 30], ["fragments", "OBSERVATION", 39, 48]]], ["However, 10 ELISA-positive (OD b 0.5) sera were identified from patients collected before SARS outbreak in 2003 with symptoms that included fever.", [["sera", "ANATOMY", 38, 42], ["SARS", "DISEASE", 90, 94], ["fever", "DISEASE", 140, 145], ["sera", "ORGANISM_SUBSTANCE", 38, 42], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["ELISA", "TEST", 12, 17], ["sera", "TEST", 38, 42], ["SARS outbreak", "PROBLEM", 90, 103], ["symptoms", "PROBLEM", 117, 125], ["fever", "PROBLEM", 140, 145]]], ["These sera were tested using the WB assay with recombinant S2 subunit and three of these were positive.", [["sera", "ANATOMY", 6, 10], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["S2", "GENE_OR_GENE_PRODUCT", 59, 61], ["recombinant S2 subunit", "PROTEIN", 47, 69], ["These sera", "TEST", 0, 10], ["the WB assay", "TEST", 29, 41], ["positive", "OBSERVATION", 94, 102]]], ["Additional testing with the recombinant S2 protein are required to determine if the WB to recombinant S2 protein will prove to be useful in evaluating ELISApositive sera from patients who do not fulfill the criteria for diagnosing SARS.DiscussionIn order to evaluate the utility of the WB assay with recombinant S2 subunit in aiding in the diagnosis of SARS, sera from SARS-suspected patients were tested with both the S2-WB and a commercial SARS ELISA assay.", [["sera", "ANATOMY", 165, 169], ["sera", "ANATOMY", 359, 363], ["SARS", "DISEASE", 231, 235], ["SARS", "DISEASE", 353, 357], ["SARS", "DISEASE", 369, 373], ["S2", "GENE_OR_GENE_PRODUCT", 40, 42], ["S2", "GENE_OR_GENE_PRODUCT", 102, 104], ["sera", "ORGANISM_SUBSTANCE", 165, 169], ["patients", "ORGANISM", 175, 183], ["S2", "GENE_OR_GENE_PRODUCT", 312, 314], ["sera", "ORGANISM_SUBSTANCE", 359, 363], ["patients", "ORGANISM", 384, 392], ["recombinant S2 protein", "PROTEIN", 28, 50], ["WB", "PROTEIN", 84, 86], ["recombinant S2 protein", "PROTEIN", 90, 112], ["recombinant S2 subunit", "PROTEIN", 300, 322], ["S2", "PROTEIN", 419, 421], ["WB", "PROTEIN", 422, 424], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 384, 392], ["Additional testing", "TEST", 0, 18], ["the recombinant S2 protein", "TEST", 24, 50], ["the WB", "TEST", 80, 86], ["diagnosing SARS", "PROBLEM", 220, 235], ["the WB assay", "TEST", 282, 294], ["SARS", "PROBLEM", 353, 357], ["SARS", "PROBLEM", 369, 373], ["a commercial SARS ELISA assay", "TEST", 429, 458]]], ["Antibodies against SARS-CoV were detected in some of the serum samples from two different groups of suspected SARS patients using the combination of SARS ELISA and S2-WB assays.", [["serum samples", "ANATOMY", 57, 70], ["SARS", "DISEASE", 110, 114], ["SARS-CoV", "ORGANISM", 19, 27], ["serum samples", "ORGANISM_SUBSTANCE", 57, 70], ["patients", "ORGANISM", 115, 123], ["S2", "PROTEIN", 164, 166], ["patients", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 19, 27], ["Antibodies", "TEST", 0, 10], ["SARS", "PROBLEM", 19, 23], ["CoV", "PROBLEM", 24, 27], ["the serum samples", "TEST", 53, 70], ["SARS ELISA", "TEST", 149, 159], ["S2-WB assays", "TEST", 164, 176]]], ["As might be expected, the positive rate in these serum samples was lower than that found in SARSconfirmed cases obtained from The First Hospital of Peking University.", [["serum samples", "ANATOMY", 49, 62], ["serum samples", "ORGANISM_SUBSTANCE", 49, 62], ["the positive rate", "TEST", 22, 39], ["these serum samples", "TEST", 43, 62]]], ["This may be due to non-SARS patients being present within these two groups and/or the absence of a significant antibody response early in the course of SARS.", [["SARS", "DISEASE", 152, 156], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["a significant antibody response", "PROBLEM", 97, 128], ["SARS", "PROBLEM", 152, 156], ["may be due to", "UNCERTAINTY", 5, 18], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["antibody response", "OBSERVATION", 111, 128]]], ["If the latter circumstance is correct, then the evaluation of the diagnostic effectiveness of a test method including ELISA or WB should be established using sera from SARSconfirmed cases rather than SARS-suspected cases.", [["sera", "ANATOMY", 158, 162], ["SARS", "DISEASE", 200, 204], ["sera", "ORGANISM_SUBSTANCE", 158, 162], ["the evaluation", "TEST", 44, 58], ["a test method", "TEST", 94, 107], ["ELISA", "TEST", 118, 123], ["WB", "TEST", 127, 129]]], ["The time course of antibody generation to SARS-CoV following the onset of symptoms is an important diagnostic issue and has been previously reported to vary widely [20] -from 3 days to more than 1 month following the onset of fever (data not shown).DiscussionSARS-CoV recombinant proteins expressed in E. coli have been shown to be recognized by antibodies in the serum from coronavirus-infected animals [21, 22] .", [["serum", "ANATOMY", 364, 369], ["SARS", "DISEASE", 42, 46], ["fever", "DISEASE", 226, 231], ["coronavirus-infected", "DISEASE", 375, 395], ["SARS-CoV", "ORGANISM", 42, 50], ["DiscussionSARS-CoV", "GENE_OR_GENE_PRODUCT", 249, 267], ["E. coli", "ORGANISM", 302, 309], ["serum", "ORGANISM_SUBSTANCE", 364, 369], ["coronavirus", "ORGANISM", 375, 386], ["DiscussionSARS-CoV recombinant proteins", "PROTEIN", 249, 288], ["antibodies", "PROTEIN", 346, 356], ["E. coli", "SPECIES", 302, 309], ["SARS-CoV", "SPECIES", 42, 50], ["E. coli", "SPECIES", 302, 309], ["antibody generation", "PROBLEM", 19, 38], ["SARS", "PROBLEM", 42, 46], ["symptoms", "PROBLEM", 74, 82], ["fever", "PROBLEM", 226, 231], ["DiscussionSARS", "TEST", 249, 263], ["CoV recombinant proteins", "PROBLEM", 264, 288], ["E. coli", "PROBLEM", 302, 309], ["the serum", "TEST", 360, 369], ["coronavirus", "PROBLEM", 375, 386], ["fever", "OBSERVATION", 226, 231]]], ["Furthermore, recombinant coronavirus proteins expressed in E. coli has been demonstrated to have antigenicity and receptor binding ability [23, 24] .", [["recombinant coronavirus", "ORGANISM", 13, 36], ["E. coli", "ORGANISM", 59, 66], ["recombinant coronavirus proteins", "PROTEIN", 13, 45], ["coronavirus", "SPECIES", 25, 36], ["E. coli", "SPECIES", 59, 66], ["E. coli", "SPECIES", 59, 66], ["recombinant coronavirus proteins", "PROBLEM", 13, 45], ["E. coli", "PROBLEM", 59, 66], ["receptor binding ability", "TEST", 114, 138], ["E. coli", "OBSERVATION_MODIFIER", 59, 66]]], ["Our data suggest that the recombinant S1-C and S2 may have potential use in the production of SARS vaccines.", [["SARS", "DISEASE", 94, 98], ["S1-C", "GENE_OR_GENE_PRODUCT", 38, 42], ["S2", "GENE_OR_GENE_PRODUCT", 47, 49], ["recombinant S1-C", "PROTEIN", 26, 42], ["S2", "PROTEIN", 47, 49], ["Our data", "TEST", 0, 8], ["the recombinant S1-C and S2", "PROBLEM", 22, 49], ["SARS vaccines", "TREATMENT", 94, 107]]], ["This is based in part on the observation that antibodies against S protein were only detected rarely in samples from healthy donors who had been in contact with SARS patients, suggesting that infection and/or immune response may not be consistently generated by common contact.", [["samples", "ANATOMY", 104, 111], ["SARS", "DISEASE", 161, 165], ["infection", "DISEASE", 192, 201], ["antibodies against S protein", "GENE_OR_GENE_PRODUCT", 46, 74], ["samples", "CANCER", 104, 111], ["donors", "ORGANISM", 125, 131], ["patients", "ORGANISM", 166, 174], ["antibodies", "PROTEIN", 46, 56], ["S protein", "PROTEIN", 65, 74], ["patients", "SPECIES", 166, 174], ["S protein", "TEST", 65, 74], ["infection", "PROBLEM", 192, 201], ["immune response", "PROBLEM", 209, 224], ["infection", "OBSERVATION", 192, 201]]], ["This could explain why the researchers are infected even after long-term contact with SARS-CoV prior to infection.DiscussionIn conclusion, our findings suggest that diagnostic approaches using SARS-CoV-specific component proteins may increase the diagnostic accuracy of testing when combined with conventional ELISA tests based on killed virus as the target antigen.", [["SARS", "DISEASE", 86, 90], ["infection", "DISEASE", 104, 113], ["SARS-CoV", "ORGANISM", 86, 94], ["SARS-CoV", "ORGANISM", 193, 201], ["SARS-CoV-specific component proteins", "PROTEIN", 193, 229], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 193, 201], ["SARS", "PROBLEM", 86, 90], ["infection", "PROBLEM", 104, 113], ["SARS", "PROBLEM", 193, 197], ["conventional ELISA tests", "TEST", 297, 321], ["killed virus", "PROBLEM", 331, 343], ["infected", "OBSERVATION", 43, 51], ["infection", "OBSERVATION", 104, 113]]]], "d9fc42fa80cbe6883609871bf1b7047203e1294e": [["IntroductionSince the first case of COVID-19 and its progression to a pandemic, healthcare systems have experienced severe difficulties coping with patient care.", [["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 148, 155], ["COVID", "TEST", 36, 41], ["severe difficulties coping with patient care", "PROBLEM", 116, 160]]], ["As a result, there are growing concerns regarding the capacity for low-and mediumincome countries (LMICs) to cope with a surge of severe COVID-19 cases [1] .", [["COVID", "DISEASE", 137, 142], ["the capacity", "TEST", 50, 62], ["severe COVID", "PROBLEM", 130, 142]]], ["Furthermore, the economic losses experienced has taken its toll on the ability to procure healthcare equipment and materials needed to cope with the rising incidence, admissions, critical care and mortalities associated with COVID-19 [2] .", [["COVID-19", "CHEMICAL", 225, 233], ["the economic losses", "PROBLEM", 13, 32], ["COVID", "TEST", 225, 230]]], ["Medical centres have had to defer elective procedures such as dental, ear, nose and throat (ENT) and plastic surgery procedures to preserve resources such as hospital beds and ICU space to manage COVID-19 patients.", [["ear", "ANATOMY", 70, 73], ["nose", "ANATOMY", 75, 79], ["COVID", "DISEASE", 196, 201], ["ear", "ORGAN", 70, 73], ["nose", "ORGANISM_SUBDIVISION", 75, 79], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["elective procedures", "TREATMENT", 34, 53], ["dental, ear, nose and throat", "PROBLEM", 62, 90], ["plastic surgery procedures", "TREATMENT", 101, 127], ["ear", "ANATOMY", 70, 73], ["nose", "ANATOMY", 75, 79], ["throat", "ANATOMY", 84, 90]]], ["In other centres, entire emergency rooms have been filled to capacity with COVID-19 patients, requiring makeshift overflow areas in parking lots, or factory and sports arena for the treatment of COVID-19 patients [3] [4] [5] [6] .", [["COVID", "DISEASE", 195, 200], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 204, 212], ["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 213, 228], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 204, 212], ["COVID", "TEST", 75, 80], ["the treatment of COVID", "TREATMENT", 178, 200]]], ["In spite of this, there are other health challenges besides COVID-19.", [["COVID-19", "CHEMICAL", 60, 68], ["COVID", "TEST", 60, 65]]], ["Some of these health challenges require treatment even in the wake of the COVID-19 pandemic.", [["treatment", "TREATMENT", 40, 49], ["the COVID", "TEST", 70, 79], ["pandemic", "PROBLEM", 83, 91]]], ["One such disease that requires on going treatment, follow-up and procedures is cancer.", [["cancer", "ANATOMY", 79, 85], ["cancer", "DISEASE", 79, 85], ["cancer", "CANCER", 79, 85], ["One such disease", "PROBLEM", 0, 16], ["treatment", "TREATMENT", 40, 49], ["cancer", "PROBLEM", 79, 85], ["disease", "OBSERVATION", 9, 16], ["cancer", "OBSERVATION", 79, 85]]], ["The COVID-19 pandemic does pose a real threat to cancer care world over.IntroductionIn some countries, patients with cancer are not able to receive care from their care givers because such facilities are filled to capacity with COVID-19 patients.", [["cancer", "ANATOMY", 49, 55], ["cancer", "ANATOMY", 117, 123], ["cancer", "DISEASE", 49, 55], ["cancer", "DISEASE", 117, 123], ["cancer", "CANCER", 49, 55], ["patients", "ORGANISM", 103, 111], ["cancer", "CANCER", 117, 123], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 237, 245], ["cancer", "PROBLEM", 117, 123], ["cancer", "OBSERVATION", 49, 55]]], ["In the unfortunate event that a COVID-19 patient with cancer requires ventilator support from severe respiratory distress, anecdotal evidence has shown that they are less favoured to receive such essential care due to the cancer comorbidity [7] .", [["cancer", "ANATOMY", 54, 60], ["respiratory", "ANATOMY", 101, 112], ["cancer", "ANATOMY", 222, 228], ["cancer", "DISEASE", 54, 60], ["respiratory distress", "DISEASE", 101, 121], ["cancer", "DISEASE", 222, 228], ["patient", "ORGANISM", 41, 48], ["cancer", "CANCER", 54, 60], ["cancer", "CANCER", 222, 228], ["patient", "SPECIES", 41, 48], ["cancer", "PROBLEM", 54, 60], ["ventilator support", "TREATMENT", 70, 88], ["severe respiratory distress", "PROBLEM", 94, 121], ["such essential care", "TREATMENT", 191, 210], ["the cancer comorbidity", "PROBLEM", 218, 240], ["cancer", "OBSERVATION", 54, 60], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["respiratory distress", "OBSERVATION", 101, 121], ["cancer", "OBSERVATION", 222, 228]]], ["Other challenges besides those above include: which patient should be prioritized or deprioritized for treatment?", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["treatment", "TREATMENT", 103, 112]]], ["Which procedure (surgery, radiotherapy and chemotherapy) should continue or be deferred?", [["procedure (surgery", "TREATMENT", 6, 24], ["radiotherapy", "TREATMENT", 26, 38], ["chemotherapy", "TREATMENT", 43, 55]]], ["And what precautionary steps should be taken to protect the health worker and patient during treatment?", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["treatment", "TREATMENT", 93, 102]]], ["Unfortunately, there are no straightforward answers to these questions.", [["no", "UNCERTAINTY", 25, 27]]], ["These LMICs are already bedeviled with weak health systems, ill equipped cancer treatment centers, with outdated machines and grossly inadequate numbers of oncologists required to treat patients with cancer.", [["cancer", "ANATOMY", 73, 79], ["cancer", "ANATOMY", 200, 206], ["cancer", "DISEASE", 73, 79], ["cancer", "DISEASE", 200, 206], ["cancer", "CANCER", 73, 79], ["patients", "ORGANISM", 186, 194], ["cancer", "CANCER", 200, 206], ["patients", "SPECIES", 186, 194], ["weak health systems", "PROBLEM", 39, 58], ["ill equipped cancer treatment centers", "TREATMENT", 60, 97], ["outdated machines", "TREATMENT", 104, 121], ["cancer", "PROBLEM", 200, 206], ["cancer", "OBSERVATION", 200, 206]]], ["Due to this inability to arrive at a consensus on how to manage cancer patients in the wake of the COVID-19 pandemic, 11 key opinion leaders had a consensus meeting to identify challenges and practical solutions on continuing cancer care during the COVID-19 pandemic.", [["cancer", "ANATOMY", 64, 70], ["cancer", "ANATOMY", 226, 232], ["cancer", "DISEASE", 64, 70], ["cancer", "DISEASE", 226, 232], ["cancer", "CANCER", 64, 70], ["patients", "ORGANISM", 71, 79], ["cancer", "CANCER", 226, 232], ["patients", "SPECIES", 71, 79], ["this inability", "PROBLEM", 7, 21], ["cancer", "PROBLEM", 64, 70], ["the COVID", "TEST", 95, 104], ["practical solutions", "TREATMENT", 192, 211], ["continuing cancer care", "TREATMENT", 215, 237], ["the COVID", "TEST", 245, 254], ["pandemic", "PROBLEM", 258, 266]]], ["The discussion was to highlight the challenges and barriers to cancer care in the Nigerian setting during the COVID-19 pandemic and proffer possible solutions that could be adopted by cancer treatment centres across the country.MethodsThe eleven discussants were invited to a Zoom meeting which took place on the 30 th of March at 5: 30pm and lasted for 1 hour 19 minutes.", [["cancer", "ANATOMY", 63, 69], ["cancer", "ANATOMY", 184, 190], ["cancer", "DISEASE", 63, 69], ["cancer", "DISEASE", 184, 190], ["cancer", "CANCER", 63, 69], ["cancer", "CANCER", 184, 190], ["barriers to cancer care", "TREATMENT", 51, 74], ["solutions", "TREATMENT", 149, 158], ["cancer treatment centres", "TREATMENT", 184, 208], ["cancer", "OBSERVATION", 184, 190]]], ["Among the eight that practice in Nigeria, 5 practice in south-western (SW), 1 in the northern (N), 1 in the south-eastern (SE), and 1 in the south-southern (SS) part of Nigeria.", [["SE", "DISEASE", 123, 125]]], ["The discussion focused on policies regarding the care of oncology patients in the COVID-19 era, in the Nigerian setting rather than individual case management.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["individual case management", "TREATMENT", 132, 158]]], ["Case vignette approach was used to ensure the policies placed individual patient care in perspective.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80]]], ["Scenario 1: a 66-year-old man with metastatic hormone refractory prostate cancer, whose disease had progressed on Zoladex.", [["metastatic hormone refractory prostate cancer", "ANATOMY", 35, 80], ["prostate cancer", "DISEASE", 65, 80], ["Zoladex", "CHEMICAL", 114, 121], ["man", "ORGANISM", 26, 29], ["prostate cancer", "CANCER", 65, 80], ["man", "SPECIES", 26, 29], ["metastatic hormone refractory prostate cancer", "PROBLEM", 35, 80], ["whose disease", "PROBLEM", 82, 95], ["Zoladex", "TREATMENT", 114, 121], ["metastatic", "OBSERVATION_MODIFIER", 35, 45], ["hormone", "OBSERVATION", 46, 53], ["refractory", "OBSERVATION_MODIFIER", 54, 64], ["prostate", "ANATOMY", 65, 73], ["cancer", "OBSERVATION", 74, 80]]], ["He is currently on intravenous Docetaxel, and has had two cycles.", [["intravenous", "ANATOMY", 19, 30], ["Docetaxel", "CHEMICAL", 31, 40], ["Docetaxel", "CHEMICAL", 31, 40], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["Docetaxel", "SIMPLE_CHEMICAL", 31, 40], ["intravenous Docetaxel", "TREATMENT", 19, 40]]], ["He calls his oncologist two days prior to his due date for his third cycle of the treatment asking if he can travel over to receive the third cycle.", [["the treatment", "TREATMENT", 78, 91]]], ["A) Tell him there will be no chemotherapy administration because of the COVID-19 pandemic and he should call you after the outbreak is controlled.", [["chemotherapy administration", "TREATMENT", 29, 56], ["the COVID", "TEST", 68, 77]]], ["C) Ask him to come over for the chemotherapy as it is business as usual.", [["the chemotherapy", "TREATMENT", 28, 44]]], ["D) Convert his treatment to Abiraterone (an oral drug).", [["oral", "ANATOMY", 44, 48], ["Abiraterone", "CHEMICAL", 28, 39], ["Abiraterone", "CHEMICAL", 28, 39], ["Abiraterone", "SIMPLE_CHEMICAL", 28, 39], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["his treatment", "TREATMENT", 11, 24], ["Abiraterone", "TREATMENT", 28, 39], ["an oral drug", "TREATMENT", 41, 53]]], ["Scenario 2: a 46-year-old widow and single mother of two diagnosed with triple negative breast cancer T3N1M0 who is yet to commence any treatment.", [["breast cancer", "ANATOMY", 88, 101], ["breast cancer", "DISEASE", 88, 101], ["breast cancer", "CANCER", 88, 101], ["triple negative breast cancer", "PROBLEM", 72, 101], ["any treatment", "TREATMENT", 132, 145], ["breast", "ANATOMY", 88, 94], ["cancer", "OBSERVATION", 95, 101]]], ["She lives in the same locality as her oncologist who saw her the previous week and obliged her to commence neoadjuvant chemotherapy.", [["She", "ORGANISM", 0, 3], ["neoadjuvant chemotherapy", "TREATMENT", 107, 131]]], ["She calls at 6am to inform her oncologist she is coming over for her chemotherapy as planned but wants to know the hospital policy regarding accompanying relatives as she wants to come with her two teenage daughters.", [["her chemotherapy", "TREATMENT", 65, 81]]], ["B) Tell her there will be no chemotherapy administration because of the COVID-19 pandemic and she should call you after the outbreak is controlled.", [["chemotherapy administration", "TREATMENT", 29, 56], ["the COVID", "TEST", 68, 77]]], ["C) Ask her to come over for the chemotherapy, but her daughters cannot accompany her.", [["the chemotherapy", "TREATMENT", 28, 44]]], ["D) Tell her that her treatment plan has changed to her having surgery first before the chemotherapy.ResultsScenario 1: the majority, 67%, chose option \"B\" to \"refer him to an oncologist in his locality.\"", [["her treatment plan", "TREATMENT", 17, 35], ["surgery", "TREATMENT", 62, 69], ["the chemotherapy", "TREATMENT", 83, 99]]], ["Scenario 2: the majority, 50%, chose option \"C\" to \"ask her to come over for the chemotherapy, but her daughters cannot accompany her.\"ResultsThe polls show majority of the discussants would want cancer care to continue in spite of the challenges the COVID-19 pandemic poses.", [["cancer", "ANATOMY", 196, 202], ["cancer", "DISEASE", 196, 202], ["cancer", "CANCER", 196, 202], ["the chemotherapy", "TREATMENT", 77, 93], ["cancer care", "TREATMENT", 196, 207]]], ["A quote during the discussion that encapsulates this tendency is: \"when this whole COVID thing is over make sure that more people have not died from the fear of COVID than from COVID itself I think that oncology is one of the places that we have to strike this balance very carefully.\"", [["COVID", "DISEASE", 161, 166], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129]]], ["(Oncologist 3, UK)BarriersIn spite of this, the discussants identified existential barriers to cancer care in Nigeria due to the COVID-19 pandemic.BarriersLockdown/Curfew: some states like Lagos and Ogun states have enforced a total lockdown, which started on the 30 th of March 2020, to curb the spread of the virus.", [["cancer", "ANATOMY", 95, 101], ["cancer", "DISEASE", 95, 101], ["cancer", "CANCER", 95, 101], ["cancer care", "TREATMENT", 95, 106], ["the COVID", "TEST", 125, 134], ["pandemic", "PROBLEM", 138, 146], ["a total lockdown", "TREATMENT", 225, 241], ["the virus", "PROBLEM", 307, 316]]], ["One of the discussants said \"There is a curfew that will start tonight and more than 50% of the patients already stopped coming\" (Oncologist 3, SW Nigeria).", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104]]], ["Another discussant noted, regarding one of the hypothetical case scenarios, that \"if this patient is coming (from out of state), she won\u00b4t be able to, even if she comes in, she won\u00b4t be able to stay long.\"", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97]]], ["(Oncologist 6, SE Nigeria).BarriersPatients fear contracting COVID-19 from health workers: apart from the lockdown/curfew which limits patients from accessing cancer care at oncology centres.", [["cancer", "ANATOMY", 159, 165], ["cancer", "DISEASE", 159, 165], ["patients", "ORGANISM", 135, 143], ["cancer", "CANCER", 159, 165], ["patients", "SPECIES", 135, 143], ["accessing cancer care", "TREATMENT", 149, 170]]], ["Some patients have refused to come for fear of contracting the virus.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["contracting the virus", "PROBLEM", 47, 68]]], ["For instance one of the discussants practicing in Lagos said that \"they are scared of the virus and they believe the hospital is a point of transmission for them Naturally our patients have dropped and they are not going to come.\"", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184]]], ["(Oncologist 3, SW Nigeria).BarriersOutpatient and Surgery: due to epidemiological spread of COVID-19 within certain hospitals, the management of some hospitals scaled down services such as outpatient services and elective surgeries.", [["Surgery", "TREATMENT", 50, 57], ["COVID", "TEST", 92, 97], ["outpatient services", "TREATMENT", 189, 208], ["elective surgeries", "TREATMENT", 213, 231]]], ["Cancer outpatient clinics and chemotherapy clinics are categorized as outpatient clinics.", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6], ["chemotherapy", "TREATMENT", 30, 42]]], ["Hence, patient evaluation, follow up, chemotherapy administration and radiotherapy procedures could not proceed as usual.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["patient evaluation", "TEST", 7, 25], ["chemotherapy administration", "TREATMENT", 38, 65], ["radiotherapy procedures", "TREATMENT", 70, 93]]], ["One of the discussants said \"there is possibility that there might be a delay in treatment, all the out-patient departments, elective surgery, chemotherapy, (and) radiotherapy have been shut down.\"", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["treatment", "TREATMENT", 81, 90], ["elective surgery", "TREATMENT", 125, 141], ["chemotherapy", "TREATMENT", 143, 155], ["radiotherapy", "TREATMENT", 163, 175]]], ["On the other hand another oncologist said \"our out-patient facilities are not locked down but we are selecting, patients that are critically ill (In addition,) chemotherapy is given to patients (if) it will actually make a difference in their patient-journey.", [["critically ill", "DISEASE", 130, 144], ["patient", "ORGANISM", 51, 58], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 185, 193], ["patient", "ORGANISM", 243, 250], ["patient", "SPECIES", 51, 58], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 185, 193], ["patient", "SPECIES", 243, 250], ["chemotherapy", "TREATMENT", 160, 172]]], ["Elective (surgery) cases have been cancelled but there is also room for (cases that are) potentially curative and we could see as an emergency. \"", [["Elective (surgery", "TREATMENT", 0, 17]]], ["(Oncologist 6, SE Nigeria).BarriersSimilarly, another oncologist noted that \"what we decided to do is suspend brachytherapy because patients come from all over the country so we have decided to suspend taking new patients till things improve.\"", [["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 213, 221], ["brachytherapy", "TREATMENT", 110, 123]]], ["Delaying chemotherapy for up front surgery is an acceptable solution.", [["Delaying chemotherapy", "TREATMENT", 0, 21], ["up front surgery", "TREATMENT", 26, 42]]], ["Yet the barrier to this option is surgeons have stopped elective procedures.", [["elective procedures", "TREATMENT", 56, 75]]], ["A discussant said \"even patients who have been initially booked for surgery have been asked to go away and I do hear you say that (upfront) surgery is okay but if your surgeons are unwilling to operate what then do you do?", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["surgery", "TREATMENT", 68, 75], ["surgery", "TREATMENT", 140, 147]]], ["Another discussant said \"we will usually have an MDT for this (patient) and I suspect we will offer her surgery first.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["her surgery", "TREATMENT", 100, 111]]], ["The surgeons will look at her that she is young and this is a potentially curable intervention and we will go ahead.\"", [["a potentially curable intervention", "TREATMENT", 60, 94]]], ["(Oncologist 6, SE Nigeria).BarriersToll free numbers: the government has made tollfree numbers available for anyone who has been exposed to call so as to be attended to appropriately.", [["Toll", "PROTEIN", 35, 39]]], ["An oncologist stated that \"I had my own fair share of this COVID symptoms, when I did the COVID checker checklist I was high risk.", [["this COVID symptoms", "PROBLEM", 54, 73]]], ["The ideal masks are N95 masks, (and) many parts of the world don\u00b4t even have enough of those for their emergency rooms.", [["N95 masks", "TREATMENT", 20, 29], ["N95 masks", "OBSERVATION", 20, 29]]], ["The discussants concluded that \"a face mask (not necessarily N95), conform gloves during the encounter for procedures, and if available; surgical gowns will suffice\".", [["a face mask", "TREATMENT", 32, 43], ["procedures", "TREATMENT", 107, 117], ["surgical gowns", "TREATMENT", 137, 151]]], ["The discussants also added \"it is not enough to have all these for the physicians but the patient must also be masked as well.\"", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97]]], ["So far we try to get everybody to wear a facemask; at least one party should wear a facemask, either the practitioner or the patient.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["a facemask", "TREATMENT", 39, 49], ["a facemask", "TREATMENT", 82, 92]]], ["In responding to the question regarding precautions and minimum acceptable and practicable protection against COVID-19, one of the oncologists asked \"If it was us that needed cancer treatment, would we be happy for nothing to be available at all until a pandemic that might take months if not longer to resolve gets resolved?\"", [["cancer", "ANATOMY", 175, 181], ["cancer", "DISEASE", 175, 181], ["cancer", "CANCER", 175, 181], ["precautions", "TREATMENT", 40, 51], ["cancer treatment", "TREATMENT", 175, 191]]], ["The discussant further stated that \"I think us having a blanket rule like if we don\u00b4t have gloves, if we don\u00b4t have mask we should not work is really (un) acceptable and I don\u00b4t think that is in keeping with the oath that we all swore as clinicians.\"", [["a blanket rule", "TREATMENT", 54, 68], ["mask", "TREATMENT", 116, 120]]], ["(Oncologist 9, UK).Precautions, protection of health worker andHowever, other oncologists indicated the ethical duty to do no harm to patients.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142]]], ["Indicating a practitioner requiring some form of protection (albeit not the ideal full gear) \"is not just about the clinicians, if I expose myself then I expose every other patient that I come in contact with endanger them as well.", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180]]], ["(By) protecting myself, I am also protecting every patient that I am going to see subsequently after seeing a possible COVID-19 positive patient.", [["patient", "ORGANISM", 51, 58], ["COVID-19", "GENE_OR_GENE_PRODUCT", 119, 127], ["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 137, 144], ["COVID", "TEST", 119, 124]]], ["\"If anyone gets infected, the setting in Nigeria is different.", [["infected", "PROBLEM", 16, 24], ["infected", "OBSERVATION", 16, 24]]], ["So, the best thing at this point is if you want to continue giving chemo (therapy) do so without putting yourself at risk.", [["chemo (therapy", "TREATMENT", 67, 81]]], ["Otherwise, more people would be affected by issues other than COVID-19, when the pandemic is over.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["COVID", "TEST", 62, 67]]], ["There is evidence to show that the disruption to health-care services in Guinea, Liberia and Sierra Leone due to the West African Ebola epidemic led to an estimate of up to 10,900 additional malaria deaths [8, 9] .", [["Ebola", "DISEASE", 130, 135], ["malaria", "DISEASE", 191, 198], ["deaths", "DISEASE", 199, 205], ["additional malaria deaths", "PROBLEM", 180, 205]]], ["However, there are background challenges to cancer care even before the COVID-19 pandemic.", [["cancer", "ANATOMY", 44, 50], ["cancer", "DISEASE", 44, 50], ["cancer", "CANCER", 44, 50], ["cancer care", "TREATMENT", 44, 55], ["the COVID", "TEST", 68, 77], ["pandemic", "PROBLEM", 81, 89]]], ["In Nigeria there are only six oncology centres with functioning radiotherapy machines.", [["functioning radiotherapy machines", "TREATMENT", 52, 85]]], ["Therefore, patients may have to travel long distances across states for oncology care.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["oncology care", "TREATMENT", 72, 85]]], ["The lockdown imposed by various states further affected the mobility of patients.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["mobility", "OBSERVATION_MODIFIER", 60, 68]]], ["It is of note that the BBC reported, on the 16 th of April, that the security forces enforcing the lockdown had killed more people (18) in Nigeria than the Coronavirus did (12) as of the date of the report [10] .The Nigerian government and even the private sector needs to improve upon the oncology centre to people ratio, as the IAEA recommends 4-8.1 radiotherapy centres per 1 million people [11, 12] .DiscussionPatients being unwilling to come for treatment for fear of contracting the disease from health workers is not unwarranted.", [["people", "ORGANISM", 309, 315], ["people", "ORGANISM", 387, 393], ["people", "SPECIES", 124, 130], ["people", "SPECIES", 309, 315], ["people", "SPECIES", 387, 393], ["the BBC", "TEST", 19, 26], ["radiotherapy centres", "TREATMENT", 352, 372], ["treatment", "TREATMENT", 451, 460]]], ["The health workers are also human.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33]]], ["And thus they entertain a reasonable fear of contracting the disease themselves.", [["the disease themselves", "PROBLEM", 57, 79], ["disease", "OBSERVATION", 61, 68]]], ["It makes the healthcare workers feel they are on their own should they come down with the virus.", [["the virus", "PROBLEM", 86, 95]]], ["Since oncology care demands synergy between fields such as surgery, radiation oncology, medical oncology, radiology and pathology; institutions need to strengthen multi-disciplinary tumour board meetings.", [["tumour", "ANATOMY", 182, 188], ["tumour", "DISEASE", 182, 188], ["tumour", "CANCER", 182, 188]]], ["However, COVID-19 has further necessitated the need for joint decision making between the disciplines for each patient.", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["COVID", "TEST", 9, 14], ["joint decision", "TREATMENT", 56, 70], ["joint", "ANATOMY", 56, 61]]], ["This is because every situation needs to be assessed case by case.DiscussionThe question of appropriate PPE in this COVID-19 pandemic will continue to be an evolving issue which would stretch the boundaries of safety and ethics.", [["appropriate PPE", "PROBLEM", 92, 107], ["this COVID", "TREATMENT", 111, 121]]], ["However, most discussants agreed it would be adequate if the practitioners wear a surgical face mask.", [["a surgical face mask", "TREATMENT", 80, 100]]], ["It would be even better if the patient also wears a mask.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["a mask", "TREATMENT", 50, 56]]], ["Gloves should be reserved for examination and other procedures and not worn for extended periods of time while frequent hand washing, particularly after seeing each patient, is essential.", [["hand", "ANATOMY", 120, 124], ["hand", "ORGANISM_SUBDIVISION", 120, 124], ["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172], ["Gloves", "TREATMENT", 0, 6], ["examination", "TEST", 30, 41], ["other procedures", "TREATMENT", 46, 62], ["frequent hand washing", "TREATMENT", 111, 132]]], ["Other challenging considerations and discussions leaders in oncology care would need to address include: What would be the appropriate PPE for radiographers/ radiotherapy technologists?", [["radiographers", "TEST", 143, 156], ["radiotherapy technologists", "TREATMENT", 158, 184]]], ["Especially considering they are exposed to multiple patients on a daily basis.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["What would be the appropriate PPE to wear during brachytherapy?", [["brachytherapy", "TREATMENT", 49, 62]]], ["What if the patient is confirmed to be COVID-19 positive?", [["COVID-19", "CHEMICAL", 39, 47], ["patient", "ORGANISM", 12, 19], ["COVID-19", "GENE_OR_GENE_PRODUCT", 39, 47], ["patient", "SPECIES", 12, 19], ["COVID", "TEST", 39, 44]]], ["Should such a patient\u00b4s treatment cease till he/she is confirmed negative?", [["a patient\u00b4s treatment", "TREATMENT", 12, 33]]], ["If one opts to continue treatment, how would the patient be isolated in a resource constrained environment like Nigeria?", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["treatment", "TREATMENT", 24, 33]]], ["Can one radiotherapy machine, one chemotherapy suite, and one team of staff be dedicated to treating suspected/confirmed cases?DiscussionPatient protection was further stressed by the fact that cancer patients could have their immunity further depressed by chemotherapy, rendering them more susceptible to COVID-19.", [["cancer", "ANATOMY", 194, 200], ["cancer", "DISEASE", 194, 200], ["depressed", "DISEASE", 244, 253], ["COVID-19", "CHEMICAL", 306, 314], ["cancer", "CANCER", 194, 200], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["radiotherapy machine", "TREATMENT", 8, 28], ["chemotherapy", "TREATMENT", 257, 269], ["COVID", "TEST", 306, 311], ["cancer", "OBSERVATION", 194, 200]]], ["A study from China by Liang et al shows that COVID-19 positive cancer patients are more likely to have severe events (ventilation or death) compared to noncancer COVID-19 patients [19] .", [["COVID-19 positive cancer", "ANATOMY", 45, 69], ["cancer", "DISEASE", 63, 69], ["death", "DISEASE", 133, 138], ["COVID", "DISEASE", 162, 167], ["COVID-19", "GENE_OR_GENE_PRODUCT", 45, 53], ["cancer", "CANCER", 63, 69], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 171, 179], ["A study", "TEST", 0, 7], ["COVID", "TEST", 45, 50], ["positive cancer", "PROBLEM", 54, 69], ["severe events", "PROBLEM", 103, 116], ["death", "PROBLEM", 133, 138], ["noncancer COVID", "TEST", 152, 167], ["cancer", "OBSERVATION", 63, 69], ["more likely", "UNCERTAINTY", 83, 94], ["severe", "OBSERVATION_MODIFIER", 103, 109]]], ["However, a critical review of the study reveals only 18 cancer patients with COVID-19 were in the sample.", [["cancer", "ANATOMY", 56, 62], ["cancer", "DISEASE", 56, 62], ["cancer", "CANCER", 56, 62], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["the study", "TEST", 30, 39], ["18 cancer", "PROBLEM", 53, 62], ["COVID", "TEST", 77, 82], ["cancer", "OBSERVATION", 56, 62]]], ["Also, the most prevalent cancer type was Lung cancer and the cancer patients were older [19] .", [["cancer", "ANATOMY", 25, 31], ["Lung cancer", "ANATOMY", 41, 52], ["cancer", "ANATOMY", 61, 67], ["cancer", "DISEASE", 25, 31], ["Lung cancer", "DISEASE", 41, 52], ["cancer", "DISEASE", 61, 67], ["cancer", "CANCER", 25, 31], ["Lung cancer", "CANCER", 41, 52], ["cancer", "CANCER", 61, 67], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Lung cancer", "PROBLEM", 41, 52], ["the cancer", "PROBLEM", 57, 67], ["most prevalent", "OBSERVATION_MODIFIER", 10, 24], ["cancer", "OBSERVATION", 25, 31], ["Lung", "ANATOMY", 41, 45], ["cancer", "OBSERVATION", 46, 52], ["cancer", "OBSERVATION", 61, 67]]], ["As earlier highlighted, the COVID-19 pandemic will raise ethical considerations.", [["the COVID", "TEST", 24, 33]]], ["Largely, younger, otherwise healthy patients were prioritized over older patients or those with pre-existing co-morbidities [7, 20] .DiscussionThe COVID-19 incidences and mortalities in Nigeria are relatively low and therefore doctors are not faced with such distressing decisions.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 73, 81], ["pre-existing co-morbidities", "PROBLEM", 96, 123], ["The COVID", "TEST", 143, 152]]], ["There is currently no consensus on the ethically acceptable stance to take when managing patients in the face of incomplete or absent PPE, as such clinicians must rely on the physician\u00b4s oath and the need for self-preservation as they deliver care.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["self-preservation", "TREATMENT", 209, 226], ["no", "UNCERTAINTY", 19, 21]]], ["Closely related to ethical issues are legal issues.", [["ethical issues", "PROBLEM", 19, 33], ["legal issues", "PROBLEM", 38, 50]]], ["Could there, possibly, be law suits or compensations due to decisions made by health care workers during this pandemic?SolutionsIn addition to the recommendation on protective gear above, the discussants proffered other practical solutions that can be achieved in Nigeria.SolutionsCase by case prioritization: given all the issues expounded above, one can deduce that cancer care cannot proceed unhindered as before the pandemic.", [["cancer", "ANATOMY", 368, 374], ["cancer", "DISEASE", 368, 374], ["cancer", "CANCER", 368, 374], ["other practical solutions", "TREATMENT", 214, 239], ["cancer", "OBSERVATION", 368, 374]]], ["Another discussant echoed this by saying \"patients where the yield of treatment is relatively low, the patient who has pancreatic cancer who is for second line treatment of course I would deprioritize that.\"", [["pancreatic cancer", "ANATOMY", 119, 136], ["pancreatic cancer", "DISEASE", 119, 136], ["patients", "ORGANISM", 42, 50], ["patient", "ORGANISM", 103, 110], ["pancreatic cancer", "CANCER", 119, 136], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 103, 110], ["treatment", "TREATMENT", 70, 79], ["pancreatic cancer", "PROBLEM", 119, 136], ["second line treatment", "TREATMENT", 148, 169], ["pancreatic", "ANATOMY", 119, 129], ["cancer", "OBSERVATION", 130, 136]]], ["(Oncologist 9, UK).SolutionsOral/metronomic chemotherapy: some of the discussants opined patients may benefit from oral drug treatment.", [["oral", "ANATOMY", 115, 119], ["patients", "ORGANISM", 89, 97], ["oral", "ORGANISM_SUBDIVISION", 115, 119], ["patients", "SPECIES", 89, 97], ["SolutionsOral/metronomic chemotherapy", "TREATMENT", 19, 56], ["oral drug treatment", "TREATMENT", 115, 134]]], ["However, it should not be done if it would jeopardize treatment outcome.SolutionsMultidisciplinary tumour boards: most surgeons have stopped elective surgeries.", [["tumour", "ANATOMY", 99, 105], ["tumour", "DISEASE", 99, 105], ["tumour", "CANCER", 99, 105], ["elective surgeries", "TREATMENT", 141, 159]]], ["Yet, amongst the oncologists practicing in Nigeria, the ones in centres with strong collaboration with their surgeons through a multidisciplinary team are more confident of getting patients who would benefit from upfront surgery to surgery.", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["upfront surgery", "TREATMENT", 213, 228], ["surgery", "TREATMENT", 232, 239]]], ["It would also be necessary to carry along the intensive care unit with any decision to operate as \"there is no point of having surgery if your ICU has then decided to prioritize your COVID patients and there is no bed.\"", [["COVID", "DISEASE", 183, 188], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["surgery", "TREATMENT", 127, 134]]], ["(Oncologist 10, UK).SolutionsScreening questionnaire and temperature: to curb the spread of COVID-19 within the hospital, all patients should be subjected to a screening questionnaire and temperature check.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["Screening questionnaire", "TEST", 29, 52], ["COVID", "TEST", 92, 97], ["a screening questionnaire", "TEST", 158, 183], ["temperature check", "TEST", 188, 205]]], ["Though this is not full proof; it could help to redirect cases to the center\u00b4s COVID response team.SolutionsSpacing: similarly, patients should not sit closely packed in waiting areas or even during chemotherapy as before the pandemic.", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["chemotherapy", "TREATMENT", 199, 211], ["the pandemic", "PROBLEM", 222, 234]]], ["Furthermore, examination procedures should only be done if absolutely necessary.Hand gloves vs hand washing vs hand sanitizers:gloves should not be worn for extended periods.", [["hand", "ANATOMY", 95, 99], ["hand", "ANATOMY", 111, 115], ["hand", "ORGANISM_SUBDIVISION", 95, 99], ["examination procedures", "TEST", 13, 35], ["Hand gloves", "TREATMENT", 80, 91], ["hand washing", "TREATMENT", 95, 107], ["hand sanitizers", "TREATMENT", 111, 126], ["gloves", "TREATMENT", 127, 133]]], ["As it creates a false sense of security while possibly spreading germs.", [["germs", "ANATOMY", 65, 70], ["germs", "ORGAN", 65, 70], ["spreading germs", "PROBLEM", 55, 70], ["false sense", "OBSERVATION", 16, 27], ["possibly", "UNCERTAINTY", 46, 54], ["spreading", "OBSERVATION_MODIFIER", 55, 64]]], ["In my clinic for instance, you see (health care workers) who wear gloves and touch everything with those gloves It would actually be safer for them not to wear (gloves) (but) wash their hands regularly.\"", [["those gloves", "TREATMENT", 99, 111]]], ["(Oncologist 4, SW Nigeria) An oncologist shared an innovation used to get people to wash hands in his/her centre; where \"we have someone who (rings) a bell every ten minutes to remind everyone to wash their hands.\"Hand sanitizers are also adequate but not better than hand washing with soap and water for at least 20 seconds.Hand gloves vs hand washing vs hand sanitizers:Appointment systems: hospitals need to change appointment systems, this may be a gain from COVID-19.", [["hand", "ANATOMY", 268, 272], ["hand", "ANATOMY", 340, 344], ["hand", "ANATOMY", 356, 360], ["people", "ORGANISM", 74, 80], ["hand", "ORGANISM_SUBDIVISION", 268, 272], ["hand", "ORGANISM_SUBDIVISION", 340, 344], ["people", "SPECIES", 74, 80], ["Hand sanitizers", "TREATMENT", 214, 229], ["Hand gloves", "TREATMENT", 325, 336], ["COVID", "TEST", 463, 468], ["sanitizers", "OBSERVATION", 219, 229]]], ["Patients should be given appointments of blocks of 15-30 minute periods, rather than appointments based on a date which results in over-crowding the waiting room.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Some oncologists also revealed that in the UK, apart from the multiple appointment blocks, patients for procedures are asked to wait at home or in their car.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["procedures", "TREATMENT", 104, 114]]], ["When the centre is absolutely ready to start the procedure, the patients are then called.Hand gloves vs hand washing vs hand sanitizers:Telemedicine: patients who are on follow-up and patients that only require a prescription do not have to appear physically at the clinic or hospital.", [["hand", "ANATOMY", 104, 108], ["hand", "ANATOMY", 120, 124], ["patients", "ORGANISM", 64, 72], ["hand", "ORGANISM_SUBDIVISION", 104, 108], ["hand", "ORGANISM_SUBDIVISION", 120, 124], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 184, 192], ["the procedure", "TREATMENT", 45, 58], ["Hand gloves", "TREATMENT", 89, 100]]], ["\"One of the good things that (will) come out of COVID is that we would begin to have more telemedicine in Nigeria and many centres (will) use apps and websites (to) keep in touch with their patients, follow up and monitor side effects.", [["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198]]], ["(Oncologist 4, SW Nigeria).Hand gloves vs hand washing vs hand sanitizers:Advocacy for patient mobility: in response to the fact that the lockdowns and curfews are negatively affecting cancer patient\u00b4s ability to travel for care, it was advised the expertise of lobbyists and advocates are employed.", [["hand", "ANATOMY", 42, 46], ["hand", "ANATOMY", 58, 62], ["cancer", "ANATOMY", 185, 191], ["cancer", "DISEASE", 185, 191], ["hand", "ORGANISM_SUBDIVISION", 42, 46], ["hand", "ORGANISM_SUBDIVISION", 58, 62], ["patient", "ORGANISM", 87, 94], ["cancer", "CANCER", 185, 191], ["patient", "SPECIES", 87, 94], ["Hand gloves", "TREATMENT", 27, 38]]], ["It would be important to get policy makers or administrators to get the message to them that yes, there is COVID but people also have cancer, and people also have medical problems that need to be resolved and they cannot put all those people under this kind of curfew.\"", [["cancer", "ANATOMY", 134, 140], ["cancer", "DISEASE", 134, 140], ["people", "ORGANISM", 117, 123], ["cancer", "CANCER", 134, 140], ["people", "ORGANISM", 146, 152], ["people", "ORGANISM", 235, 241], ["people", "SPECIES", 117, 123], ["people", "SPECIES", 146, 152], ["people", "SPECIES", 235, 241], ["cancer", "PROBLEM", 134, 140], ["medical problems", "PROBLEM", 163, 179], ["cancer", "OBSERVATION", 134, 140]]], ["(Oncologist 11, USA).ConclusionThe COVID-19 pandemic does pose threats to continuing oncological care with myriads of considerations and challenges.", [["The COVID", "TEST", 31, 40], ["continuing oncological care", "TREATMENT", 74, 101]]], ["As such there is no straightforward answer to the question \"what do we do?\"", [["no", "UNCERTAINTY", 17, 19]]], ["Only determined and practical approaches to \"risk reduce\" while being practically cautious can ensure cancer care continues albeit to a limited degree.", [["cancer", "ANATOMY", 102, 108], ["cancer", "DISEASE", 102, 108], ["cancer", "CANCER", 102, 108], ["cancer care", "TREATMENT", 102, 113], ["cancer", "OBSERVATION", 102, 108]]]], "PMC7393033": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]], "dd1ca1493adaf6da43d0089c4b5f5d30ff6f9869": [["Arnold S. Monto, MDAcute respiratory tract infections are the most common illnesses in all individuals, regardless of age or gender.", [["respiratory tract infections", "DISEASE", 25, 53], ["MDAcute respiratory tract", "ORGANISM", 17, 42], ["MDAcute respiratory tract infections", "PROBLEM", 17, 53], ["respiratory tract", "ANATOMY", 25, 42]]], ["Epidemiologic surveys and community-based studies conducted since the beginning of the 20th century have determined the rates of illness and the pathogens involved in such infections.", [["illness", "DISEASE", 129, 136], ["infections", "DISEASE", 172, 182], ["Epidemiologic surveys", "TEST", 0, 21], ["community-based studies", "TEST", 26, 49], ["illness", "PROBLEM", 129, 136], ["the pathogens", "PROBLEM", 141, 154], ["such infections", "PROBLEM", 167, 182], ["infections", "OBSERVATION", 172, 182]]], ["These studies have shown that rhinoviruses cause the great majority of these respiratory illnesses, and their findings have examined the means of transmission of respiratory illness.", [["respiratory", "ANATOMY", 77, 88], ["respiratory", "ANATOMY", 162, 173], ["rhinoviruses", "DISEASE", 30, 42], ["respiratory illnesses", "DISEASE", 77, 98], ["respiratory illness", "DISEASE", 162, 181], ["rhinoviruses", "ORGANISM", 30, 42], ["These studies", "TEST", 0, 13], ["rhinoviruses", "PROBLEM", 30, 42], ["these respiratory illnesses", "PROBLEM", 71, 98], ["respiratory illness", "PROBLEM", 162, 181], ["rhinoviruses", "OBSERVATION", 30, 42], ["great", "OBSERVATION_MODIFIER", 53, 58], ["respiratory illnesses", "OBSERVATION", 77, 98], ["respiratory illness", "OBSERVATION", 162, 181]]], ["More recently, advances in diagnostic techniques have enabled more complete identification of the viruses involved in respiratory infections, which has aided in the ability to direct specific therapeutic agents at the causative pathogens.Arnold S. Monto, MDA cute respiratory infections are the most common illnesses experienced by people of all ages worldwide.", [["respiratory", "ANATOMY", 118, 129], ["respiratory infections", "DISEASE", 118, 140], ["MDA", "CHEMICAL", 255, 258], ["respiratory infections", "DISEASE", 264, 286], ["MDA", "ORGANISM", 255, 258], ["people", "ORGANISM", 332, 338], ["people", "SPECIES", 332, 338], ["diagnostic techniques", "TEST", 27, 48], ["the viruses", "PROBLEM", 94, 105], ["respiratory infections", "PROBLEM", 118, 140], ["the causative pathogens", "PROBLEM", 214, 237], ["MDA cute respiratory infections", "PROBLEM", 255, 286], ["viruses", "OBSERVATION", 98, 105], ["respiratory", "ANATOMY", 118, 129], ["infections", "OBSERVATION", 130, 140], ["respiratory", "ANATOMY", 264, 275], ["infections", "OBSERVATION", 276, 286]]], ["Data collected by the Health Interview Survey have demonstrated the overall scope of these illnesses.", [["these illnesses", "PROBLEM", 85, 100], ["illnesses", "OBSERVATION", 91, 100]]], ["1 The Health Interview Survey defines acute conditions as those not lasting more than 3 months but requiring a physician consultation or restriction of daily activity.", [["acute conditions", "PROBLEM", 38, 54], ["acute", "OBSERVATION_MODIFIER", 38, 43]]], ["Only illnesses with onsets in the 2 weeks before the survey were reported.", [["illnesses", "PROBLEM", 5, 14], ["illnesses", "OBSERVATION", 5, 14]]], ["Table 1 shows the 1995 survey data on all acute conditions, categorized by age of the patient and, more specifically, by conditions involving the respiratory tract.", [["respiratory tract", "ANATOMY", 146, 163], ["patient", "ORGANISM", 86, 93], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["patient", "SPECIES", 86, 93], ["all acute conditions", "PROBLEM", 38, 58], ["respiratory tract", "ANATOMY", 146, 163]]], ["Of all acute illnesses, respiratory conditions are the most common, generally occurring twice as frequently as the next most common condition.", [["respiratory", "ANATOMY", 24, 35], ["all acute illnesses", "PROBLEM", 3, 22], ["respiratory conditions", "PROBLEM", 24, 46], ["all", "OBSERVATION_MODIFIER", 3, 6], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["illnesses", "OBSERVATION", 13, 22], ["respiratory conditions", "OBSERVATION", 24, 46]]], ["1 Within the category of respiratory conditions, influenza was reported more frequently than the common cold, despite the fact that colds occur more commonly.", [["influenza", "DISEASE", 49, 58], ["colds", "DISEASE", 132, 137], ["respiratory conditions", "PROBLEM", 25, 47], ["influenza", "PROBLEM", 49, 58], ["colds", "PROBLEM", 132, 137], ["respiratory conditions", "OBSERVATION", 25, 47], ["colds", "OBSERVATION", 132, 137]]], ["Illnesses were identified based simply by name, and not based on clinical characteristics.", [["Illnesses", "PROBLEM", 0, 9]]], ["This is likely because of the fact that reporting in this survey was limited to more severe conditions (those involving a physician consultation or restricted activity), which are more apt to be recalled by the respondent.", [["more severe conditions", "PROBLEM", 80, 102], ["likely because of", "UNCERTAINTY", 8, 25]]], ["Therefore, in the Health Interview Survey the incidence of influenza is probably overestimated and that of the common cold underestimated.", [["influenza", "DISEASE", 59, 68], ["influenza", "PROBLEM", 59, 68], ["influenza", "OBSERVATION", 59, 68]]], ["Although this survey may not represent the true incidence of these infections, the data do report all respiratory illnesses in the context of conditions requiring physician consultation.", [["infections", "DISEASE", 67, 77], ["respiratory illnesses", "DISEASE", 102, 123], ["these infections", "PROBLEM", 61, 77], ["all respiratory illnesses", "PROBLEM", 98, 123], ["may not represent", "UNCERTAINTY", 21, 38], ["infections", "OBSERVATION", 67, 77]]], ["They support the finding that respiratory infections cause significant morbidity and are a major reason for physician visits and restricted activity.Early Epidemiologic StudiesCompared with the Health Interview Survey, a more accurate estimation of the frequency of viral respiratory infections (VRIs) in the US population is derived from long-term family and community studies.", [["respiratory", "ANATOMY", 30, 41], ["respiratory", "ANATOMY", 272, 283], ["respiratory infections", "DISEASE", 30, 52], ["viral respiratory infections", "DISEASE", 266, 294], ["VRIs", "DISEASE", 296, 300], ["respiratory infections", "PROBLEM", 30, 52], ["significant morbidity", "PROBLEM", 59, 80], ["viral respiratory infections", "PROBLEM", 266, 294], ["community studies", "TEST", 360, 377], ["respiratory", "ANATOMY", 30, 41], ["infections", "OBSERVATION", 42, 52], ["viral", "OBSERVATION_MODIFIER", 266, 271], ["respiratory infections", "OBSERVATION", 272, 294]]], ["These studies began about 80 years ago and successfully documented the frequency of common respiratory illnesses, which are now recognized to be almost exclusively viral in cause.", [["respiratory", "ANATOMY", 91, 102], ["respiratory illnesses", "DISEASE", 91, 112], ["These studies", "TEST", 0, 13], ["common respiratory illnesses", "PROBLEM", 84, 112], ["common", "OBSERVATION_MODIFIER", 84, 90], ["respiratory illnesses", "OBSERVATION", 91, 112]]], ["2 In studies reported during the 1920s and 1930s, observations were made that are supported by the findings of current epidemiologic studies.", [["current epidemiologic studies", "TEST", 111, 140]]], ["Very early studies showed that children are at particular risk of developing VRIs, that the frequency of respiratory illnesses is higher among females, and that illnesses with coryza peak in autumn.", [["respiratory", "ANATOMY", 105, 116], ["VRIs", "DISEASE", 77, 81], ["respiratory illnesses", "DISEASE", 105, 126], ["coryza", "DISEASE", 176, 182], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["Very early studies", "TEST", 0, 18], ["developing VRIs", "PROBLEM", 66, 81], ["respiratory illnesses", "PROBLEM", 105, 126], ["coryza", "PROBLEM", 176, 182]]], ["[3] [4] [5] At the time these observations were reported, the causative pathogens had not been identified.", [["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10], ["the causative pathogens", "PROBLEM", 58, 81]]], ["2The Cleveland Family StudyIn the late 1940s and 1950s there was an increased interest in respiratory illnesses, with research again concentrating on the influence of familial or household factors on incidence.", [["respiratory", "ANATOMY", 90, 101], ["respiratory illnesses", "DISEASE", 90, 111], ["an increased interest in respiratory illnesses", "PROBLEM", 65, 111], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["respiratory illnesses", "OBSERVATION", 90, 111]]], ["2 These studies were important because of the emerging ability to identify viruses as the causative agents.The Cleveland Family StudyThe Cleveland family study was a seminal investigation conducted from 1948 to 1957.", [["These studies", "TEST", 2, 15], ["a seminal investigation", "TEST", 164, 187]]], ["6 Its methods and observations provided a standard against which subsequent investigations were measured.", [["subsequent investigations", "TEST", 65, 90]]], ["2 This study serves as a bridge between the early studies that were carried out without any supporting virology and later studies in which laboratory data were an integral part of the investigation.", [["This study", "TEST", 2, 12], ["the early studies", "TEST", 40, 57], ["later studies", "TEST", 116, 129], ["laboratory data", "TEST", 139, 154], ["the investigation", "TEST", 180, 197]]], ["When the study began in 1948, only influenza and \"typical\" bacteria could be identified.", [["influenza", "DISEASE", 35, 44], ["the study", "TEST", 5, 14], ["influenza", "PROBLEM", 35, 44], ["\"typical\" bacteria", "PROBLEM", 49, 67]]], ["By 1953 adenovirus could also be identified.", [["adenovirus", "ORGANISM", 8, 18], ["adenovirus", "SPECIES", 8, 18], ["adenovirus", "PROBLEM", 8, 18], ["could also be", "UNCERTAINTY", 19, 32]]], ["2 By the late 1950s and early 1960s it became possible to identify most viruses now known to be involved in respiratory illness, although the techniques have improved since, especially recently with the development of the polymerase chain reaction methodology.", [["respiratory", "ANATOMY", 108, 119], ["respiratory illness", "DISEASE", 108, 127], ["most viruses", "PROBLEM", 67, 79], ["respiratory illness", "PROBLEM", 108, 127], ["the polymerase chain reaction methodology", "PROBLEM", 218, 259], ["respiratory", "ANATOMY", 108, 119], ["illness", "OBSERVATION", 120, 127], ["improved", "OBSERVATION_MODIFIER", 158, 166]]], ["2 The Cleveland study followed nearly 100 families in association with the Case Western Reserve Medical Center; it identified common respiratory illnesses and their cause to the extent possible at the time.", [["respiratory", "ANATOMY", 133, 144], ["respiratory illnesses", "DISEASE", 133, 154], ["The Cleveland study", "TEST", 2, 21], ["common respiratory illnesses", "PROBLEM", 126, 154], ["common", "OBSERVATION_MODIFIER", 126, 132], ["respiratory illnesses", "OBSERVATION", 133, 154]]], ["The occurrence of VRIs was determined by home visits in which illness symptoms were recorded and by obtaining blood specimens for serological testing in an attempt to identify the organism involved.The Cleveland Family StudyThe cohabitating family unit was the focus of the study.", [["blood specimens", "ANATOMY", 110, 125], ["VRIs", "DISEASE", 18, 22], ["illness", "DISEASE", 62, 69], ["VRIs", "CANCER", 18, 22], ["blood specimens", "ORGANISM_SUBSTANCE", 110, 125], ["illness symptoms", "PROBLEM", 62, 78], ["blood specimens", "TEST", 110, 125], ["serological testing", "TEST", 130, 149], ["the study", "TEST", 270, 279]]], ["6 The important contribution of the research was the reliable and accurate data obtained on the frequency of respiratory illnesses in the family setting and the importance of the family setting in transmission.", [["respiratory illnesses", "DISEASE", 109, 130], ["respiratory illnesses", "PROBLEM", 109, 130]]], ["The data obtained were probably the most accurate in terms of the annual frequency of respiratory infections.", [["respiratory", "ANATOMY", 86, 97], ["respiratory infections", "DISEASE", 86, 108], ["The data", "TEST", 0, 8], ["respiratory infections", "PROBLEM", 86, 108], ["respiratory", "ANATOMY", 86, 97], ["infections", "OBSERVATION", 98, 108]]], ["6 Table 2 shows the number of respiratory illnesses reported, categorized by age.", [["respiratory", "ANATOMY", 30, 41], ["respiratory illnesses", "DISEASE", 30, 51], ["respiratory illnesses", "PROBLEM", 30, 51], ["respiratory illnesses", "OBSERVATION", 30, 51]]], ["6 The highest numbers of illnesses were in young children (up to 4 years of age); illnesses decreased with increasing age.The Cleveland Family StudyThe importance of young children has undoubtedly increased in recent years with the dramatic increase in day care, but the exact effect is hard to quantify because of the lack of comprehensive studies from which incidence can be determined.", [["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 172, 180], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 172, 180], ["illnesses", "PROBLEM", 82, 91], ["comprehensive studies", "TEST", 327, 348], ["highest", "OBSERVATION_MODIFIER", 6, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21], ["illnesses", "OBSERVATION", 25, 34], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["dramatic", "OBSERVATION_MODIFIER", 232, 240], ["increase", "OBSERVATION_MODIFIER", 241, 249]]], ["Although this study was relatively small, there was a concentrated effort to report information carefully so that the numbers were the most accurate as determined in a US population.The Cleveland Family StudyThe investigators found that there was an increased risk of developing an illness if another family member was sick.", [["this study", "TEST", 9, 19], ["a US population", "TEST", 166, 181], ["small", "OBSERVATION_MODIFIER", 35, 40], ["increased", "OBSERVATION_MODIFIER", 250, 259], ["illness", "OBSERVATION", 282, 289]]], ["6 In the family setting, it was found that the most likely introducers of infection were children in various age categories, particularly children in preschool; mothers were the next most common introducers.", [["infection", "DISEASE", 74, 83], ["children", "ORGANISM", 89, 97], ["children", "ORGANISM", 138, 146], ["mothers", "ORGANISM", 161, 168], ["children", "SPECIES", 89, 97], ["children", "SPECIES", 138, 146], ["infection", "PROBLEM", 74, 83], ["most likely", "UNCERTAINTY", 47, 58], ["infection", "OBSERVATION", 74, 83]]], ["Fathers were the least likely introducers of illness into the family.The Tecumseh, Michigan, StudiesMore recent investigations have continued to focus on the family, with the added ability to identify the causal agents.", [["illness", "DISEASE", 45, 52]]], ["7, 8 The studies of acute infection began in 1965 and continued through 1971, phase 1.", [["acute infection", "DISEASE", 20, 35], ["The studies", "TEST", 5, 16], ["acute infection", "PROBLEM", 20, 35], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["infection", "OBSERVATION", 26, 35]]], ["The second part began again in 1976 and concluded in 1981.The Tecumseh, Michigan, StudiesData were collected using weekly questionnaires to identify illness onset, specimen collection for agent isolation from participants with illness, and regular blood collection for serologic identification of infection.", [["specimen", "ANATOMY", 164, 172], ["blood", "ANATOMY", 248, 253], ["illness", "DISEASE", 149, 156], ["illness", "DISEASE", 227, 234], ["infection", "DISEASE", 297, 306], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["participants", "SPECIES", 209, 221], ["StudiesData", "TEST", 82, 93], ["specimen collection", "TEST", 164, 183], ["agent isolation", "TREATMENT", 188, 203], ["illness", "PROBLEM", 227, 234], ["regular blood collection", "TEST", 240, 264], ["serologic identification", "TEST", 269, 293], ["infection", "PROBLEM", 297, 306], ["infection", "OBSERVATION", 297, 306]]], ["2 Simple reporting of an illness without specific required symptoms was insufficient for an episode to be recognized as an acute respiratory illness.", [["respiratory", "ANATOMY", 129, 140], ["illness", "DISEASE", 25, 32], ["respiratory illness", "DISEASE", 129, 148], ["an illness", "PROBLEM", 22, 32], ["specific required symptoms", "PROBLEM", 41, 67], ["an acute respiratory illness", "PROBLEM", 120, 148], ["illness", "OBSERVATION", 25, 32], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory illness", "OBSERVATION", 129, 148]]], ["The mean annual incidence of total respiratory infections (mostly viral) is shown in Table 3 .", [["respiratory", "ANATOMY", 35, 46], ["respiratory infections", "DISEASE", 35, 57], ["total respiratory infections", "PROBLEM", 29, 57], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["total", "OBSERVATION_MODIFIER", 29, 34], ["respiratory infections", "OBSERVATION", 35, 57]]], ["7 Illnesses were more frequent in young boys than in girls up to 3 years of age, at which point the incidence became more frequent in females.", [["Illnesses", "DISEASE", 2, 11], ["boys", "SPECIES", 40, 44], ["girls", "SPECIES", 53, 58], ["Illnesses", "PROBLEM", 2, 11]]], ["At age 5 to 9 years, the frequency of respiratory illnesses in general began to decrease.", [["respiratory", "ANATOMY", 38, 49], ["respiratory illnesses", "DISEASE", 38, 59], ["respiratory illnesses", "PROBLEM", 38, 59], ["respiratory", "ANATOMY", 38, 49], ["illnesses", "OBSERVATION", 50, 59]]], ["The increase in frequency at age 20 to 29 years might be explained by exposure of family members to young children with respiratory infections.", [["respiratory", "ANATOMY", 120, 131], ["respiratory infections", "DISEASE", 120, 142], ["children", "ORGANISM", 106, 114], ["children", "SPECIES", 106, 114], ["respiratory infections", "PROBLEM", 120, 142], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["respiratory", "ANATOMY", 120, 131], ["infections", "OBSERVATION", 132, 142]]], ["The increase occurred to a greater extent in females.The Tecumseh, Michigan, StudiesFurther analysis of data from the study 8 showed that women who did not work outside the home had higher rates of respiratory illness than women who worked out of the home.", [["respiratory illness", "DISEASE", 198, 217], ["women", "ORGANISM", 138, 143], ["women", "ORGANISM", 223, 228], ["women", "SPECIES", 138, 143], ["women", "SPECIES", 223, 228], ["the study", "TEST", 114, 123], ["respiratory illness", "PROBLEM", 198, 217], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["greater", "OBSERVATION_MODIFIER", 27, 34], ["extent", "OBSERVATION_MODIFIER", 35, 41], ["females", "OBSERVATION", 45, 52]]], ["Among women working out of the home, however, the frequency of illness was still greater than that experienced by males.", [["illness", "DISEASE", 63, 70], ["women", "ORGANISM", 6, 11], ["women", "SPECIES", 6, 11], ["illness", "PROBLEM", 63, 70]]], ["These data seemed to confirm that exposure to the children in the family increased the likelihood of respiratory illnesses.The Tecumseh, Michigan, StudiesAdditional analysis of infection occurrences shows an inverse relationship between income and frequency of respiratory illness (Table 4) .", [["respiratory", "ANATOMY", 101, 112], ["respiratory", "ANATOMY", 261, 272], ["respiratory illnesses", "DISEASE", 101, 122], ["infection", "DISEASE", 177, 186], ["respiratory illness", "DISEASE", 261, 280], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["respiratory illnesses", "PROBLEM", 101, 122], ["infection occurrences", "PROBLEM", 177, 198], ["respiratory illness", "PROBLEM", 261, 280], ["respiratory illnesses", "OBSERVATION", 101, 122], ["infection", "OBSERVATION", 177, 186], ["respiratory illness", "OBSERVATION", 261, 280]]], ["7 This is probably a reflection of greater household crowding.", [["greater household crowding", "PROBLEM", 35, 61], ["probably a", "UNCERTAINTY", 10, 20], ["reflection", "OBSERVATION_MODIFIER", 21, 31], ["greater", "OBSERVATION_MODIFIER", 35, 42], ["household crowding", "OBSERVATION", 43, 61]]], ["This relationship has been directly demonstrated for rhinovirus infection by studies reporting the relationship between the number of individuals sharing a bedroom and seroconversion rates for the 3 most common rhinovirus serotypes (Table 5 ).", [["rhinovirus infection", "DISEASE", 53, 73], ["rhinovirus", "ORGANISM", 53, 63], ["rhinovirus", "ORGANISM", 211, 221], ["rhinovirus infection", "PROBLEM", 53, 73], ["seroconversion rates", "TREATMENT", 168, 188], ["the 3 most common rhinovirus serotypes", "PROBLEM", 193, 231], ["rhinovirus", "OBSERVATION_MODIFIER", 53, 63], ["infection", "OBSERVATION", 64, 73], ["rhinovirus", "OBSERVATION", 211, 221]]], ["9 Illness frequency increased with crowding of sleeping conditions.", [["Illness frequency", "PROBLEM", 2, 19], ["crowding of sleeping conditions", "PROBLEM", 35, 66]]], ["Illness incidence also varied by day of infection onset ( Figure 2 ).", [["infection", "DISEASE", 40, 49], ["infection onset", "PROBLEM", 40, 55], ["infection", "OBSERVATION", 40, 49]]], ["9 Data were collected on the day of illness onset so the researchers could calculate secondary attack rates and determine family transmission.", [["illness", "DISEASE", 36, 43], ["secondary attack rates", "PROBLEM", 85, 107]]], ["In the school-age children, illnesses were less frequent in the middle of the week.", [["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26], ["illnesses", "PROBLEM", 28, 37]]], ["Assuming an incubation period of 2 to 4 days, school transmission could explain this kind of pattern, which is most pronounced in individuals 5 to 19 years old.Cause of Viral Respiratory InfectionsCommunity-based studies have made it possible to determine the cause of common VRIs.", [["VRIs", "DISEASE", 276, 280], ["VRIs", "PATHOLOGICAL_FORMATION", 276, 280], ["Viral Respiratory InfectionsCommunity", "PROBLEM", 169, 206], ["based studies", "TEST", 207, 220], ["common VRIs", "PROBLEM", 269, 280], ["most pronounced", "OBSERVATION_MODIFIER", 111, 126], ["Viral", "OBSERVATION_MODIFIER", 169, 174], ["Respiratory InfectionsCommunity", "OBSERVATION", 175, 206], ["common VRIs", "ANATOMY", 269, 280]]], ["In the Tecumseh study, the viruses causing all respiratory infections were reported.", [["respiratory", "ANATOMY", 47, 58], ["respiratory infections", "DISEASE", 47, 69], ["the Tecumseh study", "TEST", 3, 21], ["the viruses", "PROBLEM", 23, 34], ["all respiratory infections", "PROBLEM", 43, 69], ["viruses", "OBSERVATION", 27, 34], ["all", "OBSERVATION_MODIFIER", 43, 46], ["respiratory infections", "OBSERVATION", 47, 69]]], ["The distribution of pathogens was determined by self-reported illness, whether it was a specific syndrome (ie, influenza) or an illness with only 1 symptom.", [["illness", "DISEASE", 62, 69], ["influenza", "DISEASE", 111, 120], ["pathogens", "PROBLEM", 20, 29], ["a specific syndrome", "PROBLEM", 86, 105], ["influenza", "PROBLEM", 111, 120], ["an illness", "PROBLEM", 125, 135], ["1 symptom", "PROBLEM", 146, 155], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["pathogens", "OBSERVATION", 20, 29]]], ["In the Tecumseh study, rhinoviruses were by far the most frequent viral isolate identified in the overall population (Figure 3 ).", [["rhinoviruses", "ORGANISM", 23, 35], ["the Tecumseh study", "TEST", 3, 21], ["rhinoviruses", "PROBLEM", 23, 35], ["rhinoviruses", "OBSERVATION", 23, 35]]], ["10 In the first phase of the study, an infectious agent was detected in only approximately 25% of the specimens collected.", [["specimens", "ANATOMY", 102, 111], ["specimens", "CANCER", 102, 111], ["the study", "TEST", 25, 34], ["an infectious agent", "PROBLEM", 36, 55], ["the specimens", "TEST", 98, 111], ["infectious", "OBSERVATION", 39, 49]]], ["2 Not all specimens collected yielded virus isolates, partly because advanced diagnostic techniques, such as polymerase chain reaction (PCR), were not available at the time the study was conducted.", [["specimens", "ANATOMY", 10, 19], ["specimens", "CANCER", 10, 19], ["all specimens", "TEST", 6, 19], ["virus isolates", "PROBLEM", 38, 52], ["diagnostic techniques", "TEST", 78, 99], ["polymerase chain reaction", "PROBLEM", 109, 134], ["PCR", "TEST", 136, 139], ["the study", "TEST", 173, 182]]], ["Table 6 shows the annual isolation rates of various respiratory viruses by age (actual rates per 1,000 person-years) during the second phase of the study, from 1976 to 1981.", [["respiratory viruses", "DISEASE", 52, 71], ["person", "SPECIES", 103, 109], ["various respiratory viruses", "PROBLEM", 44, 71], ["the study", "TEST", 144, 153], ["respiratory viruses", "OBSERVATION", 52, 71]]], ["Rates per 100 person-years were adjusted by the proportion of illnesses actually sampled.", [["illnesses", "PROBLEM", 62, 71]]], ["8 The adjustments approximate isolation rates as if all infections had been sampled.", [["infections", "DISEASE", 56, 66], ["The adjustments approximate isolation rates", "TREATMENT", 2, 45], ["all infections", "PROBLEM", 52, 66]]], ["Both rates were based on actual isolation of virus.", [["actual isolation of virus", "PROBLEM", 25, 50], ["virus", "OBSERVATION", 45, 50]]], ["Nonculturable viruses, or those lost during shipping from the site to the laboratory, were not included.", [["Nonculturable viruses", "PROBLEM", 0, 21], ["viruses", "OBSERVATION", 14, 21]]], ["Again, in this second phase, rhinoviruses were the most frequently isolated agents in all age groups.", [["rhinoviruses", "ORGANISM", 29, 41], ["rhinoviruses", "PROBLEM", 29, 41], ["rhinoviruses", "OBSERVATION", 29, 41]]], ["Table 7 shows the relative role or impact of various respiratory viruses in producing acute respiratory infections.", [["respiratory", "ANATOMY", 92, 103], ["acute respiratory infections", "DISEASE", 86, 114], ["various respiratory viruses", "PROBLEM", 45, 72], ["acute respiratory infections", "PROBLEM", 86, 114], ["respiratory viruses", "OBSERVATION", 53, 72], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["respiratory infections", "OBSERVATION", 92, 114]]], ["8 In this table, estimates were made of the degree to which virus-isolation techniques underestimated the actual role of each agent in infection, and an appropriate adjustment was made.", [["infection", "DISEASE", 135, 144], ["virus-isolation techniques", "TREATMENT", 60, 86], ["infection", "PROBLEM", 135, 144], ["an appropriate adjustment", "TREATMENT", 150, 175], ["infection", "OBSERVATION", 135, 144]]], ["(As mentioned, PCR techniques did not exist at the time this study was conducted.)", [["PCR techniques", "TEST", 15, 29], ["this study", "TEST", 56, 66]]], ["Rhinovirus rates were adjusted based on a study of the common cold in which previous organ culture technique identified viruses that did not replicate in ordinary cell culture.", [["organ", "ANATOMY", 85, 90], ["cell", "ANATOMY", 163, 167], ["organ", "ORGAN", 85, 90], ["cell culture", "CELL", 163, 175], ["ordinary cell culture", "CELL_LINE", 154, 175], ["Rhinovirus rates", "PROBLEM", 0, 16], ["a study", "TEST", 40, 47], ["previous organ culture technique", "TEST", 76, 108], ["viruses", "PROBLEM", 120, 127], ["ordinary cell culture", "TEST", 154, 175]]], ["Based on these studies, rhinoviruses were still the most common isolate.", [["rhinoviruses", "ORGANISM", 24, 36], ["these studies", "TEST", 9, 22], ["rhinoviruses", "PROBLEM", 24, 36], ["rhinoviruses", "OBSERVATION", 24, 36]]], ["Of note is the large percentage of illnesses for which the cause could not be determined.", [["illnesses", "PROBLEM", 35, 44], ["large", "OBSERVATION_MODIFIER", 15, 20], ["percentage", "OBSERVATION_MODIFIER", 21, 31], ["illnesses", "OBSERVATION", 35, 44]]], ["Also, although rhinoviruses caused a less severe illness syndrome than some of the other pathogens, especially influenza, owing to its high frequency rhinovirus infection resulted in more physician consultations in the United States than any other single agent.Seasonality of Respiratory Infection Identified in Epidemiologic StudiesVirus isolation is valuable in determining seasonality of the pathogens causing respiratory infection.", [["respiratory", "ANATOMY", 413, 424], ["rhinoviruses", "DISEASE", 15, 27], ["influenza", "DISEASE", 111, 120], ["rhinovirus infection", "DISEASE", 150, 170], ["Respiratory Infection", "DISEASE", 276, 297], ["respiratory infection", "DISEASE", 413, 434], ["rhinoviruses", "ORGANISM", 15, 27], ["rhinovirus", "ORGANISM", 150, 160], ["rhinoviruses", "PROBLEM", 15, 27], ["a less severe illness syndrome", "PROBLEM", 35, 65], ["the other pathogens", "PROBLEM", 79, 98], ["influenza", "PROBLEM", 111, 120], ["its high frequency rhinovirus infection", "PROBLEM", 131, 170], ["Respiratory Infection", "PROBLEM", 276, 297], ["Virus isolation", "TREATMENT", 333, 348], ["the pathogens", "PROBLEM", 391, 404], ["respiratory infection", "PROBLEM", 413, 434], ["rhinoviruses", "OBSERVATION", 15, 27], ["less", "OBSERVATION_MODIFIER", 37, 41], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["illness", "OBSERVATION", 49, 56], ["Respiratory", "ANATOMY", 276, 287], ["Infection", "OBSERVATION", 288, 297], ["infection", "OBSERVATION", 425, 434]]], ["2 Seasonality is one of the characteristics of respiratory viruses that has been identified in epidemiologic studies, but the reasons for this seasonality are unclear.", [["respiratory viruses", "DISEASE", 47, 66], ["respiratory viruses", "PROBLEM", 47, 66], ["epidemiologic studies", "TEST", 95, 116], ["one of", "OBSERVATION_MODIFIER", 17, 23], ["respiratory viruses", "OBSERVATION", 47, 66]]], ["Although clinical signs and symptoms of various VRIs can overlap, it is possible to determine the probability of illnesses being caused by a specific virus based on the syndrome produced and on the differing seasonalities of those viruses.Seasonality of Respiratory Infection Identified in Epidemiologic StudiesAs shown in Figure 4 , respiratory syncytial virus and influenza virus occur mainly in the winter to early spring.", [["VRIs", "DISEASE", 48, 52], ["Respiratory Infection", "DISEASE", 254, 275], ["respiratory syncytial virus", "DISEASE", 334, 361], ["influenza virus", "DISEASE", 366, 381], ["respiratory syncytial virus", "ORGANISM", 334, 361], ["influenza virus", "ORGANISM", 366, 381], ["respiratory syncytial virus", "SPECIES", 334, 361], ["influenza virus", "SPECIES", 366, 381], ["respiratory syncytial virus", "SPECIES", 334, 361], ["influenza virus", "SPECIES", 366, 381], ["clinical signs", "PROBLEM", 9, 23], ["symptoms", "PROBLEM", 28, 36], ["various VRIs", "PROBLEM", 40, 52], ["illnesses", "PROBLEM", 113, 122], ["a specific virus", "PROBLEM", 139, 155], ["the syndrome", "PROBLEM", 165, 177], ["those viruses", "PROBLEM", 225, 238], ["Respiratory Infection", "PROBLEM", 254, 275], ["Epidemiologic StudiesAs", "TEST", 290, 313], ["Figure 4", "PROBLEM", 323, 331], ["respiratory syncytial virus", "PROBLEM", 334, 361], ["influenza virus", "PROBLEM", 366, 381], ["Respiratory", "ANATOMY", 254, 265], ["Infection", "OBSERVATION", 266, 275], ["respiratory", "ANATOMY", 334, 345], ["syncytial virus", "OBSERVATION", 346, 361], ["influenza virus", "OBSERVATION", 366, 381]]], ["11 Although they occur in most months, parainfluenza viruses predominate in the late autumn into the winter.", [["parainfluenza viruses", "DISEASE", 39, 60], ["parainfluenza viruses", "ORGANISM", 39, 60], ["parainfluenza", "SPECIES", 39, 52], ["parainfluenza viruses", "PROBLEM", 39, 60], ["parainfluenza viruses", "OBSERVATION", 39, 60]]], ["Rhinoviruses cause VRIs in all months of the year, with peaks of illness in the fall (the major peak) and in the spring, as shown in Figure 5 .", [["Rhinoviruses", "DISEASE", 0, 12], ["VRIs", "DISEASE", 19, 23], ["illness", "DISEASE", 65, 72], ["Rhinoviruses", "PROBLEM", 0, 12], ["VRIs", "PROBLEM", 19, 23], ["illness", "PROBLEM", 65, 72], ["the fall", "PROBLEM", 76, 84]]], ["12 The rhinovirus outbreaks in the fall are a result of children returning to school.", [["rhinovirus outbreaks", "DISEASE", 7, 27], ["rhinovirus", "ORGANISM", 7, 17], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["The rhinovirus outbreaks", "PROBLEM", 3, 27], ["rhinovirus", "OBSERVATION", 7, 17]]], ["These seasonality data were confirmed in studies that used interferon-alpha for seasonal prophylaxis against rhinovirus infection in a university student population.", [["interferon-alpha", "CHEMICAL", 59, 75], ["rhinovirus infection", "DISEASE", 109, 129], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 59, 75], ["rhinovirus", "ORGANISM", 109, 119], ["interferon-alpha", "PROTEIN", 59, 75], ["interferon", "TREATMENT", 59, 69], ["alpha", "TREATMENT", 70, 75], ["seasonal prophylaxis", "TREATMENT", 80, 100], ["rhinovirus infection", "PROBLEM", 109, 129]]], ["13 The small peak in the spring has a variable pattern because of the size of the United States and differing seasonal weather patterns nationwide.", [["The small peak in the spring", "PROBLEM", 3, 31], ["small", "OBSERVATION_MODIFIER", 7, 12], ["peak", "OBSERVATION_MODIFIER", 13, 17], ["spring", "OBSERVATION_MODIFIER", 25, 31], ["variable", "OBSERVATION_MODIFIER", 38, 46], ["pattern", "OBSERVATION_MODIFIER", 47, 54], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["2 Worldwide, the seasonality of rhinoviruses and other respiratory agents varies geographically, according to temperate versus cold and/or rainy climates.", [["respiratory", "ANATOMY", 55, 66], ["rhinoviruses", "DISEASE", 32, 44], ["rhinoviruses", "ORGANISM", 32, 44], ["rhinoviruses", "PROBLEM", 32, 44], ["other respiratory agents", "TREATMENT", 49, 73], ["rhinoviruses", "OBSERVATION", 32, 44]]], ["14 Whereas it is difficult to determine, based on current data, how climate affects the known occurrence of rhinovirus in temperate areas, such data are available for influenza, which is most prevalent in the rainy season in those areas with little temperature fluctuation.", [["rhinovirus", "DISEASE", 108, 118], ["influenza", "DISEASE", 167, 176], ["rhinovirus", "ORGANISM", 108, 118], ["rhinovirus", "PROBLEM", 108, 118], ["influenza", "PROBLEM", 167, 176], ["little temperature fluctuation", "PROBLEM", 242, 272], ["rhinovirus", "OBSERVATION", 108, 118], ["little temperature", "OBSERVATION_MODIFIER", 242, 260]]], ["Nonetheless, it has been shown that rhinoviruses are the most common cause of viral respiratory disease globally.", [["respiratory", "ANATOMY", 84, 95], ["viral respiratory disease", "DISEASE", 78, 103], ["rhinoviruses", "ORGANISM", 36, 48], ["rhinoviruses", "PROBLEM", 36, 48], ["viral respiratory disease globally", "PROBLEM", 78, 112], ["rhinoviruses", "OBSERVATION", 36, 48], ["most common", "OBSERVATION_MODIFIER", 57, 68], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["respiratory disease", "OBSERVATION", 84, 103]]], ["This is particularly true in the developing world, where crowding results in higher transmission and illness frequency early in life.Transmission of Rhinovirus InfectionThe pathogens that cause viral respiratory disease vary in their ability to initiate and transmit infection.", [["respiratory", "ANATOMY", 200, 211], ["illness", "DISEASE", 101, 108], ["viral respiratory disease", "DISEASE", 194, 219], ["infection", "DISEASE", 267, 276], ["Rhinovirus", "ORGANISM", 149, 159], ["illness frequency", "PROBLEM", 101, 118], ["Rhinovirus Infection", "PROBLEM", 149, 169], ["The pathogens", "PROBLEM", 169, 182], ["viral respiratory disease", "PROBLEM", 194, 219], ["transmit infection", "PROBLEM", 258, 276], ["true", "OBSERVATION_MODIFIER", 21, 25], ["higher", "OBSERVATION_MODIFIER", 77, 83], ["Rhinovirus Infection", "OBSERVATION", 149, 169], ["viral", "OBSERVATION_MODIFIER", 194, 199], ["respiratory disease", "OBSERVATION", 200, 219], ["infection", "OBSERVATION", 267, 276]]], ["The mode of transmission of rhinovirus has been widely debated over the years.", [["rhinovirus", "DISEASE", 28, 38], ["rhinovirus", "ORGANISM", 28, 38], ["rhinovirus", "PROBLEM", 28, 38], ["rhinovirus", "OBSERVATION", 28, 38], ["widely", "OBSERVATION_MODIFIER", 48, 54]]], ["2 Experimental studies of natural transmission of rhinovirus to determine routes and probability of transmission are rarely feasible and often cannot approximate natural transmission.", [["rhinovirus", "ORGANISM", 50, 60], ["Experimental studies", "TEST", 2, 22], ["rhinovirus", "PROBLEM", 50, 60], ["rhinovirus", "OBSERVATION", 50, 60]]], ["Therefore, conclusions are typically drawn from epidemiologic observations.Transmission of Rhinovirus InfectionFor example, influenza can transmit easily by airborne spread, that is, by aerosol as well as by large droplet.", [["influenza", "DISEASE", 124, 133], ["epidemiologic observations", "TEST", 48, 74], ["Rhinovirus Infection", "PROBLEM", 91, 111], ["influenza", "PROBLEM", 124, 133], ["Rhinovirus", "OBSERVATION", 91, 101], ["large", "OBSERVATION_MODIFIER", 208, 213], ["droplet", "OBSERVATION", 214, 221]]], ["15 Colds were believed to be transmitted by large droplet only.", [["Colds", "PROBLEM", 3, 8], ["believed to be", "UNCERTAINTY", 14, 28], ["large", "OBSERVATION_MODIFIER", 44, 49], ["droplet", "OBSERVATION", 50, 57]]], ["However, it was shown experimentally that rhinovirus infection could be produced by inoculating contaminated secretions from infected individuals into the noses or eyes of volunteers.", [["secretions", "ANATOMY", 109, 119], ["noses", "ANATOMY", 155, 160], ["eyes", "ANATOMY", 164, 168], ["rhinovirus infection", "DISEASE", 42, 62], ["rhinovirus", "ORGANISM", 42, 52], ["secretions", "ORGANISM_SUBSTANCE", 109, 119], ["noses", "ORGANISM_SUBDIVISION", 155, 160], ["eyes", "ORGAN", 164, 168], ["volunteers", "ORGANISM", 172, 182], ["rhinovirus infection", "PROBLEM", 42, 62], ["inoculating contaminated secretions", "PROBLEM", 84, 119], ["infected individuals into the noses or eyes of volunteers", "PROBLEM", 125, 182], ["rhinovirus", "OBSERVATION", 42, 52], ["noses", "ANATOMY", 155, 160], ["eyes", "ANATOMY", 164, 168]]], ["15 The question remained as to whether rhinovirus is transmitted primarily by direct contact, that is, by droplet nuclei or by indirect contact.", [["droplet nuclei", "ANATOMY", 106, 120], ["rhinovirus", "ORGANISM", 39, 49], ["nuclei", "CELLULAR_COMPONENT", 114, 120], ["rhinovirus", "PROBLEM", 39, 49], ["rhinovirus", "OBSERVATION", 39, 49]]], ["The transmission issue is still controversial.Transmission of Rhinovirus InfectionGwaltney and Hendley 16 showed that rhinoviruses could survive on (Adapted from N Engl J Med.", [["Rhinovirus", "ORGANISM", 62, 72], ["rhinoviruses", "ORGANISM", 118, 130], ["Rhinovirus Infection", "PROBLEM", 62, 82], ["rhinoviruses", "PROBLEM", 118, 130], ["N Engl J Med", "TREATMENT", 162, 174], ["Rhinovirus", "OBSERVATION", 62, 72], ["rhinoviruses", "OBSERVATION", 118, 130]]], ["12 ) surfaces and that rhinoviruses could be transmitted by finger-to-nose inoculation.", [["finger", "ANATOMY", 60, 66], ["nose", "ANATOMY", 70, 74], ["rhinoviruses", "ORGANISM", 23, 35], ["finger", "ORGANISM_SUBDIVISION", 60, 66], ["nose", "ORGANISM_SUBDIVISION", 70, 74], ["rhinoviruses", "PROBLEM", 23, 35], ["rhinoviruses", "OBSERVATION", 23, 35], ["nose", "ANATOMY", 70, 74], ["inoculation", "OBSERVATION", 75, 86]]], ["This group from the University of Virginia at Charlottesville considered that contact with infected secretions is the principal mode of transmission.", [["secretions", "ANATOMY", 100, 110], ["infected secretions", "DISEASE", 91, 110], ["secretions", "ORGANISM", 100, 110], ["infected secretions", "PROBLEM", 91, 110], ["infected", "OBSERVATION_MODIFIER", 91, 99], ["secretions", "OBSERVATION", 100, 110]]], ["They found that volunteers in contact with contaminated objects or with the fingers of individuals with rhinovirus colds had a high rate of infection if they inoculated their own noses or eyes.", [["eyes", "ANATOMY", 188, 192], ["rhinovirus colds", "DISEASE", 104, 120], ["infection", "DISEASE", 140, 149], ["volunteers", "ORGANISM", 16, 26], ["fingers", "ORGANISM_SUBDIVISION", 76, 83], ["rhinovirus", "ORGANISM", 104, 114], ["eyes", "ORGAN", 188, 192], ["rhinovirus colds", "PROBLEM", 104, 120], ["a high rate of infection", "PROBLEM", 125, 149], ["fingers", "ANATOMY", 76, 83], ["infection", "OBSERVATION", 140, 149], ["eyes", "ANATOMY", 188, 192]]], ["Furthermore, the investigators discovered that transmission could be interrupted by treating surfaces of contaminated objects with disinfectant or by applying iodine to the fingers.", [["iodine", "CHEMICAL", 159, 165], ["iodine", "CHEMICAL", 159, 165], ["iodine", "SIMPLE_CHEMICAL", 159, 165], ["fingers", "ORGANISM_SUBDIVISION", 173, 180], ["iodine", "TREATMENT", 159, 165], ["fingers", "ANATOMY", 173, 180]]], ["They found little evidence of transmission by means of droplets.", [["little evidence of", "UNCERTAINTY", 11, 29]]], ["17 In contrast, Dick et al, 18 from the University of Wisconsin, showed that this mechanism is not required for rhinovirus transmission, and they found evidence that rhinovirus could be spread by droplet transmission.", [["rhinovirus", "ORGANISM", 112, 122], ["rhinovirus", "ORGANISM", 166, 176], ["rhinovirus transmission", "PROBLEM", 112, 135], ["rhinovirus", "PROBLEM", 166, 176], ["rhinovirus", "OBSERVATION", 166, 176]]], ["Those studies were carried out with volunteers, one of whom was inoculated with virus.", [["volunteers", "ORGANISM", 36, 46], ["Those studies", "TEST", 0, 13], ["virus", "PROBLEM", 80, 85]]], ["Others were known to be susceptible to the virus and were exposed to the infected individuals under different circumstances.", [["the virus", "PROBLEM", 39, 48], ["virus", "OBSERVATION", 43, 48], ["infected", "OBSERVATION", 73, 81]]], ["In the final experiment, the volunteers played cards with each other.", [["volunteers", "ORGANISM", 29, 39]]], ["One was experimentally infected, and all wore collars preventing their putting hands in their noses or eyes.", [["eyes", "ANATOMY", 103, 107], ["hands", "ORGANISM_SUBDIVISION", 79, 84], ["eyes", "ORGAN", 103, 107], ["experimentally infected", "PROBLEM", 8, 31], ["all wore collars", "TREATMENT", 37, 53], ["infected", "OBSERVATION", 23, 31], ["eyes", "ANATOMY", 103, 107]]], ["Transmission still took place.Transmission of Rhinovirus InfectionIn summary, whereas some experts agree that indirect contact with contaminated secretions appears to be the most efficient means of transmission, 19 others find that large-droplet transmission of such secretions is more important.", [["secretions", "ANATOMY", 145, 155], ["secretions", "ANATOMY", 267, 277], ["secretions", "ORGANISM", 145, 155], ["Rhinovirus", "PROBLEM", 46, 56], ["contaminated secretions", "PROBLEM", 132, 155], ["such secretions", "PROBLEM", 262, 277], ["Rhinovirus", "OBSERVATION", 46, 56], ["large", "OBSERVATION_MODIFIER", 232, 237]]], ["It is probably futile to hope that hand disinfection alone will result in interruption of transmission.", [["hand", "ANATOMY", 35, 39], ["hand", "ORGANISM_SUBDIVISION", 35, 39], ["hand disinfection", "TREATMENT", 35, 52], ["probably", "UNCERTAINTY", 6, 14], ["disinfection", "OBSERVATION", 40, 52]]], ["There are thus sufficient data to suggest that close exposure to a person with infection, especially in the family setting, is required and is a major risk factor for acquiring rhinovirus infection.", [["infection", "DISEASE", 79, 88], ["rhinovirus infection", "DISEASE", 177, 197], ["rhinovirus", "ORGANISM", 177, 187], ["person", "SPECIES", 67, 73], ["infection", "PROBLEM", 79, 88], ["acquiring rhinovirus infection", "PROBLEM", 167, 197], ["infection", "OBSERVATION", 79, 88], ["rhinovirus", "OBSERVATION", 177, 187]]], ["This finding is further supported by data indicating that crowding in the home facilitates transmission.", [["crowding", "OBSERVATION_MODIFIER", 58, 66]]], ["7The Epidemiologic Significance of Rhinovirus SerotypesThe large number of rhinovirus serotypes (over 100) has been a challenge, both in terms of laboratory procedures and reagents required for identification and in the development of a vaccine or antiviral medication to combat rhinovirus.", [["rhinovirus", "DISEASE", 279, 289], ["rhinovirus", "ORGANISM", 75, 85], ["rhinovirus", "ORGANISM", 279, 289], ["Rhinovirus Serotypes", "PROBLEM", 35, 55], ["rhinovirus serotypes", "PROBLEM", 75, 95], ["laboratory procedures", "TEST", 146, 167], ["reagents", "TREATMENT", 172, 180], ["identification", "TEST", 194, 208], ["a vaccine", "TREATMENT", 235, 244], ["antiviral medication", "TREATMENT", 248, 268], ["rhinovirus", "PROBLEM", 279, 289], ["Rhinovirus Serotypes", "OBSERVATION", 35, 55], ["large", "OBSERVATION_MODIFIER", 59, 64], ["number", "OBSERVATION_MODIFIER", 65, 71], ["rhinovirus serotypes", "OBSERVATION", 75, 95]]], ["The finding of a multiplicity of serotypes allowed demonstration of the fact that the seasonal outbreaks were actually a summation of mini-outbreaks, in which a large number of serotypes spread in a similar fashion.", [["a multiplicity of serotypes", "PROBLEM", 15, 42], ["the seasonal outbreaks", "PROBLEM", 82, 104], ["a summation of mini-outbreaks", "PROBLEM", 119, 148], ["serotypes", "PROBLEM", 177, 186], ["serotypes", "OBSERVATION", 33, 42], ["seasonal", "OBSERVATION_MODIFIER", 86, 94], ["outbreaks", "OBSERVATION", 95, 104], ["large", "OBSERVATION_MODIFIER", 161, 166], ["number", "OBSERVATION_MODIFIER", 167, 173], ["serotypes", "OBSERVATION", 177, 186]]], ["It also allowed demonstration that even in the same family, more than 1 serotype can be circulating, which indicates multiple introductions.", [["multiple", "OBSERVATION_MODIFIER", 117, 125], ["introductions", "OBSERVATION", 126, 139]]], ["9,10,20The Epidemiologic Significance of Rhinovirus SerotypesThe number of serotypes became critical, because vaccine prevention initially appeared to be the ideal way to prevent rhinovirus infections.", [["rhinovirus infections", "DISEASE", 179, 200], ["rhinovirus", "ORGANISM", 179, 189], ["Rhinovirus Serotypes", "PROBLEM", 41, 61], ["serotypes", "PROBLEM", 75, 84], ["vaccine prevention", "TREATMENT", 110, 128], ["rhinovirus infections", "PROBLEM", 179, 200], ["Rhinovirus Serotypes", "OBSERVATION", 41, 61], ["serotypes", "OBSERVATION_MODIFIER", 75, 84], ["rhinovirus", "OBSERVATION", 179, 189]]], ["The first question was whether the number of serotypes was fixed or whether, like influenza, new serotypes were continuing to evolve.", [["influenza", "DISEASE", 82, 91], ["serotypes", "PROBLEM", 45, 54], ["influenza", "PROBLEM", 82, 91], ["new serotypes", "PROBLEM", 93, 106]]], ["It gradually emerged that the number of serotypes is fixed.", [["number", "OBSERVATION_MODIFIER", 30, 36], ["serotypes", "OBSERVATION", 40, 49], ["fixed", "OBSERVATION_MODIFIER", 53, 58]]], ["10, 21 The second question related to whether there was a difference in the relative activity of various rhinovirus serotypes and whether certain rhinoviruses transmit more easily than others.", [["rhinovirus", "ORGANISM", 105, 115], ["rhinoviruses", "ORGANISM", 146, 158], ["various rhinovirus serotypes", "PROBLEM", 97, 125], ["certain rhinoviruses", "PROBLEM", 138, 158], ["rhinovirus", "OBSERVATION", 105, 115], ["rhinoviruses", "OBSERVATION", 146, 158]]], ["This was initially based on recognition of certain types as more \"common\" causes of respiratory infections while others are rarely seen.", [["respiratory", "ANATOMY", 84, 95], ["respiratory infections", "DISEASE", 84, 106], ["respiratory infections", "PROBLEM", 84, 106], ["respiratory", "ANATOMY", 84, 95], ["infections", "OBSERVATION", 96, 106]]], ["2, 9, 20 These common serotypes would be a priority for vaccine development.The Epidemiologic Significance of Rhinovirus SerotypesThe hypothesis of common serotypes causing respiratory infections was confirmed by several studies.", [["respiratory", "ANATOMY", 173, 184], ["respiratory infections", "DISEASE", 173, 195], ["2, 9, 20", "CHEMICAL", 0, 8], ["vaccine development", "TREATMENT", 56, 75], ["Rhinovirus Serotypes", "PROBLEM", 110, 130], ["common serotypes", "PROBLEM", 148, 164], ["respiratory infections", "PROBLEM", 173, 195], ["several studies", "TEST", 213, 228], ["Rhinovirus Serotypes", "OBSERVATION", 110, 130], ["common", "OBSERVATION_MODIFIER", 148, 154], ["serotypes", "OBSERVATION_MODIFIER", 155, 164], ["respiratory", "ANATOMY", 173, 184], ["infections", "OBSERVATION", 185, 195]]], ["10, 22, 23 It was finally determined, however, that although common serotypes existed, those that were common changed over time.", [["common serotypes", "PROBLEM", 61, 77]]], ["2, 10 Because of this fact and similar findings, the development of specific antiviral agents appeared to offer more promise than vaccine development for control of VRIs resulting from rhinovirus.Recent Developments Help to Confirm the Epidemiology of RhinovirusIsolation rates of viruses have varied from early studies to the more recent studies as diagnostic testing has become more sophisticated.", [["VRIs", "DISEASE", 165, 169], ["VRIs", "CANCER", 165, 169], ["rhinovirus", "ORGANISM", 185, 195], ["specific antiviral agents", "TREATMENT", 68, 93], ["vaccine development", "TREATMENT", 130, 149], ["VRIs", "PROBLEM", 165, 169], ["rhinovirus", "PROBLEM", 185, 195], ["viruses", "PROBLEM", 281, 288], ["diagnostic testing", "TEST", 350, 368], ["rhinovirus", "OBSERVATION", 185, 195], ["viruses", "OBSERVATION", 281, 288]]], ["The development of PCR has allowed identification of rhinoviruses and confirmation of the proportion of respiratory infections caused by the rhinoviruses.", [["respiratory", "ANATOMY", 104, 115], ["respiratory infections", "DISEASE", 104, 126], ["rhinoviruses", "ORGANISM", 53, 65], ["rhinoviruses", "ORGANISM", 141, 153], ["PCR", "TEST", 19, 22], ["rhinoviruses", "PROBLEM", 53, 65], ["respiratory infections", "PROBLEM", 104, 126], ["the rhinoviruses", "PROBLEM", 137, 153], ["rhinoviruses", "OBSERVATION", 53, 65], ["respiratory", "ANATOMY", 104, 115], ["infections", "OBSERVATION", 116, 126], ["rhinoviruses", "OBSERVATION", 141, 153]]], ["PCR has been shown to be more sensitive and often more rapid than culture isolation of respiratory viruses.", [["respiratory viruses", "DISEASE", 87, 106], ["PCR", "TEST", 0, 3], ["respiratory viruses", "PROBLEM", 87, 106], ["respiratory viruses", "OBSERVATION", 87, 106]]], ["24 Another reason for the differences in picornavirus isolation rates between epidemiologic studies is at least in part related to the case definitions used and timing of the studies (eg, length of study and season in which it is conducted).", [["picornavirus", "ORGANISM", 41, 53], ["the differences in picornavirus isolation rates", "PROBLEM", 22, 69], ["epidemiologic studies", "TEST", 78, 99], ["the studies", "TEST", 171, 182], ["study", "TEST", 198, 203], ["picornavirus", "OBSERVATION", 41, 53]]], ["Self-diagnosed illnesses in which only 1 respiratory symptom was required (as in the Tecumseh studies) yield fewer isolates than sampling illnesses in which more symptoms are required.Recent Developments Help to Confirm the Epidemiology of RhinovirusFor example, in Finland, a study in 200 young adults with selfdiagnosed colds and clinical evidence of symptoms (rhinorrhea, nasal congestion, and sore throat confirmed by the physician) was conducted over a 10-month period.", [["nasal", "ANATOMY", 375, 380], ["colds", "DISEASE", 322, 327], ["rhinorrhea", "DISEASE", 363, 373], ["nasal congestion", "DISEASE", 375, 391], ["sore throat", "DISEASE", 397, 408], ["nasal", "ORGANISM_SUBDIVISION", 375, 380], ["Self-diagnosed illnesses", "PROBLEM", 0, 24], ["1 respiratory symptom", "PROBLEM", 39, 60], ["fewer isolates", "PROBLEM", 109, 123], ["sampling illnesses", "PROBLEM", 129, 147], ["more symptoms", "PROBLEM", 157, 170], ["Rhinovirus", "PROBLEM", 240, 250], ["a study", "TEST", 275, 282], ["selfdiagnosed colds", "PROBLEM", 308, 327], ["symptoms", "PROBLEM", 353, 361], ["rhinorrhea", "PROBLEM", 363, 373], ["nasal congestion", "PROBLEM", 375, 391], ["sore throat", "PROBLEM", 397, 408], ["Rhinovirus", "OBSERVATION", 240, 250], ["nasal", "ANATOMY", 375, 380], ["congestion", "OBSERVATION", 381, 391]]], ["25 In total, a viral cause was found in 69% of cases.", [["a viral cause", "PROBLEM", 13, 26]]], ["The rhinovirus isolation rate was 40%.", [["rhinovirus", "ORGANISM", 4, 14], ["The rhinovirus isolation rate", "TEST", 0, 29], ["rhinovirus", "OBSERVATION", 4, 14]]], ["An additional 12% of rhinovirus-positive samples were detected by PCR, with a total rhinovirus identification rate of 52%.Recent Developments Help to Confirm the Epidemiology of RhinovirusA Virginia study of young adults with self-diagnosed colds confirmed that PCR increases the rate of picornavirus detection.", [["samples", "ANATOMY", 41, 48], ["colds", "DISEASE", 241, 246], ["rhinovirus", "ORGANISM", 21, 31], ["adults", "ORGANISM", 214, 220], ["picornavirus", "ORGANISM", 288, 300], ["rhinovirus", "TEST", 21, 31], ["PCR", "TEST", 66, 69], ["a total rhinovirus identification rate", "TEST", 76, 114], ["self-diagnosed colds", "PROBLEM", 226, 246], ["PCR", "TEST", 262, 265], ["picornavirus detection", "PROBLEM", 288, 310], ["picornavirus", "OBSERVATION", 288, 300]]], ["26 This study was conducted over a 2-month period during the autumn peak of illness.", [["illness", "DISEASE", 76, 83], ["This study", "TEST", 3, 13], ["illness", "PROBLEM", 76, 83]]], ["The isolation rate of rhinoviruses (and a few other picornaviruses) using culture was 67%.", [["rhinoviruses", "ORGANISM", 22, 34], ["The isolation rate", "TEST", 0, 18], ["rhinoviruses", "PROBLEM", 22, 34], ["culture", "TEST", 74, 81], ["rhinoviruses", "OBSERVATION", 22, 34]]], ["With the addition of PCR, the total picornavirus identification rate increased to 82%.ConclusionsEarly epidemiologic studies documenting that children are at particular risk for VRIs have stood the test of time, as have other findings, such as a higher frequency of illnesses in females and autumn and spring peaks of illness.", [["VRIs", "DISEASE", 178, 182], ["illness", "DISEASE", 318, 325], ["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150], ["PCR", "TREATMENT", 21, 24], ["the total picornavirus identification rate", "TEST", 26, 68], ["Early epidemiologic studies", "TEST", 97, 124], ["illness", "PROBLEM", 318, 325]]], ["Rhinoviruses are by far the most frequent viral isolate identified in persons with colds.", [["colds", "DISEASE", 83, 88], ["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["persons", "ORGANISM", 70, 77], ["persons", "SPECIES", 70, 77], ["Rhinoviruses", "PROBLEM", 0, 12], ["frequent viral isolate", "TREATMENT", 33, 55], ["colds", "PROBLEM", 83, 88]]], ["They cause VRIs in all months of the year, but major peaks occur in the fall and in the spring; the fall peak follows the opening of schools.", [["VRIs", "DISEASE", 11, 15], ["VRIs", "PROBLEM", 11, 15], ["the fall peak", "PROBLEM", 96, 109]]], ["The mechanism of transmission of rhinovirus remains unclear, and the significance of indirect transmission is still under debate.", [["rhinovirus", "DISEASE", 33, 43], ["rhinovirus", "ORGANISM", 33, 43], ["rhinovirus", "PROBLEM", 33, 43], ["rhinovirus", "OBSERVATION", 33, 43]]], ["PCR techniques have been able to identify more completely rhinoviruses in studies of persons with suspected VRIs.", [["rhinoviruses", "DISEASE", 58, 70], ["VRIs", "DISEASE", 108, 112], ["rhinoviruses", "ORGANISM", 58, 70], ["persons", "ORGANISM", 85, 92], ["persons", "SPECIES", 85, 92], ["PCR techniques", "TEST", 0, 14], ["suspected VRIs", "PROBLEM", 98, 112], ["rhinoviruses", "OBSERVATION", 58, 70]]], ["However, they have not been used in population-based studies, so the actual role of these agents in important syndromes can only be inferred.", [["based studies", "TEST", 47, 60], ["these agents", "TREATMENT", 84, 96], ["important syndromes", "PROBLEM", 100, 119]]], ["A particular need for future work is to determine the seasonality of rhinoviruses in areas without a clear winter season and the role of symptoms in predicting which infections are likely caused by rhinovirus.", [["rhinoviruses", "DISEASE", 69, 81], ["infections", "DISEASE", 166, 176], ["rhinoviruses", "ORGANISM", 69, 81], ["rhinovirus", "ORGANISM", 198, 208], ["rhinoviruses", "PROBLEM", 69, 81], ["symptoms", "PROBLEM", 137, 145], ["infections", "PROBLEM", 166, 176], ["rhinovirus", "PROBLEM", 198, 208], ["rhinoviruses", "OBSERVATION", 69, 81], ["likely caused", "UNCERTAINTY", 181, 194], ["rhinovirus", "OBSERVATION", 198, 208]]], ["Such determinations will be of value in identifying which patients with respiratory illnesses should be treated when antirhinovirus drugs are available.", [["respiratory", "ANATOMY", 72, 83], ["respiratory illnesses", "DISEASE", 72, 93], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["respiratory illnesses", "PROBLEM", 72, 93], ["antirhinovirus drugs", "TREATMENT", 117, 137]]]], "a20ad9eed0e63723266886d899b9def924eb453c": [["Of those who opted in, however, only two-thirds had all the required information (ethics approval if needed, declaration of interests, funding statement, and prospective registration for randomised controlled trials).", [["randomised controlled trials", "TREATMENT", 187, 215]]]], "1e43c4a6fdab67e532a453a38fc4f2ed4ff20ebd": [["DNA and RNA sequence information uniquely identify biological organisms, from human to microbe.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["DNA", "PROBLEM", 0, 3], ["RNA sequence information", "TEST", 8, 32], ["biological organisms", "PROBLEM", 51, 71]]], ["Consequently, detection of specific DNA sequences has become a critical part of precision medicine, from pathogen identification to human genetic disease risk assessment to disease prognosis.", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["human", "ORGANISM", 132, 137], ["DNA sequences", "DNA", 36, 49], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["specific DNA sequences", "PROBLEM", 27, 49]]], ["It is evident that as our understanding of disease genomics improves, translation of this scientific knowledge into actionable clinical practice will be facilitated by DNA diagnostic platforms that are simultaneously fast, affordable, sensitive, massively multiplexed, quantitative, and easy to operate.", [["DNA", "CELLULAR_COMPONENT", 168, 171], ["disease genomics", "PROBLEM", 43, 59]]]], "PMC7431914": [["Experimental Infection in the 18th\u201319th CenturyThe intentional infection of human beings with pathogens with the aim of achieving benefits (chiefly, the prevention of more severe disease) has occurred for centuries; the (semi-)systematic testing and recording of such methods dates to the 18th Century in England (Halsband 1953; Weiss and Esparza 2015).", [["infection", "DISEASE", 63, 72], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["Experimental Infection", "PROBLEM", 0, 22], ["The intentional infection of human", "PROBLEM", 47, 81], ["pathogens", "PROBLEM", 94, 103], ["more severe disease)", "PROBLEM", 167, 187], ["the (semi-)systematic testing", "TEST", 216, 245], ["Infection", "OBSERVATION", 13, 22], ["intentional", "OBSERVATION_MODIFIER", 51, 62], ["infection", "OBSERVATION", 63, 72]]], ["Although the credit for initiating a modern science of vaccination is usually accorded to Edward Jenner (1749\u20131823), who pioneered the use of cowpox (cow giving rise to the vache in vaccine, a term coined by Jenner) to prevent smallpox, variolation (sometimes referred to as \u2018inoculation\u2019, i.e., the prevention of smallpox by injection or insufflation of material believed to produce a mild infection and thus convey an attenuated risk of the disease) began much earlier, in Asia and the Eastern Mediterranean, and was introduced to England and North America in the early 18th Century (Timonius and Woodward 1714; Halsband 1953, Gross and Sepkowitz 1998; Weiss and Esparza 2015).", [["cowpox", "DISEASE", 142, 148], ["smallpox", "DISEASE", 227, 235], ["variolation", "DISEASE", 237, 248], ["smallpox", "DISEASE", 314, 322], ["infection", "DISEASE", 391, 400], ["cowpox", "ORGANISM", 142, 148], ["cow", "ORGANISM", 150, 153], ["cow", "SPECIES", 150, 153], ["cow", "SPECIES", 150, 153], ["a modern science of vaccination", "TREATMENT", 35, 66], ["cowpox", "PROBLEM", 142, 148], ["the vache in vaccine", "TREATMENT", 169, 189], ["smallpox", "PROBLEM", 227, 235], ["smallpox", "TREATMENT", 314, 322], ["insufflation of material", "TREATMENT", 339, 363], ["a mild infection", "PROBLEM", 384, 400], ["the disease", "PROBLEM", 439, 450], ["mild", "OBSERVATION_MODIFIER", 386, 390], ["infection", "OBSERVATION", 391, 400], ["disease", "OBSERVATION", 443, 450]]], ["Furthermore, that prior infection with cowpox protected humans against infection with smallpox was widely believed in cattle farming communities in England (and elsewhere) long before Jenner\u2019s experiments; at least one English farmer, Benjamin Jesty, is known to have intentionally infected members of his family with cowpox as a means of preventing smallpox in 1774 (i.e., 25 years before Jenner\u2019s experiments) (Gross and Sepkowitz 1998).", [["infection", "DISEASE", 24, 33], ["cowpox", "DISEASE", 39, 45], ["infection", "DISEASE", 71, 80], ["smallpox", "DISEASE", 86, 94], ["cowpox", "DISEASE", 318, 324], ["smallpox", "DISEASE", 350, 358], ["cowpox", "ORGANISM", 39, 45], ["humans", "ORGANISM", 56, 62], ["cowpox", "ORGANISM", 318, 324], ["humans", "SPECIES", 56, 62], ["cattle", "SPECIES", 118, 124], ["humans", "SPECIES", 56, 62], ["cattle", "SPECIES", 118, 124], ["prior infection", "PROBLEM", 18, 33], ["cowpox", "PROBLEM", 39, 45], ["infection", "PROBLEM", 71, 80], ["infection", "OBSERVATION", 24, 33], ["infected", "OBSERVATION", 282, 290]]], ["Yet, although there were some earlier \u2018trials\u2019 of smallpox variolation and cowpox vaccination, Jenner\u2019s testing of the cowpox vaccine was more systematic, and involved intentional exposure to smallpox after vaccination (with cowpox) to test efficacy in 1796.", [["variolation", "DISEASE", 59, 70], ["cowpox", "DISEASE", 75, 81], ["smallpox", "DISEASE", 192, 200], ["cowpox", "ORGANISM", 75, 81], ["cowpox", "ORGANISM", 119, 125], ["cowpox", "ORGANISM", 225, 231], ["cowpox", "SPECIES", 75, 81], ["cowpox", "SPECIES", 119, 125], ["smallpox variolation", "TREATMENT", 50, 70], ["cowpox vaccination", "TREATMENT", 75, 93], ["Jenner\u2019s testing", "TEST", 95, 111], ["the cowpox vaccine", "TREATMENT", 115, 133], ["smallpox after vaccination", "TREATMENT", 192, 218]]], ["However, unlike modern human challenge studies, Jenner\u2019s investigations in the late 18th Century did not involve (i) systematic study of the methods required to induce disease safely and reliably in humans or (ii) the testing of preventive/therapeutic interventions against a reliable model of infection.Experimental Infection in the 18th\u201319th CenturyOne of Jenner\u2019s teachers had been the prominent Scottish surgeon John Hunter, a local pioneer of smallpox variolation (which carried higher risks than the later practice of vaccination) (Turk and Allen 1990).", [["infection", "DISEASE", 294, 303], ["human", "ORGANISM", 23, 28], ["humans", "ORGANISM", 199, 205], ["human", "SPECIES", 23, 28], ["humans", "SPECIES", 199, 205], ["human", "SPECIES", 23, 28], ["humans", "SPECIES", 199, 205], ["modern human challenge studies", "TEST", 16, 46], ["systematic study", "TEST", 117, 133], ["the methods", "TREATMENT", 137, 148], ["disease", "PROBLEM", 168, 175], ["the testing", "TEST", 214, 225], ["preventive/therapeutic interventions", "TREATMENT", 229, 265], ["infection", "PROBLEM", 294, 303], ["Experimental Infection", "PROBLEM", 304, 326], ["smallpox variolation", "TREATMENT", 448, 468], ["infection", "OBSERVATION", 294, 303], ["Infection", "OBSERVATION", 317, 326], ["prominent", "OBSERVATION_MODIFIER", 389, 398]]], ["Although Hunter is credited with many positive achievements, he has also become infamous for his attempt to prove his (later falsified) theory that gonorrhoea and syphilis were in fact the same disease.", [["gonorrhoea", "DISEASE", 148, 158], ["syphilis", "DISEASE", 163, 171], ["gonorrhoea", "PROBLEM", 148, 158], ["syphilis", "PROBLEM", 163, 171], ["the same disease", "PROBLEM", 185, 201]]], ["In 1767, Hunter used an experimental (challenge) technique: the injection of \u201cvenereal matter\u201d from a patient with gonorrhoea into the penis of a single research subject (Dempster 1978).", [["penis", "ANATOMY", 135, 140], ["gonorrhoea", "DISEASE", 115, 125], ["patient", "ORGANISM", 102, 109], ["penis", "ORGAN", 135, 140], ["patient", "SPECIES", 102, 109], ["an experimental (challenge) technique", "TREATMENT", 21, 58], ["\u201cvenereal matter", "TREATMENT", 77, 93], ["gonorrhoea", "PROBLEM", 115, 125], ["penis", "ANATOMY", 135, 140]]], ["Though it is sometimes claimed, even in recent times (Gladstein 2005), that Hunter himself was the subject, there is no contemporaneous evidence to support this theory, and it appears more likely that Hunter experimented on another individual\u2014especially since it was known that he had attempted to transmit gonorrhoea to others via inoculation of the skin (Dempster 1978).", [["skin", "ANATOMY", 351, 355], ["gonorrhoea", "DISEASE", 307, 317], ["skin", "ORGAN", 351, 355], ["appears more likely", "UNCERTAINTY", 176, 195], ["skin", "ANATOMY", 351, 355]]], ["Importantly, the research subject developed evidence of syphilis, which Hunter took (erroneously) as evidence in favour of his theory (that gonorrhoea and syphilis were the same disease); it now appears more likely that the patient with gonorrhoea from whom the sample was obtained was also infected with syphilis.", [["syphilis", "DISEASE", 56, 64], ["gonorrhoea", "DISEASE", 140, 150], ["syphilis", "DISEASE", 155, 163], ["gonorrhoea", "DISEASE", 237, 247], ["syphilis", "DISEASE", 305, 313], ["patient", "ORGANISM", 224, 231], ["patient", "SPECIES", 224, 231], ["syphilis", "PROBLEM", 56, 64], ["gonorrhoea", "PROBLEM", 140, 150], ["syphilis", "PROBLEM", 155, 163], ["the same disease", "PROBLEM", 169, 185], ["gonorrhoea", "PROBLEM", 237, 247], ["syphilis", "PROBLEM", 305, 313], ["syphilis", "OBSERVATION", 56, 64], ["appears more likely", "UNCERTAINTY", 195, 214]]], ["Thus, the experiment was scientifically flawed and (although mercury-based treatment was provided for the experimental syphilis infection (Wright 1981)) arguably carried significant risks that many would consider unacceptably high\u2014especially on the assumption that this was not a case of self-experimentation (self-experimentation is discussed further below).Experimental Infection in the 18th\u201319th CenturyDuring the 19th Century there were significant developments in microbiological understanding of infectious disease.", [["mercury", "CHEMICAL", 61, 68], ["syphilis infection", "DISEASE", 119, 137], ["infectious disease", "DISEASE", 502, 520], ["mercury", "CHEMICAL", 61, 68], ["mercury", "SIMPLE_CHEMICAL", 61, 68], ["mercury-based treatment", "TREATMENT", 61, 84], ["the experimental syphilis infection", "PROBLEM", 102, 137], ["Experimental Infection", "PROBLEM", 359, 381], ["infectious disease", "PROBLEM", 502, 520], ["Infection", "OBSERVATION", 372, 381], ["significant", "OBSERVATION_MODIFIER", 441, 452], ["infectious", "OBSERVATION", 502, 512]]], ["Irish, German, and Russian physician-investigators injected infectious material from patients with gonorrhoea and syphilis into children and babies, and at least one baby died as a result.", [["gonorrhoea", "DISEASE", 99, 109], ["syphilis", "DISEASE", 114, 122], ["patients", "ORGANISM", 85, 93], ["children", "ORGANISM", 128, 136], ["babies", "ORGANISM", 141, 147], ["baby", "ORGANISM", 166, 170], ["patients", "SPECIES", 85, 93], ["children", "SPECIES", 128, 136], ["gonorrhoea", "PROBLEM", 99, 109], ["syphilis", "PROBLEM", 114, 122]]], ["Although these investigations did appear to confirm the transmission of such infections, the studies were poorly controlled (due to the rudimentary knowledge of microbiology and lack of available treatments at the time, and perhaps also to the callousness of the investigators).", [["infections", "DISEASE", 77, 87], ["these investigations", "TEST", 9, 29], ["such infections", "PROBLEM", 72, 87], ["the studies", "TEST", 89, 100], ["available treatments", "TREATMENT", 186, 206], ["infections", "OBSERVATION", 77, 87]]], ["The use of, and harm to, minors (even though some were teenagers who were said to have agreed to participate), furthermore, struck some physicians of the time as immoral and likely unnecessary (Macneill 2010).Experimental Infection in the 18th\u201319th CenturyOne reason it was not necessary to experiment on others (including minors) is that challenge studies can involve self-experimentation, which\u2014especially under such uncontrolled and uncertain conditions\u2014might be considered ethically preferable to the recruitment of others.", [["Experimental Infection", "PROBLEM", 209, 231], ["challenge studies", "TEST", 339, 356], ["Infection", "OBSERVATION", 222, 231]]], ["For example, two scientists deliberately infected themselves with cholera bacteria in 1892.", [["cholera bacteria", "DISEASE", 66, 82], ["cholera bacteria", "PROBLEM", 66, 82]]], ["One developed clinical cholera, and this was taken as significant evidence linking the microbe with the disease (Benyajati 1966).", [["cholera", "DISEASE", 23, 30], ["clinical cholera", "PROBLEM", 14, 30], ["the disease", "PROBLEM", 100, 111]]], ["Another early challenge study, testing a typhoid vaccine in two \u2018Officers of the Indian Medical Service\u2019 took place in 1896.", [["typhoid", "DISEASE", 41, 48], ["Another early challenge study", "TEST", 0, 29], ["a typhoid vaccine", "TREATMENT", 39, 56]]], ["Though few details are supplied, if these individuals were medically trained and aware of the details of the study then they may have been able to provide (what would now be considered) proper informed consent to the risks to which they were exposed (Wright 1896).Early Challenge Studies with Vector-Borne DiseasesIn the late 19th and early 20th Century additional early challenge experiments began to occur on a larger scale and (generally) with increasing scientific rigor.", [["the study", "TEST", 105, 114], ["Borne Diseases", "PROBLEM", 300, 314], ["a larger scale", "TREATMENT", 411, 425], ["increasing scientific rigor", "PROBLEM", 447, 474]]], ["Challenge studies investigating what would now be referred to as vector-borne diseases (e.g., yellow fever, malaria, and dengue) were particularly prominent at the time, and often conducted in endemic countries (in contrast to later challenge studies which have been predominantly conducted in non-endemic countries).", [["yellow fever", "DISEASE", 94, 106], ["malaria", "DISEASE", 108, 115], ["dengue", "DISEASE", 121, 127], ["dengue", "SPECIES", 121, 127], ["Challenge studies", "TEST", 0, 17], ["borne diseases", "PROBLEM", 72, 86], ["yellow fever", "PROBLEM", 94, 106], ["malaria", "PROBLEM", 108, 115], ["dengue", "PROBLEM", 121, 127]]], ["Famous early examples of such experiments include (i) the failed attempts by Carlos Finlay to transmit yellow fever from symptomatic patients to healthy individuals in Cuba from 1881\u201318931 (Finlay 1886, 1937; Clements and Harbach 2017) and (ii) the successful transmission of malaria via infected mosquitoes in Italy in 1898 by Battista Grassi (Grassi et al. 1898; Capanna 2006).", [["yellow fever", "DISEASE", 103, 115], ["malaria", "DISEASE", 276, 283], ["infected mosquitoes", "DISEASE", 288, 307], ["yellow fever", "ORGANISM", 103, 115], ["patients", "ORGANISM", 133, 141], ["malaria", "ORGANISM", 276, 283], ["patients", "SPECIES", 133, 141], ["transmit yellow fever", "PROBLEM", 94, 115], ["malaria", "PROBLEM", 276, 283], ["malaria", "OBSERVATION", 276, 283]]], ["The latter study provided the first experimental evidence that malaria was transmitted to humans by mosquitoes.2 Since malaria was, at that time, endemic to much of Italy (potentially casting doubt on Grassi\u2019s findings, because individuals exposed to mosquitoes during the trial could have contracted the disease elsewhere), a similar experiment was repeated in London (with infected mosquitoes transported from Italy) by Patrick Manson in 1900 (Manson 1900).", [["malaria", "DISEASE", 63, 70], ["malaria", "DISEASE", 119, 126], ["malaria", "ORGANISM", 63, 70], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["The latter study", "TEST", 0, 16], ["malaria", "PROBLEM", 63, 70], ["malaria", "PROBLEM", 119, 126], ["the disease elsewhere", "PROBLEM", 301, 322], ["malaria", "OBSERVATION", 63, 70], ["malaria", "OBSERVATION", 119, 126]]], ["Manson infected two volunteers (thought to include his son), and successfully cured the induced infection by administration of quinine (Cox 2010).Early Challenge Studies with Vector-Borne DiseasesElsewhere during the same period, other early research on yellow fever employed challenge study techniques, though such efforts were sometimes unsuccessful and/or harmful.", [["infection", "DISEASE", 96, 105], ["quinine", "CHEMICAL", 127, 134], ["fever", "DISEASE", 261, 266], ["quinine", "CHEMICAL", 127, 134], ["volunteers", "ORGANISM", 20, 30], ["quinine", "SIMPLE_CHEMICAL", 127, 134], ["the induced infection", "PROBLEM", 84, 105], ["quinine", "TREATMENT", 127, 134], ["Borne Diseases", "PROBLEM", 182, 196], ["yellow fever", "PROBLEM", 254, 266], ["study techniques", "TEST", 286, 302], ["infection", "OBSERVATION", 96, 105], ["early", "OBSERVATION_MODIFIER", 236, 241]]], ["In 1897, Giuseppe Sanarelli, an Italian physician in Uruguay, claimed to have isolated a bacterial cause of yellow fever (now known to be caused by a virus) and injected a culture of these bacteria into 5 hospital patients, perhaps without their knowledge or consent, of whom 3 died (Lederer 2008).", [["yellow fever", "DISEASE", 108, 120], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["yellow fever", "PROBLEM", 108, 120], ["a virus)", "PROBLEM", 148, 156], ["a culture", "TEST", 170, 179], ["these bacteria", "PROBLEM", 183, 197], ["yellow fever", "OBSERVATION", 108, 120]]], ["The famous Canadian physician William Osler condemned these experiments in the following terms:To deliberately inject a poison of known high degree of virulency into a human being, unless you obtain that man\u2019s sanction, is not ridiculous, it is criminal.", [["human", "ORGANISM", 168, 173], ["man", "ORGANISM", 204, 207], ["human", "SPECIES", 168, 173], ["man", "SPECIES", 204, 207], ["human", "SPECIES", 168, 173], ["high degree", "OBSERVATION_MODIFIER", 136, 147]]]], "04d9d77080ea914a27c9d56035f2f784cd31a2d2": [["\u25a0 INTRODUCTIONRecently, plant-derived nanovesicles were isolated from several edible plants such as grapefruits, gingers, carrots, apples, and lemons.", [["nanovesicles", "ANATOMY", 38, 50], ["grapefruits", "ANATOMY", 100, 111], ["gingers", "ANATOMY", 113, 120], ["carrots", "ANATOMY", 122, 129], ["apples", "ANATOMY", 131, 137], ["nanovesicles", "CELL", 38, 50], ["carrots", "ORGANISM_SUBDIVISION", 122, 129], ["apples", "ORGANISM_SUBDIVISION", 131, 137], ["carrots", "SPECIES", 122, 129], ["plant-derived nanovesicles", "TREATMENT", 24, 50], ["several", "OBSERVATION_MODIFIER", 70, 77], ["edible plants", "OBSERVATION", 78, 91], ["carrots", "ANATOMY", 122, 129]]], ["1\u22124 Those plant-derived nanovesicles resembled their mammalian exosome counterparts in that they carried the functional cargos such as small molecules, proteins, mRNA, and miRNA, which can modulate the fate of recipient cells.", [["nanovesicles", "ANATOMY", 24, 36], ["exosome", "ANATOMY", 63, 70], ["cells", "ANATOMY", 220, 225], ["1\u22124", "CHEMICAL", 0, 3], ["nanovesicles", "CELL", 24, 36], ["exosome counterparts", "CELL", 63, 83], ["cells", "CELL", 220, 225], ["mammalian exosome counterparts", "CELL_TYPE", 53, 83], ["small molecules", "PROTEIN", 135, 150], ["mRNA", "RNA", 162, 166], ["recipient cells", "CELL_TYPE", 210, 225], ["small molecules, proteins, mRNA, and miRNA", "PROBLEM", 135, 177], ["miRNA", "ANATOMY", 172, 177], ["recipient cells", "OBSERVATION", 210, 225]]], ["5 Several plant-derived nanovesicles have been reported, which can be used for cancer therapy, changing the gut microbiota composition, and protecting the mice from dextran sulfate sodium (DSS)-induced colitis and inflammatory bowel disease.", [["nanovesicles", "ANATOMY", 24, 36], ["cancer", "ANATOMY", 79, 85], ["gut microbiota", "ANATOMY", 108, 122], ["bowel", "ANATOMY", 227, 232], ["cancer", "DISEASE", 79, 85], ["dextran sulfate sodium", "CHEMICAL", 165, 187], ["DSS", "CHEMICAL", 189, 192], ["colitis", "DISEASE", 202, 209], ["inflammatory bowel disease", "DISEASE", 214, 240], ["sulfate sodium", "CHEMICAL", 173, 187], ["nanovesicles", "CELL", 24, 36], ["cancer", "CANCER", 79, 85], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 108, 122], ["mice", "ORGANISM", 155, 159], ["dextran sulfate sodium", "SIMPLE_CHEMICAL", 165, 187], ["DSS", "SIMPLE_CHEMICAL", 189, 192], ["colitis", "PATHOLOGICAL_FORMATION", 202, 209], ["bowel", "ORGAN", 227, 232], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 155, 159], ["Several plant-derived nanovesicles", "PROBLEM", 2, 36], ["cancer therapy", "TREATMENT", 79, 93], ["the gut microbiota composition", "TREATMENT", 104, 134], ["dextran sulfate sodium (DSS)", "TREATMENT", 165, 193], ["colitis", "PROBLEM", 202, 209], ["inflammatory bowel disease", "PROBLEM", 214, 240], ["colitis", "OBSERVATION", 202, 209], ["inflammatory bowel disease", "OBSERVATION", 214, 240]]], ["2, 5, 6 These reports indicate that plant-derived nanovesicles are involved in the interspecies communication for their biological effect.", [["nanovesicles", "ANATOMY", 50, 62], ["nanovesicles", "CELL", 50, 62]]], ["3 Although plant-derived nanovesicles are promising in anti-inflammatory and cancer therapy, the uptake mechanism of the plant-derived nanovesicles is still unknown.\u25a0 INTRODUCTIONUnderstanding the mechanisms of the mammalian exosomes can elucidate the potential mechanisms of plant-derived nanovesicles.", [["nanovesicles", "ANATOMY", 25, 37], ["cancer", "ANATOMY", 77, 83], ["exosomes", "ANATOMY", 225, 233], ["nanovesicles", "ANATOMY", 290, 302], ["cancer", "DISEASE", 77, 83], ["nanovesicles", "CELL", 25, 37], ["cancer", "CANCER", 77, 83], ["nanovesicles", "CELL", 135, 147], ["exosomes", "CELL", 225, 233], ["nanovesicles", "CELL", 290, 302], ["mammalian exosomes", "CELL_TYPE", 215, 233], ["anti-inflammatory and cancer therapy", "TREATMENT", 55, 91], ["anti-inflammatory", "OBSERVATION_MODIFIER", 55, 72], ["cancer", "OBSERVATION", 77, 83]]], ["The main uptake mechanisms for mammalian exosomes include phagocytosis, clathrin-dependent, or clathrin-independent pathways.", [["exosomes", "ANATOMY", 41, 49], ["exosomes", "CELL", 41, 49], ["clathrin", "GENE_OR_GENE_PRODUCT", 72, 80], ["clathrin", "GENE_OR_GENE_PRODUCT", 95, 103], ["mammalian exosomes", "CELL_TYPE", 31, 49], ["clathrin", "PROTEIN", 72, 80], ["clathrin", "PROTEIN", 95, 103], ["mammalian exosomes", "TREATMENT", 31, 49], ["phagocytosis", "PROBLEM", 58, 70], ["main", "OBSERVATION_MODIFIER", 4, 8], ["uptake mechanisms", "OBSERVATION", 9, 26]]], ["7\u22129 Heparan sulfate proteoglycans (HSPG) on cell surfaces could be a possible receptor for exosome endocytosis, but it has been reported that the HSPG on the surface of exosomes is not involved in the internalization of exosomes.", [["cell surfaces", "ANATOMY", 44, 57], ["exosome", "ANATOMY", 91, 98], ["surface", "ANATOMY", 158, 165], ["exosomes", "ANATOMY", 169, 177], ["exosomes", "ANATOMY", 220, 228], ["7\u22129", "CHEMICAL", 0, 3], ["Heparan sulfate", "CHEMICAL", 4, 19], ["Heparan sulfate", "CHEMICAL", 4, 19], ["Heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 4, 33], ["HSPG", "GENE_OR_GENE_PRODUCT", 35, 39], ["cell", "CELL", 44, 48], ["exosome", "CELLULAR_COMPONENT", 91, 98], ["HSPG", "GENE_OR_GENE_PRODUCT", 146, 150], ["surface", "CELLULAR_COMPONENT", 158, 165], ["exosomes", "CELL", 169, 177], ["exosomes", "CELL", 220, 228], ["Heparan sulfate proteoglycans", "PROTEIN", 4, 33], ["HSPG", "PROTEIN", 35, 39], ["HSPG", "PROTEIN", 146, 150], ["exosomes", "CELL_TYPE", 169, 177], ["exosomes", "CELL_TYPE", 220, 228], ["Heparan sulfate proteoglycans (HSPG)", "TREATMENT", 4, 40], ["cell surfaces", "TREATMENT", 44, 57], ["exosome endocytosis", "PROBLEM", 91, 110], ["endocytosis", "OBSERVATION", 99, 110], ["HSPG", "OBSERVATION_MODIFIER", 146, 150], ["not involved", "UNCERTAINTY", 181, 193]]], ["10 Another study revealed that fibronectins on the surface of myeloma cell-derived exosomes have interactions with HSPG on the target cells.", [["surface", "ANATOMY", 51, 58], ["myeloma cell", "ANATOMY", 62, 74], ["exosomes", "ANATOMY", 83, 91], ["cells", "ANATOMY", 134, 139], ["myeloma", "DISEASE", 62, 69], ["fibronectins", "GENE_OR_GENE_PRODUCT", 31, 43], ["surface", "CELLULAR_COMPONENT", 51, 58], ["myeloma cell", "CELL", 62, 74], ["exosomes", "CELL", 83, 91], ["HSPG", "GENE_OR_GENE_PRODUCT", 115, 119], ["cells", "CELL", 134, 139], ["fibronectins", "PROTEIN", 31, 43], ["myeloma cell", "CELL_LINE", 62, 74], ["exosomes", "CELL_TYPE", 83, 91], ["HSPG", "PROTEIN", 115, 119], ["target cells", "CELL_TYPE", 127, 139], ["Another study", "TEST", 3, 16], ["fibronectins", "PROBLEM", 31, 43], ["myeloma cell", "PROBLEM", 62, 74], ["myeloma cell", "OBSERVATION", 62, 74]]], ["11 Also, proteins on both the surface of ovarian cancer cell-derived exosomes and ovarian cancer cells are important for uptake.", [["surface", "ANATOMY", 30, 37], ["ovarian cancer cell", "ANATOMY", 41, 60], ["exosomes", "ANATOMY", 69, 77], ["ovarian cancer cells", "ANATOMY", 82, 102], ["ovarian cancer", "DISEASE", 41, 55], ["ovarian cancer", "DISEASE", 82, 96], ["surface", "CELLULAR_COMPONENT", 30, 37], ["ovarian cancer cell", "CELL", 41, 60], ["exosomes", "CELL", 69, 77], ["ovarian cancer cells", "CELL", 82, 102], ["ovarian cancer cell-derived exosomes", "CELL_TYPE", 41, 77], ["ovarian cancer cells", "CELL_TYPE", 82, 102], ["ovarian cancer", "PROBLEM", 41, 55], ["ovarian cancer cells", "PROBLEM", 82, 102], ["surface", "OBSERVATION_MODIFIER", 30, 37], ["ovarian", "ANATOMY", 41, 48], ["cancer cell", "OBSERVATION", 49, 60], ["ovarian", "ANATOMY", 82, 89], ["cancer", "OBSERVATION", 90, 96]]], ["12 CD98 is a transmembrane, glycoprotein heterodimer, which consists of the CD98 heavy chain (CD98hc) and several light chains (CD98lc) such as large amino acid transporter 1 (LAT 1).", [["transmembrane", "ANATOMY", 13, 26], ["amino acid", "CHEMICAL", 150, 160], ["amino acid", "CHEMICAL", 150, 160], ["CD98", "GENE_OR_GENE_PRODUCT", 3, 7], ["transmembrane", "CELLULAR_COMPONENT", 13, 26], ["CD98 heavy chain", "GENE_OR_GENE_PRODUCT", 76, 92], ["CD98hc", "GENE_OR_GENE_PRODUCT", 94, 100], ["CD98lc", "GENE_OR_GENE_PRODUCT", 128, 134], ["large amino acid transporter 1", "GENE_OR_GENE_PRODUCT", 144, 174], ["LAT 1", "GENE_OR_GENE_PRODUCT", 176, 181], ["CD98", "PROTEIN", 3, 7], ["transmembrane, glycoprotein heterodimer", "PROTEIN", 13, 52], ["CD98 heavy chain", "PROTEIN", 76, 92], ["CD98hc", "PROTEIN", 94, 100], ["light chains", "PROTEIN", 114, 126], ["CD98lc", "PROTEIN", 128, 134], ["large amino acid transporter 1", "PROTEIN", 144, 174], ["LAT 1", "PROTEIN", 176, 181], ["a transmembrane, glycoprotein heterodimer", "TEST", 11, 52], ["large amino acid transporter", "TREATMENT", 144, 172]]], ["13 The glycan on CD98hc is consist of tetra-antennary with terminal fucosylation and mannose oligosaccharides (oligomannose).", [["oligomannose", "CHEMICAL", 111, 123], ["mannose", "CHEMICAL", 85, 92], ["oligomannose", "CHEMICAL", 111, 123], ["CD98hc", "GENE_OR_GENE_PRODUCT", 17, 23], ["mannose oligosaccharides", "SIMPLE_CHEMICAL", 85, 109], ["oligomannose", "SIMPLE_CHEMICAL", 111, 123], ["CD98hc", "PROTEIN", 17, 23], ["terminal fucosylation and mannose oligosaccharides", "TREATMENT", 59, 109]]], ["13, 14 CD98 has various functions, which include mediating cell proliferation through activating the integrin-\u03b2 pathway, importing amino acid to support cell growth, and regulating cell fusion in several types of cell lines (BeWo cells, peripheral blood mononuclear cells, and L929 cells).", [["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 153, 157], ["cell", "ANATOMY", 181, 185], ["cell lines", "ANATOMY", 213, 223], ["BeWo cells", "ANATOMY", 225, 235], ["peripheral blood mononuclear cells", "ANATOMY", 237, 271], ["L929 cells", "ANATOMY", 277, 287], ["amino acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 131, 141], ["CD98", "GENE_OR_GENE_PRODUCT", 7, 11], ["cell", "CELL", 59, 63], ["integrin-\u03b2", "GENE_OR_GENE_PRODUCT", 101, 111], ["amino acid", "AMINO_ACID", 131, 141], ["cell", "CELL", 153, 157], ["cell", "CELL", 181, 185], ["cell lines", "CELL", 213, 223], ["BeWo cells", "CELL", 225, 235], ["peripheral blood mononuclear cells", "CELL", 237, 271], ["L929 cells", "CELL", 277, 287], ["CD98", "PROTEIN", 7, 11], ["integrin-\u03b2", "PROTEIN", 101, 111], ["cell lines", "CELL_LINE", 213, 223], ["BeWo cells", "CELL_LINE", 225, 235], ["peripheral blood mononuclear cells", "CELL_TYPE", 237, 271], ["L929 cells", "CELL_LINE", 277, 287], ["mediating cell proliferation", "PROBLEM", 49, 77], ["amino acid", "TREATMENT", 131, 141], ["cell growth", "PROBLEM", 153, 164], ["regulating cell fusion", "TREATMENT", 170, 192], ["cell lines", "TREATMENT", 213, 223], ["BeWo cells", "TEST", 225, 235], ["peripheral blood mononuclear cells", "TEST", 237, 271], ["L929 cells", "TEST", 277, 287], ["cell proliferation", "OBSERVATION", 59, 77], ["cell fusion", "OBSERVATION", 181, 192], ["cell lines", "OBSERVATION", 213, 223], ["peripheral", "ANATOMY_MODIFIER", 237, 247], ["blood", "ANATOMY", 248, 253], ["mononuclear cells", "OBSERVATION", 254, 271], ["L929 cells", "OBSERVATION", 277, 287]]], ["13, 15, 16 CD98 has been reported to play an important role in the internalization of human \u03b2-defensin 3 and endocytosis of mature vaccinia virus particles, and recently a study has shown that the LAT 1 may be involved in the uptake of nanoparticles.", [["CD98", "GENE_OR_GENE_PRODUCT", 11, 15], ["human", "ORGANISM", 86, 91], ["\u03b2-defensin 3", "GENE_OR_GENE_PRODUCT", 92, 104], ["vaccinia virus particles", "ORGANISM", 131, 155], ["LAT 1", "GENE_OR_GENE_PRODUCT", 197, 202], ["CD98", "PROTEIN", 11, 15], ["human \u03b2-defensin 3", "PROTEIN", 86, 104], ["LAT 1", "PROTEIN", 197, 202], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["vaccinia virus", "SPECIES", 131, 145], ["human \u03b2-defensin", "TREATMENT", 86, 102], ["mature vaccinia virus particles", "PROBLEM", 124, 155], ["a study", "TEST", 170, 177], ["the uptake of nanoparticles", "PROBLEM", 222, 249], ["vaccinia virus", "OBSERVATION", 131, 145]]], ["17\u221219 CD98 was used as a targeted protein to enhance the internalization of therapeutic nanoparticles as it is overexpressed in tumor and inflammatory tissues.", [["tumor", "ANATOMY", 128, 133], ["inflammatory tissues", "ANATOMY", 138, 158], ["tumor", "DISEASE", 128, 133], ["CD98", "GENE_OR_GENE_PRODUCT", 6, 10], ["tumor", "CANCER", 128, 133], ["inflammatory tissues", "TISSUE", 138, 158], ["17\u221219 CD98", "PROTEIN", 0, 10], ["CD98", "TEST", 6, 10], ["a targeted protein", "TREATMENT", 23, 41], ["therapeutic nanoparticles", "TREATMENT", 76, 101], ["tumor and inflammatory tissues", "PROBLEM", 128, 158], ["tumor", "OBSERVATION", 128, 133], ["inflammatory tissues", "OBSERVATION", 138, 158]]], ["20 These reports indicated that CD98 played an important role in the uptake process.", [["CD98", "GENE_OR_GENE_PRODUCT", 32, 36], ["CD98", "PROTEIN", 32, 36], ["CD98", "PROBLEM", 32, 36], ["uptake process", "OBSERVATION", 69, 83]]], ["CD98 has also been linked to the inflammatory bowel disease (IBD) and plays a potential role in chronic liver disease, e.g., nonalcoholic fatty liver disease (NAFLD).", [["bowel", "ANATOMY", 46, 51], ["liver", "ANATOMY", 104, 109], ["nonalcoholic fatty liver", "ANATOMY", 125, 149], ["inflammatory bowel disease", "DISEASE", 33, 59], ["IBD", "DISEASE", 61, 64], ["chronic liver disease", "DISEASE", 96, 117], ["nonalcoholic fatty liver disease", "DISEASE", 125, 157], ["NAFLD", "DISEASE", 159, 164], ["CD98", "GENE_OR_GENE_PRODUCT", 0, 4], ["bowel", "ORGAN", 46, 51], ["liver", "ORGAN", 104, 109], ["liver", "ORGAN", 144, 149], ["CD98", "PROTEIN", 0, 4], ["CD98", "TEST", 0, 4], ["the inflammatory bowel disease", "PROBLEM", 29, 59], ["IBD", "PROBLEM", 61, 64], ["chronic liver disease", "PROBLEM", 96, 117], ["nonalcoholic fatty liver disease", "PROBLEM", 125, 157], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["bowel", "ANATOMY", 46, 51], ["disease", "OBSERVATION", 52, 59], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["liver", "ANATOMY", 104, 109], ["disease", "OBSERVATION", 110, 117], ["nonalcoholic", "OBSERVATION_MODIFIER", 125, 137], ["liver", "ANATOMY", 144, 149]]], ["21 Thus, CD98 can be a promising target for both therapeutic and drug delivery.\u25a0 INTRODUCTIONLectin, a type of protein that has specific binding affinity to saccharides, has played an important role in the interspecies recognition.", [["CD98", "GENE_OR_GENE_PRODUCT", 9, 13], ["CD98", "PROTEIN", 9, 13], ["drug delivery", "TREATMENT", 65, 78], ["INTRODUCTIONLectin", "TREATMENT", 81, 99]]], ["For example, the innate immune recognition of coronaviruses was mediated by the interaction of certain lectins on cell membranes and the oligomannose from coronaviruses.", [["cell membranes", "ANATOMY", 114, 128], ["coronaviruses", "ORGANISM", 46, 59], ["lectins", "GENE_OR_GENE_PRODUCT", 103, 110], ["cell membranes", "CELLULAR_COMPONENT", 114, 128], ["oligomannose", "GENE_OR_GENE_PRODUCT", 137, 149], ["lectins", "PROTEIN", 103, 110], ["coronaviruses", "PROBLEM", 46, 59], ["cell membranes", "TREATMENT", 114, 128], ["coronaviruses", "PROBLEM", 155, 168], ["coronaviruses", "OBSERVATION", 46, 59], ["cell membranes", "OBSERVATION", 114, 128]]], ["22 A lectin from Sparassis latifolia (a mushroom) has shown antibacterial activity against Escherichia coli and other drug-resistant strains.", [["strains", "ANATOMY", 133, 140], ["lectin", "GENE_OR_GENE_PRODUCT", 5, 11], ["Sparassis latifolia", "ORGANISM", 17, 36], ["Escherichia coli", "ORGANISM", 91, 107], ["lectin", "PROTEIN", 5, 11], ["Sparassis latifolia", "SPECIES", 17, 36], ["Escherichia coli", "SPECIES", 91, 107], ["Sparassis latifolia", "SPECIES", 17, 36], ["Escherichia coli", "SPECIES", 91, 107], ["Sparassis latifolia", "PROBLEM", 17, 36], ["a mushroom", "TREATMENT", 38, 48], ["antibacterial activity", "TREATMENT", 60, 82], ["Escherichia coli", "PROBLEM", 91, 107], ["resistant strains", "PROBLEM", 123, 140], ["antibacterial activity", "OBSERVATION", 60, 82], ["resistant strains", "OBSERVATION", 123, 140]]], ["23 Inspired by those lectin-carbohydratemediated interspecies communications, we hypothesized that the interaction between plant-derived nanovesicles and mammalian cells was mediated by the interaction of lectins and saccharides.\u25a0 INTRODUCTIONSeveral dietary lectins have been found to exert their health benefits through inducing apoptosis after binding to the membrane.", [["nanovesicles", "ANATOMY", 137, 149], ["mammalian cells", "ANATOMY", 154, 169], ["membrane", "ANATOMY", 362, 370], ["lectin", "GENE_OR_GENE_PRODUCT", 21, 27], ["nanovesicles", "CELL", 137, 149], ["mammalian cells", "CELL", 154, 169], ["lectins", "GENE_OR_GENE_PRODUCT", 205, 212], ["saccharides", "SIMPLE_CHEMICAL", 217, 228], ["membrane", "CELLULAR_COMPONENT", 362, 370], ["lectin", "PROTEIN", 21, 27], ["nanovesicles", "CELL_TYPE", 137, 149], ["mammalian cells", "CELL_TYPE", 154, 169], ["lectins", "PROTEIN", 205, 212], ["mammalian cells", "PROBLEM", 154, 169], ["INTRODUCTIONSeveral dietary lectins", "TREATMENT", 231, 266], ["mammalian cells", "OBSERVATION", 154, 169]]], ["Among those edible plants, garlic is enriched in the lectins (1 mg of lectins per 1 g of garlic) 24 and has welldocumented health benefits in many epidemiology studies.", [["garlic", "CHEMICAL", 27, 33], ["garlic", "SIMPLE_CHEMICAL", 27, 33], ["garlic", "ORGANISM", 89, 95], ["garlic", "SPECIES", 27, 33], ["garlic", "SPECIES", 89, 95], ["garlic", "TREATMENT", 27, 33], ["the lectins", "TREATMENT", 49, 60], ["lectins", "TREATMENT", 70, 77], ["many epidemiology studies", "TEST", 142, 167]]], ["25, 26 In this study, the HepG2 cell line has been used to show the internalization of garlic-derived nanovesicles (GDVs).", [["HepG2 cell line", "ANATOMY", 26, 41], ["nanovesicles", "ANATOMY", 102, 114], ["HepG2 cell line", "CELL", 26, 41], ["garlic-derived nanovesicles", "SIMPLE_CHEMICAL", 87, 114], ["GDVs", "CELL", 116, 120], ["HepG2 cell line", "CELL_LINE", 26, 41], ["garlic", "SPECIES", 87, 93], ["this study", "TEST", 10, 20], ["the HepG2 cell line", "TREATMENT", 22, 41], ["HepG2", "ANATOMY", 26, 31], ["cell line", "OBSERVATION", 32, 41], ["internalization", "OBSERVATION_MODIFIER", 68, 83], ["garlic", "OBSERVATION_MODIFIER", 87, 93], ["nanovesicles", "OBSERVATION_MODIFIER", 102, 114]]], ["The GDVs were isolated by the well-established differential centrifugation method and the resultant GDVs were identified by the size, \u03b6-potential, and morphology as in previous studies.", [["GDVs", "ANATOMY", 4, 8], ["GDVs", "CANCER", 4, 8], ["GDVs", "GENE_OR_GENE_PRODUCT", 100, 104], ["the resultant GDVs", "PROBLEM", 86, 104], ["previous studies", "TEST", 168, 184], ["resultant", "OBSERVATION_MODIFIER", 90, 99], ["GDVs", "OBSERVATION", 100, 104], ["size", "OBSERVATION_MODIFIER", 128, 132], ["morphology", "OBSERVATION_MODIFIER", 151, 161]]], ["2, 3, 6, 27 Surface proteins from GDVs were removed by incubation of GDVs with trypsin and the internalization properties were examined in the HepG2 cells over various time points leading to the finding that the surface proteins from GDVs were involved in the uptake of their internalization.", [["HepG2 cells", "ANATOMY", 143, 154], ["surface", "ANATOMY", 212, 219], ["GDVs", "SIMPLE_CHEMICAL", 34, 38], ["GDVs", "SIMPLE_CHEMICAL", 69, 73], ["trypsin", "GENE_OR_GENE_PRODUCT", 79, 86], ["HepG2 cells", "CELL", 143, 154], ["GDVs", "GENE_OR_GENE_PRODUCT", 234, 238], ["2, 3, 6, 27 Surface proteins", "PROTEIN", 0, 28], ["GDVs", "PROTEIN", 34, 38], ["trypsin", "PROTEIN", 79, 86], ["HepG2 cells", "CELL_LINE", 143, 154], ["surface proteins", "PROTEIN", 212, 228], ["GDVs", "PROTEIN", 234, 238], ["Surface proteins", "TEST", 12, 28], ["trypsin", "TREATMENT", 79, 86], ["the internalization properties", "TREATMENT", 91, 121], ["the surface proteins", "TEST", 208, 228], ["HepG2", "ANATOMY", 143, 148]]], ["Mass spectrum-based protein identification indicated that a mannose-specific binding lectin (II lectin) was found on the surface of GDVs.", [["surface", "ANATOMY", 121, 128], ["GDVs", "ANATOMY", 132, 136], ["mannose", "CHEMICAL", 60, 67], ["mannose", "CHEMICAL", 60, 67], ["mannose", "SIMPLE_CHEMICAL", 60, 67], ["lectin (II lectin", "GENE_OR_GENE_PRODUCT", 85, 102], ["surface", "CELLULAR_COMPONENT", 121, 128], ["GDVs", "PATHOLOGICAL_FORMATION", 132, 136], ["mannose-specific binding lectin", "PROTEIN", 60, 91], ["II lectin", "PROTEIN", 93, 102], ["Mass spectrum", "TEST", 0, 13], ["based protein identification", "TEST", 14, 42], ["a mannose", "TEST", 58, 67]]], ["Saturation of the II lectins with mannose and blocking CD98 receptors with CD98 antibody significantly impaired the GDV internalization.", [["mannose", "CHEMICAL", 34, 41], ["mannose", "CHEMICAL", 34, 41], ["II lectins", "GENE_OR_GENE_PRODUCT", 18, 28], ["mannose", "SIMPLE_CHEMICAL", 34, 41], ["CD98", "GENE_OR_GENE_PRODUCT", 55, 59], ["CD98", "GENE_OR_GENE_PRODUCT", 75, 79], ["GDV", "SIMPLE_CHEMICAL", 116, 119], ["II lectins", "PROTEIN", 18, 28], ["CD98 receptors", "PROTEIN", 55, 69], ["CD98 antibody", "PROTEIN", 75, 88], ["Saturation", "TEST", 0, 10], ["mannose", "TREATMENT", 34, 41], ["blocking CD98 receptors", "TEST", 46, 69], ["CD98 antibody", "TEST", 75, 88]]], ["In addition, co-localization between GDVs and CD98 reduced significantly after trypsin digestion of the surface protein of GDVs.", [["surface", "ANATOMY", 104, 111], ["GDVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["CD98", "GENE_OR_GENE_PRODUCT", 46, 50], ["trypsin", "GENE_OR_GENE_PRODUCT", 79, 86], ["GDVs", "GENE_OR_GENE_PRODUCT", 123, 127], ["GDVs", "PROTEIN", 37, 41], ["CD98", "PROTEIN", 46, 50], ["trypsin", "PROTEIN", 79, 86], ["surface protein", "PROTEIN", 104, 119], ["GDVs", "PROTEIN", 123, 127], ["GDVs", "TEST", 37, 41], ["trypsin digestion", "TREATMENT", 79, 96], ["CD98", "OBSERVATION_MODIFIER", 46, 50], ["reduced", "OBSERVATION_MODIFIER", 51, 58]]], ["Taken together, those results indicated that both proteins in the surface of GDVs (majorly II lectin) and CD98 from the cell membranes have directly interacted during the internalization of GDVs.", [["surface", "ANATOMY", 66, 73], ["cell membranes", "ANATOMY", 120, 134], ["surface", "CELLULAR_COMPONENT", 66, 73], ["GDVs", "GENE_OR_GENE_PRODUCT", 77, 81], ["majorly II lectin", "GENE_OR_GENE_PRODUCT", 83, 100], ["CD98", "GENE_OR_GENE_PRODUCT", 106, 110], ["cell membranes", "CELLULAR_COMPONENT", 120, 134], ["GDVs", "GENE_OR_GENE_PRODUCT", 190, 194], ["GDVs", "PROTEIN", 77, 81], ["majorly II lectin", "PROTEIN", 83, 100], ["CD98", "PROTEIN", 106, 110], ["GDVs", "PROTEIN", 190, 194], ["the internalization of GDVs", "TREATMENT", 167, 194], ["cell membranes", "OBSERVATION", 120, 134]]], ["The undigested GDV-treated group showed stronger in vitro anti-inflammatory effect when compared to the digested GDVs due to the changes in GDV uptake.", [["GDVs", "ANATOMY", 113, 117], ["GDV", "CHEMICAL", 15, 18], ["GDV", "SIMPLE_CHEMICAL", 15, 18], ["GDV", "SIMPLE_CHEMICAL", 140, 143], ["The undigested GDV", "TREATMENT", 0, 18], ["vitro anti-inflammatory effect", "TREATMENT", 52, 82], ["the digested GDVs", "TEST", 100, 117], ["the changes in GDV uptake", "PROBLEM", 125, 150], ["anti-inflammatory effect", "OBSERVATION", 58, 82]]], ["This study contributed to understand a part of the interspecies communication and provided a new angle in understanding the benefit of dietary garlic.\u25a0 RESULTS AND DISCUSSIONPhysicochemical Properties of the GDVs.", [["garlic", "SIMPLE_CHEMICAL", 143, 149], ["garlic", "SPECIES", 143, 149], ["This study", "TEST", 0, 10], ["dietary garlic", "TREATMENT", 135, 149]]], ["The size and shape of GDVs ( Figure 1A ) and T4 GDVs (4 h incubation with trypsin) ( Figure 1B) were identified by transmission electron microscopy (TEM).", [["trypsin", "PROTEIN", 74, 81], ["GDVs", "TEST", 22, 26], ["T4 GDVs", "TREATMENT", 45, 52], ["trypsin", "TEST", 74, 81], ["transmission electron microscopy", "TEST", 115, 147], ["size", "OBSERVATION_MODIFIER", 4, 8], ["shape", "OBSERVATION_MODIFIER", 13, 18], ["T4", "ANATOMY", 45, 47]]], ["Both sizes were less than 150 nm with a spheroid shape.", [["spheroid", "ANATOMY", 40, 48], ["sizes", "OBSERVATION_MODIFIER", 5, 10], ["less", "OBSERVATION_MODIFIER", 16, 20], ["than 150 nm", "OBSERVATION_MODIFIER", 21, 32], ["spheroid shape", "OBSERVATION", 40, 54]]], ["The T4 GDVs showed a multivehicle body structure, this might be caused by digestion, which destroyed surface proteins and rearranged the lipid structure.", [["body", "ANATOMY", 34, 38], ["surface", "ANATOMY", 101, 108], ["T4 GDVs", "GENE_OR_GENE_PRODUCT", 4, 11], ["body", "ORGANISM_SUBDIVISION", 34, 38], ["T4 GDVs", "PROTEIN", 4, 11], ["surface proteins", "PROTEIN", 101, 117], ["The T4 GDVs", "TEST", 0, 11], ["a multivehicle body structure", "PROBLEM", 19, 48], ["digestion", "PROBLEM", 74, 83], ["T4", "ANATOMY", 4, 6], ["multivehicle body", "OBSERVATION", 21, 38], ["might be caused", "UNCERTAINTY", 55, 70], ["digestion", "OBSERVATION", 74, 83], ["lipid structure", "OBSERVATION", 137, 152]]], ["27, 28 Atomic force microscopy (AFM) study has shown that the morphology of digested GDVs and GDVs had no significant difference.", [["GDVs", "GENE_OR_GENE_PRODUCT", 85, 89], ["Atomic force microscopy (AFM) study", "TEST", 7, 42], ["digested GDVs", "PROBLEM", 76, 89], ["GDVs", "TEST", 94, 98], ["significant difference", "PROBLEM", 106, 128], ["no", "UNCERTAINTY", 103, 105], ["significant", "OBSERVATION_MODIFIER", 106, 117], ["difference", "OBSERVATION", 118, 128]]], ["The shapes of GDVs ( Figure 1C ) and T4 GDVs ( Figure 1D ) were similar but not uniform, which may be a result from the different membrane protein compositions due to the enzymatic digestion.", [["membrane", "ANATOMY", 130, 138], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["GDVs", "PROTEIN", 14, 18], ["GDVs", "TEST", 14, 18], ["T4 GDVs", "TEST", 37, 44], ["the different membrane protein compositions", "PROBLEM", 116, 159], ["the enzymatic digestion", "PROBLEM", 167, 190], ["shapes", "OBSERVATION_MODIFIER", 4, 10], ["T4", "ANATOMY", 37, 39], ["uniform", "OBSERVATION_MODIFIER", 80, 87], ["enzymatic digestion", "OBSERVATION", 171, 190]]], ["As shown in Figure 1E ,F, the blue curve shows the size distribution by number and the red curve shows the size distribution by intensity.", [["the blue curve", "TEST", 26, 40], ["the red curve", "TEST", 83, 96], ["size", "OBSERVATION_MODIFIER", 51, 55], ["distribution", "OBSERVATION_MODIFIER", 56, 68], ["number", "OBSERVATION_MODIFIER", 72, 78], ["size", "OBSERVATION_MODIFIER", 107, 111], ["distribution", "OBSERVATION_MODIFIER", 112, 124], ["intensity", "OBSERVATION_MODIFIER", 128, 137]]], ["The size of GDVs by intensity ranged from 70 to 200 nm and the average size is 191.8 \u00b1 2.0 nm ( Figure 1E ); the size of T4 GDVs ranged from 70 to 200 nm and the average size is 178.6 \u00b1 1.8 nm ( Figure 1F ).", [["GDVs", "PROTEIN", 12, 16], ["T4 GDVs", "PROTEIN", 121, 128], ["intensity", "TEST", 20, 29], ["the average size", "TEST", 59, 75], ["the size of T4 GDVs", "TEST", 109, 128], ["the average size", "TEST", 158, 174], ["size", "OBSERVATION_MODIFIER", 4, 8], ["intensity", "OBSERVATION_MODIFIER", 20, 29], ["average", "OBSERVATION_MODIFIER", 63, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["size", "OBSERVATION_MODIFIER", 113, 117], ["T4", "ANATOMY", 121, 123], ["average", "OBSERVATION_MODIFIER", 162, 169], ["size", "OBSERVATION_MODIFIER", 170, 174]]], ["The size distributions of GDVs and T4 GDVs by number showed that GDVs or T4 GDVs had a diameter of around 100 nm.\u25a0 RESULTS AND DISCUSSIONThe size curves showed a narrow size distribution as listed in Table 1 .", [["T4 GDVs", "PROTEIN", 35, 42], ["T4", "SPECIES", 73, 75], ["GDVs", "TEST", 26, 30], ["T4 GDVs", "TEST", 35, 42], ["GDVs", "TEST", 65, 69], ["The size curves", "TEST", 137, 152], ["a narrow size distribution", "PROBLEM", 160, 186], ["size", "OBSERVATION_MODIFIER", 4, 8], ["distributions", "OBSERVATION_MODIFIER", 9, 22], ["T4", "ANATOMY", 35, 37], ["T4", "ANATOMY", 73, 75], ["diameter", "OBSERVATION_MODIFIER", 87, 95], ["100 nm", "OBSERVATION_MODIFIER", 106, 112], ["size", "OBSERVATION_MODIFIER", 141, 145], ["narrow", "OBSERVATION_MODIFIER", 162, 168], ["size", "OBSERVATION_MODIFIER", 169, 173], ["distribution", "OBSERVATION_MODIFIER", 174, 186]]], ["The analysis of the size curves after trypsin digestion showed that T4 GDVs had slightly decreased size.", [["trypsin", "GENE_OR_GENE_PRODUCT", 38, 45], ["T4 GDVs", "SIMPLE_CHEMICAL", 68, 75], ["trypsin", "PROTEIN", 38, 45], ["The analysis", "TEST", 0, 12], ["the size curves", "TEST", 16, 31], ["trypsin digestion", "TEST", 38, 55], ["T4 GDVs", "PROBLEM", 68, 75], ["slightly decreased size", "PROBLEM", 80, 103], ["size", "OBSERVATION_MODIFIER", 20, 24], ["slightly", "OBSERVATION_MODIFIER", 80, 88], ["decreased", "OBSERVATION_MODIFIER", 89, 98], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["The DLS showed that the sizes were homogeneous.", [["The DLS", "TEST", 0, 7], ["sizes", "OBSERVATION_MODIFIER", 24, 29], ["homogeneous", "OBSERVATION_MODIFIER", 35, 46]]], ["The \u03b6-potential analysis showed that the \u03b6-potential of digested or undigested GDVs was negative and around \u221231 mV ( Figure 1G ,H).", [["The \u03b6-potential analysis", "TEST", 0, 24], ["undigested GDVs", "PROBLEM", 68, 83]]], ["It has been reported that the particles derived from the edible plants such as carrot, grape, grapefruit, and ginger were quite stable in both stomach-and intestine-like solutions.", [["carrot", "ANATOMY", 79, 85], ["grape", "ANATOMY", 87, 92], ["grapefruit", "ANATOMY", 94, 104], ["stomach", "ANATOMY", 143, 150], ["intestine", "ANATOMY", 155, 164], ["carrot, grape, grapefruit, and ginger", "CHEMICAL", 79, 116], ["carrot", "ORGANISM_SUBDIVISION", 79, 85], ["grape", "ORGANISM_SUBDIVISION", 87, 92], ["grapefruit", "ORGANISM_SUBDIVISION", 94, 104], ["ginger", "ORGANISM_SUBDIVISION", 110, 116], ["stomach", "ORGANISM_SUBDIVISION", 143, 150], ["intestine", "ORGAN", 155, 164], ["carrot", "SPECIES", 79, 85], ["grape", "SPECIES", 87, 92], ["grapefruit", "SPECIES", 94, 104], ["ginger", "SPECIES", 110, 116], ["carrot", "SPECIES", 79, 85], ["grape", "SPECIES", 87, 92], ["particles", "OBSERVATION_MODIFIER", 30, 39], ["stable", "OBSERVATION", 128, 134], ["stomach", "ANATOMY", 143, 150], ["intestine", "ANATOMY", 155, 164]]], ["3, 27 Moreover, plantderived nanovesicles showed intact biological effects after oral administration, indicating their stability in vivo.", [["nanovesicles", "ANATOMY", 29, 41], ["oral", "ANATOMY", 81, 85], ["nanovesicles", "SIMPLE_CHEMICAL", 29, 41], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["oral administration", "TREATMENT", 81, 100], ["intact", "OBSERVATION", 49, 55], ["biological effects", "OBSERVATION", 56, 74], ["stability", "OBSERVATION_MODIFIER", 119, 128]]], ["This latter observation is interesting as such particles (size of 200 nm such as GDVs) are suitable for both active and passive internalizations.", [["passive internalizations", "TREATMENT", 120, 144]]], ["29, 30 Altogether, these observations established that the differences of GDV uptake by the cells were only due to the deletion of surface membrane proteins on GDVs.\u25a0 RESULTS AND DISCUSSIONUptake Kinetics of GDVs is Correlated to the Surface Expression of CD98 on the HepG2 Cells.", [["cells", "ANATOMY", 92, 97], ["surface membrane", "ANATOMY", 131, 147], ["HepG2 Cells", "ANATOMY", 268, 279], ["GDV", "CHEMICAL", 74, 77], ["GDV", "CHEMICAL", 74, 77], ["GDV", "SIMPLE_CHEMICAL", 74, 77], ["cells", "CELL", 92, 97], ["surface membrane", "CELLULAR_COMPONENT", 131, 147], ["CD98", "GENE_OR_GENE_PRODUCT", 256, 260], ["HepG2 Cells", "CELL", 268, 279], ["GDV", "PROTEIN", 74, 77], ["surface membrane proteins", "PROTEIN", 131, 156], ["CD98", "PROTEIN", 256, 260], ["HepG2 Cells", "CELL_LINE", 268, 279], ["GDV uptake", "PROBLEM", 74, 84], ["the deletion of surface membrane proteins", "PROBLEM", 115, 156], ["the HepG2 Cells", "TREATMENT", 264, 279]]], ["The global incidence of nonalcoholic fatty liver disease (NAFLD) is 25%, which induces a strong burden to the society.", [["nonalcoholic fatty liver", "ANATOMY", 24, 48], ["nonalcoholic fatty liver disease", "DISEASE", 24, 56], ["NAFLD", "DISEASE", 58, 63], ["fatty", "PATHOLOGICAL_FORMATION", 37, 42], ["liver", "ORGAN", 43, 48], ["nonalcoholic fatty liver disease (NAFLD)", "PROBLEM", 24, 64], ["global", "OBSERVATION_MODIFIER", 4, 10], ["nonalcoholic", "OBSERVATION_MODIFIER", 24, 36], ["fatty liver disease", "OBSERVATION", 37, 56], ["25%", "OBSERVATION_MODIFIER", 68, 71], ["strong", "OBSERVATION_MODIFIER", 89, 95], ["burden", "OBSERVATION_MODIFIER", 96, 102], ["society", "OBSERVATION", 110, 117]]], ["31 In the United States, this increased incidence of NAFLD is associated with increased liver disease mortality.", [["liver", "ANATOMY", 88, 93], ["NAFLD", "DISEASE", 53, 58], ["liver disease", "DISEASE", 88, 101], ["liver", "ORGAN", 88, 93], ["NAFLD", "PROBLEM", 53, 58], ["increased liver disease mortality", "PROBLEM", 78, 111], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["NAFLD", "OBSERVATION", 53, 58], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["liver", "ANATOMY", 88, 93], ["disease", "OBSERVATION", 94, 101]]], ["32 The goal of this paper is to develop a preliminary understanding of the uptake mechanisms of the GDVs and their potential therapeutic effects to apply them further as a nanotherapeutics for inflammatory and liver disease.", [["liver", "ANATOMY", 210, 215], ["inflammatory and liver disease", "DISEASE", 193, 223], ["GDVs", "SIMPLE_CHEMICAL", 100, 104], ["liver", "ORGAN", 210, 215], ["inflammatory and liver disease", "PROBLEM", 193, 223], ["inflammatory", "OBSERVATION", 193, 205], ["liver", "ANATOMY", 210, 215], ["disease", "OBSERVATION", 216, 223]]], ["Thus, the HepG2 cell was used in this study.", [["HepG2 cell", "ANATOMY", 10, 20], ["HepG2 cell", "CELL", 10, 20], ["HepG2 cell", "CELL_LINE", 10, 20], ["the HepG2 cell", "TREATMENT", 6, 20], ["this study", "TEST", 33, 43], ["HepG2", "ANATOMY", 10, 15]]], ["As shown in Figure 2A , we studied the cytotoxicity of GDVs on the HepG2 cells and found that both the undigested and digested GDVs were not cytotoxic in the HepG2 cells after 24 h incubation with 100 \u03bcg/mL of GDVs (more than 98% of the viable cells).", [["HepG2 cells", "ANATOMY", 67, 78], ["HepG2 cells", "ANATOMY", 158, 169], ["cells", "ANATOMY", 244, 249], ["GDVs", "CHEMICAL", 55, 59], ["GDVs", "CHEMICAL", 55, 59], ["GDVs", "SIMPLE_CHEMICAL", 55, 59], ["HepG2 cells", "CELL", 67, 78], ["GDVs", "SIMPLE_CHEMICAL", 127, 131], ["HepG2 cells", "CELL", 158, 169], ["GDVs", "SIMPLE_CHEMICAL", 210, 214], ["cells", "CELL", 244, 249], ["HepG2 cells", "CELL_LINE", 67, 78], ["HepG2 cells", "CELL_LINE", 158, 169], ["the HepG2 cells", "TEST", 63, 78], ["the undigested and digested GDVs", "PROBLEM", 99, 131], ["cytotoxic in the HepG2 cells", "PROBLEM", 141, 169], ["GDVs", "TEST", 210, 214], ["HepG2", "ANATOMY", 158, 163]]], ["Hence, GDV uptake within 24 h of exposure was used to track GDV endocytosis.\u25a0 RESULTS AND DISCUSSIONThe uptake of GDVs by the HepG2 cells was concentrationand time-dependent.", [["HepG2 cells", "ANATOMY", 126, 137], ["GDV", "CHEMICAL", 7, 10], ["GDVs", "CHEMICAL", 114, 118], ["GDV", "CHEMICAL", 7, 10], ["GDV", "SIMPLE_CHEMICAL", 7, 10], ["GDV", "GENE_OR_GENE_PRODUCT", 60, 63], ["GDVs", "SIMPLE_CHEMICAL", 114, 118], ["HepG2 cells", "CELL", 126, 137], ["HepG2 cells", "CELL_LINE", 126, 137], ["GDV", "SPECIES", 60, 63], ["GDV uptake", "PROBLEM", 7, 17], ["The uptake of GDVs", "PROBLEM", 100, 118], ["the HepG2 cells", "TEST", 122, 137], ["uptake", "OBSERVATION_MODIFIER", 104, 110], ["HepG2", "ANATOMY", 126, 131]]], ["As shown in Figure 2B , we investigated the uptake of GDVs by the HepG2 cells by flow cytometry.", [["HepG2 cells", "ANATOMY", 66, 77], ["GDVs", "SIMPLE_CHEMICAL", 54, 58], ["HepG2 cells", "CELL", 66, 77], ["HepG2 cells", "CELL_LINE", 66, 77], ["the uptake of GDVs", "PROBLEM", 40, 58], ["flow cytometry", "TEST", 81, 95], ["HepG2", "ANATOMY", 66, 71], ["flow cytometry", "OBSERVATION", 81, 95]]], ["We tagged GDVs with coumarin-6.", [["coumarin-6", "CHEMICAL", 20, 30], ["coumarin-6", "CHEMICAL", 20, 30], ["GDVs", "GENE_OR_GENE_PRODUCT", 10, 14], ["coumarin-6", "SIMPLE_CHEMICAL", 20, 30], ["coumarin", "TREATMENT", 20, 28]]], ["We studied the kinetics uptake at the range of concentration of coumarin-6-tagged GDVs of 25\u2212150 \u03bcg/mL for 6 h.", [["coumarin", "CHEMICAL", 64, 72], ["coumarin", "CHEMICAL", 64, 72], ["coumarin-6-tagged GDVs", "SIMPLE_CHEMICAL", 64, 86], ["the kinetics uptake", "PROBLEM", 11, 30], ["coumarin", "TREATMENT", 64, 72]]], ["GDVs were incubated with the HepG2 cells for different times (1\u22126 h at 100 \u03bcg/mL of GDVs).", [["GDVs", "ANATOMY", 0, 4], ["HepG2 cells", "ANATOMY", 29, 40], ["GDVs", "SIMPLE_CHEMICAL", 0, 4], ["HepG2 cells", "CELL", 29, 40], ["GDVs", "CELL_TYPE", 0, 4], ["HepG2 cells", "CELL_LINE", 29, 40], ["the HepG2 cells", "TREATMENT", 25, 40]]], ["The uptake was measured by flow cytometry ( Figure 2C ) and it showed that the GDV uptake was fast and reached a plateau after 1 h of incubation.\u25a0 RESULTS AND DISCUSSIONOur study also investigated the kinetics uptake of GDVs on cells (HepG2) expressing the differential levels of expression of CD98.", [["cells", "ANATOMY", 228, 233], ["HepG2", "ANATOMY", 235, 240], ["GDV", "CHEMICAL", 79, 82], ["GDV", "SIMPLE_CHEMICAL", 79, 82], ["GDVs", "SIMPLE_CHEMICAL", 220, 224], ["cells", "CELL", 228, 233], ["HepG2", "CELL", 235, 240], ["CD98", "GENE_OR_GENE_PRODUCT", 294, 298], ["HepG2", "CELL_LINE", 235, 240], ["CD98", "PROTEIN", 294, 298], ["The uptake", "TEST", 0, 10], ["flow cytometry", "TEST", 27, 41], ["the GDV uptake", "PROBLEM", 75, 89], ["incubation", "TREATMENT", 134, 144], ["DISCUSSIONOur study", "TEST", 159, 178], ["the kinetics uptake of GDVs on cells", "PROBLEM", 197, 233], ["CD98", "PROBLEM", 294, 298], ["uptake", "OBSERVATION", 4, 10]]], ["Many groups have found that LPS stimulation increased the expression level of CD98 mRNA.", [["LPS", "CHEMICAL", 28, 31], ["LPS", "SIMPLE_CHEMICAL", 28, 31], ["CD98", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD98 mRNA", "RNA", 78, 87], ["LPS stimulation", "PROBLEM", 28, 43], ["CD98 mRNA", "PROBLEM", 78, 87], ["CD98 mRNA", "OBSERVATION", 78, 87]]], ["33\u221235 In this study, the three differential expression levels of CD98 proteins were accessed by LPS stimulation (upregulation), regular condition, and CD98 siRNA (downregulation).", [["33\u221235", "CHEMICAL", 0, 5], ["LPS", "CHEMICAL", 96, 99], ["CD98", "GENE_OR_GENE_PRODUCT", 65, 69], ["LPS", "SIMPLE_CHEMICAL", 96, 99], ["CD98", "GENE_OR_GENE_PRODUCT", 151, 155], ["CD98 proteins", "PROTEIN", 65, 78], ["CD98", "PROTEIN", 151, 155], ["this study", "TEST", 9, 19], ["CD98 proteins", "PROBLEM", 65, 78], ["LPS stimulation", "TEST", 96, 111], ["CD98 siRNA", "OBSERVATION", 151, 161]]], ["Both immunofluorescent images and Western blot successfully confirmed that CD98 express at different levels on the HepG2 cell surface.", [["HepG2 cell surface", "ANATOMY", 115, 133], ["CD98", "GENE_OR_GENE_PRODUCT", 75, 79], ["HepG2 cell", "CELL", 115, 125], ["surface", "CELLULAR_COMPONENT", 126, 133], ["CD98", "PROTEIN", 75, 79], ["Both immunofluorescent images", "TEST", 0, 29], ["Western blot", "TEST", 34, 46], ["CD98", "TEST", 75, 79], ["HepG2", "ANATOMY", 115, 120], ["cell", "OBSERVATION", 121, 125], ["surface", "OBSERVATION_MODIFIER", 126, 133]]], ["The basal level (HepG2 cells under regular culture condition) was set as control ( Figure 3B ).", [["HepG2 cells", "ANATOMY", 17, 28], ["HepG2 cells", "CELL", 17, 28], ["HepG2 cells", "CELL_LINE", 17, 28], ["The basal level", "TEST", 0, 15], ["regular culture condition", "TEST", 35, 60], ["basal", "ANATOMY_MODIFIER", 4, 9]]], ["A higher CD98 expression level was observed by supplementing the cell medium with LPS ( Figure 3A) , while a lower level was found by transfecting the cells with the CD98 siRNA ( Figure 3C ).", [["cell", "ANATOMY", 65, 69], ["cells", "ANATOMY", 151, 156], ["LPS", "CHEMICAL", 82, 85], ["CD98", "GENE_OR_GENE_PRODUCT", 9, 13], ["cell", "CELL", 65, 69], ["LPS", "SIMPLE_CHEMICAL", 82, 85], ["cells", "CELL", 151, 156], ["CD98", "GENE_OR_GENE_PRODUCT", 166, 170], ["CD98", "PROTEIN", 9, 13], ["CD98", "PROTEIN", 166, 170], ["A higher CD98 expression level", "PROBLEM", 0, 30], ["the CD98 siRNA", "TEST", 162, 176], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["CD98 expression", "OBSERVATION", 9, 24], ["CD98 siRNA", "OBSERVATION", 166, 176]]], ["The Western blot (Figures 3D, and S1A) obviously verified that we were able to generate differential CD98 expression with the HepG2 cells (control, LPS, siRNA).", [["HepG2 cells", "ANATOMY", 126, 137], ["CD98", "GENE_OR_GENE_PRODUCT", 101, 105], ["HepG2 cells", "CELL", 126, 137], ["LPS", "SIMPLE_CHEMICAL", 148, 151], ["S1A", "PROTEIN", 34, 37], ["CD98", "PROTEIN", 101, 105], ["HepG2 cells", "CELL_LINE", 126, 137], ["The Western blot", "TEST", 0, 16], ["the HepG2 cells", "TREATMENT", 122, 137]]], ["Since the CD98 is already highly overexpressed in the liver cancer cells, the changes in the amount of CD98 are further investigated by the quantification of the Western blot films.", [["liver cancer cells", "ANATOMY", 54, 72], ["liver cancer", "DISEASE", 54, 66], ["CD98", "GENE_OR_GENE_PRODUCT", 10, 14], ["liver cancer cells", "CELL", 54, 72], ["CD98", "GENE_OR_GENE_PRODUCT", 103, 107], ["CD98", "PROTEIN", 10, 14], ["liver cancer cells", "CELL_TYPE", 54, 72], ["CD98", "PROTEIN", 103, 107], ["the liver cancer cells", "PROBLEM", 50, 72], ["the Western blot films", "TEST", 158, 180], ["highly", "OBSERVATION_MODIFIER", 26, 32], ["overexpressed", "OBSERVATION", 33, 46], ["liver", "ANATOMY", 54, 59], ["cancer cells", "OBSERVATION", 60, 72], ["amount", "OBSERVATION_MODIFIER", 93, 99], ["CD98", "OBSERVATION", 103, 107]]], ["The quantification of Western blot ( Figure S1B ) showed that LPS can increase the expression of CD98 by 10% when compared with the control group (HepG2 cell under regular culture condition).", [["HepG2 cell", "ANATOMY", 147, 157], ["LPS", "CHEMICAL", 62, 65], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["CD98", "GENE_OR_GENE_PRODUCT", 97, 101], ["HepG2 cell", "CELL", 147, 157], ["CD98", "PROTEIN", 97, 101], ["HepG2 cell", "CELL_LINE", 147, 157], ["Western blot", "TEST", 22, 34], ["LPS", "PROBLEM", 62, 65], ["regular culture condition", "TEST", 164, 189]]], ["In contrast, CD98 siRNA significantly decreased CD98 expression by 37%.\u25a0 RESULTS AND DISCUSSIONBy comparing Figure 3A \u2212C, we observed the effect of CD98 cell expression on the uptake of GDVs.", [["CD98 cell", "ANATOMY", 148, 157], ["CD98", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD98", "GENE_OR_GENE_PRODUCT", 48, 52], ["CD98", "GENE_OR_GENE_PRODUCT", 148, 152], ["cell", "CELL", 153, 157], ["GDVs", "PATHOLOGICAL_FORMATION", 186, 190], ["CD98", "PROTEIN", 13, 17], ["CD98", "PROTEIN", 48, 52], ["CD98", "PROTEIN", 148, 152], ["CD98 siRNA", "TEST", 13, 23], ["CD98 expression", "TEST", 48, 63], ["CD98 cell expression", "TREATMENT", 148, 168], ["CD98 cell expression", "OBSERVATION", 148, 168]]], ["The intensity of uptake was detected using the CD98-silenced HepG2 cells (Figure Table 1 2D), untreated HepG2 ( Figure 2E ) cells, and LPS-stimulated HepG2 cells ( Figure 2F ).", [["HepG2 cells", "ANATOMY", 61, 72], ["HepG2 ( Figure 2E ) cells", "ANATOMY", 104, 129], ["HepG2 cells", "ANATOMY", 150, 161], ["LPS", "CHEMICAL", 135, 138], ["CD98", "GENE_OR_GENE_PRODUCT", 47, 51], ["HepG2 cells", "CELL", 61, 72], ["HepG2 ( Figure 2E ) cells", "CELL", 104, 129], ["LPS", "SIMPLE_CHEMICAL", 135, 138], ["HepG2 cells", "CELL", 150, 161], ["Figure 2F", "CELL", 164, 173], ["CD98", "PROTEIN", 47, 51], ["HepG2 cells", "CELL_LINE", 61, 72], ["HepG2 ( Figure 2E ) cells", "CELL_LINE", 104, 129], ["LPS-stimulated HepG2 cells", "CELL_LINE", 135, 161], ["the CD98", "TEST", 43, 51], ["Figure Table", "TEST", 74, 86], ["untreated HepG2 ( Figure 2E ) cells", "TREATMENT", 94, 129], ["LPS", "TEST", 135, 138], ["uptake", "OBSERVATION", 17, 23]]], ["As shown in Figure 2D \u2212F, the GDV uptake was proportionally increased with the expression of CD98 as shown by the position of the peak maximum and the area under the curve of each flow cytometry experiment.\u25a0 RESULTS AND DISCUSSIONComparing each line within the same plot, we showed that for any CD98 expression, the surface protein digestion reduced the uptakes of GDVs.", [["surface", "ANATOMY", 316, 323], ["GDV", "SIMPLE_CHEMICAL", 30, 33], ["CD98", "GENE_OR_GENE_PRODUCT", 93, 97], ["CD98", "GENE_OR_GENE_PRODUCT", 295, 299], ["surface", "CELLULAR_COMPONENT", 316, 323], ["CD98", "PROTEIN", 93, 97], ["CD98", "PROTEIN", 295, 299], ["the GDV uptake", "TEST", 26, 40], ["any CD98 expression", "PROBLEM", 291, 310], ["the surface protein digestion", "PROBLEM", 312, 341], ["the uptakes of GDVs", "PROBLEM", 350, 369], ["flow cytometry", "OBSERVATION", 180, 194]]], ["Similarly, in the literature, proteins on the membranes of exosomes were digested by protease K, which inhibited the uptake by the cells.", [["membranes", "ANATOMY", 46, 55], ["exosomes", "ANATOMY", 59, 67], ["cells", "ANATOMY", 131, 136], ["K", "CHEMICAL", 94, 95], ["membranes", "CELLULAR_COMPONENT", 46, 55], ["exosomes", "CELL", 59, 67], ["protease K", "GENE_OR_GENE_PRODUCT", 85, 95], ["cells", "CELL", 131, 136], ["exosomes", "CELL_TYPE", 59, 67], ["protease K", "PROTEIN", 85, 95], ["protease K", "TEST", 85, 95]]], ["12 Trypsin-digested GDV uptake was significantly decreased compared to native GDVs, demonstrating the importance of the ligands present on their surface.", [["surface", "ANATOMY", 145, 152], ["GDV", "CHEMICAL", 20, 23], ["Trypsin", "GENE_OR_GENE_PRODUCT", 3, 10], ["GDV", "SIMPLE_CHEMICAL", 20, 23], ["GDVs", "PATHOLOGICAL_FORMATION", 78, 82], ["surface", "CELLULAR_COMPONENT", 145, 152], ["Trypsin-digested GDV uptake", "TEST", 3, 30], ["significantly", "OBSERVATION_MODIFIER", 35, 48], ["decreased", "OBSERVATION_MODIFIER", 49, 58]]], ["Also, comparing each curve of the same color in the three different experiments, we showed that for the same GDV surface protein profile, the uptake of GDVs was correlated to CD98 expression.", [["surface", "ANATOMY", 113, 120], ["GDVs", "GENE_OR_GENE_PRODUCT", 152, 156], ["CD98", "GENE_OR_GENE_PRODUCT", 175, 179], ["GDV surface protein", "PROTEIN", 109, 128], ["GDVs", "PROTEIN", 152, 156], ["CD98", "PROTEIN", 175, 179], ["the uptake of GDVs", "PROBLEM", 138, 156]]], ["This result was further demonstrated by investigating the uptake of GDVs with differential CD98 expression by fluorescent microscopy ( Figure 4 ).", [["GDVs", "SIMPLE_CHEMICAL", 68, 72], ["CD98", "GENE_OR_GENE_PRODUCT", 91, 95], ["CD98", "PROTEIN", 91, 95], ["the uptake of GDVs", "PROBLEM", 54, 72], ["fluorescent microscopy", "TEST", 110, 132]]], ["The intensity of uptake was also quantified by the geometric mean, as shown in Figure 3E .", [["uptake", "OBSERVATION", 17, 23]]], ["Intake of T4 GDVs was lesser than that of intact GDVs by the HepG2 cells.", [["GDVs", "ANATOMY", 49, 53], ["HepG2 cells", "ANATOMY", 61, 72], ["T4 GDVs", "SIMPLE_CHEMICAL", 10, 17], ["GDVs", "SIMPLE_CHEMICAL", 49, 53], ["HepG2 cells", "CELL", 61, 72], ["HepG2 cells", "CELL_LINE", 61, 72], ["T4 GDVs", "TEST", 10, 17], ["T4", "ANATOMY", 10, 12], ["lesser", "OBSERVATION_MODIFIER", 22, 28], ["intact", "OBSERVATION", 42, 48]]], ["For the uptake of GDVs, it was shown that CD98 silencing significantly decreased the uptake of GDVs by 33.85% compared with that in the HepG2 cells under regular culture condition.", [["HepG2 cells", "ANATOMY", 136, 147], ["GDVs", "SIMPLE_CHEMICAL", 18, 22], ["CD98", "GENE_OR_GENE_PRODUCT", 42, 46], ["GDVs", "SIMPLE_CHEMICAL", 95, 99], ["HepG2 cells", "CELL", 136, 147], ["GDVs", "PROTEIN", 18, 22], ["CD98", "PROTEIN", 42, 46], ["HepG2 cells", "CELL_LINE", 136, 147], ["the uptake of GDVs", "PROBLEM", 4, 22], ["CD98 silencing", "PROBLEM", 42, 56], ["the uptake of GDVs", "PROBLEM", 81, 99], ["HepG2", "ANATOMY", 136, 141]]], ["In contrast, LPS-stimulated HepG2 increased the uptake of GDVs by 17.16%.", [["HepG2", "ANATOMY", 28, 33], ["LPS", "CHEMICAL", 13, 16], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["HepG2", "CELL", 28, 33], ["GDVs", "PATHOLOGICAL_FORMATION", 58, 62], ["HepG2", "CELL_LINE", 28, 33], ["LPS", "TEST", 13, 16], ["GDVs", "TEST", 58, 62]]], ["These results together showed that the uptake of GDVs by the HepG2 cells was correlated to the level of expression of CD98 on the HepG2 cells. .", [["HepG2 cells", "ANATOMY", 61, 72], ["HepG2 cells", "ANATOMY", 130, 141], ["GDVs", "CHEMICAL", 49, 53], ["GDVs", "SIMPLE_CHEMICAL", 49, 53], ["HepG2 cells", "CELL", 61, 72], ["CD98", "GENE_OR_GENE_PRODUCT", 118, 122], ["HepG2 cells", "CELL", 130, 141], ["HepG2 cells", "CELL_LINE", 61, 72], ["CD98", "PROTEIN", 118, 122], ["HepG2 cells", "CELL_LINE", 130, 141], ["the uptake of GDVs", "PROBLEM", 35, 53], ["the HepG2 cells", "TEST", 57, 72], ["the HepG2 cells", "TREATMENT", 126, 141], ["CD98", "OBSERVATION", 118, 122]]], ["Cross study of the modulation of GDV endocytosis by the HepG2 cells by tuning the expression level of CD98 on the HepG2 cells and the integrity of the surface proteins of GDVs.", [["HepG2 cells", "ANATOMY", 56, 67], ["HepG2 cells", "ANATOMY", 114, 125], ["surface", "ANATOMY", 151, 158], ["GDV", "GENE_OR_GENE_PRODUCT", 33, 36], ["HepG2 cells", "CELL", 56, 67], ["CD98", "GENE_OR_GENE_PRODUCT", 102, 106], ["HepG2 cells", "CELL", 114, 125], ["GDVs", "GENE_OR_GENE_PRODUCT", 171, 175], ["GDV", "PROTEIN", 33, 36], ["HepG2 cells", "CELL_LINE", 56, 67], ["CD98", "PROTEIN", 102, 106], ["HepG2 cells", "CELL_LINE", 114, 125], ["surface proteins", "PROTEIN", 151, 167], ["GDVs", "PROTEIN", 171, 175], ["Cross study", "TEST", 0, 11], ["GDV endocytosis", "PROBLEM", 33, 48], ["the HepG2 cells", "TREATMENT", 52, 67], ["the HepG2 cells", "TREATMENT", 110, 125]]], ["The HepG2 cells were incubated with 100 \u03bcg/mL GDVs for 6 h except column A (noted phosphatebuffered saline (PBS)), which represents the HepG2 cells without GDVs.", [["HepG2 cells", "ANATOMY", 4, 15], ["HepG2 cells", "ANATOMY", 136, 147], ["HepG2 cells", "CELL", 4, 15], ["phosphatebuffered saline", "SIMPLE_CHEMICAL", 82, 106], ["HepG2 cells", "CELL", 136, 147], ["GDVs", "CELL", 156, 160], ["HepG2 cells", "CELL_LINE", 4, 15], ["HepG2 cells", "CELL_LINE", 136, 147], ["The HepG2 cells", "TEST", 0, 15], ["phosphatebuffered saline (PBS", "TREATMENT", 82, 111], ["the HepG2 cells", "PROBLEM", 132, 147], ["GDVs", "PROBLEM", 156, 160], ["HepG2", "ANATOMY", 4, 9], ["HepG2 cells", "OBSERVATION", 136, 147]]], ["The GDVs were labeled with coumarin-6 (green), the HepG2 cells were stained for actin with phalloidin (red), and the nuclei were stained with DAPI (blue).", [["GDVs", "ANATOMY", 4, 8], ["HepG2 cells", "ANATOMY", 51, 62], ["nuclei", "ANATOMY", 117, 123], ["coumarin-6 (green", "CHEMICAL", 27, 44], ["coumarin-6", "CHEMICAL", 27, 37], ["phalloidin", "CHEMICAL", 91, 101], ["DAPI", "CHEMICAL", 142, 146], ["GDVs", "SIMPLE_CHEMICAL", 4, 8], ["coumarin-6", "SIMPLE_CHEMICAL", 27, 37], ["green", "SIMPLE_CHEMICAL", 39, 44], ["HepG2 cells", "CELL", 51, 62], ["actin", "GENE_OR_GENE_PRODUCT", 80, 85], ["phalloidin", "SIMPLE_CHEMICAL", 91, 101], ["nuclei", "CELLULAR_COMPONENT", 117, 123], ["DAPI", "SIMPLE_CHEMICAL", 142, 146], ["GDVs", "PROTEIN", 4, 8], ["HepG2 cells", "CELL_LINE", 51, 62], ["actin", "PROTEIN", 80, 85], ["phalloidin (red)", "PROTEIN", 91, 107], ["coumarin", "TREATMENT", 27, 35], ["the HepG2 cells", "TEST", 47, 62], ["phalloidin", "TREATMENT", 91, 101], ["DAPI (blue", "TREATMENT", 142, 152], ["HepG2", "ANATOMY", 51, 56], ["nuclei", "ANATOMY", 117, 123]]], ["Vertically, other columns (B\u2212F) represent a different \"type\" of GDV treatment.", [["GDV", "CHEMICAL", 64, 67], ["B\u2212F", "GENE_OR_GENE_PRODUCT", 27, 30], ["GDV", "SIMPLE_CHEMICAL", 64, 67], ["GDV treatment", "TREATMENT", 64, 77], ["GDV treatment", "OBSERVATION", 64, 77]]], ["(B)\u2212(F) columns represent, respectively, intact GDVs (GDVs in B), 1 h trypsin-digested GDVs (T1 GDVs in (C)), 2 h trypsin-digested GDVs (T2 GDVs in (D)), 3 h trypsin-digested GDVs (T3 GDVs in (E)), and 4 h trypsin-digested GDVs (T4 GDVs in (F)).", [["B", "CELL", 62, 63], ["trypsin", "PROTEIN", 70, 77], ["trypsin", "PROTEIN", 114, 121], ["trypsin", "PROTEIN", 158, 165], ["trypsin", "PROTEIN", 206, 213], ["(B)\u2212(F) columns", "TEST", 0, 15], ["trypsin", "TEST", 70, 77], ["GDVs", "TEST", 87, 91], ["T1 GDVs", "TEST", 93, 100], ["trypsin", "TEST", 114, 121], ["GDVs", "TEST", 131, 135], ["T2 GDVs", "TEST", 137, 144], ["trypsin", "TEST", 158, 165], ["GDVs", "TEST", 175, 179], ["T3 GDVs", "TEST", 181, 188], ["trypsin", "TEST", 206, 213]]], ["Horizontally, line 1 (noted LPS) represents the LPS-stimulated HepG2 cells (overexpressing surface CD98 on the HepG2 cells).", [["HepG2 cells", "ANATOMY", 63, 74], ["surface", "ANATOMY", 91, 98], ["HepG2 cells", "ANATOMY", 111, 122], ["LPS", "CHEMICAL", 48, 51], ["line 1", "CELL", 14, 20], ["LPS", "SIMPLE_CHEMICAL", 48, 51], ["HepG2 cells", "CELL", 63, 74], ["CD98", "GENE_OR_GENE_PRODUCT", 99, 103], ["HepG2 cells", "CELL", 111, 122], ["LPS-stimulated HepG2 cells", "CELL_LINE", 48, 74], ["CD98", "PROTEIN", 99, 103], ["HepG2 cells", "CELL_LINE", 111, 122], ["the LPS", "TEST", 44, 51], ["stimulated HepG2 cells", "PROBLEM", 52, 74], ["the HepG2 cells", "TREATMENT", 107, 122], ["line", "OBSERVATION", 14, 18]]], ["The second line (noted HepG2) represents the basal expression of CD98 on the HepG2 cells.", [["HepG2", "ANATOMY", 23, 28], ["HepG2 cells", "ANATOMY", 77, 88], ["HepG2", "CELL", 23, 28], ["CD98", "GENE_OR_GENE_PRODUCT", 65, 69], ["HepG2 cells", "CELL", 77, 88], ["HepG2", "CELL_LINE", 23, 28], ["CD98", "PROTEIN", 65, 69], ["HepG2 cells", "CELL_LINE", 77, 88], ["The second line", "TREATMENT", 0, 15], ["the HepG2 cells", "TREATMENT", 73, 88], ["second line", "OBSERVATION", 4, 15], ["basal", "ANATOMY_MODIFIER", 45, 50], ["CD98", "OBSERVATION", 65, 69], ["HepG2", "ANATOMY", 77, 82]]], ["Finally, line 3 (noted CD98 siRNA) shows the HepG2 cells with lower expression of CD98 (blocked by pretreatment with CD98 siRNA).\u25a0 RESULTS AND DISCUSSIONThe uptake of GDVs was visualized by fluorescence microscopy (Figure 4 ).", [["HepG2 cells", "ANATOMY", 45, 56], ["line 3", "CELL", 9, 15], ["CD98", "GENE_OR_GENE_PRODUCT", 23, 27], ["HepG2 cells", "CELL", 45, 56], ["CD98", "GENE_OR_GENE_PRODUCT", 82, 86], ["CD98", "GENE_OR_GENE_PRODUCT", 117, 121], ["GDVs", "SIMPLE_CHEMICAL", 167, 171], ["CD98 siRNA", "PROTEIN", 23, 33], ["HepG2 cells", "CELL_LINE", 45, 56], ["CD98", "PROTEIN", 82, 86], ["CD98", "PROTEIN", 117, 121], ["GDVs", "PROTEIN", 167, 171], ["line", "TEST", 9, 13], ["CD98 siRNA", "TEST", 23, 33], ["the HepG2 cells", "PROBLEM", 41, 56], ["CD98", "PROBLEM", 82, 86], ["CD98 siRNA", "TREATMENT", 117, 127], ["The uptake of GDVs", "PROBLEM", 153, 171], ["fluorescence microscopy", "TEST", 190, 213], ["HepG2 cells", "OBSERVATION", 45, 56], ["lower expression", "OBSERVATION_MODIFIER", 62, 78], ["CD98", "OBSERVATION", 82, 86], ["CD98 siRNA", "OBSERVATION", 117, 127], ["uptake", "OBSERVATION_MODIFIER", 157, 163]]], ["Figure 4 showed the uptake of GDVs (i) by the LPS-stimulated HepG2 cells (first panel), (ii) by the regular HepG2 cells (second panel), and (iii) by the HepG2 cells treated with CD98 siRNA (third panel).", [["HepG2 cells", "ANATOMY", 61, 72], ["HepG2 cells", "ANATOMY", 108, 119], ["HepG2 cells", "ANATOMY", 153, 164], ["LPS", "CHEMICAL", 46, 49], ["GDVs", "SIMPLE_CHEMICAL", 30, 34], ["LPS", "SIMPLE_CHEMICAL", 46, 49], ["HepG2 cells", "CELL", 61, 72], ["HepG2 cells", "CELL", 108, 119], ["HepG2 cells", "CELL", 153, 164], ["CD98", "GENE_OR_GENE_PRODUCT", 178, 182], ["LPS-stimulated HepG2 cells", "CELL_LINE", 46, 72], ["HepG2 cells", "CELL_LINE", 108, 119], ["HepG2 cells", "CELL_LINE", 153, 164], ["CD98", "PROTEIN", 178, 182], ["Figure", "TEST", 0, 6], ["the uptake of GDVs", "PROBLEM", 16, 34], ["the LPS", "TEST", 42, 49], ["stimulated HepG2 cells", "PROBLEM", 50, 72], ["second panel", "TEST", 121, 133], ["the HepG2 cells", "TEST", 149, 164], ["CD98 siRNA", "TREATMENT", 178, 188], ["HepG2", "ANATOMY", 153, 158]]], ["As expected, there is no coumarin-6 signal (GDVs) in the cells without GDVs (PBS column in Figure 4 ).", [["cells", "ANATOMY", 57, 62], ["coumarin", "CHEMICAL", 25, 33], ["coumarin-6", "GENE_OR_GENE_PRODUCT", 25, 35], ["cells", "CELL", 57, 62], ["coumarin", "TEST", 25, 33], ["GDVs", "PROBLEM", 71, 75], ["no", "UNCERTAINTY", 22, 24], ["coumarin", "OBSERVATION", 25, 33], ["cells", "ANATOMY", 57, 62], ["without", "UNCERTAINTY", 63, 70]]], ["The fluorescent study showed clearly that intake of the intact GDV group was significantly more than that of the trypsin-digested GDV groups.", [["GDV", "CHEMICAL", 63, 66], ["GDV", "SIMPLE_CHEMICAL", 63, 66], ["trypsin", "GENE_OR_GENE_PRODUCT", 113, 120], ["GDV", "SIMPLE_CHEMICAL", 130, 133], ["trypsin", "PROTEIN", 113, 120], ["The fluorescent study", "TEST", 0, 21]]], ["Within the GDV-supplemented cell column, we also observed that the kinetics of GDV uptake by the HepG2 cells was directly correlated with the CD98 expression levels.", [["cell", "ANATOMY", 28, 32], ["HepG2 cells", "ANATOMY", 97, 108], ["GDV", "CHEMICAL", 79, 82], ["GDV", "CHEMICAL", 79, 82], ["GDV", "SIMPLE_CHEMICAL", 11, 14], ["cell", "CELL", 28, 32], ["GDV", "SIMPLE_CHEMICAL", 79, 82], ["HepG2 cells", "CELL", 97, 108], ["CD98", "GENE_OR_GENE_PRODUCT", 142, 146], ["HepG2 cells", "CELL_LINE", 97, 108], ["CD98", "PROTEIN", 142, 146], ["GDV uptake", "PROBLEM", 79, 89], ["the HepG2 cells", "TEST", 93, 108], ["the CD98 expression levels", "TEST", 138, 164], ["supplemented cell column", "OBSERVATION", 15, 39]]], ["CD98 downregulation (line 3 in Figure 4 ) significantly showed a decrease in the endocytosis of GDVs.", [["CD98", "GENE_OR_GENE_PRODUCT", 0, 4], ["GDVs", "GENE_OR_GENE_PRODUCT", 96, 100], ["CD98", "PROTEIN", 0, 4], ["GDVs", "PROTEIN", 96, 100], ["CD98 downregulation", "TEST", 0, 19], ["a decrease in the endocytosis of GDVs", "PROBLEM", 63, 100], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["endocytosis", "OBSERVATION", 81, 92]]], ["These indicated that CD98 expression in the HepG2 cell played an important role in the recognition and uptake process of GDVs.\u25a0 RESULTS AND DISCUSSIONImportant Presence of II Lectin on the GDV Surface.", [["HepG2 cell", "ANATOMY", 44, 54], ["CD98", "GENE_OR_GENE_PRODUCT", 21, 25], ["HepG2 cell", "CELL", 44, 54], ["GDVs", "PATHOLOGICAL_FORMATION", 121, 125], ["CD98", "PROTEIN", 21, 25], ["HepG2 cell", "CELL_LINE", 44, 54], ["II Lectin", "PROTEIN", 172, 181], ["CD98 expression", "PROBLEM", 21, 36], ["CD98 expression", "OBSERVATION", 21, 36], ["HepG2", "ANATOMY", 44, 49]]], ["After establishing that CD98 expression in the HepG2 cells is a key factor for GDV uptake, a proteomics study was carried out to investigate which proteins on the GDVs' surface might interact with CD98.\u25a0 RESULTS AND DISCUSSIONGDVs' surface proteins were isolated using a standard protocol of membrane isolation for the cells.", [["HepG2 cells", "ANATOMY", 47, 58], ["GDVs' surface", "ANATOMY", 163, 176], ["surface", "ANATOMY", 232, 239], ["membrane", "ANATOMY", 292, 300], ["cells", "ANATOMY", 319, 324], ["CD98", "GENE_OR_GENE_PRODUCT", 24, 28], ["HepG2 cells", "CELL", 47, 58], ["GDV", "SIMPLE_CHEMICAL", 79, 82], ["GDVs", "GENE_OR_GENE_PRODUCT", 163, 167], ["surface", "CELLULAR_COMPONENT", 169, 176], ["CD98", "GENE_OR_GENE_PRODUCT", 197, 201], ["membrane", "CELLULAR_COMPONENT", 292, 300], ["cells", "CELL", 319, 324], ["CD98", "PROTEIN", 24, 28], ["HepG2 cells", "CELL_LINE", 47, 58], ["GDVs", "PROTEIN", 163, 167], ["CD98", "PROTEIN", 197, 201], ["surface proteins", "PROTEIN", 232, 248], ["GDV uptake", "PROBLEM", 79, 89], ["a proteomics study", "TEST", 91, 109], ["a standard protocol of membrane isolation", "TREATMENT", 269, 310], ["the cells", "PROBLEM", 315, 324], ["HepG2", "ANATOMY", 47, 52]]], ["GDVs' surface proteins were digested using trypsin (0.25%) and separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (4\u221215%, 135 V, 80 min).", [["surface", "ANATOMY", 6, 13], ["sodium dodecyl sulfate", "CHEMICAL", 79, 101], ["sodium dodecyl sulfate", "CHEMICAL", 79, 101], ["polyacrylamide", "CHEMICAL", 102, 116], ["trypsin", "GENE_OR_GENE_PRODUCT", 43, 50], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 79, 101], ["GDVs", "PROTEIN", 0, 4], ["surface proteins", "PROTEIN", 6, 22], ["trypsin", "PROTEIN", 43, 50], ["trypsin", "TEST", 43, 50], ["sodium dodecyl sulfate", "TREATMENT", 79, 101], ["polyacrylamide gel electrophoresis", "TREATMENT", 102, 136]]], ["As shown in Figure 5A , the channels from left to right are protein markers, undigested plasma proteins from GDVs (undigested), and GDVs' plasma proteins digested by trypsin for 4 h (digested).", [["plasma", "ANATOMY", 88, 94], ["GDVs", "ANATOMY", 109, 113], ["plasma", "ANATOMY", 138, 144], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["trypsin", "GENE_OR_GENE_PRODUCT", 166, 173], ["protein markers", "PROTEIN", 60, 75], ["undigested plasma proteins", "PROTEIN", 77, 103], ["GDVs", "PROTEIN", 109, 113], ["GDVs", "PROTEIN", 132, 136], ["plasma proteins", "PROTEIN", 138, 153], ["trypsin", "PROTEIN", 166, 173], ["protein markers", "TEST", 60, 75], ["undigested plasma proteins", "PROBLEM", 77, 103], ["left", "ANATOMY_MODIFIER", 42, 46], ["right", "ANATOMY_MODIFIER", 50, 55], ["protein markers", "OBSERVATION", 60, 75], ["plasma proteins", "OBSERVATION", 88, 103]]], ["While fewer bands in the GDVs' plasma membranes digested by the trypsin channel indicated that most proteins were degraded, the \"undigested\" plasma membrane proteins showed interesting significant bands (corresponding to the dominant presence surface proteins).", [["plasma membranes", "ANATOMY", 31, 47], ["plasma membrane", "ANATOMY", 141, 156], ["surface", "ANATOMY", 243, 250], ["GDVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["plasma membranes", "CELLULAR_COMPONENT", 31, 47], ["trypsin", "GENE_OR_GENE_PRODUCT", 64, 71], ["plasma membrane", "CELLULAR_COMPONENT", 141, 156], ["trypsin channel", "PROTEIN", 64, 79], ["plasma membrane proteins", "PROTEIN", 141, 165], ["dominant presence surface proteins", "PROTEIN", 225, 259], ["fewer bands in the GDVs' plasma membranes", "PROBLEM", 6, 47], ["the trypsin channel", "TEST", 60, 79], ["the \"undigested\" plasma membrane proteins", "TEST", 124, 165], ["interesting significant bands", "PROBLEM", 173, 202]]], ["As shown in Figure 5A , the bands between 110, 55, 25\u221237, 20\u221225, and 15 kDa were observed.", [["the bands", "TEST", 24, 33]]], ["These bands were cut off the gel and analyzed by mass spectroscopy (MS/MS), as described in the supplemental method section.", [["These bands", "PROBLEM", 0, 11], ["the gel", "TREATMENT", 25, 32], ["mass spectroscopy", "TEST", 49, 66], ["MS/MS)", "PROBLEM", 68, 74]]], ["The result of protein identification is shown in Figure 5B (table section) .", [["protein identification", "TEST", 14, 36]]], ["Some proteins, abundant in garlic, were found from protein identification, such as alliinase, ribulose bisphosphate carboxylase large chain, and ATP synthase subunit \u03b2.", [["garlic", "ANATOMY", 27, 33], ["bisphosphate", "CHEMICAL", 103, 115], ["ATP", "CHEMICAL", 145, 148], ["ribulose bisphosphate", "CHEMICAL", 94, 115], ["ATP", "CHEMICAL", 145, 148], ["garlic", "SIMPLE_CHEMICAL", 27, 33], ["alliinase", "GENE_OR_GENE_PRODUCT", 83, 92], ["ribulose bisphosphate carboxylase", "GENE_OR_GENE_PRODUCT", 94, 127], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 145, 157], ["alliinase", "PROTEIN", 83, 92], ["ribulose bisphosphate carboxylase large chain", "PROTEIN", 94, 139], ["ATP synthase subunit", "PROTEIN", 145, 165], ["garlic", "SPECIES", 27, 33], ["Some proteins", "PROBLEM", 0, 13], ["protein identification", "TEST", 51, 73], ["alliinase", "TEST", 83, 92], ["ribulose bisphosphate carboxylase large chain", "TREATMENT", 94, 139], ["ATP synthase subunit", "TREATMENT", 145, 165], ["abundant", "OBSERVATION_MODIFIER", 15, 23]]], ["Interestingly, a mannose high-affinity lectin, i.e., II lectin, was found.", [["mannose", "CHEMICAL", 17, 24], ["mannose", "SIMPLE_CHEMICAL", 17, 24], ["lectin", "GENE_OR_GENE_PRODUCT", 39, 45], ["II lectin", "GENE_OR_GENE_PRODUCT", 53, 62], ["mannose high-affinity lectin", "PROTEIN", 17, 45], ["II lectin", "PROTEIN", 53, 62], ["a mannose high-affinity lectin", "PROBLEM", 15, 45]]], ["Because II lectin had been investigated before for specific interaction with the certain surface cell receptors, 36, 37 we decided to study further the specific interaction.\u25a0 RESULTS AND DISCUSSIONSpecific Interaction between the GDV Surface Ligands (II Lectin) and CD98.", [["surface cell", "ANATOMY", 89, 101], ["II lectin", "GENE_OR_GENE_PRODUCT", 8, 17], ["II Lectin", "GENE_OR_GENE_PRODUCT", 251, 260], ["CD98", "GENE_OR_GENE_PRODUCT", 266, 270], ["II lectin", "PROTEIN", 8, 17], ["surface cell receptors", "PROTEIN", 89, 111], ["GDV Surface Ligands", "PROTEIN", 230, 249], ["II Lectin", "PROTEIN", 251, 260], ["CD98", "PROTEIN", 266, 270], ["II lectin", "PROBLEM", 8, 17], ["CD98", "TEST", 266, 270]]], ["The mechanism of extracellular vesicle endocytosis is diverse, including membrane fusions, protein interactions, and lipid raft-mediated internalization.", [["extracellular vesicle", "ANATOMY", 17, 38], ["membrane", "ANATOMY", 73, 81], ["lipid raft", "ANATOMY", 117, 127], ["extracellular vesicle", "CELLULAR_COMPONENT", 17, 38], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["lipid raft", "CELLULAR_COMPONENT", 117, 127], ["extracellular vesicle endocytosis", "PROBLEM", 17, 50], ["membrane fusions", "TREATMENT", 73, 89], ["protein interactions", "PROBLEM", 91, 111], ["extracellular", "ANATOMY_MODIFIER", 17, 30], ["vesicle endocytosis", "OBSERVATION", 31, 50], ["diverse", "OBSERVATION_MODIFIER", 54, 61], ["membrane fusions", "OBSERVATION", 73, 89], ["lipid raft", "OBSERVATION", 117, 127]]], ["8 As shown in Figure 6A , a significant \"left\" shift of the fluorescent channel peak was observed when the GDVs were exposed to the cells (2 h) at 4\u00b0C versus 37\u00b0C. This observation supports the fact that the uptake of GDVs by the mammalian cells was significantly inhibited under 4\u00b0C, indicating that a predominant part of the uptake of GDVs by the cells was energy-dependent.", [["GDVs", "ANATOMY", 107, 111], ["cells", "ANATOMY", 132, 137], ["mammalian cells", "ANATOMY", 230, 245], ["cells", "ANATOMY", 349, 354], ["GDVs", "CHEMICAL", 218, 222], ["GDVs", "CHEMICAL", 337, 341], ["cells", "CELL", 132, 137], ["GDVs", "GENE_OR_GENE_PRODUCT", 218, 222], ["mammalian cells", "CELL", 230, 245], ["GDVs", "SIMPLE_CHEMICAL", 337, 341], ["cells", "CELL", 349, 354], ["GDVs", "PROTEIN", 107, 111], ["mammalian cells", "CELL_TYPE", 230, 245], ["GDVs", "PROTEIN", 337, 341], ["a significant \"left\" shift", "PROBLEM", 26, 52], ["the fluorescent channel peak", "PROBLEM", 56, 84], ["the GDVs", "TEST", 103, 111], ["the uptake of GDVs", "PROBLEM", 204, 222], ["the mammalian cells", "PROBLEM", 226, 245], ["the uptake of GDVs", "PROBLEM", 323, 341], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["left", "ANATOMY_MODIFIER", 41, 45], ["mammalian cells", "OBSERVATION", 230, 245], ["predominant", "OBSERVATION_MODIFIER", 303, 314], ["uptake", "OBSERVATION", 327, 333]]], ["In Figure 6B , the colocalization study of CD98 (stained in red) and undigested GDVs (stained in green) showed significant co-localization clusters visualized in yellow.", [["GDVs", "ANATOMY", 80, 84], ["CD98", "GENE_OR_GENE_PRODUCT", 43, 47], ["GDVs", "GENE_OR_GENE_PRODUCT", 80, 84], ["CD98", "PROTEIN", 43, 47], ["undigested GDVs", "PROTEIN", 69, 84], ["the colocalization study", "TEST", 15, 39], ["CD98", "TEST", 43, 47], ["undigested GDVs", "PROBLEM", 69, 84], ["significant co-localization clusters", "PROBLEM", 111, 147], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["co-localization clusters", "OBSERVATION", 123, 147], ["yellow", "OBSERVATION_MODIFIER", 162, 168]]], ["To confirm that plasma membrane proteins were playing a key role in endocytosis, we conducted the same experiments (6 h incubation, 37\u00b0C) after 1 h ( Figure 6C ) and 4 h ( Figure 6D ) digestion of GDVs' plasma membrane proteins by trypsin.", [["plasma membrane", "ANATOMY", 16, 31], ["plasma membrane", "ANATOMY", 203, 218], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["GDVs", "SIMPLE_CHEMICAL", 197, 201], ["plasma", "ORGANISM_SUBSTANCE", 203, 209], ["membrane", "CELLULAR_COMPONENT", 210, 218], ["trypsin", "GENE_OR_GENE_PRODUCT", 231, 238], ["plasma membrane proteins", "PROTEIN", 16, 40], ["GDVs", "PROTEIN", 197, 201], ["plasma membrane proteins", "PROTEIN", 203, 227], ["trypsin", "PROTEIN", 231, 238], ["plasma membrane proteins", "PROBLEM", 16, 40], ["GDVs' plasma membrane proteins", "PROBLEM", 197, 227]]], ["The results of this fluorescent microscopy study showed clearly that T1 GDVs (1 h trypsin digestion, Figure 6C ) and T4 GDVs (4 h trypsin digestion, Figure 6D ) showed significantly less co-localization signals than the undigested GDVs ( Figure 6D ).", [["trypsin", "PROTEIN", 82, 89], ["trypsin", "PROTEIN", 130, 137], ["this fluorescent microscopy study", "TEST", 15, 48], ["T1 GDVs", "TEST", 69, 76], ["trypsin digestion", "TEST", 82, 99], ["Figure 6C", "TEST", 101, 110], ["T4 GDVs", "TEST", 117, 124], ["trypsin digestion", "TEST", 130, 147], ["significantly less co-localization signals", "PROBLEM", 168, 210], ["the undigested GDVs", "PROBLEM", 216, 235]]], ["Combining the scientific literature with the results of the flow cytometry, mass spectroscopy, and the fluorescent microscopy experiments, we concluded that lectin family proteins present on GDVs are playing the major role in the endocytosis of GDVs mediated by CD98 interactions.", [["lectin", "GENE_OR_GENE_PRODUCT", 157, 163], ["GDVs", "GENE_OR_GENE_PRODUCT", 191, 195], ["GDVs", "GENE_OR_GENE_PRODUCT", 245, 249], ["CD98", "GENE_OR_GENE_PRODUCT", 262, 266], ["lectin family proteins", "PROTEIN", 157, 179], ["GDVs", "PROTEIN", 191, 195], ["CD98", "PROTEIN", 262, 266], ["the flow cytometry", "TEST", 56, 74], ["mass spectroscopy", "TEST", 76, 93], ["the fluorescent microscopy experiments", "TEST", 99, 137], ["lectin family proteins", "PROBLEM", 157, 179]]], ["A reminder, lectins are a type of proteins that can bind to glycoproteins, including CD98 glycoprotein, and lectins are found in mammals, bacteria, and plants.", [["CD98", "GENE_OR_GENE_PRODUCT", 85, 89], ["lectins", "GENE_OR_GENE_PRODUCT", 108, 115], ["glycoproteins", "PROTEIN", 60, 73], ["CD98 glycoprotein", "PROTEIN", 85, 102], ["lectins", "PROTEIN", 108, 115], ["CD98 glycoprotein", "TEST", 85, 102], ["lectins", "PROBLEM", 108, 115], ["bacteria", "PROBLEM", 138, 146], ["bacteria", "OBSERVATION", 138, 146]]], ["Animal lectins such as galectin-3 have been proved to be a ligand of CD98 and plant lectins such as GSL-IB4 have been reported to have similar carbohydrate-binding specificities with galectin-3.", [["carbohydrate", "CHEMICAL", 143, 155], ["galectin-3", "GENE_OR_GENE_PRODUCT", 23, 33], ["CD98", "GENE_OR_GENE_PRODUCT", 69, 73], ["GSL-IB4", "GENE_OR_GENE_PRODUCT", 100, 107], ["galectin-3", "GENE_OR_GENE_PRODUCT", 183, 193], ["galectin-3", "PROTEIN", 23, 33], ["CD98", "PROTEIN", 69, 73], ["GSL", "PROTEIN", 100, 103], ["IB4", "PROTEIN", 104, 107], ["galectin-3", "PROTEIN", 183, 193], ["Animal lectins", "TEST", 0, 14], ["galectin", "TEST", 23, 31], ["galectin", "TEST", 183, 191]]], ["38\u221240 Based on the literature and our corroborating results, we deduced that the interaction between a ligand (II lectin) on GDVs and CD98 glycoprotein determines the uptake of GDVs in the HepG2 cells.", [["HepG2 cells", "ANATOMY", 189, 200], ["II lectin", "GENE_OR_GENE_PRODUCT", 111, 120], ["GDVs", "GENE_OR_GENE_PRODUCT", 125, 129], ["CD98 glycoprotein", "GENE_OR_GENE_PRODUCT", 134, 151], ["GDVs", "SIMPLE_CHEMICAL", 177, 181], ["HepG2 cells", "CELL", 189, 200], ["II lectin", "PROTEIN", 111, 120], ["GDVs", "PROTEIN", 125, 129], ["CD98 glycoprotein", "PROTEIN", 134, 151], ["GDVs", "PROTEIN", 177, 181], ["HepG2 cells", "CELL_LINE", 189, 200], ["GDVs", "TEST", 125, 129], ["CD98 glycoprotein", "TEST", 134, 151], ["the uptake of GDVs in the HepG2 cells", "PROBLEM", 163, 200], ["HepG2", "ANATOMY", 189, 194]]], ["8 The next step aims to demonstrate that CD98 is the receptor involved on the side of the HepG2 and that the specific ligand on GDVs is the II lectin significantly found on the surface of GDVs by MS/MS.\u25a0 RESULTS AND DISCUSSIONCD98 is the Main Receptor of GDVs via II Lectin-Coated GDVs.", [["HepG2", "ANATOMY", 90, 95], ["surface", "ANATOMY", 177, 184], ["GDVs", "ANATOMY", 188, 192], ["CD98", "GENE_OR_GENE_PRODUCT", 41, 45], ["HepG2", "CELL", 90, 95], ["GDVs", "GENE_OR_GENE_PRODUCT", 128, 132], ["II lectin", "GENE_OR_GENE_PRODUCT", 140, 149], ["surface", "CELLULAR_COMPONENT", 177, 184], ["GDVs", "SIMPLE_CHEMICAL", 188, 192], ["Lectin", "GENE_OR_GENE_PRODUCT", 267, 273], ["CD98", "PROTEIN", 41, 45], ["HepG2", "CELL_LINE", 90, 95], ["GDVs", "PROTEIN", 128, 132], ["II lectin", "PROTEIN", 140, 149], ["Lectin", "PROTEIN", 267, 273], ["GDVs via II Lectin", "TREATMENT", 255, 273], ["Coated GDVs", "TREATMENT", 274, 285], ["HepG2", "ANATOMY", 90, 95]]], ["As we showed previously in this study ( Figure 3E ), the downregulation of CD98 by its specific siRNA significantly inhibited the uptake of GDVs by 33% and decreased the co-localization of CD98 and GDVs, demonstrating that the uptake was highly related with CD98 on the side of the HepG2 membrane.", [["HepG2 membrane", "ANATOMY", 282, 296], ["CD98", "GENE_OR_GENE_PRODUCT", 75, 79], ["GDVs", "PATHOLOGICAL_FORMATION", 140, 144], ["CD98", "GENE_OR_GENE_PRODUCT", 189, 193], ["GDVs", "GENE_OR_GENE_PRODUCT", 198, 202], ["CD98", "GENE_OR_GENE_PRODUCT", 258, 262], ["HepG2 membrane", "CELLULAR_COMPONENT", 282, 296], ["CD98", "PROTEIN", 75, 79], ["CD98", "PROTEIN", 189, 193], ["GDVs", "PROTEIN", 198, 202], ["CD98", "PROTEIN", 258, 262], ["this study", "TEST", 27, 37], ["the downregulation of CD98", "PROBLEM", 53, 79], ["GDVs", "TEST", 140, 144], ["GDVs", "TEST", 198, 202], ["the uptake", "TEST", 223, 233], ["CD98", "OBSERVATION", 189, 193], ["CD98", "OBSERVATION", 258, 262], ["HepG2", "ANATOMY", 282, 287], ["membrane", "ANATOMY_MODIFIER", 288, 296]]], ["To further confirm this, we preincubated the HepG2 cells with CD98 antibody before conducting the flow cytometry uptake assay.", [["HepG2 cells", "ANATOMY", 45, 56], ["HepG2 cells", "CELL", 45, 56], ["CD98", "GENE_OR_GENE_PRODUCT", 62, 66], ["HepG2 cells", "CELL_LINE", 45, 56], ["CD98 antibody", "PROTEIN", 62, 75], ["CD98 antibody", "TEST", 62, 75], ["the flow cytometry uptake assay", "TEST", 94, 125]]], ["As observed in Figure 6E , we noticed a significant left shift of the fluorescent signal related to endocytosis of GDVs by the HepG2 cells.", [["HepG2 cells", "ANATOMY", 127, 138], ["GDVs", "GENE_OR_GENE_PRODUCT", 115, 119], ["HepG2 cells", "CELL", 127, 138], ["GDVs", "PROTEIN", 115, 119], ["HepG2 cells", "CELL_LINE", 127, 138], ["a significant left shift", "PROBLEM", 38, 62], ["the fluorescent signal", "PROBLEM", 66, 88], ["endocytosis of GDVs", "PROBLEM", 100, 119], ["the HepG2 cells", "PROBLEM", 123, 138], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["left", "ANATOMY_MODIFIER", 52, 56], ["shift", "OBSERVATION", 57, 62], ["fluorescent signal", "OBSERVATION", 70, 88], ["endocytosis", "OBSERVATION", 100, 111], ["HepG2", "ANATOMY", 127, 132]]], ["Based on Figure 6E , the uptake of GDVs after blocking the CD98 receptors on the HepG2 cells with a specific CD98 antibody (10 \u03bcg/mL, 1 h) decreased as much as 47.01%.", [["HepG2 cells", "ANATOMY", 81, 92], ["GDVs", "CHEMICAL", 35, 39], ["GDVs", "SIMPLE_CHEMICAL", 35, 39], ["CD98", "GENE_OR_GENE_PRODUCT", 59, 63], ["HepG2 cells", "CELL", 81, 92], ["CD98", "GENE_OR_GENE_PRODUCT", 109, 113], ["CD98 receptors", "PROTEIN", 59, 73], ["HepG2 cells", "CELL_LINE", 81, 92], ["CD98 antibody", "PROTEIN", 109, 122], ["the uptake of GDVs", "PROBLEM", 21, 39], ["blocking the CD98 receptors", "PROBLEM", 46, 73], ["the HepG2 cells", "TEST", 77, 92], ["a specific CD98 antibody", "TEST", 98, 122]]], ["These results combined with the ones previously described in this study definitively set CD98 as the main receptor on the HepG2 cells involved in this endocytosis.\u25a0 RESULTS AND DISCUSSIONThus, we aimed to demonstrate that \"on the other side\", it was II lectin protein that was the ligand of CD98.", [["HepG2 cells", "ANATOMY", 122, 133], ["CD98", "GENE_OR_GENE_PRODUCT", 89, 93], ["HepG2 cells", "CELL", 122, 133], ["II lectin", "GENE_OR_GENE_PRODUCT", 250, 259], ["CD98", "GENE_OR_GENE_PRODUCT", 291, 295], ["CD98", "PROTEIN", 89, 93], ["HepG2 cells", "CELL_LINE", 122, 133], ["II lectin protein", "PROTEIN", 250, 267], ["CD98", "PROTEIN", 291, 295], ["this study", "TEST", 61, 71], ["the HepG2 cells", "TREATMENT", 118, 133], ["this endocytosis", "PROBLEM", 146, 162], ["HepG2", "ANATOMY", 122, 127]]], ["To confirm this hypothesis based on the MS/MS results and scientific literature, we deduced that if our hypothesis was right, the uptake of GDVs could be inhibited by preincubated GDVs with free mannose highly bounding lectin.", [["GDVs", "CHEMICAL", 140, 144], ["mannose", "CHEMICAL", 195, 202], ["GDVs", "SIMPLE_CHEMICAL", 140, 144], ["GDVs", "SIMPLE_CHEMICAL", 180, 184], ["mannose", "SIMPLE_CHEMICAL", 195, 202], ["lectin", "GENE_OR_GENE_PRODUCT", 219, 225], ["lectin", "PROTEIN", 219, 225], ["this hypothesis", "PROBLEM", 11, 26], ["the uptake of GDVs", "PROBLEM", 126, 144]]], ["12 Our strategy was to block lectin via free mannose and observe the potential effects on the endocytosis of GDVs by the HepG2 cells.", [["HepG2 cells", "ANATOMY", 121, 132], ["mannose", "CHEMICAL", 45, 52], ["mannose", "CHEMICAL", 45, 52], ["lectin", "GENE_OR_GENE_PRODUCT", 29, 35], ["mannose", "SIMPLE_CHEMICAL", 45, 52], ["GDVs", "SIMPLE_CHEMICAL", 109, 113], ["HepG2 cells", "CELL", 121, 132], ["lectin", "PROTEIN", 29, 35], ["GDVs", "PROTEIN", 109, 113], ["HepG2 cells", "CELL_LINE", 121, 132], ["block lectin via free mannose", "TREATMENT", 23, 52], ["the endocytosis of GDVs", "PROBLEM", 90, 113], ["HepG2", "ANATOMY", 121, 126]]], ["To complete the study, we decided to experiment on the different types of carbohydrates (mono-or disaccharides).", [["mono-or disaccharides", "CHEMICAL", 89, 110], ["carbohydrates", "CHEMICAL", 74, 87], ["mono-or disaccharides", "CHEMICAL", 89, 110], ["carbohydrates", "SIMPLE_CHEMICAL", 74, 87], ["mono-or disaccharides", "SIMPLE_CHEMICAL", 89, 110], ["the study", "TEST", 12, 21], ["carbohydrates (mono", "TREATMENT", 74, 93], ["disaccharides", "TREATMENT", 97, 110]]], ["The choice of free carbohydrates was defined by literature search, where it is clearly shown that lectins are a family of proteins that have high affinity to carbohydrates such as glucose, 41 mannose, 42 galactose, 43 fructose, 44 N-acetylgalactosamine (noted Gal-Nac), 45 lactose, 46 and maltose.", [["glucose", "CHEMICAL", 180, 187], ["41 mannose, 42 galactose, 43 fructose, 44 N-acetylgalactosamine", "CHEMICAL", 189, 252], ["lactose, 46 and maltose", "CHEMICAL", 273, 296], ["carbohydrates", "CHEMICAL", 19, 32], ["carbohydrates", "CHEMICAL", 158, 171], ["glucose", "CHEMICAL", 180, 187], ["mannose", "CHEMICAL", 192, 199], ["galactose", "CHEMICAL", 204, 213], ["fructose", "CHEMICAL", 218, 226], ["N-acetylgalactosamine", "CHEMICAL", 231, 252], ["Gal-Nac", "CHEMICAL", 260, 267], ["lactose", "CHEMICAL", 273, 280], ["maltose", "CHEMICAL", 289, 296], ["lectins", "GENE_OR_GENE_PRODUCT", 98, 105], ["glucose", "SIMPLE_CHEMICAL", 180, 187], ["mannose", "SIMPLE_CHEMICAL", 192, 199], ["galactose", "SIMPLE_CHEMICAL", 204, 213], ["fructose", "SIMPLE_CHEMICAL", 218, 226], ["44 N-acetylgalactosamine", "SIMPLE_CHEMICAL", 228, 252], ["Gal-Nac", "SIMPLE_CHEMICAL", 260, 267], ["lactose", "SIMPLE_CHEMICAL", 273, 280], ["maltose", "SIMPLE_CHEMICAL", 289, 296], ["lectins", "PROTEIN", 98, 105], ["free carbohydrates", "TREATMENT", 14, 32], ["glucose", "TEST", 180, 187], ["galactose", "TEST", 204, 213], ["fructose", "TEST", 218, 226], ["-acetylgalactosamine", "TREATMENT", 232, 252], ["lactose", "TEST", 273, 280]]], ["47 It has been demonstrated that the II lectin has a high affinity for the mannose compared with other sugars.", [["mannose", "CHEMICAL", 75, 82], ["mannose", "CHEMICAL", 75, 82], ["sugars", "CHEMICAL", 103, 109], ["II lectin", "GENE_OR_GENE_PRODUCT", 37, 46], ["mannose", "SIMPLE_CHEMICAL", 75, 82], ["sugars", "SIMPLE_CHEMICAL", 103, 109], ["II lectin", "PROTEIN", 37, 46], ["the II lectin", "PROBLEM", 33, 46], ["the mannose", "TREATMENT", 71, 82], ["other sugars", "TEST", 97, 109], ["high affinity", "OBSERVATION_MODIFIER", 53, 66]]], ["48, 49 The uptake of GDVs after preincubation with free carbohydrates (150 mM) was investigated using flow cytometry ( Figure 6F ).", [["GDVs", "CHEMICAL", 21, 25], ["carbohydrates", "CHEMICAL", 56, 69], ["GDVs", "SIMPLE_CHEMICAL", 21, 25], ["carbohydrates", "SIMPLE_CHEMICAL", 56, 69], ["preincubation with free carbohydrates", "TREATMENT", 32, 69], ["flow cytometry", "TEST", 102, 116], ["uptake", "OBSERVATION_MODIFIER", 11, 17]]], ["The GDVs without incubation with carbohydrates (noted control in Figure 6F ) were normalized as 100%.", [["carbohydrates", "CHEMICAL", 33, 46], ["carbohydrates", "TREATMENT", 33, 46], ["without", "UNCERTAINTY", 9, 16]]], ["As shown in Figure 6F , the highest relative decrease (\u221244% compared to control) of the uptake of GDVs by the HepG2 cells was caused by the preincubation of GDVs with the mannose.", [["HepG2 cells", "ANATOMY", 110, 121], ["GDVs", "CHEMICAL", 98, 102], ["mannose", "CHEMICAL", 171, 178], ["mannose", "CHEMICAL", 171, 178], ["GDVs", "SIMPLE_CHEMICAL", 98, 102], ["HepG2 cells", "CELL", 110, 121], ["GDVs", "SIMPLE_CHEMICAL", 157, 161], ["mannose", "SIMPLE_CHEMICAL", 171, 178], ["HepG2 cells", "CELL_LINE", 110, 121], ["the uptake of GDVs", "PROBLEM", 84, 102], ["the HepG2 cells", "PROBLEM", 106, 121], ["the mannose", "TREATMENT", 167, 178], ["decrease", "OBSERVATION_MODIFIER", 45, 53], ["HepG2", "ANATOMY", 110, 115]]], ["Notably, galactose preincubation decreased uptake by 30%, while glucose did not affect the uptake .", [["galactose", "CHEMICAL", 9, 18], ["glucose", "CHEMICAL", 64, 71], ["galactose", "CHEMICAL", 9, 18], ["glucose", "CHEMICAL", 64, 71], ["galactose", "SIMPLE_CHEMICAL", 9, 18], ["glucose", "SIMPLE_CHEMICAL", 64, 71], ["galactose preincubation", "TEST", 9, 32], ["glucose", "TEST", 64, 71]]], ["Intact GDVs had a biological effect on reducing the expression of an anti-inflammatory gene (interferon \u03b3 noted IFN-\u03b3 and interleukin 6 noted IL-6).", [["GDVs", "CHEMICAL", 7, 11], ["GDVs", "GENE_OR_GENE_PRODUCT", 7, 11], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 93, 105], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 112, 117], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 122, 135], ["IL-6", "GENE_OR_GENE_PRODUCT", 142, 146], ["anti-inflammatory gene", "DNA", 69, 91], ["interferon \u03b3", "PROTEIN", 93, 105], ["IFN", "PROTEIN", 112, 115], ["\u03b3", "PROTEIN", 116, 117], ["interleukin 6 noted IL-6", "PROTEIN", 122, 146], ["an anti-inflammatory gene (interferon", "TREATMENT", 66, 103], ["IFN", "TEST", 112, 115], ["interleukin", "TREATMENT", 122, 133]]], ["The HepG2 cells were incubated without (control noted control), with GDVs (100 \u03bcg/mL), or with T4 GDVs (100 \u03bcg/mL) for 24 h and total RNAs of (A) interferon \u03b3 noted IFN-\u03b3 and (B) interleukin 6 noted IL-6 were isolated by using the RNA extraction kits.", [["HepG2 cells", "ANATOMY", 4, 15], ["GDVs", "CHEMICAL", 69, 73], ["GDVs", "CHEMICAL", 98, 102], ["GDVs", "CHEMICAL", 69, 73], ["HepG2 cells", "CELL", 4, 15], ["GDVs", "SIMPLE_CHEMICAL", 69, 73], ["T4 GDVs", "SIMPLE_CHEMICAL", 95, 102], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 146, 158], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 165, 170], ["(B) interleukin 6", "GENE_OR_GENE_PRODUCT", 175, 192], ["IL-6", "GENE_OR_GENE_PRODUCT", 199, 203], ["HepG2 cells", "CELL_LINE", 4, 15], ["interferon \u03b3", "PROTEIN", 146, 158], ["IFN", "PROTEIN", 165, 168], ["\u03b3", "PROTEIN", 169, 170], ["interleukin 6", "PROTEIN", 179, 192], ["IL-6", "PROTEIN", 199, 203], ["T4", "SPECIES", 95, 97], ["The HepG2 cells", "TREATMENT", 0, 15], ["GDVs", "TEST", 69, 73], ["T4 GDVs", "TEST", 95, 102], ["total RNAs", "TEST", 128, 138], ["interferon", "TEST", 146, 156], ["IFN", "TEST", 165, 168], ["interleukin", "TEST", 179, 190], ["IL", "TEST", 199, 201], ["the RNA extraction kits", "TREATMENT", 227, 250]]], ["The CD98 expression was regulated by LPS, CD98 siRNA, and without any treatment (regular).", [["LPS", "CHEMICAL", 37, 40], ["CD98", "GENE_OR_GENE_PRODUCT", 4, 8], ["LPS", "SIMPLE_CHEMICAL", 37, 40], ["CD98", "GENE_OR_GENE_PRODUCT", 42, 46], ["CD98", "PROTEIN", 4, 8], ["CD98", "PROTEIN", 42, 46], ["CD98 siRNA", "TEST", 42, 52], ["CD98 expression", "OBSERVATION", 4, 19], ["CD98 siRNA", "OBSERVATION", 42, 52], ["without", "UNCERTAINTY", 58, 65]]], ["The HepG2 cell without any treatments was set as 1.", [["HepG2 cell", "ANATOMY", 4, 14], ["HepG2 cell", "CELL", 4, 14], ["HepG2 cell", "CELL_LINE", 4, 14], ["The HepG2 cell", "TREATMENT", 0, 14], ["any treatments", "TREATMENT", 23, 37], ["HepG2 cell", "OBSERVATION", 4, 14]]], ["Normalization of the results has been done over a gene known as stable expression (housekeeping gene) gene glyceraldehyde 3-phosphate dehydrogenase (GAPGH). efficiency.", [["glyceraldehyde 3-phosphate", "CHEMICAL", 107, 133], ["glyceraldehyde 3-phosphate", "CHEMICAL", 107, 133], ["glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 107, 147], ["GAPGH", "GENE_OR_GENE_PRODUCT", 149, 154], ["housekeeping gene) gene glyceraldehyde 3-phosphate dehydrogenase", "PROTEIN", 83, 147], ["GAPGH", "PROTEIN", 149, 154], ["gene glyceraldehyde", "TEST", 102, 121]]], ["Lactose, GalNac, maltose, and fructose preincubations did not significantly modify the uptake of GDVs by HepG2 (less than 5% change).", [["HepG2", "ANATOMY", 105, 110], ["Lactose", "CHEMICAL", 0, 7], ["GalNac", "CHEMICAL", 9, 15], ["maltose", "CHEMICAL", 17, 24], ["fructose", "CHEMICAL", 30, 38], ["GDVs", "CHEMICAL", 97, 101], ["Lactose", "CHEMICAL", 0, 7], ["GalNac", "CHEMICAL", 9, 15], ["maltose", "CHEMICAL", 17, 24], ["fructose", "CHEMICAL", 30, 38], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["GalNac", "SIMPLE_CHEMICAL", 9, 15], ["maltose", "SIMPLE_CHEMICAL", 17, 24], ["fructose", "SIMPLE_CHEMICAL", 30, 38], ["GDVs", "SIMPLE_CHEMICAL", 97, 101], ["HepG2", "CELL", 105, 110], ["HepG2", "CELL_LINE", 105, 110], ["Lactose", "TREATMENT", 0, 7], ["maltose", "TREATMENT", 17, 24], ["fructose preincubations", "TREATMENT", 30, 53], ["HepG2", "TEST", 105, 110]]], ["The data indicated that the uptake of GDVs was highly inhibited by mannose preincubation, strongly supporting the role of the lectins on GDV surfaces.", [["GDVs", "CHEMICAL", 38, 42], ["mannose", "CHEMICAL", 67, 74], ["mannose", "CHEMICAL", 67, 74], ["GDVs", "SIMPLE_CHEMICAL", 38, 42], ["mannose", "SIMPLE_CHEMICAL", 67, 74], ["The data", "TEST", 0, 8], ["the uptake of GDVs", "PROBLEM", 24, 42], ["mannose preincubation", "TREATMENT", 67, 88]]], ["Taken together, we can conclude that CD98 is a key receptor for GDV uptake and that the mannose preincubation coupled with the MS/MS results strongly supports that this interaction with CD98 is lectin-dependent on the GDV surface side.\u25a0 RESULTS AND DISCUSSIONGDVs Uptake by the HepG2 Cells Reduced the LPS-Induced Inflammation.", [["GDV surface", "ANATOMY", 218, 229], ["HepG2 Cells", "ANATOMY", 278, 289], ["mannose", "CHEMICAL", 88, 95], ["LPS", "CHEMICAL", 302, 305], ["Inflammation", "DISEASE", 314, 326], ["mannose", "CHEMICAL", 88, 95], ["CD98", "GENE_OR_GENE_PRODUCT", 37, 41], ["GDV", "SIMPLE_CHEMICAL", 64, 67], ["mannose", "SIMPLE_CHEMICAL", 88, 95], ["CD98", "GENE_OR_GENE_PRODUCT", 186, 190], ["lectin", "GENE_OR_GENE_PRODUCT", 194, 200], ["HepG2 Cells", "CELL", 278, 289], ["LPS", "SIMPLE_CHEMICAL", 302, 305], ["CD98", "PROTEIN", 37, 41], ["CD98", "PROTEIN", 186, 190], ["lectin", "PROTEIN", 194, 200], ["HepG2 Cells", "CELL_LINE", 278, 289], ["GDV uptake", "PROBLEM", 64, 74], ["the mannose preincubation", "TREATMENT", 84, 109], ["the GDV surface side", "TREATMENT", 214, 234], ["the HepG2 Cells", "TEST", 274, 289], ["the LPS", "PROBLEM", 298, 305], ["Induced Inflammation", "PROBLEM", 306, 326], ["HepG2", "ANATOMY", 278, 283], ["LPS", "OBSERVATION_MODIFIER", 302, 305], ["Inflammation", "OBSERVATION", 314, 326]]], ["Knowing the biological effect of GDVs on the liver cells could help understand the benefit of garlic in the human diet.", [["liver cells", "ANATOMY", 45, 56], ["GDVs", "CHEMICAL", 33, 37], ["garlic", "CHEMICAL", 94, 100], ["GDVs", "SIMPLE_CHEMICAL", 33, 37], ["liver cells", "CELL", 45, 56], ["garlic", "SIMPLE_CHEMICAL", 94, 100], ["human", "ORGANISM", 108, 113], ["liver cells", "CELL_TYPE", 45, 56], ["garlic", "SPECIES", 94, 100], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["GDVs", "PROBLEM", 33, 37], ["the liver cells", "TREATMENT", 41, 56], ["garlic in the human diet", "TREATMENT", 94, 118], ["liver", "ANATOMY", 45, 50]]], ["The IFN-\u03b3 and IL-6 have been reported to play an important role in many pathological conditions, such as inflammation, cancer, and infection.", [["cancer", "ANATOMY", 119, 125], ["inflammation", "DISEASE", 105, 117], ["cancer", "DISEASE", 119, 125], ["infection", "DISEASE", 131, 140], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["cancer", "CANCER", 119, 125], ["IFN-\u03b3 and IL-6", "PROTEIN", 4, 18], ["The IFN-\u03b3 and IL-6", "TREATMENT", 0, 18], ["inflammation", "PROBLEM", 105, 117], ["cancer", "PROBLEM", 119, 125], ["infection", "PROBLEM", 131, 140], ["inflammation", "OBSERVATION", 105, 117], ["cancer", "OBSERVATION", 119, 125], ["infection", "OBSERVATION", 131, 140]]], ["34,50\u221252 The in vivo amount of LPS was majorly produced by the gut Gram-negative bacteria and the LPS was considered as the inducer of hepatic inflammation and the colitis (gut\u2212liver axis).", [["hepatic", "ANATOMY", 135, 142], ["34,50\u221252", "CHEMICAL", 0, 8], ["LPS", "CHEMICAL", 31, 34], ["LPS", "CHEMICAL", 98, 101], ["hepatic inflammation", "DISEASE", 135, 155], ["colitis", "DISEASE", 164, 171], ["LPS", "SIMPLE_CHEMICAL", 31, 34], ["gut", "ORGANISM_SUBDIVISION", 63, 66], ["Gram", "GENE_OR_GENE_PRODUCT", 67, 71], ["LPS", "SIMPLE_CHEMICAL", 98, 101], ["hepatic", "ORGAN", 135, 142], ["colitis", "PATHOLOGICAL_FORMATION", 164, 171], ["LPS", "PROBLEM", 31, 34], ["the gut Gram", "TEST", 59, 71], ["the LPS", "TEST", 94, 101], ["hepatic inflammation", "PROBLEM", 135, 155], ["the colitis (gut\u2212liver axis)", "PROBLEM", 160, 188], ["amount", "OBSERVATION_MODIFIER", 21, 27], ["negative bacteria", "OBSERVATION_MODIFIER", 72, 89], ["hepatic", "ANATOMY", 135, 142], ["inflammation", "OBSERVATION", 143, 155], ["colitis", "OBSERVATION", 164, 171]]], ["53\u221255 LPS mainly stimulated the liver cell by interacting with the different toll-like receptors.", [["liver cell", "ANATOMY", 32, 42], ["LPS", "CHEMICAL", 6, 9], ["LPS", "SIMPLE_CHEMICAL", 6, 9], ["liver cell", "CELL", 32, 42], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 77, 96], ["liver cell", "CELL_TYPE", 32, 42], ["toll-like receptors", "PROTEIN", 77, 96], ["LPS", "TEST", 6, 9], ["liver", "ANATOMY", 32, 37], ["cell", "OBSERVATION", 38, 42]]], ["The induction of IL-6 by LPS is through the MyD88-dependent signaling pathway, while the generation of IFN-\u03b3 was in the MyD88-independent way.", [["LPS", "CHEMICAL", 25, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["MyD88", "GENE_OR_GENE_PRODUCT", 44, 49], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 103, 108], ["MyD88", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-6", "PROTEIN", 17, 21], ["MyD88", "PROTEIN", 44, 49], ["IFN", "PROTEIN", 103, 106], ["MyD88", "PROTEIN", 120, 125], ["The induction of IL", "TREATMENT", 0, 19]]], ["56 As shown in Figure 7 , the anti-inflammatory effects of GDVs or T4 GDVs were tested on the HepG2 cells with different expression levels of CD98.", [["HepG2 cells", "ANATOMY", 94, 105], ["GDVs", "CHEMICAL", 59, 63], ["GDVs", "SIMPLE_CHEMICAL", 59, 63], ["T4 GDVs", "SIMPLE_CHEMICAL", 67, 74], ["HepG2 cells", "CELL", 94, 105], ["CD98", "GENE_OR_GENE_PRODUCT", 142, 146], ["HepG2 cells", "CELL_LINE", 94, 105], ["CD98", "PROTEIN", 142, 146], ["GDVs", "TREATMENT", 59, 63], ["T4 GDVs", "PROBLEM", 67, 74], ["the HepG2 cells", "TEST", 90, 105], ["CD98", "TEST", 142, 146], ["anti-inflammatory", "OBSERVATION_MODIFIER", 30, 47]]], ["The regular HepG2 cell control group was treated with PBS only and their relative expressions of IFN-\u03b3 ( Figure 7A ) and IL-6 ( Figure 7B ) mRNA were used as the baseline and set to 1.", [["HepG2 cell", "ANATOMY", 12, 22], ["HepG2 cell", "CELL", 12, 22], ["IFN-\u03b3 ( Figure 7A", "GENE_OR_GENE_PRODUCT", 97, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["Figure 7B", "GENE_OR_GENE_PRODUCT", 128, 137], ["HepG2 cell control group", "CELL_LINE", 12, 36], ["IFN-\u03b3 ( Figure 7A", "RNA", 97, 114], ["IL-6 ( Figure 7B ) mRNA", "RNA", 121, 144], ["The regular HepG2 cell control group", "TREATMENT", 0, 36], ["PBS", "TREATMENT", 54, 57], ["IFN", "TEST", 97, 100], ["IL", "TEST", 121, 123]]], ["After the treatment of GDVs or T4 GDVs, the expression levels of IFN-\u03b3 were reduced by 42% (p < 0.001) and 29% (p < 0.05), respectively.", [["GDVs", "SIMPLE_CHEMICAL", 23, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 65, 70], ["IFN", "PROTEIN", 65, 68], ["T4", "SPECIES", 31, 33], ["GDVs", "PROBLEM", 23, 27], ["T4 GDVs", "PROBLEM", 31, 38], ["the expression levels", "TEST", 40, 61], ["IFN", "TEST", 65, 68]]], ["A similar result was observed in the IL-6 mRNA expression.", [["IL-6", "GENE_OR_GENE_PRODUCT", 37, 41], ["IL-6 mRNA", "RNA", 37, 46]]], ["Moreover, more inhibition on the expression of IFN-\u03b3 and IL-6 was found in the GDV-treated groups.", [["GDV", "CHEMICAL", 79, 82], ["GDV", "CHEMICAL", 79, 82], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["GDV", "SIMPLE_CHEMICAL", 79, 82], ["IFN", "PROTEIN", 47, 50], ["IL-6", "PROTEIN", 57, 61], ["IFN", "TEST", 47, 50], ["IL", "TEST", 57, 59]]], ["The LPS stimulation increased the expression level of IFN-\u03b3 and IL-6.", [["LPS", "CHEMICAL", 4, 7], ["LPS", "SIMPLE_CHEMICAL", 4, 7], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 54, 59], ["IL-6", "GENE_OR_GENE_PRODUCT", 64, 68], ["IFN", "PROTEIN", 54, 57], ["IL-6", "PROTEIN", 64, 68], ["The LPS stimulation", "TEST", 0, 19], ["IFN", "TEST", 54, 57], ["IL", "TEST", 64, 66]]], ["57 The expression of IFN-\u03b3 and IL-6 mRNA on the LPS-treated HepG2 cells was significantly inhibited by applying GDVs or T4 GDVs.", [["HepG2 cells", "ANATOMY", 60, 71], ["LPS", "CHEMICAL", 48, 51], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 21, 26], ["IL-6", "GENE_OR_GENE_PRODUCT", 31, 35], ["LPS", "SIMPLE_CHEMICAL", 48, 51], ["HepG2 cells", "CELL", 60, 71], ["IFN-\u03b3 and IL-6 mRNA", "RNA", 21, 40], ["HepG2 cells", "CELL_LINE", 60, 71], ["IFN", "TEST", 21, 24], ["IL", "TEST", 31, 33], ["the LPS", "TEST", 44, 51], ["HepG2 cells", "PROBLEM", 60, 71], ["T4 GDVs", "TREATMENT", 120, 127]]], ["Strikingly, the expression level of IFN-\u03b3 mRNA in the GDV-treated LPS-stimulated HepG2 cells was significantly lower than that induced by its counterpart (T4 GDVs).", [["HepG2 cells", "ANATOMY", 81, 92], ["GDV", "CHEMICAL", 54, 57], ["LPS", "CHEMICAL", 66, 69], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 36, 41], ["GDV", "SIMPLE_CHEMICAL", 54, 57], ["LPS", "SIMPLE_CHEMICAL", 66, 69], ["HepG2 cells", "CELL", 81, 92], ["IFN-\u03b3 mRNA", "RNA", 36, 46], ["GDV-treated LPS-stimulated HepG2 cells", "CELL_LINE", 54, 92], ["IFN-\u03b3 mRNA", "TREATMENT", 36, 46], ["the GDV", "TEST", 50, 57], ["LPS", "TEST", 66, 69], ["stimulated HepG2 cells", "TEST", 70, 92]]], ["The stronger anti-inflammatory effects were observed on the GDVtreated groups rather than the T4 GDV-treated groups, confirming the higher internalization of GDVs than T4 GDVs by the HepG2 cells.", [["HepG2 cells", "ANATOMY", 183, 194], ["GDV", "CHEMICAL", 97, 100], ["GDV", "CHEMICAL", 97, 100], ["T4", "SIMPLE_CHEMICAL", 94, 96], ["GDV", "SIMPLE_CHEMICAL", 97, 100], ["GDVs", "SIMPLE_CHEMICAL", 158, 162], ["T4 GDVs", "SIMPLE_CHEMICAL", 168, 175], ["HepG2 cells", "CELL", 183, 194], ["HepG2 cells", "CELL_LINE", 183, 194], ["T4", "SPECIES", 168, 170], ["The stronger anti-inflammatory effects", "PROBLEM", 0, 38], ["the T4 GDV", "TREATMENT", 90, 100], ["the higher internalization of GDVs", "PROBLEM", 128, 162], ["stronger", "OBSERVATION_MODIFIER", 4, 12], ["anti-inflammatory effects", "OBSERVATION", 13, 38], ["higher", "OBSERVATION_MODIFIER", 132, 138], ["internalization", "OBSERVATION_MODIFIER", 139, 154], ["HepG2", "ANATOMY", 183, 188]]], ["After the treatment of GDVs, the level of IFN-\u03b3 and IL-6 mRNA was close to the baseline, indicating the strong anti-inflammatory effect of GDVs.", [["GDVs", "PATHOLOGICAL_FORMATION", 23, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-6", "GENE_OR_GENE_PRODUCT", 52, 56], ["GDVs", "SIMPLE_CHEMICAL", 139, 143], ["IFN-\u03b3 and IL-6 mRNA", "RNA", 42, 61], ["GDVs", "PROBLEM", 23, 27], ["IFN", "TEST", 42, 45], ["IL", "TEST", 52, 54], ["strong", "OBSERVATION_MODIFIER", 104, 110], ["anti-inflammatory effect", "OBSERVATION", 111, 135]]], ["Silencing CD98 decreased the expression of IFN-\u03b3 and IL-6.", [["CD98", "GENE_OR_GENE_PRODUCT", 10, 14], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 43, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 53, 57], ["CD98", "PROTEIN", 10, 14], ["IFN-\u03b3 and IL-6", "PROTEIN", 43, 57], ["Silencing CD98", "PROBLEM", 0, 14], ["IFN", "TEST", 43, 46], ["IL", "TEST", 53, 55]]], ["Thus, even on being treated with GDVs or T4 GDVs, no significant difference was found in the expression level of IFN-\u03b3 and IL-6.", [["GDVs", "SIMPLE_CHEMICAL", 33, 37], ["T4", "SIMPLE_CHEMICAL", 41, 43], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 113, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 123, 127], ["IFN", "PROTEIN", 113, 116], ["IL-6", "PROTEIN", 123, 127], ["GDVs", "TREATMENT", 33, 37], ["T4 GDVs", "TREATMENT", 41, 48], ["significant difference", "PROBLEM", 53, 75], ["IFN", "TEST", 113, 116], ["IL", "TEST", 123, 125], ["no", "UNCERTAINTY", 50, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["difference", "OBSERVATION", 65, 75]]], ["Recently, our group reported that CD98 could be an inducer receptor in nonalcoholic fatty liver disease (NAFLD), and the CD98 siRNA-loaded nanoparticles were shown to have therapeutic potential for this disease.", [["nonalcoholic fatty liver", "ANATOMY", 71, 95], ["nonalcoholic fatty liver disease", "DISEASE", 71, 103], ["NAFLD", "DISEASE", 105, 110], ["CD98", "GENE_OR_GENE_PRODUCT", 34, 38], ["nonalcoholic fatty", "CANCER", 71, 89], ["liver", "ORGAN", 90, 95], ["CD98", "GENE_OR_GENE_PRODUCT", 121, 125], ["CD98", "PROTEIN", 34, 38], ["CD98", "PROTEIN", 121, 125], ["nonalcoholic fatty liver disease", "PROBLEM", 71, 103], ["the CD98 siRNA", "TEST", 117, 131], ["this disease", "PROBLEM", 198, 210], ["nonalcoholic", "OBSERVATION_MODIFIER", 71, 83], ["fatty", "OBSERVATION", 84, 89], ["liver", "ANATOMY", 90, 95]]], ["These nanoparticles downregulated the expression of CD98 both in vitro and in vivo, decreasing the level of NAFLD-related proinflammatory cytokines such as TNF-\u03b1, IFN-\u03b3, and IL-1beta.", [["NAFLD", "DISEASE", 108, 113], ["CD98", "GENE_OR_GENE_PRODUCT", 52, 56], ["NAFLD", "SIMPLE_CHEMICAL", 108, 113], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 156, 161], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 163, 168], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 174, 182], ["CD98", "PROTEIN", 52, 56], ["proinflammatory cytokines", "PROTEIN", 122, 147], ["TNF", "PROTEIN", 156, 159], ["IFN", "PROTEIN", 163, 166], ["IL-1beta", "PROTEIN", 174, 182], ["NAFLD", "PROBLEM", 108, 113], ["proinflammatory cytokines", "PROBLEM", 122, 147], ["TNF", "TEST", 156, 159], ["IFN", "TEST", 163, 166], ["CD98", "OBSERVATION", 52, 56], ["NAFLD", "OBSERVATION", 108, 113], ["proinflammatory cytokines", "OBSERVATION", 122, 147]]], ["34 These results associated with the previous conclusions suggested that GDVs showed broad anti-inflammatory potentials against the LPSinduced inflammation on the liver cells.", [["liver cells", "ANATOMY", 163, 174], ["GDVs", "CHEMICAL", 73, 77], ["inflammation", "DISEASE", 143, 155], ["GDVs", "CHEMICAL", 73, 77], ["GDVs", "SIMPLE_CHEMICAL", 73, 77], ["liver cells", "CELL", 163, 174], ["liver cells", "CELL_TYPE", 163, 174], ["GDVs", "TEST", 73, 77], ["broad anti-inflammatory potentials", "PROBLEM", 85, 119], ["the LPSinduced inflammation on the liver cells", "PROBLEM", 128, 174], ["LPSinduced", "OBSERVATION_MODIFIER", 132, 142], ["inflammation", "OBSERVATION", 143, 155], ["liver", "ANATOMY", 163, 168]]], ["Taken together, GDVs could be a promising strategy to reduce the anti-inflammatory process in pathologies like fibrosis or colitis.\u25a0 CONCLUSIONSIn summary, this study demonstrated that the CD98 glycoprotein (rich of mannose motifs) on the HepG2 cells was involved in the internalization of GDVs via binding with lectin-type proteins.", [["HepG2 cells", "ANATOMY", 239, 250], ["GDVs", "CHEMICAL", 16, 20], ["fibrosis", "DISEASE", 111, 119], ["colitis", "DISEASE", 123, 130], ["mannose", "CHEMICAL", 216, 223], ["GDVs", "SIMPLE_CHEMICAL", 16, 20], ["colitis", "PATHOLOGICAL_FORMATION", 123, 130], ["CD98", "GENE_OR_GENE_PRODUCT", 189, 193], ["HepG2 cells", "CELL", 239, 250], ["GDVs", "SIMPLE_CHEMICAL", 290, 294], ["lectin-type proteins", "GENE_OR_GENE_PRODUCT", 312, 332], ["CD98 glycoprotein", "PROTEIN", 189, 206], ["mannose motifs", "PROTEIN", 216, 230], ["HepG2 cells", "CELL_LINE", 239, 250], ["GDVs", "PROTEIN", 290, 294], ["lectin-type proteins", "PROTEIN", 312, 332], ["a promising strategy", "TREATMENT", 30, 50], ["the anti-inflammatory process", "PROBLEM", 61, 90], ["pathologies", "PROBLEM", 94, 105], ["fibrosis", "PROBLEM", 111, 119], ["colitis", "PROBLEM", 123, 130], ["this study", "TEST", 156, 166], ["the CD98 glycoprotein (rich of mannose motifs", "TREATMENT", 185, 230], ["the HepG2 cells", "TREATMENT", 235, 250], ["anti-inflammatory", "OBSERVATION_MODIFIER", 65, 82], ["fibrosis", "OBSERVATION", 111, 119], ["colitis", "OBSERVATION", 123, 130]]], ["As CD98 is highly expressed in many types of cancers, intestinal inflammation, and nonalcoholic fatty liver disease, we could investigate the potential therapeutic interest of oral administration of native GDVs in different disease models.", [["cancers", "ANATOMY", 45, 52], ["intestinal", "ANATOMY", 54, 64], ["nonalcoholic fatty liver", "ANATOMY", 83, 107], ["oral", "ANATOMY", 176, 180], ["cancers", "DISEASE", 45, 52], ["intestinal inflammation", "DISEASE", 54, 77], ["nonalcoholic fatty liver disease", "DISEASE", 83, 115], ["GDVs", "CHEMICAL", 206, 210], ["CD98", "GENE_OR_GENE_PRODUCT", 3, 7], ["cancers", "CANCER", 45, 52], ["intestinal", "ORGAN", 54, 64], ["liver", "ORGAN", 102, 107], ["oral", "ORGANISM_SUBDIVISION", 176, 180], ["GDVs", "SIMPLE_CHEMICAL", 206, 210], ["CD98", "PROTEIN", 3, 7], ["cancers", "PROBLEM", 45, 52], ["intestinal inflammation", "PROBLEM", 54, 77], ["nonalcoholic fatty liver disease", "PROBLEM", 83, 115], ["oral administration", "TREATMENT", 176, 195], ["native GDVs", "TREATMENT", 199, 210], ["cancers", "OBSERVATION", 45, 52], ["intestinal", "ANATOMY", 54, 64], ["inflammation", "OBSERVATION", 65, 77], ["nonalcoholic", "OBSERVATION_MODIFIER", 83, 95], ["fatty liver disease", "OBSERVATION", 96, 115]]], ["GDVs are great therapeutic potential to target CD98 based on their significant anti-inflammatory effect and high nontoxicity specifically.", [["GDVs", "SIMPLE_CHEMICAL", 0, 4], ["CD98", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD98", "PROTEIN", 47, 51], ["high nontoxicity", "PROBLEM", 108, 124], ["great", "OBSERVATION_MODIFIER", 9, 14], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["anti-inflammatory effect", "OBSERVATION", 79, 103]]], ["GDVs may open a novel therapeutic platform for acute or chronic diseases via oral administration.", [["oral", "ANATOMY", 77, 81], ["GDVs", "CHEMICAL", 0, 4], ["GDVs", "SIMPLE_CHEMICAL", 0, 4], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["acute or chronic diseases", "PROBLEM", 47, 72], ["oral administration", "TREATMENT", 77, 96], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["diseases", "OBSERVATION", 64, 72]]], ["Cell Culture.", [["Cell", "ANATOMY", 0, 4], ["Cell Culture", "CELL", 0, 12], ["Cell Culture", "TEST", 0, 12]]], ["The HepG2 cell line was cultured in the 1 g/ L L-glutamine DMEM medium with 10% FBS, 5% penicillin, and streptomycin (100\u00d7 Corning) at 5% CO 2 and 37\u00b0C. LPS stimulation was conducted by adding 10 \u03bcg/mL of LPS into the culture medium for 24 h.", [["HepG2 cell line", "ANATOMY", 4, 19], ["FBS", "ANATOMY", 80, 83], ["L-glutamine", "CHEMICAL", 47, 58], ["penicillin", "CHEMICAL", 88, 98], ["streptomycin", "CHEMICAL", 104, 116], ["LPS", "CHEMICAL", 153, 156], ["LPS", "CHEMICAL", 205, 208], ["L-glutamine", "CHEMICAL", 47, 58], ["penicillin", "CHEMICAL", 88, 98], ["streptomycin", "CHEMICAL", 104, 116], ["CO", "CHEMICAL", 138, 140], ["HepG2 cell line", "CELL", 4, 19], ["FBS", "ORGANISM_SUBSTANCE", 80, 83], ["penicillin", "SIMPLE_CHEMICAL", 88, 98], ["streptomycin", "SIMPLE_CHEMICAL", 104, 116], ["LPS", "SIMPLE_CHEMICAL", 153, 156], ["LPS", "SIMPLE_CHEMICAL", 205, 208], ["HepG2 cell line", "CELL_LINE", 4, 19], ["The HepG2 cell line", "TREATMENT", 0, 19], ["the 1 g/ L L-glutamine DMEM medium", "TREATMENT", 36, 70], ["10% FBS", "TREATMENT", 76, 83], ["penicillin", "TREATMENT", 88, 98], ["streptomycin", "TREATMENT", 104, 116], ["LPS stimulation", "TREATMENT", 153, 168], ["LPS", "TREATMENT", 205, 208], ["HepG2", "ANATOMY", 4, 9], ["cell line", "OBSERVATION", 10, 19]]], ["34 CD98 siRNA specific downregulation was performed following the oligofectamine transfection procedure.", [["CD98", "GENE_OR_GENE_PRODUCT", 3, 7], ["CD98", "PROTEIN", 3, 7], ["CD98 siRNA specific downregulation", "TREATMENT", 3, 37], ["the oligofectamine transfection procedure", "TREATMENT", 62, 103]]], ["Briefly, serum-free medium (SFM) was gently mixed with oligofectamine and let for incubation at room temperature for 5 min.", [["serum", "ANATOMY", 9, 14], ["oligofectamine", "CHEMICAL", 55, 69], ["oligofectamine", "CHEMICAL", 55, 69], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["oligofectamine", "SIMPLE_CHEMICAL", 55, 69], ["serum", "TEST", 9, 14], ["oligofectamine", "TREATMENT", 55, 69]]], ["The diluted CD98 siRNA was combined to the mix oligofectamine/SFM and incubated for 15 min at room temperature to form a complex.", [["oligofectamine", "CHEMICAL", 47, 61], ["oligofectamine", "CHEMICAL", 47, 61], ["CD98", "GENE_OR_GENE_PRODUCT", 12, 16], ["CD98", "PROTEIN", 12, 16], ["The diluted CD98 siRNA", "TREATMENT", 0, 22], ["the mix oligofectamine/SFM", "TREATMENT", 39, 65], ["CD98 siRNA", "OBSERVATION", 12, 22]]], ["The complex was then added into the cells for a 4 h incubation at 37\u00b0C (the final concentration of siRNA is 100 nM).", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["a 4 h incubation", "TREATMENT", 46, 62], ["the final concentration of siRNA", "TREATMENT", 72, 104], ["complex", "OBSERVATION_MODIFIER", 4, 11]]], ["After the 4 h incubation, the reaction was stopped by adding concentrated FBS to reach a final concentration of 10% of FBS in the medium.\u25a0 CONCLUSIONSIsolation of the Garlic-Derived Nanovesicles (GDVs).", [["FBS", "ANATOMY", 74, 77], ["FBS", "ANATOMY", 119, 122], ["FBS", "ORGANISM_SUBSTANCE", 74, 77], ["FBS", "ORGANISM_SUBSTANCE", 119, 122], ["Garlic-Derived Nanovesicles", "PROTEIN", 167, 194], ["Garlic", "SPECIES", 167, 173], ["the reaction", "PROBLEM", 26, 38], ["concentrated FBS", "TREATMENT", 61, 77], ["FBS in the medium", "TREATMENT", 119, 136]]], ["Garlic was washed three times with 1\u00d7 PBS buffer and then was homogenized using a blender with precold PBS (4\u00b0C).", [["Garlic", "ORGANISM", 0, 6], ["Garlic", "SPECIES", 0, 6], ["Garlic", "TREATMENT", 0, 6], ["PBS buffer", "TREATMENT", 38, 48], ["a blender", "TREATMENT", 80, 89], ["precold PBS", "TREATMENT", 95, 106]]], ["The collected juice was centrifuged according to a multistep procedure optimized in our laboratory to get GDVs.", [["juice", "ANATOMY", 14, 19], ["juice", "ORGANISM_SUBSTANCE", 14, 19], ["The collected juice", "TREATMENT", 0, 19], ["a multistep procedure", "TREATMENT", 49, 70]]], ["The pellet was washed with cold PBS three times and resuspended in PBS.", [["pellet", "ANATOMY", 4, 10], ["cold PBS", "TREATMENT", 27, 35], ["pellet", "OBSERVATION", 4, 10]]], ["The size was detected using the dynamic light scattering (DLS) method, atomic force microscopy (AFM), and transmission electron microscopy (TEM).", [["atomic force microscopy", "TEST", 71, 94], ["transmission electron microscopy", "TEST", 106, 138], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["The \u03b6-potential was measured by Malvern nano ZS90.\u25a0 CONCLUSIONSDigest the Surface Protein of GDVs.", [["GDVs", "PROTEIN", 93, 97], ["GDVs", "TEST", 93, 97]]], ["The concentration of the GDVs was calculated by the total protein concentration using the detergent compatible (DC) assay (BIORAD, Hercules, CA).", [["DC", "ANATOMY", 112, 114], ["GDVs", "SIMPLE_CHEMICAL", 25, 29], ["the total protein concentration", "TREATMENT", 48, 79], ["the detergent", "TREATMENT", 86, 99], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["GDVs were incubated with trypsin (0.25%, Corning) at a mass ratio of 2:1 at 37\u00b0C for 1, 2, 3, and 4 h.", [["GDVs", "SIMPLE_CHEMICAL", 0, 4], ["trypsin", "SIMPLE_CHEMICAL", 25, 32], ["trypsin", "PROTEIN", 25, 32], ["trypsin", "TREATMENT", 25, 32], ["a mass ratio", "TEST", 53, 65]]], ["After digestion, the pellets were collected by ultracentrifugation at 120 000g for 2 h.", [["the pellets", "TREATMENT", 17, 28]]], ["The pellet was washed with cold PBS three times and resuspended with 1\u00d7 PBS and labeled as T1, T2, T3, and T4 GDVs, respectively, for 1, 2, 3, and 4 h of enzymatic digestion.", [["cold PBS", "TREATMENT", 27, 35], ["PBS", "TEST", 72, 75], ["T1", "TEST", 91, 93], ["T2", "TEST", 95, 97], ["T3", "TEST", 99, 101], ["enzymatic digestion", "PROBLEM", 154, 173], ["pellet", "OBSERVATION", 4, 10], ["T3", "ANATOMY", 99, 101], ["T4", "ANATOMY", 107, 109], ["enzymatic digestion", "OBSERVATION", 154, 173]]], ["The cells (treated or not) were lysed with radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, Roche phoSTOP, and EDTA-free protease tablets).", [["cells", "ANATOMY", 4, 9], ["NaCl", "CHEMICAL", 96, 100], ["Triton X-100", "CHEMICAL", 107, 119], ["sodium deoxycholate", "CHEMICAL", 126, 145], ["NaCl", "CHEMICAL", 96, 100], ["sodium deoxycholate", "CHEMICAL", 126, 145], ["EDTA", "CHEMICAL", 195, 199], ["cells", "CELL", 4, 9], ["Triton X-100", "SIMPLE_CHEMICAL", 107, 119], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 126, 145], ["Roche phoSTOP", "SIMPLE_CHEMICAL", 176, 189], ["EDTA", "SIMPLE_CHEMICAL", 195, 199], ["radioimmunoprecipitation assay", "TEST", 43, 73], ["NaCl", "TEST", 96, 100], ["0.5% sodium deoxycholate", "TREATMENT", 121, 145], ["Tris pH", "TEST", 163, 170], ["Roche phoSTOP", "TEST", 176, 189], ["EDTA-free protease tablets", "TREATMENT", 195, 221]]], ["The concentration of protein was analyzed using the DC assay.", [["DC", "ANATOMY", 52, 54], ["DC", "CELL_TYPE", 52, 54], ["The concentration of protein", "TREATMENT", 0, 28], ["the DC assay", "TEST", 48, 60]]], ["The samples were loaded into the 4\u221220% SDS-PAGE and transferred the samples to a nitrocellulose membrane.", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 68, 75], ["membrane", "ANATOMY", 96, 104], ["SDS-PAGE", "CHEMICAL", 39, 47], ["SDS", "CHEMICAL", 39, 42], ["nitrocellulose", "CHEMICAL", 81, 95], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["The samples", "TEST", 0, 11], ["a nitrocellulose membrane", "TREATMENT", 79, 104]]], ["After 1 h blocking, the membrane was incubated with the primary antibody at room temperature for 2 h.", [["membrane", "ANATOMY", 24, 32], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["primary antibody", "PROTEIN", 56, 72]]], ["The membrane was washed with TBST buffer for three times.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["TBST buffer", "TREATMENT", 29, 40], ["membrane", "OBSERVATION_MODIFIER", 4, 12]]], ["The membrane was incubated with the secondary antibody for 1 h at room temperature.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["secondary antibody", "PROTEIN", 36, 54]]], ["Primary antibodies CD98, \u03b2-actin, and GAPDH were diluted in 1:1000, and the secondary antibodies goat anti-Rabbit IgG (H + L) ads-HRP and goat anti-Mouse IgG (H + L) HRP conjugate were diluted at 1:5000.", [["CD98", "GENE_OR_GENE_PRODUCT", 19, 23], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 25, 32], ["GAPDH", "GENE_OR_GENE_PRODUCT", 38, 43], ["goat", "ORGANISM", 97, 101], ["H + L", "SIMPLE_CHEMICAL", 119, 124], ["HRP", "SIMPLE_CHEMICAL", 130, 133], ["goat", "ORGANISM", 138, 142], ["anti-Mouse IgG", "SIMPLE_CHEMICAL", 143, 157], ["H + L) HRP conjugate", "SIMPLE_CHEMICAL", 159, 179], ["Primary antibodies", "PROTEIN", 0, 18], ["CD98", "PROTEIN", 19, 23], ["\u03b2-actin", "PROTEIN", 25, 32], ["GAPDH", "PROTEIN", 38, 43], ["secondary antibodies", "PROTEIN", 76, 96], ["goat anti-Rabbit IgG (H + L) ads-HRP", "PROTEIN", 97, 133], ["goat anti-Mouse IgG (H + L) HRP conjugate", "PROTEIN", 138, 179], ["goat", "SPECIES", 97, 101], ["goat", "SPECIES", 138, 142], ["goat", "SPECIES", 97, 101], ["goat", "SPECIES", 138, 142], ["Primary antibodies CD98", "TEST", 0, 23], ["\u03b2-actin", "TEST", 25, 32], ["GAPDH", "TEST", 38, 43], ["the secondary antibodies", "TEST", 72, 96], ["anti-Rabbit IgG", "TEST", 102, 117], ["HRP", "TEST", 130, 133], ["goat anti-Mouse IgG", "TEST", 138, 157], ["HRP conjugate", "TREATMENT", 166, 179]]], ["The films were developed using a SERIES 2000 A Processor film developer.\u25a0 CONCLUSIONSMTT Assay.", [["The films", "TEST", 0, 9], ["A Processor film", "TEST", 45, 61], ["CONCLUSIONSMTT Assay", "TEST", 74, 94]]], ["To assess the potential toxicity of GDVs and digested GDVs, MTT assays were performed.", [["toxicity", "DISEASE", 24, 32], ["GDVs", "CHEMICAL", 36, 40], ["MTT", "CHEMICAL", 60, 63], ["GDVs", "SIMPLE_CHEMICAL", 36, 40], ["GDVs", "SIMPLE_CHEMICAL", 54, 58], ["the potential toxicity of GDVs", "PROBLEM", 10, 40], ["digested GDVs", "PROBLEM", 45, 58], ["MTT assays", "TEST", 60, 70]]], ["The HepG2 cells were seeded in 96-well plates at a density of 5 \u00d7 10 5 cells/ well and exposed to 100 \u03bcg/mL GDVs for 24 h.", [["HepG2 cells", "ANATOMY", 4, 15], ["cells", "ANATOMY", 71, 76], ["HepG2 cells", "CELL", 4, 15], ["cells", "CELL", 71, 76], ["HepG2 cells", "CELL_LINE", 4, 15], ["The HepG2 cells", "TEST", 0, 15], ["HepG2", "ANATOMY", 4, 9]]], ["The 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added to the wells for 4 h incubation and was reduced by the metabolically active cells to form the purple formazan dye crystals.", [["cells", "ANATOMY", 156, 161], ["3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide", "CHEMICAL", 4, 63], ["MTT", "CHEMICAL", 65, 68], ["formazan", "CHEMICAL", 181, 189], ["3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide", "CHEMICAL", 4, 63], ["MTT", "CHEMICAL", 65, 68], ["formazan", "CHEMICAL", 181, 189], ["3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 4, 63], ["MTT", "SIMPLE_CHEMICAL", 65, 68], ["cells", "CELL", 156, 161], ["formazan dye crystals", "SIMPLE_CHEMICAL", 181, 202], ["4,5dimethylthiazol", "TREATMENT", 7, 25], ["diphenyltetrazolium bromide (MTT)", "TREATMENT", 36, 69], ["the purple formazan dye crystals", "PROBLEM", 170, 202], ["purple", "OBSERVATION_MODIFIER", 174, 180], ["formazan dye crystals", "OBSERVATION", 181, 202]]], ["The detergent solution was then added to the wells, solubilizing the crystals, so the absorbance can be read using a spectrophotometer.", [["The detergent solution", "TREATMENT", 0, 22], ["solubilizing the crystals", "TREATMENT", 52, 77], ["a spectrophotometer", "TREATMENT", 115, 134]]], ["The wavelength for measuring the absorbance of the formazan product was 570 nm.", [["formazan", "CHEMICAL", 51, 59], ["formazan", "CHEMICAL", 51, 59], ["formazan", "SIMPLE_CHEMICAL", 51, 59], ["The wavelength", "TREATMENT", 0, 14], ["the formazan product", "TREATMENT", 47, 67], ["wavelength", "OBSERVATION_MODIFIER", 4, 14]]], ["Nontreated cells (controls) were set to 100% viability.\u25a0 CONCLUSIONSCell Uptake Assay.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["CONCLUSIONSCell Uptake Assay", "TEST", 57, 85], ["Uptake Assay", "OBSERVATION", 73, 85]]], ["GDVs (100 \u03bcg) were incubated with 1 \u03bcM coumarin-6 at room temperature for 30 min and then the pellets were collected by ultracentrifugation with three times of wash.", [["GDVs", "CHEMICAL", 0, 4], ["coumarin-6", "CHEMICAL", 39, 49], ["GDVs", "CHEMICAL", 0, 4], ["coumarin", "CHEMICAL", 39, 47], ["GDVs", "SIMPLE_CHEMICAL", 0, 4], ["GDVs", "TEST", 0, 4], ["1 \u03bcM coumarin", "TREATMENT", 34, 47], ["the pellets", "TREATMENT", 90, 101]]], ["The labeled GDVs were resuspended in cold PBS buffer and incubated with the HepG2 cells at 37 or 4\u00b0C.\u25a0 CONCLUSIONSUptake study was conducted by treating the HepG2 cells a concentration of 100 \u03bcg/mL labeled GDVs for 1 to 6 h.", [["GDVs", "ANATOMY", 12, 16], ["HepG2 cells", "ANATOMY", 76, 87], ["HepG2 cells", "ANATOMY", 157, 168], ["GDVs", "SIMPLE_CHEMICAL", 12, 16], ["HepG2 cells", "CELL", 76, 87], ["HepG2 cells", "CELL", 157, 168], ["HepG2 cells", "CELL_LINE", 76, 87], ["HepG2 cells", "CELL_LINE", 157, 168], ["The labeled GDVs", "TREATMENT", 0, 16], ["cold PBS buffer", "TREATMENT", 37, 52], ["the HepG2 cells", "TREATMENT", 72, 87], ["CONCLUSIONSUptake study", "TEST", 103, 126], ["the HepG2 cells", "TREATMENT", 153, 168]]], ["The blocking test was carried by preincubating HepG2 with 10 \u03bcg/ mL CD98 antibody for 1 h before incubation with GDVs for 2 h.", [["HepG2", "ANATOMY", 47, 52], ["HepG2", "CELL", 47, 52], ["CD98", "GENE_OR_GENE_PRODUCT", 68, 72], ["HepG2", "CELL_LINE", 47, 52], ["CD98 antibody", "PROTEIN", 68, 81], ["The blocking test", "TEST", 0, 17], ["GDVs", "TREATMENT", 113, 117]]], ["58, 59 GDVs were incubated with carbohydrates for 30 min before the uptake assay.", [["GDVs", "ANATOMY", 7, 11], ["carbohydrates", "CHEMICAL", 32, 45], ["GDVs", "CELL", 7, 11], ["carbohydrates", "SIMPLE_CHEMICAL", 32, 45], ["carbohydrates", "TREATMENT", 32, 45], ["the uptake assay", "TEST", 64, 80]]], ["12 The carbohydrates were D-glucose, D-mannose, D-galactose, D-fructose, N-acetylglucosamine, lactose, and maltose.", [["D-glucose", "CHEMICAL", 26, 35], ["D-mannose", "CHEMICAL", 37, 46], ["D-galactose", "CHEMICAL", 48, 59], ["D-fructose", "CHEMICAL", 61, 71], ["N-acetylglucosamine", "CHEMICAL", 73, 92], ["lactose", "CHEMICAL", 94, 101], ["maltose", "CHEMICAL", 107, 114], ["carbohydrates", "CHEMICAL", 7, 20], ["D-glucose", "CHEMICAL", 26, 35], ["D-mannose", "CHEMICAL", 37, 46], ["D-galactose", "CHEMICAL", 48, 59], ["D-fructose", "CHEMICAL", 61, 71], ["N-acetylglucosamine", "CHEMICAL", 73, 92], ["lactose", "CHEMICAL", 94, 101], ["maltose", "CHEMICAL", 107, 114], ["carbohydrates", "SIMPLE_CHEMICAL", 7, 20], ["D-glucose", "SIMPLE_CHEMICAL", 26, 35], ["D-mannose", "SIMPLE_CHEMICAL", 37, 46], ["D-galactose", "SIMPLE_CHEMICAL", 48, 59], ["D-fructose", "SIMPLE_CHEMICAL", 61, 71], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 73, 92], ["lactose", "SIMPLE_CHEMICAL", 94, 101], ["maltose", "SIMPLE_CHEMICAL", 107, 114], ["The carbohydrates", "TEST", 3, 20], ["D-mannose", "TEST", 37, 46], ["D-fructose", "TREATMENT", 61, 71], ["acetylglucosamine", "TREATMENT", 75, 92], ["lactose", "TREATMENT", 94, 101], ["maltose", "TREATMENT", 107, 114]]], ["The results of uptake were visualized and analyzed by immunofluorescence microscopy and flow cytometry described below.\u25a0 CONCLUSIONSImmunofluorescence Microscopy.", [["immunofluorescence microscopy", "TEST", 54, 83], ["flow cytometry", "TEST", 88, 102], ["CONCLUSIONSImmunofluorescence Microscopy", "TEST", 121, 161]]], ["For CD98 staining, the cells were fixed with 4% paraformaldehyde for 15 min at room temperature.", [["cells", "ANATOMY", 23, 28], ["paraformaldehyde", "CHEMICAL", 48, 64], ["CD98", "GENE_OR_GENE_PRODUCT", 4, 8], ["cells", "CELL", 23, 28], ["paraformaldehyde", "SIMPLE_CHEMICAL", 48, 64], ["CD98", "PROTEIN", 4, 8], ["CD98 staining", "PROBLEM", 4, 17], ["4% paraformaldehyde", "TREATMENT", 45, 64]]], ["Then, the chamber slides were washed three times using the Dulbecco's phosphate-buffered saline (DPBS).", [["phosphate", "CHEMICAL", 70, 79], ["phosphate", "CHEMICAL", 70, 79], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 70, 95], ["the chamber slides", "TREATMENT", 6, 24], ["the Dulbecco's phosphate", "TREATMENT", 55, 79], ["buffered saline (DPBS", "TREATMENT", 80, 101]]], ["The cells were incubated with 5% BSA for 1 h at room temperature (blocking solution).", [["cells", "ANATOMY", 4, 9], ["BSA", "CHEMICAL", 33, 36], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 33, 36], ["5% BSA", "TREATMENT", 30, 36], ["blocking solution", "TREATMENT", 66, 83]]], ["Then, the cells were incubated with CD98 (1:1000 containing 1% BSA and 0.01% of Tween-20) antibody overnight at 4\u00b0C. The cells were washed three times and incubated with the anti-rabbit IgG (1:4000) for 1 h at room temperature.", [["cells", "ANATOMY", 10, 15], ["cells", "ANATOMY", 121, 126], ["Tween-20", "CHEMICAL", 80, 88], ["Tween-20", "CHEMICAL", 80, 88], ["cells", "CELL", 10, 15], ["CD98", "GENE_OR_GENE_PRODUCT", 36, 40], ["BSA", "SIMPLE_CHEMICAL", 63, 66], ["Tween-20", "SIMPLE_CHEMICAL", 80, 88], ["cells", "CELL", 121, 126], ["CD98", "PROTEIN", 36, 40], ["anti-rabbit IgG", "PROTEIN", 174, 189], ["anti-rabbit", "SPECIES", 174, 185], ["anti-rabbit", "SPECIES", 174, 185], ["CD98", "TEST", 36, 40], ["BSA", "TEST", 63, 66], ["Tween", "TEST", 80, 85], ["antibody", "TEST", 90, 98], ["The cells", "TREATMENT", 117, 126], ["the anti-rabbit IgG", "TREATMENT", 170, 189]]], ["After three washes with the DPBS, the cells were stained with DAPI for 5 min.", [["cells", "ANATOMY", 38, 43], ["DAPI", "CHEMICAL", 62, 66], ["cells", "CELL", 38, 43], ["DAPI", "SIMPLE_CHEMICAL", 62, 66], ["the DPBS", "TREATMENT", 24, 32], ["DAPI", "TREATMENT", 62, 66], ["cells", "ANATOMY", 38, 43]]], ["Finally, the cells were washed with DPBS for three times and sealed with the Prolong Gold Antifade Reagent.\u25a0 CONCLUSIONSAfter the uptake incubation, the medium was removed and the cells were washed with DPBS three times.", [["cells", "ANATOMY", 13, 18], ["cells", "ANATOMY", 180, 185], ["cells", "CELL", 13, 18], ["cells", "CELL", 180, 185], ["DPBS", "TREATMENT", 36, 40], ["the Prolong Gold Antifade Reagent", "TREATMENT", 73, 106], ["the uptake incubation", "TREATMENT", 126, 147], ["DPBS", "TREATMENT", 203, 207], ["uptake incubation", "OBSERVATION", 130, 147], ["medium", "OBSERVATION_MODIFIER", 153, 159]]], ["The cells were fixed with 4% paraformaldehyde for 15 min at room temperature.", [["cells", "ANATOMY", 4, 9], ["paraformaldehyde", "CHEMICAL", 29, 45], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 29, 45], ["4% paraformaldehyde", "TREATMENT", 26, 45]]], ["Then, the slides were washed three times and incubated with the Alexa Fluor 568 phalloidin (1:1000) for 1 h at room temperature.", [["Alexa Fluor 568 phalloidin", "CHEMICAL", 64, 90], ["Alexa Fluor 568 phalloidin", "CHEMICAL", 64, 90], ["Fluor 568 phalloidin", "SIMPLE_CHEMICAL", 70, 90], ["Alexa Fluor 568 phalloidin", "SPECIES", 64, 90], ["the Alexa Fluor", "TREATMENT", 60, 75]]], ["The cells were stained with DAPI for 5 min.", [["cells", "ANATOMY", 4, 9], ["DAPI", "CHEMICAL", 28, 32], ["cells", "CELL", 4, 9], ["DAPI", "SIMPLE_CHEMICAL", 28, 32], ["DAPI", "TREATMENT", 28, 32]]], ["Finally, the cells were washed with DPBS three times and sealed with the Prolong Gold Antifade Reagent for fluorescent microscopy.\u25a0 CONCLUSIONSFlow Cytometry.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["DPBS", "TREATMENT", 36, 40], ["fluorescent microscopy", "TEST", 107, 129], ["CONCLUSIONSFlow Cytometry", "TEST", 132, 157]]], ["After the incubation with GDVs, the growth medium was removed and the cells were washed with DPBS for three times.", [["cells", "ANATOMY", 70, 75], ["GDVs", "SIMPLE_CHEMICAL", 26, 30], ["cells", "CELL", 70, 75], ["DPBS", "SIMPLE_CHEMICAL", 93, 97], ["the incubation", "TREATMENT", 6, 20], ["GDVs", "TREATMENT", 26, 30], ["the growth medium", "TREATMENT", 32, 49], ["the cells", "TREATMENT", 66, 75], ["DPBS", "TREATMENT", 93, 97]]], ["The cells were fixed with 4% paraformaldehyde acid (PFA) for 10 min at room temperature.", [["cells", "ANATOMY", 4, 9], ["paraformaldehyde acid", "CHEMICAL", 29, 50], ["PFA", "CHEMICAL", 52, 55], ["paraformaldehyde acid", "CHEMICAL", 29, 50], ["PFA", "CHEMICAL", 52, 55], ["cells", "CELL", 4, 9], ["paraformaldehyde acid", "SIMPLE_CHEMICAL", 29, 50], ["PFA", "SIMPLE_CHEMICAL", 52, 55], ["The cells", "TREATMENT", 0, 9], ["4% paraformaldehyde acid (PFA", "TREATMENT", 26, 55]]], ["At the end, the cells were resuspended in PBS with 5% FBS.", [["cells", "ANATOMY", 16, 21], ["FBS", "ANATOMY", 54, 57], ["cells", "CELL", 16, 21], ["FBS", "ORGANISM_SUBSTANCE", 54, 57], ["the cells", "TREATMENT", 12, 21], ["5% FBS", "TREATMENT", 51, 57]]], ["Flow cytometric analysis was performed on a BD LSRFortessa flow cytometer (BD Biosciences), and data were analyzed using FlowJo version 10.", [["Flow cytometric analysis", "TEST", 0, 24], ["BD Biosciences", "TEST", 75, 89], ["FlowJo version", "TREATMENT", 121, 135]]], ["The gate was set using the cells without any treatment (negative control) versus labeled GDVtreated (positive control) cells measured by the fluorescein isothiocyanate (FITC) channel.", [["cells", "ANATOMY", 27, 32], ["cells", "ANATOMY", 119, 124], ["fluorescein isothiocyanate", "CHEMICAL", 141, 167], ["fluorescein isothiocyanate", "CHEMICAL", 141, 167], ["FITC", "CHEMICAL", 169, 173], ["cells", "CELL", 27, 32], ["GDVtreated", "SIMPLE_CHEMICAL", 89, 99], ["cells", "CELL", 119, 124], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 141, 167], ["FITC", "SIMPLE_CHEMICAL", 169, 173], ["GDVtreated (positive control) cells", "CELL_LINE", 89, 124], ["fluorescein isothiocyanate (FITC) channel", "PROTEIN", 141, 182], ["The gate", "TREATMENT", 0, 8], ["the cells", "TREATMENT", 23, 32], ["any treatment", "TREATMENT", 41, 54], ["labeled GDVtreated (positive control) cells", "PROBLEM", 81, 124], ["the fluorescein isothiocyanate (FITC) channel", "TREATMENT", 137, 182]]], ["The intensity of uptake was calculated using the geometric mean of the population (n = 10).\u25a0 CONCLUSIONSQuantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR).", [["intensity", "OBSERVATION_MODIFIER", 4, 13], ["uptake", "OBSERVATION", 17, 23]]], ["Total RNA was extracted from the HepG2 cells using a SpinSmart RNA mini purification kit as per the manufacturer's manual.", [["HepG2 cells", "ANATOMY", 33, 44], ["HepG2 cells", "CELL", 33, 44], ["HepG2 cells", "CELL_LINE", 33, 44], ["Total RNA", "PROBLEM", 0, 9], ["the HepG2 cells", "TREATMENT", 29, 44], ["a SpinSmart RNA", "TREATMENT", 51, 66], ["HepG2", "ANATOMY", 33, 38]]], ["RNA was quantified by a Synergy H1 plate reader (BioTek, Winooski). cDNA was synthesized from the total RNA using cDNA synthesis master mix according to the manufacturer's instructions.", [["RNA", "RNA", 0, 3], ["cDNA", "DNA", 68, 72], ["a Synergy H1 plate", "TREATMENT", 22, 40], ["the total RNA", "TREATMENT", 94, 107], ["cDNA synthesis master mix", "TREATMENT", 114, 139]]], ["Gene-specific cDNAs were quantified by RT-qPCR using a SB-Green qPCR Master Kit.", [["Gene-specific cDNAs", "DNA", 0, 19], ["Gene-specific cDNAs", "TEST", 0, 19]]], ["The GAPDH gene was used as a housekeeping gene in RT-qPCR.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 4, 9], ["GAPDH gene", "DNA", 4, 14], ["housekeeping gene", "DNA", 29, 46], ["The GAPDH gene", "TREATMENT", 0, 14], ["GAPDH gene", "OBSERVATION", 4, 14]]], ["Fold induction was calculated using the C t method: \u0394\u0394Ct = (Ct target gene \u2212 Ct housekeeping gene ) treatment \u2212 (Ct target gene \u2212 Ct housekeeping gene ) nontreatment , and the result was calculated using the formulation 2 \u2212\u0394\u0394Ct .\u25a0 CONCLUSIONSThe primers used for qRT-PCR: IL-6 Fwd: 5\u2032-CAATCTG-G A T T C A A T G A G G A G A C \u2212 3 \u2032 , IL-6 Rvs: 5\u2032 -CTCTGGCTTGTTCCTCACTACTC\u22123\u2032, IFN-\u03b3 Fwd: 5\u2032-GCTTGAATCTAAATTATCAGTC-3\u2032, IFN-\u03b3 Rvs: 5\u2032-GAA-GATTCAAATTGCATCTTTAT-3\u2032.\u25a0 CONCLUSIONSStatistical Analysis.", [["IL-6", "GENE_OR_GENE_PRODUCT", 272, 276], ["IL-6", "GENE_OR_GENE_PRODUCT", 333, 337], ["C t method", "DNA", 40, 50], ["Ct target gene", "DNA", 60, 74], ["Ct housekeeping gene", "DNA", 77, 97], ["Ct target gene", "DNA", 113, 127], ["Ct housekeeping gene", "DNA", 130, 150], ["qRT", "DNA", 263, 266], ["IFN", "PROTEIN", 375, 378], ["IFN", "PROTEIN", 416, 419], ["Fold induction", "TREATMENT", 0, 14], ["the C t method", "TREATMENT", 36, 50], ["\u0394\u0394Ct", "TEST", 52, 56], ["treatment", "TREATMENT", 100, 109], ["the formulation", "TREATMENT", 204, 219], ["CONCLUSIONSThe primers", "TEST", 231, 253], ["qRT", "TEST", 263, 266], ["IL", "TEST", 272, 274], ["Fwd", "TEST", 277, 280], ["CAATCTG", "TEST", 285, 292], ["C", "TEST", 323, 324], ["IL", "TEST", 333, 335], ["Rvs", "TEST", 338, 341], ["CTCTGGCTTGTTCCTCACTACTC", "TEST", 347, 370], ["GCTTGAATCTAAATTATCAGTC", "TEST", 389, 411], ["Rvs", "TEST", 422, 425], ["5\u2032-GAA-GATTCAAATTGCATCTTTAT", "TEST", 427, 454]]], ["Two-way ANOVA analysis was performed to obtain statistical differences among the groups.", [["Two-way ANOVA analysis", "TEST", 0, 22]]], ["The t-test was used for comparison between the two groups and the p-value less than 0.05 was considered as significant.\u25a0 CONCLUSIONSIn-gel digestion and MS experiments, AFM measurement, TEM measurement, the quantitative CD98 expression ( Figure S1 ), and the secondary antibody only immunofluorescent image of the LPS-induced HepG2 cells ( Figure S2 ) (PDF)", [["HepG2 cells", "ANATOMY", 326, 337], ["LPS", "CHEMICAL", 314, 317], ["CD98", "GENE_OR_GENE_PRODUCT", 220, 224], ["LPS", "SIMPLE_CHEMICAL", 314, 317], ["HepG2 cells", "CELL", 326, 337], ["CD98", "PROTEIN", 220, 224], ["LPS-induced HepG2 cells", "CELL_LINE", 314, 337], ["The t-test", "TEST", 0, 10], ["the p-value", "TEST", 62, 73], ["CONCLUSIONSIn", "TEST", 121, 134], ["gel digestion", "PROBLEM", 135, 148], ["MS experiments", "TEST", 153, 167], ["AFM measurement", "TEST", 169, 184], ["TEM measurement", "TEST", 186, 201], ["the secondary antibody", "TEST", 255, 277], ["immunofluorescent image", "TEST", 283, 306], ["the LPS", "TEST", 310, 317], ["induced HepG2 cells", "PROBLEM", 318, 337], ["HepG2", "ANATOMY", 326, 331]]]], "PMC7392194": [["IntroductionAt the end of 2019, the first cases of coronavirus disease were reported in the Chinese city of Wuhan.", [["coronavirus disease", "DISEASE", 51, 70], ["coronavirus", "ORGANISM", 51, 62], ["coronavirus disease", "PROBLEM", 51, 70], ["coronavirus disease", "OBSERVATION", 51, 70]]], ["Acute respiratory tract inflammation caused by SARS-CoV-2 is an infectious disease, often fatal, that is characterized by the rapid and unexpected spread.", [["respiratory tract", "ANATOMY", 6, 23], ["respiratory tract inflammation", "DISEASE", 6, 36], ["SARS", "DISEASE", 47, 51], ["infectious disease", "DISEASE", 64, 82], ["tract", "ORGANISM_SUBDIVISION", 18, 23], ["SARS-CoV-2", "ORGANISM", 47, 57], ["SARS-CoV-2", "SPECIES", 47, 57], ["Acute respiratory tract inflammation", "PROBLEM", 0, 36], ["SARS", "PROBLEM", 47, 51], ["an infectious disease", "PROBLEM", 61, 82], ["the rapid and unexpected spread", "PROBLEM", 122, 153], ["respiratory tract", "ANATOMY", 6, 23], ["inflammation", "OBSERVATION", 24, 36], ["SARS", "OBSERVATION", 47, 51], ["CoV", "OBSERVATION_MODIFIER", 52, 55], ["infectious", "OBSERVATION_MODIFIER", 64, 74], ["disease", "OBSERVATION", 75, 82], ["fatal", "OBSERVATION_MODIFIER", 90, 95], ["rapid", "OBSERVATION_MODIFIER", 126, 131], ["spread", "OBSERVATION_MODIFIER", 147, 153]]], ["In response to a series of virus outbreaks in other countries and continents, the World Health Organization (WHO) announced the Covid-19 pandemic on March 11 (L. T. F. Ho et al., 2020).", [["virus outbreaks", "PROBLEM", 27, 42]]], ["By July 14, WHO had reported 12 964 809 confirmed cases in 213 countries around the world, of which 4.40% were confirmed deaths.", [["deaths", "DISEASE", 121, 127]]], ["Figure 1shows the number of reported Covid-19 cases from January 11 to July 14, 2020 for individual WHO regions (Europe, the Americas, the West Pacific, the Eastern Mediterranean, Southeast Asia and Africa).IntroductionChina was the first epicenter of Covid-19.", [["Covid", "TEST", 37, 42], ["Covid", "TEST", 252, 257]]], ["At present, the Americas and Europe are struggling the most with the pandemic of Covid-19.", [["Covid", "TEST", 81, 86]]], ["By July 14, 3 286 063 coronavirus infections have been reported in the United States of America (39 times more than in China).", [["coronavirus infections", "DISEASE", 22, 44], ["coronavirus", "ORGANISM", 22, 33], ["coronavirus infections", "PROBLEM", 22, 44], ["infections", "OBSERVATION", 34, 44]]], ["In the Middle East, Iran and Turkey have also seen a significant sustained increase in particular infected with Covid-19 (259 652 and 214 001, respectively) (WHO, 2020).IntroductionThe actual number of infected is probably much higher due to asymptomatic cases that may contribute to the development of the pandemic.", [["increase in particular infected", "DISEASE", 75, 106], ["asymptomatic cases", "PROBLEM", 242, 260], ["the pandemic", "PROBLEM", 303, 315], ["Middle", "ANATOMY_MODIFIER", 7, 13], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["sustained", "OBSERVATION_MODIFIER", 65, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["infected", "OBSERVATION", 202, 210], ["pandemic", "OBSERVATION", 307, 315]]], ["Restrictions, such as the use of personal protective equipment (masks, gloves, antibacterial gels), self-isolation or quarantine, and even border closing to reduce the number of cases have been introduced in several countries.It is not known how long this situation will continue.", [["personal protective equipment (masks", "TREATMENT", 33, 69], ["gloves, antibacterial gels", "TREATMENT", 71, 97], ["self-isolation", "TREATMENT", 100, 114], ["quarantine", "TREATMENT", 118, 128], ["not known", "UNCERTAINTY", 232, 241]]], ["Perhaps Covid-19 will turn out to be a seasonal virus and, like flu, there will be a significant decrease in infected people in the summer season.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["Covid", "TEST", 8, 13], ["a seasonal virus", "PROBLEM", 37, 53], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["decrease", "OBSERVATION_MODIFIER", 97, 105], ["infected", "OBSERVATION", 109, 117]]], ["This would allow for better preparation for the next wave of the illness.", [["illness", "DISEASE", 65, 72], ["the illness", "PROBLEM", 61, 72]]], ["Be it as it may, the persistent state can lead to significant economic losses in all countries around the world, even those not affected by the virus.", [["significant economic losses", "PROBLEM", 50, 77], ["the virus", "PROBLEM", 140, 149], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["economic", "OBSERVATION_MODIFIER", 62, 70], ["losses", "OBSERVATION", 71, 77], ["virus", "OBSERVATION", 144, 149]]], ["There are several scenarios for the progression of the pandemic, but there are still many unknowns (Johnson et al., 2020).", [["the pandemic", "PROBLEM", 51, 63], ["several", "OBSERVATION_MODIFIER", 10, 17], ["scenarios", "OBSERVATION", 18, 27], ["progression", "OBSERVATION_MODIFIER", 36, 47]]], ["Therefore, understanding how the virus operates and spreads is crucial in finding drugs or vaccines to fight SARS-CoV-2 infection.IntroductionSARS-CoV-2 is RNA virus, the genome sequence of which shows only moderate homology to other known coronaviruses.", [["SARS-CoV-2 infection", "DISEASE", 109, 129], ["SARS-CoV-2", "ORGANISM", 109, 119], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 152], ["coronaviruses", "ORGANISM", 240, 253], ["IntroductionSARS-CoV-2", "DNA", 130, 152], ["SARS-CoV-2", "SPECIES", 109, 119], ["the virus", "PROBLEM", 29, 38], ["vaccines", "TREATMENT", 91, 99], ["fight SARS", "PROBLEM", 103, 113], ["CoV-2 infection", "PROBLEM", 114, 129], ["IntroductionSARS", "TEST", 130, 146], ["CoV", "TEST", 147, 150], ["RNA virus", "PROBLEM", 156, 165], ["the genome sequence", "TEST", 167, 186], ["moderate homology to other known coronaviruses", "PROBLEM", 207, 253], ["infection", "OBSERVATION", 120, 129], ["coronaviruses", "OBSERVATION", 240, 253]]], ["The viral genome encodes a protease, which plays a crucial role in the production of viral proteins and controlling the activity of the replicase complex.", [["viral genome", "DNA", 4, 16], ["protease", "PROTEIN", 27, 35], ["viral proteins", "PROTEIN", 85, 99], ["replicase complex", "PROTEIN", 136, 153], ["a protease", "TREATMENT", 25, 35], ["viral proteins", "TREATMENT", 85, 99], ["viral genome", "OBSERVATION", 4, 16], ["viral proteins", "OBSERVATION", 85, 99]]], ["This enzyme is necessary for virus replication and infection, making it a perfect target for designing antiviral therapies.", [["infection", "DISEASE", 51, 60], ["This enzyme", "TEST", 0, 11], ["virus replication", "PROBLEM", 29, 46], ["infection", "PROBLEM", 51, 60], ["designing antiviral therapies", "TREATMENT", 93, 122], ["infection", "OBSERVATION", 51, 60]]], ["Acute respiratory syndrome (SARS-CoV) coronavirus enzymes are one of the most promising targets for the discovery of anti-SARS drugs because of its key role in the life cycle of the virus.", [["Acute respiratory syndrome (SARS-CoV) coronavirus", "DISEASE", 0, 49], ["SARS-CoV", "ORGANISM", 28, 36], ["coronavirus enzymes", "PROTEIN", 38, 57], ["SARS-CoV) coronavirus", "SPECIES", 28, 49], ["Acute respiratory syndrome", "PROBLEM", 0, 26], ["SARS-CoV) coronavirus enzymes", "PROBLEM", 28, 57], ["anti-SARS drugs", "TREATMENT", 117, 132], ["the virus", "PROBLEM", 178, 187], ["respiratory syndrome", "OBSERVATION", 6, 26]]], ["Natural inhibitors like betulinic acid, indigo, aloeemodine, luteolin, and quinomethyl triterpenoids, quercitin or gallates can be effective as antiviral preparations (Nguyen et al., 2012, Ryu et al., 2010).", [["betulinic acid", "CHEMICAL", 24, 38], ["indigo", "CHEMICAL", 40, 46], ["aloeemodine", "CHEMICAL", 48, 59], ["luteolin", "CHEMICAL", 61, 69], ["quinomethyl triterpenoids", "CHEMICAL", 75, 100], ["quercitin", "CHEMICAL", 102, 111], ["gallates", "CHEMICAL", 115, 123], ["betulinic acid", "CHEMICAL", 24, 38], ["indigo", "CHEMICAL", 40, 46], ["aloeemodine", "CHEMICAL", 48, 59], ["luteolin", "CHEMICAL", 61, 69], ["quinomethyl triterpenoids", "CHEMICAL", 75, 100], ["quercitin or gallates", "CHEMICAL", 102, 123], ["betulinic acid", "SIMPLE_CHEMICAL", 24, 38], ["indigo", "SIMPLE_CHEMICAL", 40, 46], ["aloeemodine", "SIMPLE_CHEMICAL", 48, 59], ["luteolin", "SIMPLE_CHEMICAL", 61, 69], ["quinomethyl triterpenoids", "SIMPLE_CHEMICAL", 75, 100], ["quercitin", "SIMPLE_CHEMICAL", 102, 111], ["gallates", "SIMPLE_CHEMICAL", 115, 123], ["Natural inhibitors", "TREATMENT", 0, 18], ["betulinic acid", "TREATMENT", 24, 38], ["indigo", "TREATMENT", 40, 46], ["aloeemodine", "TREATMENT", 48, 59], ["luteolin", "TREATMENT", 61, 69], ["quinomethyl triterpenoids", "TREATMENT", 75, 100], ["quercitin", "TREATMENT", 102, 111], ["gallates", "TREATMENT", 115, 123], ["antiviral preparations", "TREATMENT", 144, 166]]], ["These substances act through the mechanism of enzyme inhibition.", [["enzyme inhibition", "TREATMENT", 46, 63]]], ["Enzymatic tests have shown that these natural molecules have IC50 values \u200b\u200bwithin the range from 3 to 300 \u00b5M.", [["Enzymatic tests", "TEST", 0, 15], ["IC50 values", "TEST", 61, 72]]], ["The studies were conducted on early SARS-CoV 3CLpro.", [["SARS-CoV 3CLpro", "SPECIES", 36, 51], ["The studies", "TEST", 0, 11], ["CoV 3CLpro", "TREATMENT", 41, 51]]], ["Phytochemicals were isolated from medicinal plants, diterpenoids, biflavonoids - with SARS-CoV 3CLpro inhibitory activity, by obtaining ethanol extracts.", [["extracts", "ANATOMY", 144, 152], ["biflavonoids", "CHEMICAL", 66, 78], ["ethanol", "CHEMICAL", 136, 143], ["diterpenoids", "CHEMICAL", 52, 64], ["biflavonoids", "CHEMICAL", 66, 78], ["ethanol", "CHEMICAL", 136, 143], ["diterpenoids", "SIMPLE_CHEMICAL", 52, 64], ["biflavonoids", "SIMPLE_CHEMICAL", 66, 78], ["SARS-CoV 3CLpro", "SIMPLE_CHEMICAL", 86, 101], ["ethanol extracts", "ORGANISM_SUBSTANCE", 136, 152], ["medicinal plants", "TREATMENT", 34, 50], ["diterpenoids", "TREATMENT", 52, 64], ["biflavonoids", "TREATMENT", 66, 78], ["SARS", "PROBLEM", 86, 90], ["CoV 3CLpro inhibitory activity", "TREATMENT", 91, 121], ["medicinal plants", "OBSERVATION", 34, 50]]], ["Biologically active compounds (quercetin, epigallocatechin gallate and galusatechin gallate (GCG)) showed good inhibition properties by binding to the 3CLpro active site and the 3-OH galooyl group, which was required for virus inhibitory activity (Nguyen et al., 2012).", [["quercetin", "CHEMICAL", 31, 40], ["epigallocatechin gallate", "CHEMICAL", 42, 66], ["galusatechin gallate", "CHEMICAL", 71, 91], ["GCG", "CHEMICAL", 93, 96], ["3-OH", "CHEMICAL", 178, 182], ["galooyl", "CHEMICAL", 183, 190], ["quercetin", "CHEMICAL", 31, 40], ["epigallocatechin gallate", "CHEMICAL", 42, 66], ["galusatechin gallate", "CHEMICAL", 71, 91], ["3-OH galooyl", "CHEMICAL", 178, 190], ["quercetin", "SIMPLE_CHEMICAL", 31, 40], ["epigallocatechin gallate", "SIMPLE_CHEMICAL", 42, 66], ["galusatechin gallate", "SIMPLE_CHEMICAL", 71, 91], ["GCG", "SIMPLE_CHEMICAL", 93, 96], ["3-OH galooyl", "SIMPLE_CHEMICAL", 178, 190], ["3CLpro active site", "PROTEIN", 151, 169], ["virus inhibitory activity", "PROBLEM", 221, 246], ["active", "OBSERVATION_MODIFIER", 13, 19]]], ["Quercetin (Fig. 2a) is a polyhydroxy-flavonoid compound that supports body immunity and occurs in flowers, leaves and fruit of plants.", [["body", "ANATOMY", 70, 74], ["flowers", "ANATOMY", 98, 105], ["leaves", "ANATOMY", 107, 113], ["fruit", "ANATOMY", 118, 123], ["Quercetin", "CHEMICAL", 0, 9], ["polyhydroxy-flavonoid", "CHEMICAL", 25, 46], ["Quercetin", "CHEMICAL", 0, 9], ["polyhydroxy-flavonoid", "CHEMICAL", 25, 46], ["Quercetin", "SIMPLE_CHEMICAL", 0, 9], ["Fig. 2a", "SIMPLE_CHEMICAL", 11, 18], ["polyhydroxy-flavonoid", "SIMPLE_CHEMICAL", 25, 46], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["flowers", "ORGANISM_SUBDIVISION", 98, 105], ["leaves", "ORGANISM_SUBDIVISION", 107, 113], ["fruit", "ORGANISM_SUBDIVISION", 118, 123], ["Quercetin (Fig. 2a", "TREATMENT", 0, 18], ["a polyhydroxy-flavonoid compound", "TREATMENT", 23, 55], ["flavonoid compound", "OBSERVATION", 37, 55]]], ["In turn, gallic acid (Fig. 2b) has antiseptic properties and blocks carcinogenic compounds.IntroductionSARS-CoV-2 is a virus with a genetic structure similar to that of SARS-CoV or MERS-CoV.", [["gallic acid", "CHEMICAL", 9, 20], ["SARS", "DISEASE", 169, 173], ["gallic acid", "CHEMICAL", 9, 20], ["gallic acid", "SIMPLE_CHEMICAL", 9, 20], ["Fig. 2b", "SIMPLE_CHEMICAL", 22, 29], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 91, 113], ["SARS-CoV", "ORGANISM", 169, 177], ["MERS-CoV", "ORGANISM", 181, 189], ["SARS-CoV", "SPECIES", 169, 177], ["MERS-CoV", "SPECIES", 181, 189], ["gallic acid (Fig.", "TREATMENT", 9, 26], ["antiseptic properties", "TREATMENT", 35, 56], ["blocks carcinogenic compounds", "PROBLEM", 61, 90], ["IntroductionSARS", "TEST", 91, 107], ["a virus", "PROBLEM", 117, 124], ["a genetic structure", "PROBLEM", 130, 149], ["SARS", "PROBLEM", 169, 173], ["carcinogenic compounds", "OBSERVATION", 68, 90]]], ["This similarity allowed Chinese scientists to test the possibility of using 26 herbal plants with the potential to inhibit SARS-CoV-2.", [["SARS-CoV-2", "ORGANISM", 123, 133], ["SARS-CoV", "SPECIES", 123, 131], ["26 herbal plants", "TREATMENT", 76, 92]]], ["The active compounds of these plants combined with the virus proteins showed potential antiviral activity (Zhang et al., 2020).IntroductionThe SARS-CoV-2 genome is composed of approximately 30,000 nucleotides (Jin et al., 2020) and codes 16 non-structural and 4 structural proteins, among which some are necessary for entry into the host cell and replication (Jim\u00e9nez-Alberto et al., 2020).", [["cell", "ANATOMY", 338, 342], ["nucleotides", "CHEMICAL", 197, 208], ["SARS-CoV-2", "ORGANISM", 143, 153], ["host cell", "CELL", 333, 342], ["virus proteins", "PROTEIN", 55, 69], ["SARS-CoV-2 genome", "DNA", 143, 160], ["SARS-CoV", "SPECIES", 143, 151], ["these plants", "PROBLEM", 24, 36], ["the virus proteins", "PROBLEM", 51, 69], ["The SARS", "TEST", 139, 147], ["codes 16 non-structural and 4 structural proteins", "PROBLEM", 232, 281], ["active", "OBSERVATION_MODIFIER", 4, 10], ["compounds", "OBSERVATION_MODIFIER", 11, 20], ["antiviral activity", "OBSERVATION", 87, 105], ["host cell", "OBSERVATION", 333, 342]]], ["At the infection stage, the virus attaches itself to the cell with a spike glycoprotein (protein S), which is located in the outer envelope.", [["cell", "ANATOMY", 57, 61], ["outer envelope", "ANATOMY", 125, 139], ["infection", "DISEASE", 7, 16], ["cell", "CELL", 57, 61], ["protein S", "GENE_OR_GENE_PRODUCT", 89, 98], ["outer envelope", "CELLULAR_COMPONENT", 125, 139], ["spike glycoprotein", "PROTEIN", 69, 87], ["protein S", "PROTEIN", 89, 98], ["the infection stage", "PROBLEM", 3, 22], ["the virus attaches", "PROBLEM", 24, 42], ["a spike glycoprotein (protein S", "PROBLEM", 67, 98], ["infection", "OBSERVATION", 7, 16], ["virus", "OBSERVATION", 28, 33], ["cell", "ANATOMY", 57, 61], ["outer", "ANATOMY_MODIFIER", 125, 130], ["envelope", "ANATOMY_MODIFIER", 131, 139]]], ["This protein consists of two subunits, responsible for cell attachment and subsequent fusion (Zhou et al., 2020).", [["cell", "ANATOMY", 55, 59], ["cell", "CELL", 55, 59], ["This protein", "TEST", 0, 12], ["two subunits", "TREATMENT", 25, 37], ["cell attachment", "TREATMENT", 55, 70], ["subsequent fusion", "TREATMENT", 75, 92], ["two subunits", "OBSERVATION_MODIFIER", 25, 37], ["responsible for", "UNCERTAINTY", 39, 54], ["cell attachment", "OBSERVATION", 55, 70]]], ["The target of the binding is the cellular membrane protein, angiotensin-converting enzyme 2 (ACE2).", [["cellular membrane", "ANATOMY", 33, 50], ["angiotensin", "CHEMICAL", 60, 71], ["cellular membrane", "CELLULAR_COMPONENT", 33, 50], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 60, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["cellular membrane protein", "PROTEIN", 33, 58], ["angiotensin-converting enzyme 2", "PROTEIN", 60, 91], ["ACE2", "PROTEIN", 93, 97], ["angiotensin", "TREATMENT", 60, 71]]], ["The ability to bind the virus to the ACE2 membrane receptor is much stronger for SARS-CoV-2 compared to SARS-CoV, which has the same binding site (Liu et al., 2020).", [["membrane", "ANATOMY", 42, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["SARS-CoV", "ORGANISM", 104, 112], ["ACE2 membrane receptor", "PROTEIN", 37, 59], ["SARS-CoV", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 104, 112], ["the ACE2 membrane receptor", "TREATMENT", 33, 59], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89], ["SARS", "PROBLEM", 104, 108]]], ["Protein S is cut by endosomal proteases (cathepsin or serine protease 2 (TMPRSS2)) which results in membrane fusion.", [["endosomal", "ANATOMY", 20, 29], ["membrane", "ANATOMY", 100, 108], ["serine", "CHEMICAL", 54, 60], ["Protein S", "GENE_OR_GENE_PRODUCT", 0, 9], ["cathepsin or serine protease 2", "GENE_OR_GENE_PRODUCT", 41, 71], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 73, 80], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["Protein S", "PROTEIN", 0, 9], ["endosomal proteases", "PROTEIN", 20, 39], ["cathepsin", "PROTEIN", 41, 50], ["serine protease 2", "PROTEIN", 54, 71], ["TMPRSS2", "PROTEIN", 73, 80], ["Protein S", "TEST", 0, 9], ["cathepsin or serine protease", "TREATMENT", 41, 69], ["membrane fusion", "TREATMENT", 100, 115], ["membrane fusion", "OBSERVATION", 100, 115]]], ["Both the receptor itself and the proteases cutting spike protein are potential therapeutic targets (Zhou et al., 2020).", [["proteases", "PROTEIN", 33, 42], ["spike protein", "PROTEIN", 51, 64], ["the proteases cutting spike protein", "TREATMENT", 29, 64]]], ["After fusion with a human cell, the virus releases its nucleotide into the cytoplasm and a number of molecular mechanisms are involved to produce the new RNA of the virus and the proteins that form its envelope.", [["cell", "ANATOMY", 26, 30], ["cytoplasm", "ANATOMY", 75, 84], ["nucleotide", "CHEMICAL", 55, 65], ["nucleotide", "CHEMICAL", 55, 65], ["human", "ORGANISM", 20, 25], ["cell", "CELL", 26, 30], ["cytoplasm", "ORGANISM_SUBSTANCE", 75, 84], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["fusion", "TREATMENT", 6, 12], ["a human cell", "TREATMENT", 18, 30], ["the virus", "PROBLEM", 32, 41], ["the new RNA of the virus", "PROBLEM", 146, 170], ["cytoplasm", "OBSERVATION_MODIFIER", 75, 84]]], ["Key proteins involved in the replication and proliferation of the virus are an attractive target for antiviral compounds.", [["Key proteins", "PROBLEM", 0, 12], ["the virus", "PROBLEM", 62, 71], ["antiviral compounds", "PROBLEM", 101, 120]]], ["Proteases, including papain-like protease (PLpro) and chymotrypsin-like protease (3CLpro), are identified as the most important targets.", [["papain-like protease", "GENE_OR_GENE_PRODUCT", 21, 41], ["PLpro", "GENE_OR_GENE_PRODUCT", 43, 48], ["chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 54, 80], ["3CLpro", "GENE_OR_GENE_PRODUCT", 82, 88], ["Proteases", "PROTEIN", 0, 9], ["papain-like protease", "PROTEIN", 21, 41], ["PLpro", "PROTEIN", 43, 48], ["chymotrypsin", "PROTEIN", 54, 66], ["like protease", "PROTEIN", 67, 80], ["3CLpro", "PROTEIN", 82, 88], ["Proteases", "TREATMENT", 0, 9], ["papain", "TREATMENT", 21, 27], ["protease (PLpro)", "TREATMENT", 33, 49], ["chymotrypsin", "TREATMENT", 54, 66], ["protease (3CLpro)", "TREATMENT", 72, 89]]], ["In view of the high similarity of SARS-CoV-2 with SARS-CoV and MERS-CoV, the mechanism of action of compounds of plant origin may be similar (Table 1).IntroductionEarlier outbreaks of SARS-CoV and MERS-CoV have provided us with the data about antiviral phytochemicals with health beneficial activity.", [["SARS", "DISEASE", 34, 38], ["SARS", "DISEASE", 184, 188], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV", "ORGANISM", 50, 58], ["MERS-CoV", "ORGANISM", 63, 71], ["SARS-CoV", "ORGANISM", 184, 192], ["MERS-CoV", "ORGANISM", 197, 205], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 50, 58], ["MERS-CoV", "SPECIES", 63, 71], ["SARS-CoV", "SPECIES", 184, 192], ["MERS-CoV", "SPECIES", 197, 205], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["SARS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 68, 71], ["SARS", "PROBLEM", 184, 188], ["antiviral phytochemicals", "TREATMENT", 243, 267], ["plant origin", "OBSERVATION", 113, 125]]], ["Coronavirus is an RNA virus, the genome of which encodes a protease essential in the production of viral proteins and controlling the activity of the replicase complex.", [["Coronavirus", "GENE_OR_GENE_PRODUCT", 0, 11], ["protease", "PROTEIN", 59, 67], ["viral proteins", "PROTEIN", 99, 113], ["replicase complex", "PROTEIN", 150, 167], ["Coronavirus", "PROBLEM", 0, 11], ["an RNA virus", "PROBLEM", 15, 27], ["a protease", "TREATMENT", 57, 67], ["viral proteins", "PROBLEM", 99, 113], ["RNA virus", "OBSERVATION", 18, 27], ["viral proteins", "OBSERVATION", 99, 113]]], ["It is crucial for virus replication and infection, making it a perfect target for designing antiviral therapies.", [["infection", "DISEASE", 40, 49], ["virus replication", "TREATMENT", 18, 35], ["infection", "PROBLEM", 40, 49], ["designing antiviral therapies", "TREATMENT", 82, 111], ["crucial for", "UNCERTAINTY", 6, 17], ["infection", "OBSERVATION", 40, 49]]], ["The paper describes phytochemicals that are potentially effective as antiviral preparations (natural inhibitors).", [["antiviral preparations (natural inhibitors", "TREATMENT", 69, 111]]], ["These are betulinic acid, indigo, aloeemodine, luteolin, and quinomethyl triterpenoids, quercitin or gallates.", [["betulinic acid", "CHEMICAL", 10, 24], ["indigo", "CHEMICAL", 26, 32], ["aloeemodine", "CHEMICAL", 34, 45], ["luteolin", "CHEMICAL", 47, 55], ["quinomethyl triterpenoids", "CHEMICAL", 61, 86], ["quercitin", "CHEMICAL", 88, 97], ["betulinic acid", "CHEMICAL", 10, 24], ["indigo", "CHEMICAL", 26, 32], ["aloeemodine", "CHEMICAL", 34, 45], ["luteolin", "CHEMICAL", 47, 55], ["quinomethyl triterpenoids", "CHEMICAL", 61, 86], ["quercitin", "CHEMICAL", 88, 97], ["gallates", "CHEMICAL", 101, 109], ["betulinic acid", "SIMPLE_CHEMICAL", 10, 24], ["indigo", "SIMPLE_CHEMICAL", 26, 32], ["aloeemodine", "SIMPLE_CHEMICAL", 34, 45], ["luteolin", "SIMPLE_CHEMICAL", 47, 55], ["quinomethyl triterpenoids", "SIMPLE_CHEMICAL", 61, 86], ["quercitin", "SIMPLE_CHEMICAL", 88, 97], ["gallates", "SIMPLE_CHEMICAL", 101, 109], ["betulinic acid", "TREATMENT", 10, 24], ["indigo", "TREATMENT", 26, 32], ["aloeemodine", "TREATMENT", 34, 45], ["luteolin", "TREATMENT", 47, 55], ["quinomethyl triterpenoids", "TREATMENT", 61, 86], ["quercitin", "TREATMENT", 88, 97], ["gallates", "TREATMENT", 101, 109], ["betulinic acid", "OBSERVATION", 10, 24]]], ["They are all enzyme inhibitors.", [["all enzyme inhibitors", "TREATMENT", 9, 30]]], ["This article reviews the possibility of using phytochemicals isolated from plants as water and ethanol extracts as a source of biologically active substances (e.g., quercetin and gallates), effective in inhibiting the development of Covid-19-inducing coronavirus.", [["extracts", "ANATOMY", 103, 111], ["ethanol", "CHEMICAL", 95, 102], ["quercetin", "CHEMICAL", 165, 174], ["Covid-19", "CHEMICAL", 233, 241], ["coronavirus", "DISEASE", 251, 262], ["ethanol", "CHEMICAL", 95, 102], ["quercetin", "CHEMICAL", 165, 174], ["gallates", "CHEMICAL", 179, 187], ["water", "SIMPLE_CHEMICAL", 85, 90], ["ethanol extracts", "ORGANISM_SUBSTANCE", 95, 111], ["quercetin", "SIMPLE_CHEMICAL", 165, 174], ["gallates", "SIMPLE_CHEMICAL", 179, 187], ["Covid-19-inducing coronavirus", "ORGANISM", 233, 262], ["phytochemicals", "TREATMENT", 46, 60], ["ethanol extracts", "TREATMENT", 95, 111], ["quercetin", "TREATMENT", 165, 174], ["Covid", "TEST", 233, 238], ["coronavirus", "PROBLEM", 251, 262]]], ["There is potential for the use of plant-derived polyphenols as functional foods and pharmaceutical preparations.", [["polyphenols", "CHEMICAL", 48, 59], ["polyphenols", "SIMPLE_CHEMICAL", 48, 59], ["plant-derived polyphenols", "TREATMENT", 34, 59], ["functional foods", "TREATMENT", 63, 79], ["pharmaceutical preparations", "TREATMENT", 84, 111]]], ["The method of implementing such preparations is fast because the raw materials for their preparation, namely herbs and consumable plants, are approved for human consumption worldwide.Bioactive extracts from acorns ::: The potential use of plant extracts containing polyphenols to inhibit Covid-19-inducing coronavirusNuts of wild plants were a valuable food resource during times of crisis.", [["extracts", "ANATOMY", 193, 201], ["extracts", "ANATOMY", 245, 253], ["polyphenols", "CHEMICAL", 265, 276], ["Covid-19", "CHEMICAL", 288, 296], ["polyphenols", "CHEMICAL", 265, 276], ["human", "ORGANISM", 155, 160], ["extracts", "ORGANISM_SUBSTANCE", 193, 201], ["acorns", "ORGANISM_SUBDIVISION", 207, 213], ["extracts", "ORGANISM_SUBSTANCE", 245, 253], ["polyphenols", "SIMPLE_CHEMICAL", 265, 276], ["Covid-19", "ORGANISM", 288, 296], ["coronavirus", "ORGANISM", 306, 317], ["human", "SPECIES", 155, 160], ["coronavirus", "SPECIES", 306, 317], ["human", "SPECIES", 155, 160], ["implementing such preparations", "TREATMENT", 14, 44], ["plant extracts", "TREATMENT", 239, 253], ["polyphenols", "TREATMENT", 265, 276], ["Covid", "TEST", 288, 293], ["crisis", "PROBLEM", 383, 389]]], ["Acorns, which are the fruits of Quercus trees, can also be food and highly nutritional feed.", [["fruits", "ANATOMY", 22, 28], ["Acorns", "CHEMICAL", 0, 6], ["Acorns", "SIMPLE_CHEMICAL", 0, 6], ["fruits", "ORGANISM_SUBDIVISION", 22, 28], ["Quercus trees", "ORGANISM", 32, 45]]], ["Their folk food applications for humans and in the feed are known, especially for poultry (Sekeroglu et al., 2017; J. Xu et al., 2018).", [["humans", "ORGANISM", 33, 39], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39]]], ["Indian Pomo Communities in America use acorns in traditional dishes such as acorn soup and dumplings (Meyers et al., 2007).Bioactive extracts from acorns ::: The potential use of plant extracts containing polyphenols to inhibit Covid-19-inducing coronavirusAcorns are used in the treatment of hemorrhoids, diabetes and kidney stones as a therapeutic agent in folk medicine.", [["extracts", "ANATOMY", 133, 141], ["extracts", "ANATOMY", 185, 193], ["kidney stones", "ANATOMY", 319, 332], ["polyphenols", "CHEMICAL", 205, 216], ["Covid-19", "CHEMICAL", 228, 236], ["coronavirus", "DISEASE", 246, 257], ["Acorns", "CHEMICAL", 257, 263], ["hemorrhoids", "DISEASE", 293, 304], ["diabetes", "DISEASE", 306, 314], ["kidney stones", "DISEASE", 319, 332], ["polyphenols", "CHEMICAL", 205, 216], ["extracts", "ORGANISM_SUBSTANCE", 133, 141], ["acorns", "ORGANISM_SUBDIVISION", 147, 153], ["extracts", "ORGANISM_SUBSTANCE", 185, 193], ["polyphenols", "SIMPLE_CHEMICAL", 205, 216], ["Covid-19", "GENE_OR_GENE_PRODUCT", 228, 236], ["coronavirus", "ORGANISM", 246, 257], ["Acorns", "SIMPLE_CHEMICAL", 257, 263], ["kidney", "ORGAN", 319, 325], ["coronavirus", "SPECIES", 246, 257], ["plant extracts", "TREATMENT", 179, 193], ["polyphenols", "TREATMENT", 205, 216], ["Covid", "TEST", 228, 233], ["coronavirus", "PROBLEM", 246, 257], ["hemorrhoids", "PROBLEM", 293, 304], ["diabetes", "PROBLEM", 306, 314], ["kidney stones", "PROBLEM", 319, 332], ["a therapeutic agent", "TREATMENT", 336, 355], ["folk medicine", "TREATMENT", 359, 372], ["hemorrhoids", "OBSERVATION", 293, 304], ["diabetes", "OBSERVATION", 306, 314], ["kidney", "ANATOMY", 319, 325], ["stones", "OBSERVATION", 326, 332]]], ["Acorns with their antibacterial, anti-ulcer, anti-helminthic, anti-inflammatory and antioxidant have been used in folk medicine to treat memorrhoids, diabetes, and kidney stones.", [["kidney stones", "ANATOMY", 164, 177], ["memorrhoids", "DISEASE", 137, 148], ["diabetes", "DISEASE", 150, 158], ["kidney stones", "DISEASE", 164, 177], ["kidney", "ORGAN", 164, 170], ["their antibacterial", "TREATMENT", 12, 31], ["anti-ulcer", "TREATMENT", 33, 43], ["anti-helminthic", "TREATMENT", 45, 60], ["anti-inflammatory", "TREATMENT", 62, 79], ["antioxidant", "TREATMENT", 84, 95], ["folk medicine", "TREATMENT", 114, 127], ["memorrhoids", "PROBLEM", 137, 148], ["diabetes", "PROBLEM", 150, 158], ["kidney stones", "PROBLEM", 164, 177], ["diabetes", "OBSERVATION", 150, 158], ["kidney", "ANATOMY", 164, 170], ["stones", "OBSERVATION", 171, 177]]], ["They are also consumed as herbal coffee due to their characteristic aroma (Gezici & Sekeroglu, 2019).Bioactive extracts from acorns ::: The potential use of plant extracts containing polyphenols to inhibit Covid-19-inducing coronavirusAcorns are the fruit of several trees belonging to the Fagaceae family.", [["extracts", "ANATOMY", 111, 119], ["extracts", "ANATOMY", 163, 171], ["polyphenols", "CHEMICAL", 183, 194], ["Covid-19", "CHEMICAL", 206, 214], ["coronavirus", "DISEASE", 224, 235], ["polyphenols", "CHEMICAL", 183, 194], ["extracts", "ORGANISM_SUBSTANCE", 111, 119], ["acorns", "ORGANISM_SUBDIVISION", 125, 131], ["extracts", "ORGANISM_SUBSTANCE", 163, 171], ["polyphenols", "SIMPLE_CHEMICAL", 183, 194], ["Covid-19", "GENE_OR_GENE_PRODUCT", 206, 214], ["coronavirus", "ORGANISM", 224, 235], ["Acorns", "GENE_OR_GENE_PRODUCT", 235, 241], ["Fagaceae", "GENE_OR_GENE_PRODUCT", 290, 298], ["coronavirus", "SPECIES", 224, 235], ["plant extracts", "TREATMENT", 157, 171], ["polyphenols", "TREATMENT", 183, 194], ["Covid", "TEST", 206, 211], ["coronavirus", "PROBLEM", 224, 235]]], ["For instance, in Central Europe, the dominant species of this family is Quercus.", [["Central", "ANATOMY_MODIFIER", 17, 24], ["dominant", "OBSERVATION_MODIFIER", 37, 45], ["species", "OBSERVATION", 46, 53]]], ["Although this nut has an appreciable effect on human nutrition, it is a key ingredient in the development of some typical products with functional properties, such as Eichel Kaffe (acorn coffee), astringent and anti-diarrheal drink used as a traditional drug.", [["nut", "ORGANISM_SUBDIVISION", 14, 17], ["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human nutrition", "TREATMENT", 47, 62], ["Eichel Kaffe (acorn coffee)", "TREATMENT", 167, 194], ["astringent and anti-diarrheal drink", "TREATMENT", 196, 231], ["a traditional drug", "TREATMENT", 240, 258], ["appreciable", "OBSERVATION_MODIFIER", 25, 36], ["effect", "OBSERVATION_MODIFIER", 37, 43]]], ["What is more, during times of hunger, acorn flour was used to produce bread with good sensory properties and long shelf life.", [["bread", "ORGANISM_SUBDIVISION", 70, 75], ["hunger", "PROBLEM", 30, 36]]], ["Natural flavor ingredients are currently in high demand in food.", [["flavor ingredients", "OBSERVATION", 8, 26]]], ["Currently acorns are used to make a coffee drink powder that has a coffee-like flavor but is free of caffeine and gluten, which satisfies because there is the great demand for it (Coelho et al., 2018).Bioactive extracts from acorns ::: The potential use of plant extracts containing polyphenols to inhibit Covid-19-inducing coronavirusAs a food source, acorns have recently been discovered as a novel herbal product and functional food.", [["extracts", "ANATOMY", 211, 219], ["extracts", "ANATOMY", 263, 271], ["caffeine", "CHEMICAL", 101, 109], ["polyphenols", "CHEMICAL", 283, 294], ["Covid-19", "CHEMICAL", 306, 314], ["coronavirus", "DISEASE", 324, 335], ["caffeine", "CHEMICAL", 101, 109], ["polyphenols", "CHEMICAL", 283, 294], ["acorns", "ORGANISM_SUBDIVISION", 10, 16], ["caffeine", "SIMPLE_CHEMICAL", 101, 109], ["extracts", "ORGANISM_SUBSTANCE", 211, 219], ["acorns", "ORGANISM_SUBDIVISION", 225, 231], ["extracts", "ORGANISM_SUBSTANCE", 263, 271], ["polyphenols", "SIMPLE_CHEMICAL", 283, 294], ["Covid-19", "GENE_OR_GENE_PRODUCT", 306, 314], ["coronavirus", "ORGANISM", 324, 335], ["acorns", "ORGANISM_SUBDIVISION", 353, 359], ["coronavirus", "SPECIES", 324, 335], ["caffeine", "TREATMENT", 101, 109], ["gluten", "TREATMENT", 114, 120], ["plant extracts", "TREATMENT", 257, 271], ["polyphenols", "TREATMENT", 283, 294], ["Covid", "TEST", 306, 311], ["coronavirus", "PROBLEM", 324, 335]]], ["Because acorn-based extract contains useful minerals and low concentrations of heavy metals, acorn-based drinks can be consumed safely.", [["acorn-based extract", "CHEMICAL", 8, 27], ["acorn-based extract", "TREATMENT", 8, 27], ["low concentrations", "OBSERVATION_MODIFIER", 57, 75]]], ["As a functional food, it has health benefits in line with consumer preferences (Sekeroglu et al., 2017).Bioactive extracts from acorns ::: The potential use of plant extracts containing polyphenols to inhibit Covid-19-inducing coronavirusAs demonstrated by Ishida et al. (2015), water and methanol extracts from acorns contain high concentrations of gallic acid and its derivatives.", [["extracts", "ANATOMY", 114, 122], ["extracts", "ANATOMY", 166, 174], ["extracts", "ANATOMY", 298, 306], ["polyphenols", "CHEMICAL", 186, 197], ["Covid-19", "CHEMICAL", 209, 217], ["gallic acid", "CHEMICAL", 350, 361], ["polyphenols", "CHEMICAL", 186, 197], ["methanol", "CHEMICAL", 289, 297], ["gallic acid", "CHEMICAL", 350, 361], ["extracts", "ORGANISM_SUBSTANCE", 114, 122], ["acorns", "ORGANISM_SUBDIVISION", 128, 134], ["extracts", "ORGANISM_SUBSTANCE", 166, 174], ["polyphenols", "SIMPLE_CHEMICAL", 186, 197], ["Covid-19", "SIMPLE_CHEMICAL", 209, 217], ["coronavirusAs", "SIMPLE_CHEMICAL", 227, 240], ["water", "SIMPLE_CHEMICAL", 279, 284], ["methanol extracts", "ORGANISM_SUBSTANCE", 289, 306], ["acorns", "ORGANISM_SUBDIVISION", 312, 318], ["gallic acid", "SIMPLE_CHEMICAL", 350, 361], ["plant extracts", "TREATMENT", 160, 174], ["polyphenols", "TREATMENT", 186, 197], ["Covid", "TEST", 209, 214], ["coronavirusAs", "TREATMENT", 227, 240], ["water and methanol extracts", "TREATMENT", 279, 306], ["acorns", "TREATMENT", 312, 318], ["gallic acid", "TREATMENT", 350, 361], ["its derivatives", "TREATMENT", 366, 381], ["high concentrations", "OBSERVATION_MODIFIER", 327, 346], ["gallic acid", "OBSERVATION", 350, 361]]], ["This explains the high concentrations of polyphenols in acorn coffee and the antioxidant activity of its infusions.", [["polyphenols", "CHEMICAL", 41, 52], ["acorn coffee", "CHEMICAL", 56, 68], ["polyphenols", "CHEMICAL", 41, 52], ["polyphenols", "SIMPLE_CHEMICAL", 41, 52], ["polyphenols", "TREATMENT", 41, 52], ["acorn coffee", "TREATMENT", 56, 68], ["its infusions", "TREATMENT", 101, 114], ["high concentrations", "OBSERVATION_MODIFIER", 18, 37]]], ["In the study on acorn coffee, they showed twice as high concentrations of phenolic compounds than those in green coffees tested by Stelmach et al. (2015), which conforms to the findings of this study.", [["the study", "TEST", 3, 12], ["high concentrations of phenolic compounds", "PROBLEM", 51, 92], ["this study", "TEST", 189, 199]]], ["Coffee infusions prepared from acorns showed the highest antioxidant activity.", [["acorns", "ORGANISM_SUBDIVISION", 31, 37], ["Coffee infusions", "TREATMENT", 0, 16], ["antioxidant activity", "OBSERVATION", 57, 77]]], ["EC50 values \u200b\u200bobtained for the capture of DPPH free radicals were 0.063 for acorn ginseng and 0.066 mg d.m./ml for acorn coffee (Samsonowicz et al., 2019).Bioactive extracts from acorns ::: The potential use of plant extracts containing polyphenols to inhibit Covid-19-inducing coronavirusThe results showed that beverages based on Quercus have an antioxidant capacity related to the concentrations of phenols, mainly with ellagic acid as the main phenolic compound.", [["extracts", "ANATOMY", 165, 173], ["extracts", "ANATOMY", 217, 225], ["DPPH", "CHEMICAL", 42, 46], ["polyphenols", "CHEMICAL", 237, 248], ["Covid-19", "CHEMICAL", 260, 268], ["coronavirus", "DISEASE", 278, 289], ["phenols", "CHEMICAL", 402, 409], ["ellagic acid", "CHEMICAL", 423, 435], ["DPPH", "CHEMICAL", 42, 46], ["polyphenols", "CHEMICAL", 237, 248], ["phenols", "CHEMICAL", 402, 409], ["ellagic acid", "CHEMICAL", 423, 435], ["DPPH free radicals", "SIMPLE_CHEMICAL", 42, 60], ["extracts", "ORGANISM_SUBSTANCE", 165, 173], ["acorns", "ORGANISM_SUBDIVISION", 179, 185], ["extracts", "ORGANISM_SUBSTANCE", 217, 225], ["polyphenols", "SIMPLE_CHEMICAL", 237, 248], ["Covid-19", "GENE_OR_GENE_PRODUCT", 260, 268], ["coronavirus", "ORGANISM", 278, 289], ["phenols", "SIMPLE_CHEMICAL", 402, 409], ["ellagic acid", "SIMPLE_CHEMICAL", 423, 435], ["coronavirus", "SPECIES", 278, 289], ["EC50 values", "TEST", 0, 11], ["DPPH free radicals", "TREATMENT", 42, 60], ["acorn ginseng", "TREATMENT", 76, 89], ["plant extracts", "TREATMENT", 211, 225], ["polyphenols", "TREATMENT", 237, 248], ["Covid", "TEST", 260, 265], ["coronavirus", "PROBLEM", 278, 289], ["an antioxidant capacity", "PROBLEM", 345, 368], ["the concentrations of phenols", "PROBLEM", 380, 409], ["ellagic acid", "TREATMENT", 423, 435], ["antioxidant capacity", "OBSERVATION", 348, 368], ["main", "OBSERVATION_MODIFIER", 443, 447], ["phenolic compound", "OBSERVATION", 448, 465]]], ["The main fatty acids were esterified lipids: oleic, linoleic, palmitic.", [["fatty acids", "CHEMICAL", 9, 20], ["esterified lipids", "CHEMICAL", 26, 43], ["oleic, linoleic, palmitic", "CHEMICAL", 45, 70], ["fatty acids", "CHEMICAL", 9, 20], ["oleic, linoleic, palmitic", "CHEMICAL", 45, 70], ["main fatty acids", "SIMPLE_CHEMICAL", 4, 20], ["lipids", "SIMPLE_CHEMICAL", 37, 43], ["oleic", "SIMPLE_CHEMICAL", 45, 50], ["linoleic", "SIMPLE_CHEMICAL", 52, 60], ["palmitic", "SIMPLE_CHEMICAL", 62, 70], ["The main fatty acids", "TEST", 0, 20], ["main", "OBSERVATION_MODIFIER", 4, 8], ["fatty acids", "OBSERVATION", 9, 20], ["oleic", "OBSERVATION_MODIFIER", 45, 50], ["linoleic", "OBSERVATION_MODIFIER", 52, 60], ["palmitic", "OBSERVATION_MODIFIER", 62, 70]]], ["Oleic and linoleic acids were found in the free fatty acid fraction (FFA).", [["Oleic and", "CHEMICAL", 0, 9], ["linoleic acids", "CHEMICAL", 10, 24], ["fatty acid", "CHEMICAL", 48, 58], ["FFA", "CHEMICAL", 69, 72], ["Oleic and linoleic acids", "CHEMICAL", 0, 24], ["fatty acid", "CHEMICAL", 48, 58], ["Oleic", "SIMPLE_CHEMICAL", 0, 5], ["linoleic acids", "SIMPLE_CHEMICAL", 10, 24], ["free fatty acid", "SIMPLE_CHEMICAL", 43, 58], ["FFA", "SIMPLE_CHEMICAL", 69, 72], ["Oleic and linoleic acids", "TEST", 0, 24], ["the free fatty acid fraction", "TEST", 39, 67], ["linoleic acids", "OBSERVATION", 10, 24]]], ["The heat treatment reduced the total fatty acid concentration in the TG and FFA fractions.", [["fatty acid", "CHEMICAL", 37, 47], ["FFA", "CHEMICAL", 76, 79], ["fatty acid", "CHEMICAL", 37, 47], ["fatty acid", "SIMPLE_CHEMICAL", 37, 47], ["TG", "SIMPLE_CHEMICAL", 69, 71], ["FFA", "SIMPLE_CHEMICAL", 76, 79], ["The heat treatment", "TREATMENT", 0, 18], ["the total fatty acid concentration", "TREATMENT", 27, 61], ["the TG", "TEST", 65, 71], ["fatty acid", "OBSERVATION", 37, 47]]], ["It has been demonstrated that acorn smoking or coffee making does not cause genotoxic or cytotoxic compounds.", [["smoking", "CHEMICAL", 36, 43], ["coffee", "CHEMICAL", 47, 53], ["genotoxic or cytotoxic compounds", "PROBLEM", 76, 108], ["cytotoxic compounds", "OBSERVATION", 89, 108]]], ["This shows the potential of acorns to produce functional drinks i.e coffee substitutes.", [["acorns", "ORGANISM_SUBDIVISION", 28, 34]]], ["Since acorn coffee is not mutagenic, the cytotoxicity of these extracts was assessed by the MTT test.", [["extracts", "ANATOMY", 63, 71], ["MTT", "CHEMICAL", 92, 95], ["extracts", "ORGANISM_SUBSTANCE", 63, 71], ["the MTT test", "TEST", 88, 100]]], ["Ellagic acid is a phenolic compound with antimutagenic properties and is present in Quercus coffees as the main phenolic compound.", [["Ellagic acid", "CHEMICAL", 0, 12], ["Ellagic acid", "CHEMICAL", 0, 12], ["Ellagic acid", "SIMPLE_CHEMICAL", 0, 12], ["Quercus coffees", "ORGANISM", 84, 99], ["Quercus coffees", "SPECIES", 84, 99], ["Ellagic acid", "PROBLEM", 0, 12], ["antimutagenic properties", "TREATMENT", 41, 65], ["acid", "OBSERVATION_MODIFIER", 8, 12], ["antimutagenic properties", "OBSERVATION_MODIFIER", 41, 65], ["Quercus coffees", "OBSERVATION", 84, 99], ["main", "OBSERVATION_MODIFIER", 107, 111], ["phenolic compound", "OBSERVATION", 112, 129]]], ["Ellagic acid may also promote the release/formation of bioactive molecules on antimutagenic activity.", [["Ellagic acid", "CHEMICAL", 0, 12], ["Ellagic acid", "CHEMICAL", 0, 12], ["Ellagic acid", "SIMPLE_CHEMICAL", 0, 12], ["Ellagic acid", "TREATMENT", 0, 12], ["bioactive molecules", "PROBLEM", 55, 74], ["antimutagenic activity", "TREATMENT", 78, 100], ["bioactive molecules", "OBSERVATION", 55, 74], ["antimutagenic activity", "OBSERVATION", 78, 100]]], ["Fatty acid composition (FA) analysis of raw samples of two species showed that in the triglyceride (TG) fraction the main acids are: oleic (C18: 1 c9), linoleic acid (C18: 2 c9c12), palmitic acid (C16), stearic acid (C18) and cis-vaccence (C18: 1 c11).", [["samples", "ANATOMY", 44, 51], ["triglyceride", "CHEMICAL", 86, 98], ["TG", "CHEMICAL", 100, 102], ["oleic", "CHEMICAL", 133, 138], ["C18: 1 c9), linoleic acid", "CHEMICAL", 140, 165], ["C18: 2 c9c12", "CHEMICAL", 167, 179], ["palmitic acid", "CHEMICAL", 182, 195], ["C16), stearic acid", "CHEMICAL", 197, 215], ["Fatty acid", "CHEMICAL", 0, 10], ["triglyceride", "CHEMICAL", 86, 98], ["oleic", "CHEMICAL", 133, 138], ["linoleic acid", "CHEMICAL", 152, 165], ["C18: 2 c9c12", "CHEMICAL", 167, 179], ["palmitic acid", "CHEMICAL", 182, 195], ["stearic acid", "CHEMICAL", 203, 215], ["cis-vaccence", "CHEMICAL", 226, 238], ["Fatty acid", "SIMPLE_CHEMICAL", 0, 10], ["FA", "SIMPLE_CHEMICAL", 24, 26], ["triglyceride", "SIMPLE_CHEMICAL", 86, 98], ["TG", "SIMPLE_CHEMICAL", 100, 102], ["oleic", "SIMPLE_CHEMICAL", 133, 138], ["C18: 1 c9", "SIMPLE_CHEMICAL", 140, 149], ["linoleic acid", "SIMPLE_CHEMICAL", 152, 165], ["C18: 2 c9c12", "SIMPLE_CHEMICAL", 167, 179], ["palmitic acid", "SIMPLE_CHEMICAL", 182, 195], ["C16", "SIMPLE_CHEMICAL", 197, 200], ["stearic acid", "SIMPLE_CHEMICAL", 203, 215], ["C18", "SIMPLE_CHEMICAL", 217, 220], ["cis-vaccence", "SIMPLE_CHEMICAL", 226, 238], ["C18: 1 c11", "SIMPLE_CHEMICAL", 240, 250], ["Fatty acid composition", "TEST", 0, 22], ["raw samples", "TEST", 40, 51], ["two species", "TEST", 55, 66], ["the triglyceride", "TEST", 82, 98], ["the main acids", "TEST", 113, 127], ["oleic", "TEST", 133, 138], ["C18", "TEST", 140, 143], ["linoleic acid", "TEST", 152, 165], ["C18", "TEST", 167, 170], ["palmitic acid (C16", "TEST", 182, 200], ["stearic acid", "TEST", 203, 215], ["cis-vaccence", "TEST", 226, 238], ["main acids", "ANATOMY", 117, 127], ["oleic", "OBSERVATION_MODIFIER", 133, 138], ["palmitic acid", "ANATOMY", 182, 195]]], ["In the free fatty acid (FFA) fraction, oleic, linoleic and palmitic acids were also characteristic compounds.", [["fatty acid", "CHEMICAL", 12, 22], ["FFA", "CHEMICAL", 24, 27], ["oleic, linoleic and", "CHEMICAL", 39, 58], ["palmitic acids", "CHEMICAL", 59, 73], ["fatty acid", "CHEMICAL", 12, 22], ["oleic, linoleic and palmitic acids", "CHEMICAL", 39, 73], ["free fatty acid", "SIMPLE_CHEMICAL", 7, 22], ["FFA", "SIMPLE_CHEMICAL", 24, 27], ["oleic", "SIMPLE_CHEMICAL", 39, 44], ["linoleic", "SIMPLE_CHEMICAL", 46, 54], ["palmitic acids", "SIMPLE_CHEMICAL", 59, 73], ["the free fatty acid (FFA) fraction", "TEST", 3, 37], ["oleic", "TEST", 39, 44], ["linoleic and palmitic acids", "TEST", 46, 73], ["oleic", "OBSERVATION_MODIFIER", 39, 44], ["linoleic", "OBSERVATION_MODIFIER", 46, 54], ["palmitic acids", "OBSERVATION", 59, 73]]], ["The phenolic profile found ellagic acid and epicatechin gallate (-) gallate.", [["ellagic acid", "CHEMICAL", 27, 39], ["epicatechin gallate", "CHEMICAL", 44, 63], ["ellagic acid", "CHEMICAL", 27, 39], ["epicatechin gallate", "CHEMICAL", 44, 63], ["(-) gallate", "CHEMICAL", 64, 75], ["ellagic acid", "SIMPLE_CHEMICAL", 27, 39], ["epicatechin gallate (-) gallate", "SIMPLE_CHEMICAL", 44, 75], ["The phenolic profile", "TEST", 0, 20], ["ellagic acid", "TEST", 27, 39], ["epicatechin gallate", "TEST", 44, 63], ["phenolic profile", "OBSERVATION", 4, 20], ["ellagic acid", "OBSERVATION", 27, 39]]], ["The results showed that epicatechin gallate and gallic acid levels decreased together with heat treatment withan increase in ellagic acid concentrations (Coelho et al., 2018).Future perspectivesThis review provides a broad spectrum of information on the use of phytochemicals found in medicinal plants for the inhibition of coronavirus family.", [["epicatechin gallate", "CHEMICAL", 24, 43], ["gallic acid", "CHEMICAL", 48, 59], ["ellagic acid", "CHEMICAL", 125, 137], ["epicatechin gallate", "CHEMICAL", 24, 43], ["gallic acid", "CHEMICAL", 48, 59], ["ellagic acid", "CHEMICAL", 125, 137], ["epicatechin gallate", "SIMPLE_CHEMICAL", 24, 43], ["gallic acid", "SIMPLE_CHEMICAL", 48, 59], ["ellagic acid", "SIMPLE_CHEMICAL", 125, 137], ["coronavirus", "ORGANISM", 324, 335], ["coronavirus family", "PROTEIN", 324, 342], ["epicatechin gallate", "TREATMENT", 24, 43], ["gallic acid levels", "TEST", 48, 66], ["heat treatment", "TREATMENT", 91, 105], ["ellagic acid concentrations", "TREATMENT", 125, 152], ["phytochemicals", "TREATMENT", 261, 275], ["medicinal plants", "TREATMENT", 285, 301], ["ellagic acid concentrations", "OBSERVATION", 125, 152]]], ["The examples clearly prove that the formulations with specific ingredients of herb extracts that have been developed for centuries in traditional medicine (e.g. Chinese medicine) can be beneficial as the source of anti SARS-CoV agents in the treatments and prevention of Covid-19.", [["extracts", "ANATOMY", 83, 91], ["herb extracts", "ORGANISM_SUBSTANCE", 78, 91], ["the formulations", "TREATMENT", 32, 48], ["herb extracts", "TREATMENT", 78, 91], ["traditional medicine", "TREATMENT", 134, 154], ["Chinese medicine", "TREATMENT", 161, 177], ["anti SARS", "TREATMENT", 214, 223], ["CoV agents", "TREATMENT", 224, 234], ["the treatments", "TREATMENT", 238, 252], ["Covid", "TEST", 271, 276]]], ["Natural compounds can act as antioxidants, direct enzyme inhibitors and throughout interaction-blocking virus surface protein receptors.", [["virus surface protein receptors", "PROTEIN", 104, 135], ["Natural compounds", "TREATMENT", 0, 17], ["antioxidants", "TREATMENT", 29, 41], ["direct enzyme inhibitors", "TREATMENT", 43, 67], ["blocking virus surface protein receptors", "TREATMENT", 95, 135]]], ["Different medicinal plants can be used as a source of phytochemicals (polyphenols, sterols and lipids) with a broad range of biological activity (Coelho et al., 2018, Vinha et al., 2016).", [["sterols", "CHEMICAL", 83, 90], ["polyphenols", "CHEMICAL", 70, 81], ["sterols", "CHEMICAL", 83, 90], ["polyphenols", "SIMPLE_CHEMICAL", 70, 81], ["sterols", "SIMPLE_CHEMICAL", 83, 90], ["lipids", "SIMPLE_CHEMICAL", 95, 101], ["Different medicinal plants", "TREATMENT", 0, 26], ["phytochemicals (polyphenols, sterols and lipids", "TREATMENT", 54, 101], ["medicinal plants", "OBSERVATION", 10, 26]]], ["These compounds provide hope that extracts from different plants presented in this review may have antiviral properties (Karimi et al., 2013), also against the coronavirus family.Future perspectivesThe wide range of natural substances present in herbal extracts, which are underrated in conventional medicine, may constitute almost inexhaustible source of medicaments.", [["extracts", "ANATOMY", 34, 42], ["extracts", "ANATOMY", 253, 261], ["extracts", "ORGANISM_SUBSTANCE", 34, 42], ["coronavirus", "ORGANISM", 160, 171], ["coronavirus", "SPECIES", 160, 171], ["antiviral properties", "TREATMENT", 99, 119], ["wide", "OBSERVATION_MODIFIER", 202, 206], ["range", "OBSERVATION_MODIFIER", 207, 212], ["natural substances", "OBSERVATION", 216, 234], ["herbal extracts", "OBSERVATION_MODIFIER", 246, 261]]], ["The new trends in biotechnology and medicine have enabled the use of natural-origin compounds to a larger extent than in the previous decades, mostly as the dietary supplements and nutraceuticals.Their toxicity together with consumption time are yet to be investigated by means of a multidisciplinary approach (omics science-genomics, proteomics, metabolomics) (Firenzuoli and Gori, 2007, Thomford et al., 2018).", [["toxicity", "DISEASE", 202, 210], ["medicine", "TREATMENT", 36, 44], ["the dietary supplements", "TREATMENT", 153, 176], ["nutraceuticals", "TREATMENT", 181, 195], ["Their toxicity", "PROBLEM", 196, 210], ["a multidisciplinary approach", "TREATMENT", 281, 309], ["new", "OBSERVATION_MODIFIER", 4, 7], ["trends", "OBSERVATION_MODIFIER", 8, 14], ["larger", "OBSERVATION_MODIFIER", 99, 105], ["extent", "OBSERVATION_MODIFIER", 106, 112]]], ["Also, new processing and formulation technologies might help optimize the solubility of antiviral bioactive compounds, their delivery strategies and therapeutic activities (Patra et al., 2018) to adapt them as antiviral functional foods (Lin et al., 2014, Zhong et al., 2012) and drugs.Future perspectivesThe studies performed so far have contributed to the knowledge of the chemical structure of antiviral compounds.", [["formulation technologies", "TREATMENT", 25, 49], ["antiviral bioactive compounds", "TREATMENT", 88, 117], ["their delivery strategies", "TREATMENT", 119, 144], ["drugs", "TREATMENT", 280, 285], ["The studies", "TEST", 305, 316], ["antiviral compounds", "PROBLEM", 397, 416], ["chemical structure", "OBSERVATION", 375, 393], ["antiviral compounds", "OBSERVATION", 397, 416]]], ["Bioinformatic studies of the phyto-pharmacophores structures can (Qamar et al., 2020) the bioactive analogues can lead to designing new antiviral drugs.", [["Bioinformatic studies", "TEST", 0, 21], ["the bioactive analogues", "TREATMENT", 86, 109], ["new antiviral drugs", "TREATMENT", 132, 151]]], ["The use of herbal extracts might provide synergistic health beneficial effects (antioxidant, antiviral, antimutagenic, antiinflammation) between occurring phytochemical mixtures, which should be taken into account but must be deeply explored (Yu et al., 2017).ConclusionsMany examples show that nature offers the best solutions.", [["extracts", "ANATOMY", 18, 26], ["herbal extracts", "TREATMENT", 11, 26], ["antioxidant", "TREATMENT", 80, 91], ["antiviral", "TREATMENT", 93, 102], ["antimutagenic", "TREATMENT", 104, 117], ["antiinflammation", "TREATMENT", 119, 135], ["phytochemical mixtures", "TREATMENT", 155, 177]]], ["A wide variety of plant species contain biologically active substances, which in synergistic combinations are effective in combating various diseases.", [["A wide variety of plant species", "PROBLEM", 0, 31], ["various diseases", "PROBLEM", 133, 149], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14], ["plant species", "OBSERVATION", 18, 31], ["biologically", "OBSERVATION_MODIFIER", 40, 52], ["active", "OBSERVATION_MODIFIER", 53, 59], ["substances", "OBSERVATION", 60, 70]]], ["Identifying individual compounds and determining mechanisms of action is very difficult.", [["individual compounds", "PROBLEM", 12, 32], ["compounds", "OBSERVATION", 23, 32]]], ["This hinders the standardization of products, especially since plant extracts contain a wide variety of different compounds, occurring in varying concentrations, with presumably synergistic effects.", [["extracts", "ANATOMY", 69, 77], ["extracts", "ORGANISM_SUBSTANCE", 69, 77], ["plant extracts", "TREATMENT", 63, 77], ["wide", "OBSERVATION_MODIFIER", 88, 92], ["variety", "OBSERVATION_MODIFIER", 93, 100], ["different compounds", "OBSERVATION", 104, 123], ["varying", "OBSERVATION_MODIFIER", 138, 145], ["concentrations", "OBSERVATION_MODIFIER", 146, 160], ["presumably", "UNCERTAINTY", 167, 177], ["synergistic effects", "OBSERVATION", 178, 197]]], ["Despite many unknowns, scientific research unambiguously indicates that plant extracts inhibit the life cycle of coronavirus by inhibiting the protease enzyme that plays a key role in its reproduction.ConclusionsThis review of literature indicates the great potential of plant extracts and phytochemicals present in them in the development of functional foods enriched with polyphenols of plant origin or even pharmaceutical preparations.Laboratory model tests are needed to prove their efficacy in inhibiting coronavirus replication.", [["extracts", "ANATOMY", 78, 86], ["extracts", "ANATOMY", 277, 285], ["coronavirus", "DISEASE", 113, 124], ["polyphenols", "CHEMICAL", 374, 385], ["extracts", "ORGANISM_SUBSTANCE", 78, 86], ["coronavirus", "ORGANISM", 113, 124], ["extracts", "ORGANISM_SUBSTANCE", 277, 285], ["polyphenols", "SIMPLE_CHEMICAL", 374, 385], ["coronavirus", "ORGANISM", 510, 521], ["protease enzyme", "PROTEIN", 143, 158], ["coronavirus", "SPECIES", 510, 521], ["plant extracts", "PROBLEM", 72, 86], ["coronavirus", "PROBLEM", 113, 124], ["the protease enzyme", "TEST", 139, 158], ["polyphenols", "TREATMENT", 374, 385], ["pharmaceutical preparations", "TREATMENT", 410, 437], ["Laboratory model tests", "TEST", 438, 460], ["coronavirus replication", "TREATMENT", 510, 533], ["plant extracts", "OBSERVATION", 271, 285], ["functional foods", "OBSERVATION", 343, 359]]], ["The next step should be to conduct clinical trials on patients and observe the potential to reduce the multiplication of the virus in the patient's organism and thus improve clinical symptoms.", [["patients", "ORGANISM", 54, 62], ["patient", "ORGANISM", 138, 145], ["patients", "SPECIES", 54, 62], ["patient", "SPECIES", 138, 145], ["the virus", "PROBLEM", 121, 130], ["clinical symptoms", "PROBLEM", 174, 191]]], ["It is necessary to conduct laboratory tests in vitro and in vivo on animals and patients to confirm their effectiveness in inhibiting Covid-19-inducing coronavirus replication.", [["Covid-19", "CHEMICAL", 134, 142], ["patients", "ORGANISM", 80, 88], ["Covid-19", "GENE_OR_GENE_PRODUCT", 134, 142], ["coronavirus", "ORGANISM", 152, 163], ["patients", "SPECIES", 80, 88], ["laboratory tests", "TEST", 27, 43], ["Covid", "TEST", 134, 139], ["coronavirus replication", "TREATMENT", 152, 175]]], ["It is worth mentioning that the benefit of using these preparations is high safety for patients and no side effects.FundingThe work was financed by a statutory activity subsidy from the Polish Ministry of Science and Higher Education for the Faculty of Chemistry of Wroclaw University of Science and Technology number 8201003902/K26W03D05Ethics Statements FileThis paper does not conduct research on humans or animals.Uncited references", [["patients", "ORGANISM", 87, 95], ["humans", "ORGANISM", 400, 406], ["patients", "SPECIES", 87, 95], ["humans", "SPECIES", 400, 406], ["humans", "SPECIES", 400, 406], ["these preparations", "TREATMENT", 49, 67], ["side effects", "PROBLEM", 103, 115]]]]}